: The AMEDEO Literature Guide

Home The Word Brain

My Amedeo

FAQ

Privacy

About

Flying Publisher

COVID-19: Daily Top 10 Papers

Breast Cancer

Free Subscription

Articles published in Breast Cancer Res Treat
Retrieve available abstracts of 1604 articles:
HTML format

Single Articles

August 2021

LAISH I, Friedman E, Levi-Reznick G, Kedar I, et al
Double heterozygotes of BRCA1/BRCA2 and mismatch repair gene pathogenic variants: case series and clinical implications.
Breast Cancer Res Treat. 2021;188:685-694.
PubMed Abstract available

SATO S, Maki S, Yamanaka T, Hoshino D, et al
Machine learning-based image analysis for accelerating the diagnosis of complicated preneoplastic and neoplastic ductal lesions in breast biopsy tissues.
Breast Cancer Res Treat. 2021;188:649-659.
PubMed Abstract available

WEITZEL JN, Kidd J, Bernhisel R, Shehayeb S, et al
Multigene assessment of genetic risk for women for two or more breast cancers.
Breast Cancer Res Treat. 2021;188:759-768.
PubMed Abstract available

TANG A, Cohan CM, Hansen KS, Beattie G, et al
Relationship between body mass index and malignancy rates of MRI-guided breast biopsies: impact of clinicodemographic factors.
Breast Cancer Res Treat. 2021;188:739-747.
PubMed Abstract available

RUDDY KJ, Zheng Y, Tayob N, Hu J, et al
Chemotherapy-related amenorrhea (CRA) after adjuvant ado-trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH) (TBCRC033: ATEMPT Trial).
Breast Cancer Res Treat. 2021;189:103-110.
PubMed Abstract available

July 2021

HANNA A, Balko JM
Breast cancer resistance mechanisms: challenges to immunotherapy.
Breast Cancer Res Treat. 2021 Jul 28. pii: 10.1007/s10549-021-06337.
PubMed Abstract available

JERZAK KJ, Lipton N, Nofech-Mozes S, Boles D, et al
Clinical outcomes and prognostic biomarkers among pregnant, post-partum and nulliparous women with breast cancer: a prospective cohort study.
Breast Cancer Res Treat. 2021 Jul 27. pii: 10.1007/s10549-021-06327.
PubMed Abstract available

EVANS DG, Howell SJ, Gandhi A, van Veen EM, et al
Breast cancer incidence and early diagnosis in a family history risk and prevention clinic: 33-year experience in 14,311 women.
Breast Cancer Res Treat. 2021 Jul 26. pii: 10.1007/s10549-021-06333.
PubMed Abstract available

BALCH SM, Vaz-Luis I, Li T, Tayob N, et al
A phase II study of efficacy, toxicity, and the potential impact of genomic alterations on response to eribulin mesylate in combination with trastuzumab and pertuzumab in women with human epidermal growth factor receptor 2 (HER2)+ metastatic breast ca
Breast Cancer Res Treat. 2021 Jul 24. pii: 10.1007/s10549-021-06329.
PubMed Abstract available

JEON YW, Park HS, Ko Y, Sung YS, et al
Intermuscular fat density as a novel prognostic factor in breast cancer patients treated with adjuvant chemotherapy.
Breast Cancer Res Treat. 2021 Jul 20. pii: 10.1007/s10549-021-06322.
PubMed Abstract available

LEI L, Chan HC, Lu TP, Cheng SH, et al
Risk evaluation of early-stage hormone receptor-positive and human epidermal growth factor receptor 2-negative breast cancer patients: a population-based study from Taiwan.
Breast Cancer Res Treat. 2021 Jul 19. pii: 10.1007/s10549-021-06330.
PubMed Abstract available

ALFARSI LH, El Ansari R, Craze ML, Mohammed OJ, et al
SLC1A5 co-expression with TALDO1 associates with endocrine therapy failure in estrogen receptor-positive breast cancer.
Breast Cancer Res Treat. 2021 Jul 19. pii: 10.1007/s10549-021-06298.
PubMed Abstract available

BATENBURG MCT, Maarse W, van der Leij F, Baas IO, et al
The impact of hyperbaric oxygen therapy on late radiation toxicity and quality of life in breast cancer patients.
Breast Cancer Res Treat. 2021 Jul 19. pii: 10.1007/s10549-021-06332.
PubMed Abstract available

DENT R, Oliveira M, Isakoff SJ, Im SA, et al
Final results of the double-blind placebo-controlled randomized phase 2 LOTUS trial of first-line ipatasertib plus paclitaxel for inoperable locally advanced/metastatic triple-negative breast cancer.
Breast Cancer Res Treat. 2021 Jul 15. pii: 10.1007/s10549-021-06143.
PubMed Abstract available

BOTTY VAN DEN BRUELE A, Ferraro E, Sevilimedu V, Hogan MP, et al
Does preoperative MRI accurately stratify early-stage HER2 + breast cancer patients to upfront surgery vs neoadjuvant chemotherapy?
Breast Cancer Res Treat. 2021 Jul 14. pii: 10.1007/s10549-021-06331.
PubMed Abstract available

BEKELE BM, Luijendijk M, Schagen SB, de Ruiter M, et al
Fatigue and resting-state functional brain networks in breast cancer patients treated with chemotherapy.
Breast Cancer Res Treat. 2021 Jul 14. pii: 10.1007/s10549-021-06326.
PubMed Abstract available

WALBAUM B, Puschel K, Medina L, Merino T, et al
Screen-detected breast cancer is associated with better prognosis and survival compared to self-detected/symptomatic cases in a Chilean cohort of female patients.
Breast Cancer Res Treat. 2021 Jul 10. pii: 10.1007/s10549-021-06317.
PubMed Abstract available

YAN CH, Coleman C, Nabulsi NA, Chiu BC, et al
Associations between frailty and cancer-specific mortality among older women with breast cancer.
Breast Cancer Res Treat. 2021 Jul 9. pii: 10.1007/s10549-021-06323.
PubMed Abstract available

PARK J, Tacam MJ, Chauhan G, Cohen EN, et al
Nonphosphorylatable PEA15 mutant inhibits epithelial-mesenchymal transition in triple-negative breast cancer partly through the regulation of IL-8 expression.
Breast Cancer Res Treat. 2021 Jul 9. pii: 10.1007/s10549-021-06316.
PubMed Abstract available

COUGHLIN SS, Ayyala DN
Symptoms associated with comorbid diabetes among breast cancer survivors.
Breast Cancer Res Treat. 2021 Jul 9. pii: 10.1007/s10549-021-06324.
PubMed Abstract available

LIU X, Qiu R, Xu M, Meng M, et al
KMT2C is a potential biomarker of prognosis and chemotherapy sensitivity in breast cancer.
Breast Cancer Res Treat. 2021 Jul 8. pii: 10.1007/s10549-021-06325.
PubMed Abstract available

WALLNER LP, Abrahamse P, Gargaro JG, Radhakrishnan A, et al
Improving the delivery of team-based survivorship care after primary breast cancer treatment through a multi-level intervention: a pilot randomized controlled trial.
Breast Cancer Res Treat. 2021 Jul 7. pii: 10.1007/s10549-021-06257.
PubMed Abstract available

BURKS HE, Matossian MD, Rhodes LV, Phamduy T, et al
ZEB2 regulates endocrine therapy sensitivity and metastasis in luminal a breast cancer cells through a non-canonical mechanism.
Breast Cancer Res Treat. 2021 Jul 6. pii: 10.1007/s10549-021-06256.
PubMed Abstract available

KIM JY, Jeon E, Kwon S, Jung H, et al
Prediction of pathologic complete response to neoadjuvant chemotherapy using machine learning models in patients with breast cancer.
Breast Cancer Res Treat. 2021 Jul 5. pii: 10.1007/s10549-021-06310.
PubMed Abstract available

BENGTSSON Y, Sandsveden M, Borgquist S, Manjer J, et al
Serum zinc and dietary intake of zinc in relation to risk of different breast cancer subgroups and serum levels as a marker of intake: a prospective nested case-control study.
Breast Cancer Res Treat. 2021 Jul 5. pii: 10.1007/s10549-021-06318.
PubMed Abstract available

SHARMA U, Medina-Saenz K, Miller PC, Troness B, et al
Heterotypic clustering of circulating tumor cells and circulating cancer-associated fibroblasts facilitates breast cancer metastasis.
Breast Cancer Res Treat. 2021 Jul 3. pii: 10.1007/s10549-021-06299.
PubMed Abstract available

JACOBS DHM, Charaghvandi RK, Horeweg N, Maduro JH, et al
Health-related quality of life of early-stage breast cancer patients after different radiotherapy regimens.
Breast Cancer Res Treat. 2021 Jul 3. pii: 10.1007/s10549-021-06314.
PubMed Abstract available

POLLEY MC, Dickler MN, Sinnwell J, Tenner K, et al
A clinical calculator to predict disease outcomes in women with hormone receptor-positive advanced breast cancer treated with first-line endocrine therapy.
Breast Cancer Res Treat. 2021 Jul 3. pii: 10.1007/s10549-021-06319.
PubMed Abstract available

MCGUINNESS JE, Altoe ML, Marone A, Franks LE, et al
Diffuse optical tomography breast imaging measurements are modifiable with pre-surgical targeted and endocrine therapies among women with early stage breast cancer.
Breast Cancer Res Treat. 2021 Jul 2. pii: 10.1007/s10549-021-06320.
PubMed Abstract available

CASTELO M, Brown Z, D'Abbondanza JA, Wasilewski NV, et al
Psychological consequences of MRI-based screening among women with strong family histories of breast cancer.
Breast Cancer Res Treat. 2021 Jul 2. pii: 10.1007/s10549-021-06300.
PubMed Abstract available

KEARNEY MR, McGuinness JE, Kalinsky K
Clinical trial data and emerging immunotherapeutic strategies: hormone receptor-positive, HER2- negative breast cancer.
Breast Cancer Res Treat. 2021 Jul 2. pii: 10.1007/s10549-021-06291.
PubMed Abstract available

HASHIMOTO TAKIGAMI N, Kuniyoshi S, Miki Y, Tamaki K, et al
Breast Cancer, Diabetes Mellitus and Glucagon-Like Peptide-1 Receptor Toward Exploring Their Possible Associations.
Breast Cancer Res Treat. 2021 Jul 2. pii: 10.1007/s10549-021-06288.
PubMed Abstract available

MATOSSIAN MD, Elliott S, Van Hoang T, Burks HE, et al
NEK5 activity regulates the mesenchymal and migratory phenotype in breast cancer cells.
Breast Cancer Res Treat. 2021 Jul 1. pii: 10.1007/s10549-021-06295.
PubMed Abstract available

REN M, Orozco A, Shao K, Albanez A, et al
Germline variants in hereditary breast cancer genes are associated with early age at diagnosis and family history in Guatemalan breast cancer.
Breast Cancer Res Treat. 2021 Jul 1. pii: 10.1007/s10549-021-06305.
PubMed Abstract available

AL-KAWAZ A, Miligy IM, Toss MS, Mohammed OJ, et al
The prognostic significance of Flap Endonuclease 1 (FEN1) in breast ductal carcinoma in situ.
Breast Cancer Res Treat. 2021;188:53-63.
PubMed Abstract available

DEMPSEY N, Rosenthal A, Dabas N, Kropotova Y, et al
Trastuzumab-induced cardiotoxicity: a review of clinical risk factors, pharmacologic prevention, and cardiotoxicity of other HER2-directed therapies.
Breast Cancer Res Treat. 2021;188:21-36.
PubMed Abstract available

SUNDARESAN TK, Dubash TD, Zheng Z, Bardia A, et al
Evaluation of endocrine resistance using ESR1 genotyping of circulating tumor cells and plasma DNA.
Breast Cancer Res Treat. 2021;188:43-52.
PubMed Abstract available

BOYER JZ, Phillips GDL, Nitta H, Garsha K, et al
Activity of trastuzumab emtansine (T-DM1) in 3D cell culture.
Breast Cancer Res Treat. 2021;188:65-75.
PubMed Abstract available

AROLE V, Nitta H, Wei L, Shen T, et al
M2 tumor-associated macrophages play important role in predicting response to neoadjuvant chemotherapy in triple-negative breast carcinoma.
Breast Cancer Res Treat. 2021;188:37-42.
PubMed Abstract available

RAKOVITCH E, Parpia S, Koch A, Grimard L, et al
DUCHESS: an evaluation of the ductal carcinoma in situ score for decisions on radiotherapy in patients with low/intermediate-risk DCIS.
Breast Cancer Res Treat. 2021;188:133-139.
PubMed Abstract available

HABIBI M, Prasath V, Dembinski R, Sacks JM, et al
Comparison of mastectomy and breast reconstruction outcomes using low thermal dissection versus traditional electrocautery: a blinded randomized trial.
Breast Cancer Res Treat. 2021;188:101-106.
PubMed Abstract available

LERTWILAIWITTAYA P, Roothumnong E, Nakthong P, Dungort P, et al
Thai patients who fulfilled NCCN criteria for breast/ovarian cancer genetic assessment demonstrated high prevalence of germline mutations in cancer susceptibility genes: implication to Asian population testing.
Breast Cancer Res Treat. 2021;188:237-248.
PubMed Abstract available

MUNOZ-MONTANO WR, Cabrera-Galeana P, De la Garza-Ramos C, Azim HA Jr, et al
Prognosis of breast cancer diagnosed during pregnancy and early postpartum according to immunohistochemical subtype: A matched case-control study.
Breast Cancer Res Treat. 2021;188:489-500.
PubMed Abstract available

June 2021

LOPES CARDOZO JMN, Schmidt MK, van 't Veer LJ, Cardoso F, et al
Combining method of detection and 70-gene signature for enhanced prognostication of breast cancer.
Breast Cancer Res Treat. 2021 Jun 30. pii: 10.1007/s10549-021-06315.
PubMed Abstract available

ABUBAKAR M, Guo C, Koka H, Zhu B, et al
Impact of breast cancer risk factors on clinically relevant prognostic biomarkers for primary breast cancer.
Breast Cancer Res Treat. 2021 Jun 29. pii: 10.1007/s10549-021-06294.
PubMed Abstract available

JOHNSON JE, Strassle PD, de Oliveira GC, Agala CB, et al
Suboptimal therapy following breast conserving surgery in triple-negative and HER2-positive breast cancer patients.
Breast Cancer Res Treat. 2021 Jun 26. pii: 10.1007/s10549-021-06303.
PubMed Abstract available

FILIPE MD, Siesling S, Vriens MR, van Diest P, et al
The association of socioeconomic status on treatment strategy in patients with stage I and II breast cancer in the Netherlands.
Breast Cancer Res Treat. 2021 Jun 26. pii: 10.1007/s10549-021-06308.
PubMed Abstract available

ADEMUYIWA FO, Chen I, Luo J, Rimawi MF, et al
Immunogenomic profiling and pathological response results from a clinical trial of docetaxel and carboplatin in triple-negative breast cancer.
Breast Cancer Res Treat. 2021 Jun 26. pii: 10.1007/s10549-021-06307.
PubMed Abstract available

KEARNEY M, Franks L, Lee S, Tiersten A, et al
Phase I/II trial of ruxolitinib in combination with trastuzumab in metastatic HER2 positive breast cancer.
Breast Cancer Res Treat. 2021 Jun 24. pii: 10.1007/s10549-021-06306.
PubMed Abstract available

HAN X, Duan X, Liu Z, Long Y, et al
ZEB1 directly inhibits GPX4 transcription contributing to ROS accumulation in breast cancer cells.
Breast Cancer Res Treat. 2021 Jun 24. pii: 10.1007/s10549-021-06301.
PubMed Abstract available

BALIJA TM, Braz D, Hyman S, Montgomery LL, et al
Early reflector localization improves the accuracy of localization and excision of a previously positive axillary lymph node following neoadjuvant chemotherapy in patients with breast cancer.
Breast Cancer Res Treat. 2021 Jun 23. pii: 10.1007/s10549-021-06281.
PubMed Abstract available

COLE KM, Clemons M, Alzahrani M, Larocque G, et al
Developing patient-centred strategies to optimize the management of vasomotor symptoms in breast cancer patients: a survey of health care providers.
Breast Cancer Res Treat. 2021 Jun 22. pii: 10.1007/s10549-021-06186.
PubMed Abstract available

KO G, Hota S, Cil TD
COVID-19 vaccination and breast cancer surgery timing.
Breast Cancer Res Treat. 2021 Jun 22. pii: 10.1007/s10549-021-06293.
PubMed Abstract available

KIM H, Kim YJ, Park D, Park WY, et al
Dynamics of circulating tumor DNA during postoperative radiotherapy in patients with residual triple-negative breast cancer following neoadjuvant chemotherapy: a prospective observational study.
Breast Cancer Res Treat. 2021 Jun 21. pii: 10.1007/s10549-021-06296.
PubMed Abstract available

STEBBING J, Baranau YV, Baryash V, Manikhas A, et al
Long-term efficacy and safety of CT-P6 versus trastuzumab in patients with HER2-positive early breast cancer: final results from a randomized phase III trial.
Breast Cancer Res Treat. 2021 Jun 20. pii: 10.1007/s10549-021-06240.
PubMed Abstract available

REYNA C, Johnston ME, Morris MC, Lee TC, et al
National trends for axillary lymph node dissection and survival outcomes for clinical T3/T4 node-negative breast cancer patients undergoing mastectomy with positive lymph nodes.
Breast Cancer Res Treat. 2021 Jun 18. pii: 10.1007/s10549-021-06290.
PubMed Abstract available

LIVINGSTON-ROSANOFF D, Trentham-Dietz A, Hampton JM, Newcomb PA, et al
Does margin width impact breast cancer recurrence rates in women with breast conserving surgery for ductal carcinoma in situ?
Breast Cancer Res Treat. 2021 Jun 15. pii: 10.1007/s10549-021-06278.
PubMed Abstract available

PRIOR L, O'Dwyer R, Farooq AR, Greally M, et al
Pregnancy-associated breast cancer: evaluating maternal and foetal outcomes. A national study.
Breast Cancer Res Treat. 2021 Jun 14. pii: 10.1007/s10549-021-06263.
PubMed Abstract available

RUGO HS, Pennella EJ, Gopalakrishnan U, Hernandez-Bronchud M, et al
Final overall survival analysis of the phase 3 HERITAGE study demonstrates equivalence of trastuzumab-dkst to trastuzumab in HER2-positive metastatic breast cancer.
Breast Cancer Res Treat. 2021 Jun 14. pii: 10.1007/s10549-021-06197.
PubMed Abstract available

PUMPALOVA YS, Ayeni OA, Chen WC, O'Neil DS, et al
Impact of HIV infection on overall survival among women with stage IV breast cancer in South Africa.
Breast Cancer Res Treat. 2021 Jun 14. pii: 10.1007/s10549-021-06265.
PubMed Abstract available

SKARPING I, Fornvik D, Zackrisson S, Borgquist S, et al
Predicting pathological axillary lymph node status with ultrasound following neoadjuvant therapy for breast cancer.
Breast Cancer Res Treat. 2021 Jun 12. pii: 10.1007/s10549-021-06283.
PubMed Abstract available

ALMODALLAL Y, Le-Rademacher JG, Cook KD, Yadav S, et al
Observations with alpelisib in older patients (>/= 65 year of age) with breast cancer in a non-clinical trial setting.
Breast Cancer Res Treat. 2021 Jun 12. pii: 10.1007/s10549-021-06277.
PubMed Abstract available

MORIKAWA A, Grkovski M, Patil S, Jhaveri KL, et al
A phase I trial of sorafenib with whole brain radiotherapy (WBRT) in breast cancer patients with brain metastases and a correlative study of FLT-PET brain imaging.
Breast Cancer Res Treat. 2021 Jun 10. pii: 10.1007/s10549-021-06209.
PubMed Abstract available

DAMIN AP
Reply to the letter on sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with node-positive breast cancer.
Breast Cancer Res Treat. 2021 Jun 8. pii: 10.1007/s10549-021-06285.
PubMed

CAINI S, Fiorito G, Palli D, Bendinelli B, et al
Pre-diagnostic DNA methylation patterns differ according to mammographic breast density amongst women who subsequently develop breast cancer: a case-only study in the EPIC-Florence cohort.
Breast Cancer Res Treat. 2021 Jun 8. pii: 10.1007/s10549-021-06273.
PubMed Abstract available

NTELIOPOULOS G, Page K, Hills A, Howarth K, et al
Comparison of two targeted ultra-deep sequencing technologies for analysis of plasma circulating tumour DNA in endocrine-therapy-resistant breast cancer patients.
Breast Cancer Res Treat. 2021 Jun 7. pii: 10.1007/s10549-021-06220.
PubMed Abstract available

SZUHANY KL, Malgaroli M, Riley G, Miron CD, et al
Barriers and engagement in breast cancer survivorship wellness activities.
Breast Cancer Res Treat. 2021 Jun 7. pii: 10.1007/s10549-021-06279.
PubMed Abstract available

BROWN JC, Sarwer DB, Troxel AB, Sturgeon K, et al
A randomized trial of exercise and diet on body composition in survivors of breast cancer with overweight or obesity.
Breast Cancer Res Treat. 2021 Jun 5. pii: 10.1007/s10549-021-06284.
PubMed Abstract available

ORTEGA EXPOSITO C, Falo C, Pernas S, Perez Carton S, et al
The effect of omitting axillary dissection and the impact of radiotherapy on patients with breast cancer sentinel node macrometastases: a cohort study following the ACOSOG Z0011 and AMAROS trials.
Breast Cancer Res Treat. 2021 Jun 4. pii: 10.1007/s10549-021-06274.
PubMed Abstract available

LOPRESTI ML, Bian JJ, Sakr BJ, Strenger RS, et al
Neoadjuvant weekly paclitaxel and carboplatin with trastuzumab and pertuzumab in HER2-positive breast cancer: a Brown University Oncology Research Group (BrUOG) study.
Breast Cancer Res Treat. 2021 Jun 4. pii: 10.1007/s10549-021-06266.
PubMed Abstract available

DIFLORIO-ALEXANDER RM, Song Q, Dwan D, Austin-Strohbehn JA, et al
Fat-enlarged axillary lymph nodes are associated with node-positive breast cancer in obese patients.
Breast Cancer Res Treat. 2021 Jun 3. pii: 10.1007/s10549-021-06262.
PubMed Abstract available

HAGIWARA Y, Sawaki M, Uemura Y, Kawahara T, et al
Impact of chemotherapy on cognitive functioning in older patients with HER2-positive breast cancer: a sub-study in the RESPECT trial.
Breast Cancer Res Treat. 2021 Jun 2. pii: 10.1007/s10549-021-06253.
PubMed Abstract available

SAINI G, Gogineni K, Kittles RA, Aneja R, et al
Undercutting efforts of precision medicine: roadblocks to minority representation in breast cancer clinical trials.
Breast Cancer Res Treat. 2021 Jun 2. pii: 10.1007/s10549-021-06264.
PubMed Abstract available

SHAH AN, Carroll KJ, Gerratana L, Lin C, et al
Circulating tumor cells, circulating tumor DNA, and disease characteristics in young women with metastatic breast cancer.
Breast Cancer Res Treat. 2021;187:397-405.
PubMed Abstract available

MORENO G, Molina M, Wu R, Sullivan JR, et al
Unveiling the histopathologic spectrum of MRI-guided breast biopsies: an institutional pathological-radiological correlation.
Breast Cancer Res Treat. 2021;187:673-680.
PubMed Abstract available

FEGHHI M, Rezaie J, Mostafanezhad K, Jabbari N, et al
Bystander effects induced by electron beam-irradiated MCF-7 cells: a potential mechanism of therapy resistance.
Breast Cancer Res Treat. 2021;187:657-671.
PubMed Abstract available

SWARNKAR PK, Mokbel K
Patterns of invasive recurrence among patients originally treated for ductal carcinoma in situ by breast-conserving surgery versus mastectomy.
Breast Cancer Res Treat. 2021;187:919-920.
PubMed

GAO Y, Wu N, Wang S, Yang X, et al
Concurrent mutations associated with trastuzumab-resistance revealed by single cell sequencing.
Breast Cancer Res Treat. 2021;187:613-624.
PubMed Abstract available

AUSTIN-DATTA RJ, Smotherman CR, Yaghjyan L
Association between rice consumption and risk of cancer incidence in the California Teachers Study.
Breast Cancer Res Treat. 2021;187:917-918.
PubMed

TSANG JY, Lai ST, Ni YB, Shao Y, et al
SETD2 alterations and histone H3K36 trimethylation in phyllodes tumor of breast.
Breast Cancer Res Treat. 2021;187:339-347.
PubMed Abstract available

PATEL B, Merker L, Sahu A
Letter to the editor regarding: 'Impalpable breast lesion localisation, a logistical challenge: results of the UK iBRA-NET national practice questionnaire'.
Breast Cancer Res Treat. 2021;187:601-602.
PubMed

SALVIAT F, Charles C, Uzan C
Shall patients' anxiety influence surgical decisions for atypical breast lesions? A substudy of the prospective NOMAT trial.
Breast Cancer Res Treat. 2021;187:597-599.
PubMed

STOEN E, Kagihara J, Shagisultanova E, Fisher CM, et al
Real-world evidence from a University Hospital system regarding the uptake of adjuvant pertuzumab and/or neratinib before and after their FDA approval.
Breast Cancer Res Treat. 2021;187:883-891.
PubMed Abstract available

LO GULLO R, Vincenti K, Rossi Saccarelli C, Gibbs P, et al
Diagnostic value of radiomics and machine learning with dynamic contrast-enhanced magnetic resonance imaging for patients with atypical ductal hyperplasia in predicting malignant upgrade.
Breast Cancer Res Treat. 2021;187:535-545.
PubMed Abstract available

May 2021

BERNHARDT SM, Dasari P, Glynn DJ, Townsend AR, et al
Comparison of hormone-induced mRNA and protein biomarker expression changes in breast cancer cells.
Breast Cancer Res Treat. 2021 May 31. pii: 10.1007/s10549-021-06254.
PubMed Abstract available

DIBBLE KE, Baumgartner RN, Boone SD, Baumgartner KB, et al
Physical activity, ethnicity, and quality of life among breast cancer survivors and population-based controls: the long-term quality of life follow-up study.
Breast Cancer Res Treat. 2021 May 29. pii: 10.1007/s10549-021-06261.
PubMed Abstract available

TRAPANI D, Giugliano F, Uliano J, Zia VAA, et al
Benefit of adjuvant chemotherapy in patients with special histology subtypes of triple-negative breast cancer: a systematic review.
Breast Cancer Res Treat. 2021 May 27. pii: 10.1007/s10549-021-06259.
PubMed Abstract available

HARATI R, Mabondzo A, Tlili A, Khoder G, et al
Combinatorial targeting of microRNA-26b and microRNA-101 exerts a synergistic inhibition on cyclooxygenase-2 in brain metastatic triple-negative breast cancer cells.
Breast Cancer Res Treat. 2021 May 26. pii: 10.1007/s10549-021-06255.
PubMed Abstract available

MILLER MM, Meneveau MO, Rochman CM, Schroen AT, et al
Impact of the COVID-19 pandemic on breast cancer screening volumes and patient screening behaviors.
Breast Cancer Res Treat. 2021 May 25. pii: 10.1007/s10549-021-06252.
PubMed Abstract available

JOOSEN MEM, Schop SJ, Reinhoudt LL, van Kuijk SMJ, et al
The difference in local, regional and distant breast cancer recurrence between the immediate and delayed DIEP flap procedure; a retrospective cohort study.
Breast Cancer Res Treat. 2021 May 24. pii: 10.1007/s10549-021-06199.
PubMed Abstract available

DELRIEU L, Martin A, Touillaud M, Perol O, et al
Sarcopenia and serum biomarkers of oxidative stress after a 6-month physical activity intervention in women with metastatic breast cancer: results from the ABLE feasibility trial.
Breast Cancer Res Treat. 2021 May 19. pii: 10.1007/s10549-021-06238.
PubMed Abstract available

ZHOU Y, Xu Y, Wang C, Gong Y, et al
Serial circulating tumor DNA identification associated with the efficacy and prognosis of neoadjuvant chemotherapy in breast cancer.
Breast Cancer Res Treat. 2021 May 18. pii: 10.1007/s10549-021-06247.
PubMed Abstract available

EUSTACE AJ, Madden SF, Fay J, Collins DM, et al
The role of infiltrating lymphocytes in the neo-adjuvant treatment of women with HER2-positive breast cancer.
Breast Cancer Res Treat. 2021 May 13. pii: 10.1007/s10549-021-06244.
PubMed Abstract available

ARJMANDI F, Mootz A, Farr D, Reddy S, et al
New horizons in imaging and surgical assessment of breast cancer lymph node metastasis.
Breast Cancer Res Treat. 2021 May 12. pii: 10.1007/s10549-021-06248.
PubMed Abstract available

ZHU Q, Ademuyiwa FO, Young C, Appleton C, et al
Early Assessment Window for Predicting Breast Cancer Neoadjuvant Therapy using Biomarkers, Ultrasound, and Diffuse Optical Tomography.
Breast Cancer Res Treat. 2021 May 10. pii: 10.1007/s10549-021-06239.
PubMed Abstract available

CHUN JW, Kim J, Chung IIY, Ko BS, et al
Comparison of survival outcomes for axillary surgery extent based on intraoperative sentinel lymph node biopsy result after neoadjuvant chemotherapy for breast cancer.
Breast Cancer Res Treat. 2021 May 8. pii: 10.1007/s10549-021-06249.
PubMed Abstract available

WATANABE J, Mitsuya K, Nakamoto S, Harada H, et al
Leptomeningeal Metastasis in ER + HER2- Advanced Breast Cancer Patients: A Review of the Cases in a Single Institute Over a 15-year Period.
Breast Cancer Res Treat. 2021 May 8. pii: 10.1007/s10549-021-06246.
PubMed Abstract available

KUMAR S, Bal A, Das A, Loriya I, et al
Spectrum of PIK3CA/AKT mutations across molecular subtypes of triple-negative breast cancer.
Breast Cancer Res Treat. 2021 May 5. pii: 10.1007/s10549-021-06242.
PubMed Abstract available

SWARNKAR PK, Mokbel K
Sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with node-positive breast cancer: guiding a more selective axillary approach.
Breast Cancer Res Treat. 2021 May 5. pii: 10.1007/s10549-021-06222.
PubMed

TAN EH, Wong ALA, Tan CC, Wong P, et al
Facilitators and barriers to medication adherence with adjuvant endocrine therapy in women with breast cancer: a structural equation modelling approach.
Breast Cancer Res Treat. 2021 May 4. pii: 10.1007/s10549-021-06204.
PubMed Abstract available

GROEN EJ, van der Noordaa MEM, Schaapveld M, Sonke GS, et al
Pathologic response of ductal carcinoma in situ to neoadjuvant systemic treatment in HER2-positive breast cancer.
Breast Cancer Res Treat. 2021 May 4. pii: 10.1007/s10549-021-06235.
PubMed Abstract available

SILVA SN, Gomes BC, Andre S, Felix A, et al
Male and female breast cancer: the two faces of the same genetic susceptibility coin.
Breast Cancer Res Treat. 2021 May 3. pii: 10.1007/s10549-021-06159.
PubMed Abstract available

SIEGEL EL, Whiting J, Kim Y, Sun W, et al
Effect of surgical complications on outcomes in breast cancer patients treated with mastectomy and immediate reconstruction.
Breast Cancer Res Treat. 2021 May 3. pii: 10.1007/s10549-021-06241.
PubMed Abstract available

MCLEMORE LE, Albarracin CT, Gruschkus SK, Bassett RL Jr, et al
HER2 testing in breast cancers: comparison of assays and interpretation using ASCO/CAP 2013 and 2018 guidelines.
Breast Cancer Res Treat. 2021;187:95-104.
PubMed Abstract available

HUANG S, Houssami N, Brennan M, Nickel B, et al
The impact of mandatory mammographic breast density notification on supplemental screening practice in the United States: a systematic review.
Breast Cancer Res Treat. 2021;187:11-30.
PubMed Abstract available

DEL VALLE DD, Pardo JA, Maselli AM, Valero MG, et al
Evaluation of online Spanish and English health materials for preventive mastectomy. are we providing adequate information?
Breast Cancer Res Treat. 2021;187:1-9.
PubMed Abstract available

VAN DEN BRUELE AB, Chen I, Sevilimedu V, Le T, et al
Management of ipsilateral breast tumor recurrence following breast conservation surgery: a comparative study of re-conservation vs mastectomy.
Breast Cancer Res Treat. 2021;187:105-112.
PubMed Abstract available

ALANKO J, Tanner M, Vanninen R, Auvinen A, et al
Triple-negative and HER2-positive breast cancers found by mammography screening show excellent prognosis.
Breast Cancer Res Treat. 2021;187:267-274.
PubMed Abstract available

THEBERGE I, Vandal N, Perron L, Guertin MH, et al
Association between radiologists' and facilities' characteristics and mammography screening detection of ductal carcinoma in situ.
Breast Cancer Res Treat. 2021;187:255-266.
PubMed Abstract available

BYNG D, Retel VP, Schaapveld M, Wesseling J, et al
Treating (low-risk) DCIS patients: What can we learn from real-world cancer registry evidence?
Breast Cancer Res Treat. 2021;187:187-196.
PubMed Abstract available

LUITEN JD, Luiten EJT, van der Sangen MJC, Vreuls W, et al
Patterns of treatment and outcome of ductal carcinoma in situ in the Netherlands.
Breast Cancer Res Treat. 2021;187:245-254.
PubMed Abstract available

April 2021

VIDULA N, Yau C, Rugo HS
Programmed cell death 1 (PD-1) receptor and programmed death ligand 1 (PD-L1) gene expression in primary breast cancer.
Breast Cancer Res Treat. 2021 Apr 28. pii: 10.1007/s10549-021-06234.
PubMed Abstract available

MOY B, Oliveira M, Saura C, Gradishar W, et al
Neratinib + capecitabine sustains health-related quality of life in patients with HER2-positive metastatic breast cancer and >/= 2 prior HER2-directed regimens.
Breast Cancer Res Treat. 2021 Apr 28. pii: 10.1007/s10549-021-06217.
PubMed Abstract available

KAZMI S, Chatterjee D, Raju D, Hauser R, et al
Correction to: Overall survival analysis in patients with metastatic breast cancer and liver or lung metastases treated with eribulin, gemcitabine, or capecitabine.
Breast Cancer Res Treat. 2021 Apr 27. pii: 10.1007/s10549-021-06223.
PubMed

LEONARDI MC, Scognamiglio IR, Maisonneuve P, Dicuonzo S, et al
Mastectomy alone for pT1-2 pN0-1 breast cancer patients: when postmastectomy radiotherapy is indicated.
Breast Cancer Res Treat. 2021 Apr 27. pii: 10.1007/s10549-021-06227.
PubMed Abstract available

WANG Z, Liu J, Ma F, Wang J, et al
Safety and efficacy study of oral metronomic vinorelbine combined with trastuzumab (mNH) in HER2-positive metastatic breast cancer: a phase II trial.
Breast Cancer Res Treat. 2021 Apr 25. pii: 10.1007/s10549-021-06216.
PubMed Abstract available

GRUSLOVA A, McClellan B, Balinda HU, Viswanadhapalli S, et al
FASN inhibition as a potential treatment for endocrine-resistant breast cancer.
Breast Cancer Res Treat. 2021 Apr 24. pii: 10.1007/s10549-021-06231.
PubMed Abstract available

BHARDWAJ A, Embury MD, Rojo RD, Albarracin C, et al
Efficacy of fluvastatin and aspirin for prevention of hormonally insensitive breast cancer.
Breast Cancer Res Treat. 2021 Apr 24. pii: 10.1007/s10549-021-06229.
PubMed Abstract available

LEONE JP, Vallejo CT, Hassett MJ, Leone J, et al
Factors associated with late risks of breast cancer-specific mortality in the SEER registry.
Breast Cancer Res Treat. 2021 Apr 24. pii: 10.1007/s10549-021-06233.
PubMed Abstract available

KOH M, Jung J, Kim SS, Do Ahn S, et al
Prognostic value of the 21-gene recurrence score for regional recurrence in patients with estrogen receptor-positive breast cancer.
Breast Cancer Res Treat. 2021 Apr 23. pii: 10.1007/s10549-021-06228.
PubMed Abstract available

STROJNIK K, Krajc M, Dragos VS, Stegel V, et al
Genetic testing results in Slovenian male breast cancer cohort indicate the BRCA2 7806-2A > G founder variant could be associated with higher male breast cancer risk.
Breast Cancer Res Treat. 2021 Apr 23. pii: 10.1007/s10549-021-06224.
PubMed Abstract available

VERON L, Wehrer D, Annerose-Zephir G, Suciu V, et al
Effects of local laser treatment on vulvovaginal atrophy among women with breast cancer: a prospective study with long-term follow-up.
Breast Cancer Res Treat. 2021 Apr 23. pii: 10.1007/s10549-021-06226.
PubMed Abstract available

LEPROUX C, Seegers V, Patsouris A, Sauterey B, et al
Success and risks of pregnancy after breast cancer.
Breast Cancer Res Treat. 2021 Apr 21. pii: 10.1007/s10549-021-06232.
PubMed Abstract available

CHEN M, Zhao Y, Yang X, Zhao Y, et al
NSDHL promotes triple-negative breast cancer metastasis through the TGFbeta signaling pathway and cholesterol biosynthesis.
Breast Cancer Res Treat. 2021 Apr 16. pii: 10.1007/s10549-021-06213.
PubMed Abstract available

HUANG CS, Yang Y, Kwong A, Chen SC, et al
Trastuzumab emtansine (T-DM1) versus trastuzumab in Chinese patients with residual invasive disease after neoadjuvant chemotherapy and HER2-targeted therapy for HER2-positive breast cancer in the phase 3 KATHERINE study.
Breast Cancer Res Treat. 2021 Apr 15. pii: 10.1007/s10549-021-06166.
PubMed Abstract available

KOCA E, Niravath PA, Ensor J, Patel TA, et al
ANETT: PhAse II trial of NEoadjuvant TAK-228 plus Tamoxifen in patients with hormone receptor-positive breast cancer.
Breast Cancer Res Treat. 2021 Apr 15. pii: 10.1007/s10549-021-06214.
PubMed Abstract available

HEQUET D, Harrissart G, Krief D, Maumy L, et al
Prosigna test in breast cancer: real-life experience.
Breast Cancer Res Treat. 2021 Apr 15. pii: 10.1007/s10549-021-06191.
PubMed Abstract available

SALEH B, Elhawary MA, Mohamed ME, Ali IN, et al
Gail model utilization in predicting breast cancer risk in Egyptian women: a cross-sectional study.
Breast Cancer Res Treat. 2021 Apr 14. pii: 10.1007/s10549-021-06200.
PubMed Abstract available

HADDAD TC, He J, O'Sullivan CC, Chen B, et al
Randomized Phase II Trial of Capecitabine and Lapatinib with or without IMC-A12 (Cituxumumab) in Patients with HER2-Positive Advanced Breast Cancer Previously Treated with Trastuzumab and Chemotherapy: NCCTG N0733 (Alliance).
Breast Cancer Res Treat. 2021 Apr 14. pii: 10.1007/s10549-021-06221.
PubMed Abstract available

PAI T, Cornell L, Seneviratne D, Niazi S, et al
Pre-diagnosis major life stressors and breast cancer outcomes.
Breast Cancer Res Treat. 2021 Apr 12. pii: 10.1007/s10549-021-06218.
PubMed Abstract available

HOPSON MB, Lee S, Accordino M, Trivedi M, et al
Phase II study of propranolol feasibility with neoadjuvant chemotherapy in patients with newly diagnosed breast cancer.
Breast Cancer Res Treat. 2021 Apr 10. pii: 10.1007/s10549-021-06210.
PubMed Abstract available

KEELAN S, Heeney A, Downey E, Hegarty A, et al
Breast cancer patients with a negative axillary ultrasound may have clinically significant nodal metastasis.
Breast Cancer Res Treat. 2021 Apr 10. pii: 10.1007/s10549-021-06194.
PubMed Abstract available

KRISTENSEN KB, Thomsen IMN, Berg T, Kodahl AR, et al
Dose modifications of ribociclib and endocrine therapy for treatment of ER+ HER2- metastatic breast cancer.
Breast Cancer Res Treat. 2021 Apr 10. pii: 10.1007/s10549-021-06215.
PubMed Abstract available

MCSORLEY LM, Tharmabala M, Al Rahbi F, McSorley K, et al
Real-world analysis of clinical and economic impact of 21-gene recurrence score (RS) testing in early-stage breast cancer (ESBC) in Ireland.
Breast Cancer Res Treat. 2021 Apr 9. pii: 10.1007/s10549-021-06211.
PubMed Abstract available

JOHNSON AE, Coopey SB, Spring LM, Horick NK, et al
Management and outcomes of men diagnosed with primary breast cancer.
Breast Cancer Res Treat. 2021 Apr 8. pii: 10.1007/s10549-021-06174.
PubMed Abstract available

TURBOW SD, White MC, Breslau ES, Sabatino SA, et al
Correction to: Mammography use and breast cancer incidence among older U.S. women.
Breast Cancer Res Treat. 2021 Apr 5. pii: 10.1007/s10549-021-06212.
PubMed

BATTISTI NML, Andres MS, Lee KA, Ramalingam S, et al
Incidence of cardiotoxicity and validation of the Heart Failure Association-International Cardio-Oncology Society risk stratification tool in patients treated with trastuzumab for HER2-positive early breast cancer.
Breast Cancer Res Treat. 2021 Apr 5. pii: 10.1007/s10549-021-06192.
PubMed Abstract available

CHETRIT A, Ben-Avraham S, Mandelzweig L, Amitai T, et al
Breast cancer survivors: physical and mental quality of life 10 years following diagnosis, a case-control study.
Breast Cancer Res Treat. 2021 Apr 5. pii: 10.1007/s10549-021-06156.
PubMed Abstract available

SUTTON AL, Felix AS, Bandyopadhyay D, Retnam R, et al
Cardioprotective medication use in Black and white breast cancer survivors.
Breast Cancer Res Treat. 2021 Apr 2. pii: 10.1007/s10549-021-06202.
PubMed Abstract available

CHALASANI P, Farr K, Wu V, Jenkins I, et al
Single arm, phase two study of low-dose metronomic eribulin in metastatic breast cancer.
Breast Cancer Res Treat. 2021 Apr 2. pii: 10.1007/s10549-021-06175.
PubMed Abstract available

PAWLOSKI KR, Tadros AB, Sevilimedu V, Newman A, et al
Patterns of invasive recurrence among patients originally treated for ductal carcinoma in situ by breast-conserving surgery versus mastectomy.
Breast Cancer Res Treat. 2021;186:617-624.
PubMed Abstract available

KOJIMAHARA T, Kageyama T
Octopus anastomosis: selection of anastomotic configuration in lymphaticovenular anastomosis according to vessels' conditions.
Breast Cancer Res Treat. 2021;186:887-888.
PubMed

LANCETA L, Lypova N, O'Neill C, Li X, et al
Differential gene expression analysis of palbociclib-resistant TNBC via RNA-seq.
Breast Cancer Res Treat. 2021;186:677-686.
PubMed Abstract available

JIAGGE EM, Ulintz PJ, Wong S, McDermott SP, et al
Multiethnic PDX models predict a possible immune signature associated with TNBC of African ancestry.
Breast Cancer Res Treat. 2021;186:391-401.
PubMed Abstract available

PARKES A, Wang WL, Patel S, Leung CH, et al
Outcomes of systemic therapy in metastatic phyllodes tumor of the breast.
Breast Cancer Res Treat. 2021;186:871-882.
PubMed Abstract available

GRILL S, Yahiaoui-Doktor M, Basrai M, Struck J, et al
Precursor fractions of neurotensin and enkephalin might point to molecular mechanisms of cancer risk modulation during a lifestyle-intervention in germline BRCA1/2 gene mutation carriers.
Breast Cancer Res Treat. 2021;186:741-752.
PubMed Abstract available

YANG L, Roy M, Lin H, Shen Y, et al
Validation of prognostic significance of the proposed uniform classification framework in neuroendocrine neoplasms of the breast.
Breast Cancer Res Treat. 2021;186:403-415.
PubMed Abstract available

ZHI WI, Baser RE, Kwon A, Chen C, et al
Characterization of chemotherapy-induced peripheral neuropathy using patient-reported outcomes and quantitative sensory testing.
Breast Cancer Res Treat. 2021;186:761-768.
PubMed Abstract available

ALDOSARY G, Caudrelier JM, Arnaout A, Chang L, et al
Can we rely on surgical clips placed during oncoplastic breast surgery to accurately delineate the tumor bed for targeted breast radiotherapy?
Breast Cancer Res Treat. 2021;186:343-352.
PubMed Abstract available

FILIPE MD, Patuleia SIS, Vriens MR, van Diest PJ, et al
Meta-analysis and cost-effectiveness of ductoscopy, duct excision surgery and MRI for the diagnosis and treatment of patients with pathological nipple discharge.
Breast Cancer Res Treat. 2021;186:285-293.
PubMed Abstract available

GUI G, Panopoulou E, Tang S, Twelves D, et al
The INTEND 1 randomized controlled trial of duct endoscopy as an indicator of margin excision in breast conservation surgery.
Breast Cancer Res Treat. 2021;186:723-730.
PubMed Abstract available

HUANG CS, Lu TP, Liu CY, Huang CJ, et al
Residual risk stratification of Taiwanese breast cancers following curative therapies with the extended concurrent genes signature.
Breast Cancer Res Treat. 2021;186:475-485.
PubMed Abstract available

HA SM, Chang JM, Kim SY, Lee SH, et al
Prediction of axillary nodal burden in patients with invasive lobular carcinoma using MRI.
Breast Cancer Res Treat. 2021;186:463-473.
PubMed Abstract available

KELLY BN, Kantor O, Tang R, Coopey SB, et al
Similar rates of residual disease in patients with DCIS within 2 mm of lumpectomy margin regardless of the presence of invasive carcinoma.
Breast Cancer Res Treat. 2021;186:807-814.
PubMed Abstract available

HALASZ SR, O'Keefe T, Wallace AM, Blair SL, et al
Ductal carcinoma in situ in patients younger than 30 years: differences in adjuvant endocrine therapy and outcomes.
Breast Cancer Res Treat. 2021;186:551-559.
PubMed Abstract available

March 2021

HELBRICH H, Braun M, Hanusch C, Mueller G, et al
Congruence and trajectories of device-measured and self-reported physical activity during therapy for early breast cancer.
Breast Cancer Res Treat. 2021 Mar 31. pii: 10.1007/s10549-021-06195.
PubMed Abstract available

WANG YQ, Huang G, Chen J, Cao H, et al
LncRNA SNHG6 promotes breast cancer progression and epithelial-mesenchymal transition via miR-543/LAMC1 axis.
Breast Cancer Res Treat. 2021 Mar 29. pii: 10.1007/s10549-021-06190.
PubMed Abstract available

NISHIKAWA S, Uemoto Y, Kim TS, Hisada T, et al
Low RAI2 expression is a marker of poor prognosis in breast cancer.
Breast Cancer Res Treat. 2021 Mar 29. pii: 10.1007/s10549-021-06176.
PubMed Abstract available

AN KY, Arthuso FZ, Kang DW, Morielli AR, et al
Exercise and health-related fitness predictors of chemotherapy completion in breast cancer patients: pooled analysis of two multicenter trials.
Breast Cancer Res Treat. 2021 Mar 29. pii: 10.1007/s10549-021-06205.
PubMed Abstract available

REINHORN D, Kuchuk I, Shochat T, Nisenbaum B, et al
Taxane versus vinorelbine in combination with trastuzumab and pertuzumab for first-line treatment of metastatic HER2-positive breast cancer: a retrospective two-center study.
Breast Cancer Res Treat. 2021 Mar 27. pii: 10.1007/s10549-021-06198.
PubMed Abstract available

LEONE J, Freedman RA, Lin NU, Tolaney SM, et al
Tumor subtypes and survival in male breast cancer.
Breast Cancer Res Treat. 2021 Mar 26. pii: 10.1007/s10549-021-06182.
PubMed Abstract available

AHN SG, Kim SK, Shepherd JH, Cha YJ, et al
Clinical and genomic assessment of PD-L1 SP142 expression in triple-negative breast cancer.
Breast Cancer Res Treat. 2021 Mar 26. pii: 10.1007/s10549-021-06193.
PubMed Abstract available

OPPONG BA, Obeng-Gyasi S, Relation T, Adams-Campbell L, et al
Call to action: breast cancer screening recommendations for Black women.
Breast Cancer Res Treat. 2021 Mar 26. pii: 10.1007/s10549-021-06207.
PubMed Abstract available

CHEN I, Botty Van den Bruele AM, Gillespie EF, Mueller BA, et al
Salvage of locally recurrent breast cancer with repeat breast conservation using 45 Gy hyperfractionated partial breast re-irradiation.
Breast Cancer Res Treat. 2021 Mar 26. pii: 10.1007/s10549-021-06206.
PubMed Abstract available

HO PJ, Dorajoo R, Ivankovic I, Ong SS, et al
DNA methylation and breast cancer-associated variants.
Breast Cancer Res Treat. 2021 Mar 26. pii: 10.1007/s10549-021-06185.
PubMed Abstract available

MASUDA N, Bando H, Yamanaka T, Kadoya T, et al
Eribulin-based neoadjuvant chemotherapy for triple-negative breast cancer patients stratified by homologous recombination deficiency status: a multicenter randomized phase II clinical trial.
Breast Cancer Res Treat. 2021 Mar 25. pii: 10.1007/s10549-021-06184.
PubMed Abstract available

WANG C, Tong F, Cao Y, Liu P, et al
Long-term follow-up results of fluorescence and blue dye guided sentinel lymph node biopsy in early breast cancer.
Breast Cancer Res Treat. 2021 Mar 24. pii: 10.1007/s10549-021-06196.
PubMed Abstract available

MCGEE S, Alzahrani M, Vandermeer L, Cole K, et al
Adjuvant bisphosphonate use in patients with early stage breast cancer: a physician survey.
Breast Cancer Res Treat. 2021 Mar 23. pii: 10.1007/s10549-021-06147.
PubMed Abstract available

THOMAS S, Kabir M, Butcher BE, Chou S, et al
Interobserver concordance in visual assessment of Ki67 immunohistochemistry in surgical excision specimens from patients with lymph node-negative breast cancer.
Breast Cancer Res Treat. 2021 Mar 22. pii: 10.1007/s10549-021-06188.
PubMed Abstract available

BUCKLEY E, Elder E, McGill S, Kargar ZS, et al
Breast cancer treatment and survival differences in women in remote and socioeconomically disadvantaged areas, as demonstrated by linked data from New South Wales (NSW), Australia.
Breast Cancer Res Treat. 2021 Mar 21. pii: 10.1007/s10549-021-06170.
PubMed Abstract available

KUEMMEL S, Tondini CA, Abraham J, Nowecki Z, et al
Subcutaneous trastuzumab with pertuzumab and docetaxel in HER2-positive metastatic breast cancer: Final analysis of MetaPHER, a phase IIIb single-arm safety study.
Breast Cancer Res Treat. 2021 Mar 21. pii: 10.1007/s10549-021-06145.
PubMed Abstract available

IBRAGIMOVA KIE, Geurts SME, Croes S, Erdkamp F, et al
Survival before and after the introduction of pertuzumab and T-DM1 in HER2-positive advanced breast cancer, a study of the SONABRE Registry.
Breast Cancer Res Treat. 2021 Mar 20. pii: 10.1007/s10549-021-06178.
PubMed Abstract available

GHARZAI LA, Szczygiel LA, Shumway DA, Bandos H, et al
A qualitative study to evaluate physician attitudes regarding omission of surgery among exceptional responders to neoadjuvant systemic therapy for breast cancer (NRG-CC006).
Breast Cancer Res Treat. 2021 Mar 19. pii: 10.1007/s10549-021-06172.
PubMed Abstract available

WU ZY, Han HH, Kim HJ, Lee JW, et al
A propensity score-matched comparison of recurrence outcomes after immediate implant vs autologous flap reconstruction in patients receiving neoadjuvant chemotherapy for breast cancer.
Breast Cancer Res Treat. 2021 Mar 19. pii: 10.1007/s10549-021-06114.
PubMed Abstract available

SHEEAN P, Matthews L, Visotcky A, Banerjee A, et al
Every Day Counts: a randomized pilot lifestyle intervention for women with metastatic breast cancer.
Breast Cancer Res Treat. 2021 Mar 19. pii: 10.1007/s10549-021-06163.
PubMed Abstract available

LLOYD KE, Hall LH, Ziegler L, Smith SG, et al
Breast cancer worry in higher-risk women offered preventive therapy: a UK multicentre prospective study.
Breast Cancer Res Treat. 2021 Mar 17. pii: 10.1007/s10549-021-06183.
PubMed Abstract available

TOKUDA Y, Yanagawa M, Fujita Y, Honma K, et al
Prediction of pathological complete response after neoadjuvant chemotherapy in breast cancer: comparison of diagnostic performances of dedicated breast PET, whole-body PET, and dynamic contrast-enhanced MRI.
Breast Cancer Res Treat. 2021 Mar 17. pii: 10.1007/s10549-021-06179.
PubMed Abstract available

IM YH, Karabulut B, Lee KS, Park BW, et al
Safety and efficacy of everolimus (EVE) plus exemestane (EXE) in postmenopausal women with locally advanced or metastatic breast cancer: final results from EVEREXES.
Breast Cancer Res Treat. 2021 Mar 16. pii: 10.1007/s10549-021-06173.
PubMed Abstract available

SURETTE A, Yoo BH, Younis T, Matheson K, et al
Tumor levels of the mediators of ErbB2-driven anoikis resistance correlate with breast cancer relapse in patients receiving trastuzumab-based therapies.
Breast Cancer Res Treat. 2021 Mar 16. pii: 10.1007/s10549-021-06164.
PubMed Abstract available

HETTERICH M, Gerken M, Ortmann O, Inwald EC, et al
Adjuvant chemotherapy for breast cancer patients with axillary lymph node micrometastases.
Breast Cancer Res Treat. 2021 Mar 15. pii: 10.1007/s10549-021-06162.
PubMed Abstract available

WALSTRA CJEF, Schipper RJ, van Riet YE, van der Toorn PG, et al
Repeat breast-conserving treatment of ipsilateral breast cancer recurrence: a nationwide survey amongst breast surgeons and radiation oncologists in the Netherlands.
Breast Cancer Res Treat. 2021 Mar 13. pii: 10.1007/s10549-021-06154.
PubMed Abstract available

FALTINOVA M, Vehmanen L, Lyytinen H, Haanpaa M, et al
Monitoring serum estradiol levels in breast cancer patients during extended adjuvant letrozole treatment after five years of tamoxifen: a prospective trial.
Breast Cancer Res Treat. 2021 Mar 12. pii: 10.1007/s10549-021-06168.
PubMed Abstract available

LI XM, Chen HL
RE: Predictors of increased risk for early treatment non-adherence to oral anti-estrogen therapies in early stage breast cancer patients.
Breast Cancer Res Treat. 2021 Mar 11. pii: 10.1007/s10549-021-06146.
PubMed

FEI F, Siegal GP, Wei S
Characterization of estrogen receptor-low-positive breast cancer.
Breast Cancer Res Treat. 2021 Mar 10. pii: 10.1007/s10549-021-06148.
PubMed Abstract available

MOOSSDORFF M, Vane MLG, van Nijnatten TJA, van Maaren MC, et al
Conditional local recurrence risk: the effect of event-free years in different subtypes of breast cancer.
Breast Cancer Res Treat. 2021 Mar 10. pii: 10.1007/s10549-020-06040.
PubMed Abstract available

DANKWA-MULLAN I, George J, Roebuck MC, Tkacz J, et al
Variations in breast cancer surgical treatment and timing: determinants and disparities.
Breast Cancer Res Treat. 2021 Mar 10. pii: 10.1007/s10549-021-06155.
PubMed Abstract available

PRADA D, Baccarelli AA, Terry MB, Valdez L, et al
Long-term PM2.5 exposure before diagnosis is associated with worse outcome in breast cancer.
Breast Cancer Res Treat. 2021 Mar 8. pii: 10.1007/s10549-021-06167.
PubMed Abstract available

CHAWLA S, Hill A, Fearfield L, Johnston S, et al
Cutaneous toxicities occurring during palbociclib (CDK4/6 inhibitor) and endocrine therapy in patients with advanced breast cancer: a single-centre experience.
Breast Cancer Res Treat. 2021 Mar 8. pii: 10.1007/s10549-021-06169.
PubMed Abstract available

LUO J, Kroenke CH, Hendryx M, Shadyab AH, et al
Mediation analysis of racial disparities in triple-negative breast cancer incidence among postmenopausal women.
Breast Cancer Res Treat. 2021 Mar 7. pii: 10.1007/s10549-021-06158.
PubMed Abstract available

FALCONE M, Liu L, Farias A, Zhang J, et al
Evidence for racial/ethnic disparities in emergency department visits following breast cancer surgery among women in California: a population-based study.
Breast Cancer Res Treat. 2021 Mar 6. pii: 10.1007/s10549-021-06119.
PubMed Abstract available

NGUYEN T, Irwin ML, Dewan AT, Cartmel B, et al
Examining the effect of obesity-associated gene variants on breast cancer survivors in a randomized weight loss intervention.
Breast Cancer Res Treat. 2021 Mar 6. pii: 10.1007/s10549-021-06151.
PubMed Abstract available

TURBOW SD, White MC, Breslau ES, Sabatino SA, et al
Mammography use and breast cancer incidence among older U.S. women.
Breast Cancer Res Treat. 2021 Mar 5. pii: 10.1007/s10549-021-06160.
PubMed Abstract available

ZDRAVKOVIC D, Petricevic S, Toskovic B
Influence of different response after neoadjuvant chemotherapy on time of surgery in breast cancer patients.
Breast Cancer Res Treat. 2021 Mar 4. pii: 10.1007/s10549-021-06161.
PubMed

STRELL C, Stenmark Tullberg A, Jetne Edelmann R, Akslen LA, et al
Prognostic and predictive impact of stroma cells defined by PDGFRb expression in early breast cancer: results from the randomized SweBCG91RT trial.
Breast Cancer Res Treat. 2021 Mar 4. pii: 10.1007/s10549-021-06136.
PubMed Abstract available

SMITH SG, Sestak I, Morris MA, Harvie M, et al
The impact of body mass index on breast cancer incidence among women at increased risk: an observational study from the International Breast Intervention Studies.
Breast Cancer Res Treat. 2021 Mar 3. pii: 10.1007/s10549-021-06141.
PubMed Abstract available

PARK KU, Gregory M, Bazan J, Lustberg M, et al
Neoadjuvant endocrine therapy use in early stage breast cancer during the covid-19 pandemic.
Breast Cancer Res Treat. 2021 Mar 2. pii: 10.1007/s10549-021-06153.
PubMed Abstract available

O'SHAUGHNESSY J, Robert N, Annavarapu S, Zhou J, et al
Recurrence rates in patients with HER2+ breast cancer who achieved a pathological complete response after neoadjuvant pertuzumab plus trastuzumab followed by adjuvant trastuzumab: a real-world evidence study.
Breast Cancer Res Treat. 2021 Mar 1. pii: 10.1007/s10549-021-06137.
PubMed Abstract available

IACUZZO C, Giudici F, Scomersi S, Ceccherini R, et al
Direct comparison of three different mathematical models in two independent datasets of EUSOMA certified centers to predict recurrence and survival in estrogen receptor-positive breast cancer: impact on clinical practice.
Breast Cancer Res Treat. 2021 Mar 1. pii: 10.1007/s10549-021-06144.
PubMed Abstract available

February 2021

KAUFMAN PA, Hurvitz SA, O'Shaughnessy J, Mason G, et al
Baseline characteristics and first-line treatment patterns in patients with HER2-positive metastatic breast cancer in the SystHERs registry.
Breast Cancer Res Treat. 2021 Feb 28. pii: 10.1007/s10549-021-06103.
PubMed Abstract available

SUELMANN BBM, van Dooijeweert C, van der Wall E, Linn S, et al
Pregnancy-associated breast cancer: nationwide Dutch study confirms a discriminatory aggressive histopathologic profile.
Breast Cancer Res Treat. 2021 Feb 26. pii: 10.1007/s10549-021-06130.
PubMed Abstract available

TARANTINO P, Curigliano G
Activity of novel anti-HER2 agents for breast cancer based on hormone receptors expression.
Breast Cancer Res Treat. 2021 Feb 25. pii: 10.1007/s10549-021-06150.
PubMed

LIU J, Li Y, Li Q, Liang D, et al
Biomarkers of response to camrelizumab combined with apatinib: an analysis from a phase II trial in advanced triple-negative breast cancer patients.
Breast Cancer Res Treat. 2021 Feb 25. pii: 10.1007/s10549-021-06128.
PubMed Abstract available

WANG YF, Wang XJ, Lu Z, Liu SR, et al
Overexpression of Stat3 increases circulating cfDNA in breast cancer.
Breast Cancer Res Treat. 2021 Feb 25. pii: 10.1007/s10549-021-06142.
PubMed Abstract available

WARE AW, Harris JJ, Slatter TL, Cunliffe HE, et al
The epithelial sodium channel has a role in breast cancer cell proliferation.
Breast Cancer Res Treat. 2021 Feb 25. pii: 10.1007/s10549-021-06133.
PubMed Abstract available

BRUNELLE CL, Barrio AV, Taghian AG
Letter to editor re: Shah et al.: "The impact of monitoring techniques on progression to chronic breast cancer-related lymphedema: a meta-analysis comparing bioimpedance spectroscopy versus circumferential measurements".
Breast Cancer Res Treat. 2021 Feb 25. pii: 10.1007/s10549-021-06139.
PubMed

CHANDRIKA M, Chua PJ, Muniasamy U, Huang RYJ, et al
Prognostic significance of phosphoglycerate dehydrogenase in breast cancer.
Breast Cancer Res Treat. 2021 Feb 24. pii: 10.1007/s10549-021-06123.
PubMed Abstract available

PRUITT SL, Zhu H, Heitjan DF, Rahimi A, et al
Survival of women diagnosed with breast cancer and who have survived a previous cancer.
Breast Cancer Res Treat. 2021 Feb 23. pii: 10.1007/s10549-021-06122.
PubMed Abstract available

VALLA M, Opdahl S, Ytterhus B, Bofin AM, et al
DTX3 copy number increase in breast cancer: a study of associations to molecular subtype, proliferation and prognosis.
Breast Cancer Res Treat. 2021 Feb 22. pii: 10.1007/s10549-021-06138.
PubMed Abstract available

TANG M, Schaffer AL, Kiely BE, Daniels B, et al
Cardiac assessment in Australian patients receiving (neo)adjuvant trastuzumab for HER2-positive early breast cancer: a population-based study.
Breast Cancer Res Treat. 2021 Feb 22. pii: 10.1007/s10549-021-06135.
PubMed Abstract available

GUHA R, Yue B, Dong J, Banerjee A, et al
Anti-progranulin/GP88 antibody AG01 inhibits triple negative breast cancer cell proliferation and migration.
Breast Cancer Res Treat. 2021 Feb 22. pii: 10.1007/s10549-021-06120.
PubMed Abstract available

DUARTE C, Salazar A, Strasser-Weippl K, de Vries E, et al
Breast cancer in Colombia: a growing challenge for the healthcare system.
Breast Cancer Res Treat. 2021 Feb 21. pii: 10.1007/s10549-020-06091.
PubMed Abstract available

MAN V, Kwong A
Different strategies in marking axillary lymph nodes in breast cancer patients undergoing neoadjuvant medical treatment: a systematic review.
Breast Cancer Res Treat. 2021 Feb 21. pii: 10.1007/s10549-021-06118.
PubMed Abstract available

LANAHAN CR, Kelly BN, Gadd MA, Specht MC, et al
Performance of a novel protease-activated fluorescent imaging system for intraoperative detection of residual breast cancer during breast conserving surgery.
Breast Cancer Res Treat. 2021 Feb 21. pii: 10.1007/s10549-021-06106.
PubMed Abstract available

TESCH ME, Chia SK, Simmons CE, LeVasseur N, et al
Impact of sequence order of anthracyclines and taxanes in neoadjuvant chemotherapy on pathologic complete response rate in HER2-negative breast cancer patients.
Breast Cancer Res Treat. 2021 Feb 20. pii: 10.1007/s10549-021-06110.
PubMed Abstract available

JOHNSON HM, Irish W, Vohra NA, Wong JH, et al
Refining breast cancer prognosis by incorporating age at diagnosis into clinical prognostic staging: introduction of a novel online calculator.
Breast Cancer Res Treat. 2021 Feb 20. pii: 10.1007/s10549-021-06113.
PubMed Abstract available

RITTER M, Ling BM, Oberhauser I, Montagna G, et al
The impact of age on patient-reported outcomes after oncoplastic versus conventional breast cancer surgery.
Breast Cancer Res Treat. 2021 Feb 19. pii: 10.1007/s10549-021-06126.
PubMed Abstract available

CHEN QX, Yang YZ, Liang ZZ, Chen JL, et al
Time-varying effects of FOXA1 on breast cancer prognosis.
Breast Cancer Res Treat. 2021 Feb 18. pii: 10.1007/s10549-021-06125.
PubMed Abstract available

KIM J, Hong S, Lee JJ, Won YJ, et al
Analysis of the tumor characteristics in young age breast cancer patients using collaborative stage data of the Korea Central Cancer Registry.
Breast Cancer Res Treat. 2021 Feb 18. pii: 10.1007/s10549-021-06107.
PubMed Abstract available

ALBINSAAD LS, Kim J, Chung IY, Ko BS, et al
Prognostic value of p53 expression in hormone receptor-positive and human epidermal growth factor receptor 2-negative breast cancer patients receiving neoadjuvant chemotherapy.
Breast Cancer Res Treat. 2021 Feb 18. pii: 10.1007/s10549-021-06134.
PubMed Abstract available

KIM KH, Choi S, Kim K, Chang J, et al
Association between physical activity and subsequent cardiovascular disease among 5-year breast cancer survivors.
Breast Cancer Res Treat. 2021 Feb 18. pii: 10.1007/s10549-021-06140.
PubMed Abstract available

CAO S, Zhu Z, Zhou J, Li W, et al
Associations of one-carbon metabolism-related gene polymorphisms with breast cancer risk are modulated by diet, being higher when adherence to the Mediterranean dietary pattern is low.
Breast Cancer Res Treat. 2021 Feb 18. pii: 10.1007/s10549-021-06108.
PubMed Abstract available

GEBREMARIAM A, Assefa M, Addissie A, Worku A, et al
Delayed initiation of adjuvant chemotherapy among women with breast cancer in Addis Ababa, Ethiopia.
Breast Cancer Res Treat. 2021 Feb 18. pii: 10.1007/s10549-021-06131.
PubMed Abstract available

MINK VAN DER MOLEN DR, Bargon CA, Batenburg MCT, Gal R, et al
(Ex-)breast cancer patients with (pre-existing) symptoms of anxiety and/or depression experience higher barriers to contact health care providers during the COVID-19 pandemic.
Breast Cancer Res Treat. 2021 Feb 18. pii: 10.1007/s10549-021-06112.
PubMed Abstract available

WANG Y, Singh K, Dizon D, Graves T, et al
Immunohistochemical HER2 score correlates with response to neoadjuvant chemotherapy in HER2-positive primary breast cancer.
Breast Cancer Res Treat. 2021 Feb 17. pii: 10.1007/s10549-021-06124.
PubMed Abstract available

JALLOUK AP, Paravastu S, Weilbaecher K, Aft RL, et al
Long-term outcome of (neo)adjuvant zoledronic acid therapy in locally advanced breast cancer.
Breast Cancer Res Treat. 2021 Feb 16. pii: 10.1007/s10549-021-06100.
PubMed Abstract available

WARDLEY A, Cortes J, Provencher L, Miller K, et al
The efficacy and safety of enzalutamide with trastuzumab in patients with HER2+ and androgen receptor-positive metastatic or locally advanced breast cancer.
Breast Cancer Res Treat. 2021 Feb 16. pii: 10.1007/s10549-021-06109.
PubMed Abstract available

LEONE JP, Leone BA, Tayob N, Hassett MJ, et al
Twenty-year risks of breast cancer-specific mortality for stage III breast cancer in the surveillance, epidemiology, and end results registry.
Breast Cancer Res Treat. 2021 Feb 16. pii: 10.1007/s10549-021-06121.
PubMed Abstract available

NGUY S, Wu SP, Oh C, Gerber NK, et al
Outcomes of HER2-positive non-metastatic breast cancer patients treated with anti-HER2 therapy without chemotherapy.
Breast Cancer Res Treat. 2021 Feb 15. pii: 10.1007/s10549-021-06115.
PubMed Abstract available

LIZARRAGA IM, Kahl AR, Jacoby E, Charlton ME, et al
Impact of age, rurality and distance in predicting contralateral prophylactic mastectomy for breast cancer in a Midwestern state: a population-based study.
Breast Cancer Res Treat. 2021 Feb 13. pii: 10.1007/s10549-021-06105.
PubMed Abstract available

PEATE M, Saunders C, Cohen P, Hickey M, et al
Who is managing menopausal symptoms, sexual problems, mood and sleep disturbance after breast cancer and is it working? Findings from a large community-based survey of breast cancer survivors.
Breast Cancer Res Treat. 2021 Feb 11. pii: 10.1007/s10549-021-06117.
PubMed Abstract available

LIU M, Xie F, Liu M, Zhang Y, et al
Association between BRCA mutational status and survival in patients with breast cancer: a systematic review and meta-analysis.
Breast Cancer Res Treat. 2021 Feb 9. pii: 10.1007/s10549-021-06104.
PubMed Abstract available

COLETTA AM, Agha NH, Baker FL, Niemiro GM, et al
The impact of high-intensity interval exercise training on NK-cell function and circulating myokines for breast cancer prevention among women at high risk for breast cancer.
Breast Cancer Res Treat. 2021 Feb 8. pii: 10.1007/s10549-021-06111.
PubMed Abstract available

DA SILVA LR, de Andrade CA, Brenelli F, Ramalho S, et al
Real-world data on neoadjuvant endocrine therapy in ER-positive/HER2-negative breast cancer.
Breast Cancer Res Treat. 2021 Feb 4. pii: 10.1007/s10549-020-06076.
PubMed Abstract available

RAFN BS, Christensen J, Bloomquist K
Letter to the editor re: Shah et al.: "The impact of monitoring techniques on progression to chronic breast cancerrelated lymphedema: a metaanalysis comparing bioimpedance spectroscopy versus circumferential measurements".
Breast Cancer Res Treat. 2021;186:269-270.
PubMed

YANG C, Arnold AG, Catchings A, Rai V, et al
The RAD51D c.82G>A (p.Val28Met) variant disrupts normal splicing and is associated with hereditary ovarian cancer.
Breast Cancer Res Treat. 2021;185:869-877.
PubMed Abstract available

SHANI H, Bernstein-Molho R, Laitman Y, Netzer I, et al
Double heterozygosity for TP53 and BRCA1 mutations: clinical implications in populations with founder mutations.
Breast Cancer Res Treat. 2021;186:259-263.
PubMed Abstract available

SCHUMACHER K, Inciardi M, O'Neil M, Wagner JL, et al
Is axillary imaging for invasive lobular carcinoma accurate in determining clinical node staging?
Breast Cancer Res Treat. 2021;185:567-572.
PubMed Abstract available

WU JM, Galibois AA, Seebocus N, Apu A, et al
HER2 fluorescent in situ hybridization signal degradation: a 10-year retrospective study.
Breast Cancer Res Treat. 2021;186:99-105.
PubMed Abstract available

ZHANG Z, Chen X, Zhang J, Dai X, et al
Cancer stem cell transcriptome landscape reveals biomarkers driving breast carcinoma heterogeneity.
Breast Cancer Res Treat. 2021;186:89-98.
PubMed Abstract available

OHNO S, Saji S, Masuda N, Tsuda H, et al
Relationships between pathological factors and long-term outcomes in patients enrolled in two prospective randomized controlled trials comparing the efficacy of oral tegafur-uracil with CMF (N.SAS-BC 01 trial and CUBC trial).
Breast Cancer Res Treat. 2021;186:135-147.
PubMed Abstract available

KOPANS DB
The wisdom trial is based on faulty reasoning and has major design and execution problems.
Breast Cancer Res Treat. 2021;185:549-556.
PubMed Abstract available

PARKS RM, Albanghali MA, Syed BM, Green AR, et al
Patterns of biomarker expression in patients treated with primary endocrine therapy - a unique insight using core needle biopsy tissue microarray.
Breast Cancer Res Treat. 2021;185:647-655.
PubMed Abstract available

MESSORI A, Bartoli L, Ferracane E
Implant-based breast reconstruction: re-analysis of the odds ratio for skin flap necrosis.
Breast Cancer Res Treat. 2021;185:887.
PubMed

LACOUTURE ME, Dion H, Ravipaty S, Jimenez JJ, et al
A phase I safety study of topical calcitriol (BPM31543) for the prevention of chemotherapy-induced alopecia.
Breast Cancer Res Treat. 2021;186:107-114.
PubMed Abstract available

NARAYAN AK, Mercaldo SF, Gupta YP, Warner ET, et al
Potential of using mammography screening appointments to identify high-risk women: cross sectional survey results from the national health interview survey.
Breast Cancer Res Treat. 2021;186:229-235.
PubMed Abstract available

RABAGLIO M, Sun Z, Maibach R, Giobbie-Hurder A, et al
Cumulative incidence of cardiovascular events under tamoxifen and letrozole alone and in sequence: a report from the BIG 1-98 trial.
Breast Cancer Res Treat. 2021;185:697-707.
PubMed Abstract available

RASCHI E, Fusaroli M, Ardizzoni A, Poluzzi E, et al
Cyclin-dependent kinase 4/6 inhibitors and interstitial lung disease in the FDA adverse event reporting system: a pharmacovigilance assessment.
Breast Cancer Res Treat. 2021;186:219-227.
PubMed Abstract available

TARANTINO P, Prat A, Curigliano G
New anti-HER2 agents for brain metastasis: histology-agnostic weapons?
Breast Cancer Res Treat. 2021;185:879-881.
PubMed Abstract available

GOMES R, Spinola PDS, Brant AC, Matta BP, et al
Prevalence of germline variants in consensus moderate-to-high-risk predisposition genes to hereditary breast and ovarian cancer in BRCA1/2-negative Brazilian patients.
Breast Cancer Res Treat. 2021;185:851-861.
PubMed Abstract available

ALIPOUR S
Re: Naoum et al., Optimal breast reconstruction type for patients treated with neoadjuvant chemotherapy, mastectomy followed by radiation therapy.
Breast Cancer Res Treat. 2021;185:885-886.
PubMed

RAPHAEL DANIELA DB, Russell NS, van Werkhoven E, Immink JM, et al
Implementing a patient decision aid, a process evaluation of a large-scale pre- and post-implementation trial.
Breast Cancer Res Treat. 2021;185:685-695.
PubMed Abstract available

LI X, Ma Z, Styblo TM, Arciero CA, et al
Management of high-risk breast lesions diagnosed on core biopsies and experiences from prospective high-risk breast lesion conferences at an academic institution.
Breast Cancer Res Treat. 2021;185:573-581.
PubMed Abstract available

LLANOS AAM, Yao S, Singh A, Aremu JB, et al
Gene expression of adipokines and adipokine receptors in the tumor microenvironment: associations of lower expression with more aggressive breast tumor features.
Breast Cancer Res Treat. 2021;185:785-798.
PubMed Abstract available

January 2021

YAO KA, Attai D, Bleicher R, Kuchta K, et al
Covid-19 related oncologist's concerns about breast cancer treatment delays and physician well-being (the CROWN study).
Breast Cancer Res Treat. 2021 Jan 31. pii: 10.1007/s10549-021-06101.
PubMed Abstract available

SHARMA R
Global, regional, national burden of breast cancer in 185 countries: evidence from GLOBOCAN 2018.
Breast Cancer Res Treat. 2021 Jan 30. pii: 10.1007/s10549-020-06083.
PubMed Abstract available

VAN DOOIJEWEERT C, Baas IO, Deckers IAG, Siesling S, et al
The increasing importance of histologic grading in tailoring adjuvant systemic therapy in 30,843 breast cancer patients.
Breast Cancer Res Treat. 2021 Jan 30. pii: 10.1007/s10549-021-06098.
PubMed Abstract available

SUKUMAR J, Kassem M, Agnese D, Pilarski R, et al
Concurrent germline BRCA1, BRCA2, and CHEK2 pathogenic variants in hereditary breast cancer: a case series.
Breast Cancer Res Treat. 2021 Jan 28. pii: 10.1007/s10549-021-06095.
PubMed Abstract available

ZHAO H, Song R, Ye Y, Chow WH, et al
Allostatic score and its associations with demographics, healthy behaviors, tumor characteristics, and mitochondrial DNA among breast cancer patients.
Breast Cancer Res Treat. 2021 Jan 28. pii: 10.1007/s10549-021-06102.
PubMed Abstract available

KELLY KN, Hernandez A, Yadegarynia S, Ryon E, et al
Overcoming disparities: Multidisciplinary breast cancer care at a public safety net hospital.
Breast Cancer Res Treat. 2021 Jan 25. pii: 10.1007/s10549-020-06044.
PubMed Abstract available

WEBBER C, Whitehead M, Eisen A, Holloway CMB, et al
Factors associated with waiting time to breast cancer diagnosis among symptomatic breast cancer patients: a population-based study from Ontario, Canada.
Breast Cancer Res Treat. 2021 Jan 24. pii: 10.1007/s10549-020-06051.
PubMed Abstract available

SUEOKA S, Sasada S, Masumoto N, Emi A, et al
Performance of dedicated breast positron emission tomography in the detection of small and low-grade breast cancer.
Breast Cancer Res Treat. 2021 Jan 23. pii: 10.1007/s10549-020-06088.
PubMed Abstract available

DODINGTON DW, Lagree A, Tabbarah S, Mohebpour M, et al
Analysis of tumor nuclear features using artificial intelligence to predict response to neoadjuvant chemotherapy in high-risk breast cancer patients.
Breast Cancer Res Treat. 2021 Jan 23. pii: 10.1007/s10549-020-06093.
PubMed Abstract available

JAFARI L, Akhter N
Heart failure prevention and monitoring strategies in HER2-positive breast cancer: a narrative review.
Breast Cancer Res Treat. 2021 Jan 22. pii: 10.1007/s10549-021-06096.
PubMed Abstract available

AL-MASRI M, Aljalabneh B, Al-Najjar H, Al-Shamaileh T, et al
Effect of time to breast cancer surgery after neoadjuvant chemotherapy on survival outcomes.
Breast Cancer Res Treat. 2021 Jan 21. pii: 10.1007/s10549-020-06090.
PubMed Abstract available

IWASE T, Wang X, Shrimanker TV, Kolonin MG, et al
Body composition and breast cancer risk and treatment: mechanisms and impact.
Breast Cancer Res Treat. 2021 Jan 21. pii: 10.1007/s10549-020-06092.
PubMed Abstract available

MONDACA JM, Guijarro ACC, Flamini MI, Sanchez AM, et al
Heregulin-induced cell migration is prevented by trastuzumab and trastuzumab-emtansine in HER2+ breast cancer.
Breast Cancer Res Treat. 2021 Jan 20. pii: 10.1007/s10549-020-06089.
PubMed Abstract available

SHECKTER CC, Aliu O, Bailey C, Liu J, et al
Exploring provider- and practice-level drivers of cost-consciousness in breast cancer reconstruction-secondary analysis of a survey of the American Society of Plastic Surgeons.
Breast Cancer Res Treat. 2021 Jan 19. pii: 10.1007/s10549-020-06085.
PubMed Abstract available

KARADSHEH MJ, Tyrell R, Deng M, Egleston BL, et al
Early postoperative outcomes in implant, pedicled, and free flap reconstruction for breast cancer: an analysis of 23,834 patients from the ACS-NSQIP datasets.
Breast Cancer Res Treat. 2021 Jan 19. pii: 10.1007/s10549-020-06073.
PubMed Abstract available

NAKASHOJI A, Hayashida T, Yamaguchi S, Kawai Y, et al
Comprehensive analysis of the homeobox family genes in breast cancer demonstrates their similar roles in cancer and development.
Breast Cancer Res Treat. 2021 Jan 18. pii: 10.1007/s10549-020-06087.
PubMed Abstract available

COOLBRANDT A, T'Jonck A, Blauwens K, Dejaeger E, et al
Scalp cooling in breast cancer patients treated with docetaxel-cyclophosphamide: patient- and nurse-reported results.
Breast Cancer Res Treat. 2021 Jan 16. pii: 10.1007/s10549-020-06063.
PubMed Abstract available

OBA T, Ono M, Matoba H, Uehara T, et al
HDAC6 inhibition enhances the anti-tumor effect of eribulin through tubulin acetylation in triple-negative breast cancer cells.
Breast Cancer Res Treat. 2021 Jan 16. pii: 10.1007/s10549-020-06033.
PubMed Abstract available

APTECAR L, Fiteni F, Jarlier M, Delaine S, et al
Prospective evaluation of sexual health in breast cancer women during the first year of adjuvant hormonal treatment using a cancer patient's dedicated questionnaire: A glaring gap of communication between health professionals and patients.
Breast Cancer Res Treat. 2021 Jan 15. pii: 10.1007/s10549-020-06062.
PubMed Abstract available

QI P, Yang Y, Bai QM, Xue T, et al
Concordance of the 21-gene assay between core needle biopsy and resection specimens in early breast cancer patients.
Breast Cancer Res Treat. 2021 Jan 13. pii: 10.1007/s10549-020-06075.
PubMed Abstract available

RICHARDSON D, Zhan L, Mahtani R, McRoy L, et al
A prospective observational study of patient-reported functioning and quality of life in advanced and metastatic breast cancer utilizing a novel mobile application.
Breast Cancer Res Treat. 2021 Jan 11. pii: 10.1007/s10549-020-06082.
PubMed Abstract available

STJEPANOVIC N, Lubinski J, Moller P, Randall Armel S, et al
Breast cancer risk after age 60 among BRCA1 and BRCA2 mutation carriers.
Breast Cancer Res Treat. 2021 Jan 10. pii: 10.1007/s10549-020-06072.
PubMed Abstract available

ALEIXO GFP, Yu H, Chen YT, Nyrop KA, et al
Myosteatosis evaluation using erector spinae and psoas muscles to predict adverse events during adjuvant chemotherapy for breast cancer.
Breast Cancer Res Treat. 2021 Jan 10. pii: 10.1007/s10549-020-06061.
PubMed Abstract available

WEI M, Wang X, Zimmerman DN, Burt LM, et al
Endocrine therapy and radiotherapy use among older women with hormone receptor-positive, clinically node-negative breast cancer.
Breast Cancer Res Treat. 2021 Jan 9. pii: 10.1007/s10549-020-06071.
PubMed Abstract available

ZHANG J, Liu Y, Pu S, He J, et al
Spindle and kinetochoreassociated complex subunit 3 accelerates breast cancer cell proliferation and invasion through the regulation of Akt/Wnt/beta-catenin signaling.
Breast Cancer Res Treat. 2021 Jan 9. pii: 10.1007/s10549-020-06078.
PubMed Abstract available

SOARES ICS, Bello MA, Bergmann A, Thuler LCS, et al
Comparison of the performance of four staging systems in determining the prognosis of breast cancer among women undergoing neoadjuvant chemotherapy.
Breast Cancer Res Treat. 2021 Jan 8. pii: 10.1007/s10549-020-06077.
PubMed Abstract available

KUMAR U, Ardasheva A, Mahmud Z, Coombes RC, et al
FOXA1 is a determinant of drug resistance in breast cancer cells.
Breast Cancer Res Treat. 2021 Jan 8. pii: 10.1007/s10549-020-06068.
PubMed Abstract available

DI MICCO R, Classe JM, Reimer T
Letter to the Editor regarding the publication titled "Axillary lymph node dissection in node-positive breast cancer: are ten nodes adequate and when is enough, enough?"
Breast Cancer Res Treat. 2021 Jan 7. pii: 10.1007/s10549-020-06064.
PubMed

VAN MECHELEN M, Van Herck A, Punie K, Nevelsteen I, et al
Correction to: Behavior of metastatic breast cancer according to subtype.
Breast Cancer Res Treat. 2021 Jan 7. pii: 10.1007/s10549-020-06006.
PubMed

KHOURY K, Lynce F, Barac A, Geng X, et al
Long-term follow-up assessment of cardiac safety in SAFE-HEaRt, a clinical trial evaluating the use of HER2-targeted therapies in patients with breast cancer and compromised heart function.
Breast Cancer Res Treat. 2021 Jan 5. pii: 10.1007/s10549-020-06053.
PubMed Abstract available

KONISHI T, Fujiogi M, Michihata N, Morita K, et al
Comparison of short-term surgical outcomes between men and women with breast cancer: a retrospective study using nationwide inpatient data in Japan.
Breast Cancer Res Treat. 2021 Jan 5. pii: 10.1007/s10549-020-06069.
PubMed Abstract available

MACKEY JR, Lai J, Chauhan U, Beauchamp E, et al
N-myristoyltransferase proteins in breast cancer: prognostic relevance and validation as a new drug target.
Breast Cancer Res Treat. 2021 Jan 4. pii: 10.1007/s10549-020-06037.
PubMed Abstract available

GAUDET MM, Deubler E, Diver WR, Puvanesarajah S, et al
Breast cancer risk factors by mode of detection among screened women in the Cancer Prevention Study-II.
Breast Cancer Res Treat. 2021 Jan 4. pii: 10.1007/s10549-020-06025.
PubMed Abstract available

BOUWER NI, Steenbruggen TG, van Rosmalen J, Rier HN, et al
Cardiotoxicity during long-term trastuzumab use in patients with HER2-positive metastatic breast cancer: who needs cardiac monitoring?
Breast Cancer Res Treat. 2021 Jan 4. pii: 10.1007/s10549-020-06039.
PubMed Abstract available

KIM JS, Kim K, Jung W, Shin KH, et al
New brain metastases after whole-brain radiotherapy of initial brain metastases in breast cancer patients: the significance of molecular subtypes (KROG 16-12).
Breast Cancer Res Treat. 2021 Jan 4. pii: 10.1007/s10549-020-06043.
PubMed Abstract available

KLEINSTERN G, Scott CG, Tamimi RM, Jensen MR, et al
Association of mammographic density measures and breast cancer "intrinsic" molecular subtypes.
Breast Cancer Res Treat. 2021 Jan 4. pii: 10.1007/s10549-020-06049.
PubMed Abstract available

WILLIAMS AM, Khan CP, Heckler CE, Barton DL, et al
Fatigue, anxiety, and quality of life in breast cancer patients compared to non-cancer controls: a nationwide longitudinal analysis.
Breast Cancer Res Treat. 2021 Jan 4. pii: 10.1007/s10549-020-06067.
PubMed Abstract available

RAJAGOPAL T, Seshachalam A, Rathnam KK, Jothi A, et al
Impact of xenobiotic-metabolizing gene polymorphisms on breast cancer risk in South Indian women.
Breast Cancer Res Treat. 2021 Jan 4. pii: 10.1007/s10549-020-06028.
PubMed Abstract available

SUTHERLAND A, Wagner JL, Korentager S, Butterworth J, et al
Is bioimpedance spectroscopy a useful tool for objectively assessing lymphovenous bypass surgical outcomes in breast cancer-related lymphedema?
Breast Cancer Res Treat. 2021 Jan 4. pii: 10.1007/s10549-020-06059.
PubMed Abstract available

ZEIDMAN M, Schmidt H, Alberty-Oller JJ, Pisapati KV, et al
Trends in neoadjuvant chemotherapy versus surgery-first in stage I HER2-positive breast cancer patients in the National Cancer DataBase (NCDB).
Breast Cancer Res Treat. 2021 Jan 4. pii: 10.1007/s10549-020-06041.
PubMed Abstract available

MORAVEK MB, Confino R, Lawson AK, Smith KN, et al
Predictors and outcomes in breast cancer patients who did or did not pursue fertility preservation.
Breast Cancer Res Treat. 2021 Jan 4. pii: 10.1007/s10549-020-06031.
PubMed Abstract available

LI Z, Wang Y, Liu C, Wang Z, et al
Association between VEGF single nucleotide polymorphism and breast cancer in the Northern China Han population.
Breast Cancer Res Treat. 2021 Jan 3. pii: 10.1007/s10549-020-06024.
PubMed Abstract available

GOETZ MP, Okera M, Wildiers H, Campone M, et al
Safety and efficacy of abemaciclib plus endocrine therapy in older patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: an age-specific subgroup analysis of MONARCH 2 and 3 trials.
Breast Cancer Res Treat. 2021 Jan 3. pii: 10.1007/s10549-020-06029.
PubMed Abstract available

STENEHJEM DD, Telford C, Unni SK, Bauer H, et al
BRCA testing and outcomes in women with breast cancer.
Breast Cancer Res Treat. 2021 Jan 3. pii: 10.1007/s10549-020-06038.
PubMed Abstract available

POLLEY MC, Leon-Ferre RA, Leung S, Cheng A, et al
A clinical calculator to predict disease outcomes in women with triple-negative breast cancer.
Breast Cancer Res Treat. 2021 Jan 3. pii: 10.1007/s10549-020-06030.
PubMed Abstract available

JONES S, Hogan B, Patel K, Ooi S, et al
Identification of factors that influence the decision to take chemoprevention in patients with a significant family history of breast cancer: results from a patient questionnaire survey.
Breast Cancer Res Treat. 2021 Jan 3. pii: 10.1007/s10549-020-06046.
PubMed Abstract available

KENNARD K, Buckley ME, Sizer LM, Larson S, et al
Metabolic Syndrome: does this influence breast cancer outcomes in the triple-negative population?
Breast Cancer Res Treat. 2021 Jan 3. pii: 10.1007/s10549-020-06034.
PubMed Abstract available

LUANGWATTANANUN P, Junking M, Sujjitjoon J, Wutti-In Y, et al
Fourth-generation chimeric antigen receptor T cells targeting folate receptor alpha antigen expressed on breast cancer cells for adoptive T cell therapy.
Breast Cancer Res Treat. 2021 Jan 3. pii: 10.1007/s10549-020-06032.
PubMed Abstract available

KANG YJ, Oh SJ, Choi H, Cho S, et al
Clinical significance of HER2 status in T1bN0 breast cancer: a nationwide study from the Korean Breast Cancer Society.
Breast Cancer Res Treat. 2021 Jan 3. pii: 10.1007/s10549-020-06017.
PubMed Abstract available

TZEKAKI EE, Geromichalos G, Lavrentiadou SN, Tsantarliotou MP, et al
Oleuropein is a natural inhibitor of PAI-1-mediated proliferation in human ER-/PR- breast cancer cells.
Breast Cancer Res Treat. 2021 Jan 3. pii: 10.1007/s10549-020-06054.
PubMed Abstract available

SHLIAKHTUNOU YA
CTCs-oriented adjuvant personalized cytostatic therapy non-metastatic breast cancer patients: continuous non-randomized prospective study and prospective randomized controlled study.
Breast Cancer Res Treat. 2021 Jan 3. pii: 10.1007/s10549-020-06036.
PubMed Abstract available

LEONE JP, Leone BA, Zwenger AO, Vallejo CT, et al
The prognostic significance of metastatic pattern in stage IV male breast cancer at initial diagnosis: a population-based study.
Breast Cancer Res Treat. 2021 Jan 3. pii: 10.1007/s10549-020-06052.
PubMed Abstract available

KLAESTAD E, Sawicka JE, Engstrom MJ, Ytterhus B, et al
ZNF703 gene copy number and protein expression in breast cancer; associations with proliferation, prognosis and luminal subtypes.
Breast Cancer Res Treat. 2021 Jan 2. pii: 10.1007/s10549-020-06035.
PubMed Abstract available

VILLARREAL-GARZA C, Mesa-Chavez F, Garza-Ledezma MRA, Pena-Curiel O, et al
Impact of chemotherapy regimen and sequence on the effectiveness of scalp cooling for alopecia prevention.
Breast Cancer Res Treat. 2021;185:453-458.
PubMed Abstract available

COX K, Dineen N, Taylor-Phillips S, Sharma N, et al
Enhanced axillary assessment using intradermally injected microbubbles and contrast-enhanced ultrasound (CEUS) before neoadjuvant systemic therapy (NACT) identifies axillary disease missed by conventional B-mode ultrasound that may be clinically relev
Breast Cancer Res Treat. 2021;185:413-422.
PubMed Abstract available

SADEGHALVAD M, Mohammadi-Motlagh HR, Rezaei N
Immune microenvironment in different molecular subtypes of ductal breast carcinoma.
Breast Cancer Res Treat. 2021;185:261-279.
PubMed Abstract available

POLAT DS, Schopp JG, Arjmandi F, Porembka J, et al
Performance of a clinical and imaging-based multivariate model as decision support tool to help save unnecessary surgeries for high-risk breast lesions.
Breast Cancer Res Treat. 2021;185:479-494.
PubMed Abstract available

APPELMAN L, Appelman PTM, Siebers CCN, Bult P, et al
The value of mammography in women with focal breast complaints in addition to initial targeted ultrasound.
Breast Cancer Res Treat. 2021;185:381-389.
PubMed Abstract available

GALMOR L, Bernstein-Molho R, Sklair-Levy M, Madoursky-Feldman D, et al
Time trends in uptake rates of risk-reducing mastectomy in Israeli asymptomatic BRCA1 and BRCA2 mutation carriers.
Breast Cancer Res Treat. 2021;185:391-399.
PubMed Abstract available

MANNLE H, Siebers JW, Momm F, Munstedt K, et al
Impact of patients' refusal to undergo adjuvant treatment measures on survival.
Breast Cancer Res Treat. 2021;185:239-246.
PubMed Abstract available

PONDE N, Agbor-Tarh D, Dal Lago L, Korde LA, et al
Tolerability and toxicity of trastuzumab or trastuzumab + lapatinib in older patients: a sub-analysis of the ALTTO trial (BIG 2-06; NCCTG (Alliance) N063D).
Breast Cancer Res Treat. 2021;185:107-116.
PubMed Abstract available

DENG J, Thennavan A, Shah S, Bagdatlioglu E, et al
Serial single-cell profiling analysis of metastatic TNBC during Nab-paclitaxel and pembrolizumab treatment.
Breast Cancer Res Treat. 2021;185:85-94.
PubMed Abstract available

TOUSSAINT A, Piaget-Rossel R, Stormacq C, Mathevet P, et al
Width of margins in phyllodes tumors of the breast: the controversy drags on?-a systematic review and meta-analysis.
Breast Cancer Res Treat. 2021;185:21-37.
PubMed Abstract available

BAEK SY, Kim J, Chung IY, Ko BS, et al
Long-term survival outcomes of repeat lumpectomy for ipsilateral breast tumor recurrence: a propensity score-matched analysis.
Breast Cancer Res Treat. 2021;185:155-164.
PubMed Abstract available

SOMASUNDARAM SK, Potter S, Elgammal S, Maxwell AJ, et al
Impalpable breast lesion localisation, a logistical challenge: results of the UK iBRA-NET national practice questionnaire.
Breast Cancer Res Treat. 2021;185:13-20.
PubMed Abstract available

December 2020

ALTUNDAG K
Luminal subtypes and response to neoadjuvant chemotherapy for hormone receptor-positive HER2-negative patients.
Breast Cancer Res Treat. 2020;184:999.
PubMed

November 2020

SCHIZA A, Mauri D, Fredriksson I, Anna-Karin Wennstig, et al
Predictive role of HER2-status on the effectiveness of endocrine adjuvant treatment in postmenopausal breast cancer patients: a population-based cohort study.
Breast Cancer Res Treat. 2020 Nov 30. pii: 10.1007/s10549-020-06022.
PubMed Abstract available

PING J, Huang S, Wu J, Bao P, et al
Association between lincRNA expression and overall survival for patients with triple-negative breast cancer.
Breast Cancer Res Treat. 2020 Nov 27. pii: 10.1007/s10549-020-06021.
PubMed Abstract available

SHAH C, Zambelli-Weiner A, Delgado N, Sier A, et al
The impact of monitoring techniques on progression to chronic breast cancer-related lymphedema: a meta-analysis comparing bioimpedance spectroscopy versus circumferential measurements.
Breast Cancer Res Treat. 2020 Nov 27. pii: 10.1007/s10549-020-05988.
PubMed Abstract available

PAK LM, Gaither R, Rosenberg SM, Ruddy KJ, et al
Tumor phenotype and concordance in synchronous bilateral breast cancer in young women.
Breast Cancer Res Treat. 2020 Nov 26. pii: 10.1007/s10549-020-06027.
PubMed Abstract available

BRAAL CL, Hussaarts KGAM, Seuren L, Oomen-deHoop E, et al
Correction to: Influence of green tea consumption on endoxifen steady-state concentration in breast cancer patients treated with tamoxifen.
Breast Cancer Res Treat. 2020 Nov 23. pii: 10.1007/s10549-020-05979.
PubMed Abstract available

RICHMAN J, Ring A, Dowsett M, Sestak I, et al
Clinical validity of clinical treatment score 5 (CTS5) for estimating risk of late recurrence in unselected, non-trial patients with early oestrogen receptor-positive breast cancer.
Breast Cancer Res Treat. 2020 Nov 21. pii: 10.1007/s10549-020-06013.
PubMed Abstract available

CLIFTON K, Luo J, Tao Y, Saam J, et al
Mutation profile differences in younger and older patients with advanced breast cancer using circulating tumor DNA (ctDNA).
Breast Cancer Res Treat. 2020 Nov 20. pii: 10.1007/s10549-020-06019.
PubMed Abstract available

PRAKASH I, Thomas SM, Greenup RA, Plichta JK, et al
Time to surgery among women treated with neoadjuvant systemic therapy and upfront surgery for breast cancer.
Breast Cancer Res Treat. 2020 Nov 18. pii: 10.1007/s10549-020-06012.
PubMed Abstract available

SACHDEV JC, Munster P, Northfelt DW, Han HS, et al
Phase I study of liposomal irinotecan in patients with metastatic breast cancer: findings from the expansion phase.
Breast Cancer Res Treat. 2020 Nov 17. pii: 10.1007/s10549-020-05995.
PubMed Abstract available

XIE E, Lapinski MM, Talamantes S, Nonyane BAS, et al
Relationship of circulating immune cells with lifestyle factors and cancer recurrence in early-stage breast cancer.
Breast Cancer Res Treat. 2020 Nov 13. pii: 10.1007/s10549-020-06016.
PubMed Abstract available

CHOBRUTSKIY A, Chobrutskiy BI, Zaman S, Hsiang M, et al
Chemical features of blood-borne TRG CDR3s associated with an increased overall survival in breast cancer.
Breast Cancer Res Treat. 2020 Nov 12. pii: 10.1007/s10549-020-05996.
PubMed Abstract available

TROPEE R, de la Pena Avalos B, Gough M, Snell C, et al
The SWI/SNF subunit SMARCD3 regulates cell cycle progression and predicts survival outcome in ER+ breast cancer.
Breast Cancer Res Treat. 2020 Nov 12. pii: 10.1007/s10549-020-05997.
PubMed Abstract available

LUGTENBERG RT, de Groot S, Kaptein AA, Fischer MJ, et al
Quality of life and illness perceptions in patients with breast cancer using a fasting mimicking diet as an adjunct to neoadjuvant chemotherapy in the phase 2 DIRECT (BOOG 2013-14) trial.
Breast Cancer Res Treat. 2020 Nov 11. pii: 10.1007/s10549-020-05991.
PubMed Abstract available

SAKHUJA S, Deveaux A, Wilson LE, Vin-Raviv N, et al
Patterns of de-novo metastasis and breast cancer-specific mortality by race and molecular subtype in the SEER population-based dataset.
Breast Cancer Res Treat. 2020 Nov 11. pii: 10.1007/s10549-020-06007.
PubMed Abstract available

METCALFE KA, Candib A, Giannakeas V, Eisen A, et al
The relationship between the predicted risk of death and psychosocial functioning among women with early-stage breast cancer.
Breast Cancer Res Treat. 2020 Nov 10. pii: 10.1007/s10549-020-05992.
PubMed Abstract available

PALLESCHI M, Iaia ML, Casadei C
Germline BRCA-mutated metastatic breast cancer with positive hormone receptor.
Breast Cancer Res Treat. 2020 Nov 10. pii: 10.1007/s10549-020-06010.
PubMed

DAMIN AP, Zancan M, Melo MP, Biazus JV, et al
Sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with node-positive breast cancer: guiding a more selective axillary approach.
Breast Cancer Res Treat. 2020 Nov 9. pii: 10.1007/s10549-020-06011.
PubMed Abstract available

LIU S, Zeng S, Xia L, Yu M, et al
Tumor-infiltrating lymphocytes benefit prediction of axillary pathologic response and prognostication of event-free survival in HER2-positive and biopsy-proven node-positive breast cancer treated with neoadjuvant therapy.
Breast Cancer Res Treat. 2020 Nov 9. pii: 10.1007/s10549-020-06015.
PubMed Abstract available

ELSHARAWY KA, Althobiti M, Mohammed OJ, Aljohani AI, et al
Nucleolar protein 10 (NOP10) predicts poor prognosis in invasive breast cancer.
Breast Cancer Res Treat. 2020 Nov 8. pii: 10.1007/s10549-020-05999.
PubMed Abstract available

SHAH H, Surujballi J, Awan AA, Hutton B, et al
A scoping review characterizing "Choosing Wisely(R)" recommendations for breast cancer management.
Breast Cancer Res Treat. 2020 Nov 6. pii: 10.1007/s10549-020-06009.
PubMed Abstract available

DAHLMAN D, Magnusson H, Li X, Sundquist J, et al
Drug use disorder and risk of incident and fatal breast cancer: a nationwide epidemiological study.
Breast Cancer Res Treat. 2020 Nov 6. pii: 10.1007/s10549-020-05998.
PubMed Abstract available

KOPPELMANS V, van der Willik KD, Aleman BMP, van Leeuwen FE, et al
Long-term effects of adjuvant treatment for breast cancer on carotid plaques and brain perfusion.
Breast Cancer Res Treat. 2020 Nov 5. pii: 10.1007/s10549-020-05990.
PubMed Abstract available

SELLA T, Gelber SI, Poorvu PD, Kim HJ, et al
Response to neoadjuvant chemotherapy and the 21-gene Breast Recurrence Score test in young women with estrogen receptor-positive early breast cancer.
Breast Cancer Res Treat. 2020 Nov 4. pii: 10.1007/s10549-020-05989.
PubMed Abstract available

CADILI L, DeGirolamo K, McKevitt E, Brown CJ, et al
COVID-19 and breast cancer at a Regional Breast Centre: our flexible approach during the pandemic.
Breast Cancer Res Treat. 2020 Nov 4. pii: 10.1007/s10549-020-06008.
PubMed Abstract available

SOPIK V
International variation in breast cancer incidence and mortality in young women.
Breast Cancer Res Treat. 2020 Nov 3. pii: 10.1007/s10549-020-06003.
PubMed Abstract available

CHEN X, Guo K, Lin J
Letter to the editor regarding the article "Bazedoxifene is a novel IL-6/GP130 inhibitor for treating triple-negative breast cancer".
Breast Cancer Res Treat. 2020 Nov 2. pii: 10.1007/s10549-020-05987.
PubMed

HU X, Myers KS, Oluyemi ET, Philip M, et al
Presentation and characteristics of breast cancer in young women under age 40.
Breast Cancer Res Treat. 2020 Nov 2. pii: 10.1007/s10549-020-06000.
PubMed Abstract available

October 2020

WEN Y, Wu X, Peng H, Li C, et al
Breast cancer risk in patients with polycystic ovary syndrome: a Mendelian randomization analysis.
Breast Cancer Res Treat. 2020 Oct 31. pii: 10.1007/s10549-020-05973.
PubMed Abstract available

KOYUNCU D, Sharma U, Goka ET, Lippman ME, et al
Spindle assembly checkpoint gene BUB1B is essential in breast cancer cell survival.
Breast Cancer Res Treat. 2020 Oct 31. pii: 10.1007/s10549-020-05962.
PubMed Abstract available

USISKIN I, Li F, Irwin ML, Cartmel B, et al
Association of relative dose intensity with BMI and pathologic complete response in patients treated with neoadjuvant chemotherapy for breast cancer.
Breast Cancer Res Treat. 2020 Oct 30. pii: 10.1007/s10549-020-05994.
PubMed Abstract available

FINDLAY-SHIRRAS L, Lima I, Smith G, Clemons M, et al
Canada follows the US in the rise of bilateral mastectomies for unilateral breast cancer: a 23-year population cohort study.
Breast Cancer Res Treat. 2020 Oct 30. pii: 10.1007/s10549-020-05965.
PubMed Abstract available

SHAIK AN, Kiavash K, Stark K, Boerner JL, et al
Inflammation markers on benign breast biopsy are associated with risk of invasive breast cancer in African American women.
Breast Cancer Res Treat. 2020 Oct 28. pii: 10.1007/s10549-020-05983.
PubMed Abstract available

LATTIMORE V, Parsons MT, Spurdle AB, Pearson J, et al
Under-ascertainment of breast cancer susceptibility gene carriers in a cohort of New Zealand female breast cancer patients.
Breast Cancer Res Treat. 2020 Oct 28. pii: 10.1007/s10549-020-05986.
PubMed Abstract available

DACKUS GMHE, Jozwiak K, van der Wall E, van Diest PJ, et al
Concurrent versus sequential use of trastuzumab and chemotherapy in early HER2+ breast cancer.
Breast Cancer Res Treat. 2020 Oct 28. pii: 10.1007/s10549-020-05978.
PubMed Abstract available

ZHAO F, Copley B, Niu Q, Liu F, et al
Racial disparities in survival outcomes among breast cancer patients by molecular subtypes.
Breast Cancer Res Treat. 2020 Oct 27. pii: 10.1007/s10549-020-05984.
PubMed Abstract available

HERBERT SL, Wockel A, Kreienberg R, Kuhn T, et al
To which extent do breast cancer survivors feel well informed about disease and treatment 5 years after diagnosis?
Breast Cancer Res Treat. 2020 Oct 26. pii: 10.1007/s10549-020-05974.
PubMed Abstract available

BREZDEN-MASLEY C, Fathers KE, Coombes ME, Pourmirza B, et al
A population-based comparison of treatment, resource utilization, and costs by cancer stage for Ontario patients with HER2-positive breast cancer.
Breast Cancer Res Treat. 2020 Oct 22. pii: 10.1007/s10549-020-05976.
PubMed Abstract available

KARIRI YA, Alsaleem M, Joseph C, Alsaeed S, et al
The prognostic significance of interferon-stimulated gene 15 (ISG15) in invasive breast cancer.
Breast Cancer Res Treat. 2020 Oct 19. pii: 10.1007/s10549-020-05955.
PubMed Abstract available

SIMONS JM, Jacobs JG, Roijers JP, Beek MA, et al
Disease-free and overall survival after neoadjuvant chemotherapy in breast cancer: breast-conserving surgery compared to mastectomy in a large single-centre cohort study.
Breast Cancer Res Treat. 2020 Oct 19. pii: 10.1007/s10549-020-05966.
PubMed Abstract available

WEISER R, Haque W, Polychronopoulou E, Hatch SS, et al
The 21-gene recurrence score in node-positive, hormone receptor-positive, HER2-negative breast cancer: a cautionary tale from an NCDB analysis.
Breast Cancer Res Treat. 2020 Oct 18. pii: 10.1007/s10549-020-05971.
PubMed Abstract available

GARCIA-TEJEDOR A, Fernandez-Gonzalez S, Ortega R, Gil-Gil M, et al
Can we avoid axillary lymph node dissection in N2 breast cancer patients with chemo-sensitive tumours such as HER2 and TNBC?
Breast Cancer Res Treat. 2020 Oct 17. pii: 10.1007/s10549-020-05970.
PubMed Abstract available

SIM EJ, Ko KP, Ahn C, Park SM, et al
Isoflavone intake on the risk of overall breast cancer and molecular subtypes in women at high risk for hereditary breast cancer.
Breast Cancer Res Treat. 2020 Oct 17. pii: 10.1007/s10549-020-05875.
PubMed Abstract available

LU YC, Huang DW, Chen PT, Tsai CF, et al
Association between statin use and second cancer risk in breast cancer patients: a nationwide population-based cohort study.
Breast Cancer Res Treat. 2020 Oct 16. pii: 10.1007/s10549-020-05969.
PubMed Abstract available

BREZDEN-MASLEY C, Fathers KE, Coombes ME, Pourmirza B, et al
A population-based comparison of treatment patterns, resource utilization, and costs by cancer stage for Ontario patients with hormone receptor-positive/HER2-negative breast cancer.
Breast Cancer Res Treat. 2020 Oct 16. pii: 10.1007/s10549-020-05960.
PubMed Abstract available

KUMAR R, Kuligina E, Sokolenko A, Siddiqui Q, et al
Genetic ablation of pregnancy zone protein promotes breast cancer progression by activating TGF-beta/SMAD signaling.
Breast Cancer Res Treat. 2020 Oct 15. pii: 10.1007/s10549-020-05958.
PubMed Abstract available

ZHOU M, Venkata PP, Viswanadhapalli S, Palacios B, et al
KDM1A inhibition is effective in reducing stemness and treating triple negative breast cancer.
Breast Cancer Res Treat. 2020 Oct 14. pii: 10.1007/s10549-020-05963.
PubMed Abstract available

WU ZY, Kim N, Ko B
Tumor localization for breast cancer patients receiving neoadjuvant chemotherapy.
Breast Cancer Res Treat. 2020 Oct 14. pii: 10.1007/s10549-020-05950.
PubMed

TURNBULL AK, Patel S, Martinez-Perez C, Rigg A, et al
Risk of chemotherapy-related amenorrhoea (CRA) in premenopausal women undergoing chemotherapy for early stage breast cancer.
Breast Cancer Res Treat. 2020 Oct 12. pii: 10.1007/s10549-020-05951.
PubMed Abstract available

BEN-ZION BERLINER M, Yerushalmi R, Lavie I, Benouaich-Amiel A, et al
Central nervous system metastases in breast cancer: the impact of age on patterns of development and outcome.
Breast Cancer Res Treat. 2020 Oct 10. pii: 10.1007/s10549-020-05959.
PubMed Abstract available

HATONO M, Ikeda H, Suzuki Y, Kajiwara Y, et al
Effect of isoflavones on breast cancer cell development and their impact on breast cancer treatments.
Breast Cancer Res Treat. 2020 Oct 9. pii: 10.1007/s10549-020-05957.
PubMed Abstract available

PESCE C, Jaffe J, Kuchta K, Yao K, et al
Patient-reported outcomes among women with unilateral breast cancer undergoing breast conservation versus single or double mastectomy.
Breast Cancer Res Treat. 2020 Oct 8. pii: 10.1007/s10549-020-05964.
PubMed Abstract available

ABRAHAM HG, Xia Y, Mukherjee B, Merajver SD, et al
Incidence and survival of inflammatory breast cancer between 1973 and 2015 in the SEER database.
Breast Cancer Res Treat. 2020 Oct 8. pii: 10.1007/s10549-020-05938.
PubMed Abstract available

FILHO OM, Giobbie-Hurder A, Lin NU, Faggen M, et al
A dynamic portrait of adverse events for breast cancer patients: results from a phase II clinical trial of eribulin in advanced HER2-negative breast cancer.
Breast Cancer Res Treat. 2020 Oct 6. pii: 10.1007/s10549-020-05928.
PubMed Abstract available

GOYAL A, Puri S, Marshall A, Valassiadou K, et al
A multicentre prospective feasibility study of carbon dye tattooing of biopsied axillary node and surgical localisation in breast cancer patients.
Breast Cancer Res Treat. 2020 Oct 6. pii: 10.1007/s10549-020-05961.
PubMed Abstract available

PARK JW, Han K, Shin DW, Yeo Y, et al
Obesity and breast cancer risk for pre- and postmenopausal women among over 6 million Korean women.
Breast Cancer Res Treat. 2020 Oct 3. pii: 10.1007/s10549-020-05952.
PubMed Abstract available

KOELMEYER LA, Moloney E, Boyages J, Sherman KA, et al
Prospective surveillance model in the home for breast cancer-related lymphoedema: a feasibility study.
Breast Cancer Res Treat. 2020 Oct 1. pii: 10.1007/s10549-020-05953.
PubMed Abstract available

YAN S, Dey P, Ziegler Y, Jiao X, et al
Contrasting activities of estrogen receptor beta isoforms in triple negative breast cancer.
Breast Cancer Res Treat. 2020 Oct 1. pii: 10.1007/s10549-020-05948.
PubMed Abstract available

LAI V, Hajjaj O, Le D, Shokoohi A, et al
Impact of wait time from neoadjuvant chemotherapy to surgery in breast cancer: Does time to surgery affect patient outcomes? : Time from Neoadjuvant Chemotherapy to Surgery.
Breast Cancer Res Treat. 2020 Oct 1. pii: 10.1007/s10549-020-05894.
PubMed Abstract available

September 2020

VAN RAEMDONCK E, Floris G, Berteloot P, Laenen A, et al
Efficacy of anti-HER2 therapy in metastatic breast cancer by discordance of HER2 expression between primary and metastatic breast cancer.
Breast Cancer Res Treat. 2020 Sep 27. pii: 10.1007/s10549-020-05935.
PubMed Abstract available

JIANG YZ, Ge LP, Jin X, Fan L, et al
Randomized phase II clinical trial and biomarker analysis of paclitaxel plus epirubicin versus vinorelbine plus epirubicin as neoadjuvant chemotherapy in locally advanced HER2-negative breast cancer with TEKT4 variations.
Breast Cancer Res Treat. 2020 Sep 25. pii: 10.1007/s10549-020-05940.
PubMed Abstract available

HERNANZ F
Comments on patient-reported outcome after oncoplastic breast surgery compared with conventional breast-conserving surgery in breast cancer.
Breast Cancer Res Treat. 2020 Sep 24. pii: 10.1007/s10549-020-05945.
PubMed

MOHAMADZADE Z, Mahjoubi F, Soltani BM
Introduction of hsa-miR-512-3p as a new regulator of HER2 signaling pathway in breast cancer.
Breast Cancer Res Treat. 2020 Sep 24. pii: 10.1007/s10549-020-05937.
PubMed Abstract available

ZAHL PH, Kristiansen IS
Re: Stage-specific survival has improved for young breast cancer patients since 2000: but not equally?
Breast Cancer Res Treat. 2020 Sep 24. pii: 10.1007/s10549-020-05941.
PubMed

ABDEL-RAZEQ H, Edaily S, Iweir S, Salam M, et al
Effect of level of hormone-receptor expression on treatment outcomes of "triple-positive" early-stage breast cancer.
Breast Cancer Res Treat. 2020 Sep 24. pii: 10.1007/s10549-020-05942.
PubMed Abstract available

MARSH S, Borges VF, Coons HL, Afghahi A, et al
Sexual health after a breast cancer diagnosis in young women: clinical implications for patients and providers.
Breast Cancer Res Treat. 2020 Sep 23. pii: 10.1007/s10549-020-05880.
PubMed Abstract available

JACOBSE JN, Schaapveld M, Boekel NB, Hooning MJ, et al
Risk of heart failure after systemic treatment for early breast cancer: results of a cohort study.
Breast Cancer Res Treat. 2020 Sep 22. pii: 10.1007/s10549-020-05930.
PubMed Abstract available

NICHOLS HB, Graff M, Bensen JT, Lunetta KL, et al
Genetic variants in anti-Mullerian hormone-related genes and breast cancer risk: results from the AMBER consortium.
Breast Cancer Res Treat. 2020 Sep 22. pii: 10.1007/s10549-020-05944.
PubMed Abstract available

JERZAK KJ, Lohmann AE, Ennis M, Nemeth E, et al
Prognostic associations of plasma hepcidin in women with early breast cancer.
Breast Cancer Res Treat. 2020 Sep 22. pii: 10.1007/s10549-020-05903.
PubMed Abstract available

KONISHI T, Fujiogi M, Michihata N, Morita K, et al
Association between body mass index and localization of breast cancer: results from a nationwide inpatient database in Japan.
Breast Cancer Res Treat. 2020 Sep 19. pii: 10.1007/s10549-020-05934.
PubMed Abstract available

TIAINEN S, Rilla K, Hamalainen K, Oikari S, et al
The prognostic and predictive role of the neutrophil-to-lymphocyte ratio and the monocyte-to-lymphocyte ratio in early breast cancer, especially in the HER2+ subtype.
Breast Cancer Res Treat. 2020 Sep 18. pii: 10.1007/s10549-020-05925.
PubMed Abstract available

GEBREMARIAM A, Dereje N, Addissie A, Worku A, et al
Factors associated with late-stage diagnosis of breast cancer among women in Addis Ababa, Ethiopia.
Breast Cancer Res Treat. 2020 Sep 18. pii: 10.1007/s10549-020-05919.
PubMed Abstract available

XUE L, Chen F, Yue F, Camacho L, et al
Metformin and an insulin/IGF-1 receptor inhibitor are synergistic in blocking growth of triple-negative breast cancer.
Breast Cancer Res Treat. 2020 Sep 17. pii: 10.1007/s10549-020-05927.
PubMed Abstract available

DENT SF, Botros J, Rushton M, Aseyev O, et al
Anthracycline-induced cardiotoxicity in patients with early-stage breast cancer: the Canadian Cancer Trials Group (CCTG) MA.21 experience.
Breast Cancer Res Treat. 2020 Sep 17. pii: 10.1007/s10549-020-05887.
PubMed Abstract available

LOSK K, Freedman RA, Laws A, Kantor O, et al
Oncotype DX testing in node-positive breast cancer strongly impacts chemotherapy use at a comprehensive cancer center.
Breast Cancer Res Treat. 2020 Sep 16. pii: 10.1007/s10549-020-05931.
PubMed Abstract available

WANG B, Huang T, Fang Q, Zhang X, et al
Bone-protective and anti-tumor effect of baicalin in osteotropic breast cancer via induction of apoptosis.
Breast Cancer Res Treat. 2020 Sep 16. pii: 10.1007/s10549-020-05904.
PubMed Abstract available

VAN NIJNATTEN TJA, van Tiel LPT, Voogd AC, Groothuis-Oudshoorn CGM, et al
The effect of breast MRI on disease-free and overall survival in breast cancer patients: a retrospective population-based study.
Breast Cancer Res Treat. 2020 Sep 15. pii: 10.1007/s10549-020-05906.
PubMed Abstract available

GOLDFARB SB, Turan V, Bedoschi G, Taylan E, et al
Impact of adjuvant chemotherapy or tamoxifen-alone on the ovarian reserve of young women with breast cancer.
Breast Cancer Res Treat. 2020 Sep 15. pii: 10.1007/s10549-020-05933.
PubMed Abstract available

PALLESCHI M, Scarpi E, Casadei C
Body mass index (BMI) and benefit from adjuvant chemotherapy in breast cancer: is it enough?
Breast Cancer Res Treat. 2020 Sep 14. pii: 10.1007/s10549-020-05923.
PubMed

MONTAGNA E, Pagan E, Bagnardi V, Colleoni M, et al
Evaluation of endocrine therapy and patients preferences in early breast cancer: results of Elena study.
Breast Cancer Res Treat. 2020 Sep 14. pii: 10.1007/s10549-020-05900.
PubMed Abstract available

HAN Y, Miao ZF, Lian M, Peterson LL, et al
Racial and ethnic disparities in 21-gene recurrence scores, chemotherapy, and survival among women with hormone receptor-positive, node-negative breast cancer.
Breast Cancer Res Treat. 2020 Sep 14. pii: 10.1007/s10549-020-05902.
PubMed Abstract available

KOU K, Cameron J, Aitken JF, Youl P, et al
Factors associated with being diagnosed with high severity of breast cancer: a population-based study in Queensland, Australia.
Breast Cancer Res Treat. 2020 Sep 14. pii: 10.1007/s10549-020-05905.
PubMed Abstract available

ABDELHAFEZ AH, Musall BC, Adrada BE, Hess K, et al
Tumor necrosis by pretreatment breast MRI: association with neoadjuvant systemic therapy (NAST) response in triple-negative breast cancer (TNBC).
Breast Cancer Res Treat. 2020 Sep 13. pii: 10.1007/s10549-020-05917.
PubMed Abstract available

TAKAHASHI M, Ohtani S, Nagai SE, Takashima S, et al
The efficacy and safety of pertuzumab plus trastuzumab and docetaxel as a first-line therapy in Japanese patients with inoperable or recurrent HER2-positive breast cancer: the COMACHI study.
Breast Cancer Res Treat. 2020 Sep 13. pii: 10.1007/s10549-020-05921.
PubMed Abstract available

MENEVEAU MO, Keim-Malpass J, Camacho TF, Anderson RT, et al
Predicting adjuvant endocrine therapy initiation and adherence among older women with early-stage breast cancer.
Breast Cancer Res Treat. 2020 Sep 12. pii: 10.1007/s10549-020-05908.
PubMed Abstract available

FRISELL A, Lagergren J, Halle M, de Boniface J, et al
Risk factors for implant failure following revision surgery in breast cancer patients with a previous immediate implant-based breast reconstruction.
Breast Cancer Res Treat. 2020 Sep 12. pii: 10.1007/s10549-020-05911.
PubMed Abstract available

VOGSEN M, Jensen JD, Christensen IY, Gerke O, et al
FDG-PET/CT in high-risk primary breast cancer-a prospective study of stage migration and clinical impact.
Breast Cancer Res Treat. 2020 Sep 12. pii: 10.1007/s10549-020-05929.
PubMed Abstract available

LIN Y, Lin L, Fu F, Wang C, et al
Quantitative proteomics reveals stage-specific protein regulation of triple negative breast cancer.
Breast Cancer Res Treat. 2020 Sep 12. pii: 10.1007/s10549-020-05916.
PubMed Abstract available

YUSUFOV M, Nathan M, Wiley A, Russell J, et al
Predictors of increased risk for early treatment non-adherence to oral anti-estrogen therapies in early-stage breast cancer patients.
Breast Cancer Res Treat. 2020 Sep 12. pii: 10.1007/s10549-020-05920.
PubMed Abstract available

MAO D, Hachem H, Chang H, Dima D, et al
Treatment interruption and discontinuation of hormonal therapy in hormone receptor-positive breast cancer patients.
Breast Cancer Res Treat. 2020 Sep 12. pii: 10.1007/s10549-020-05892.
PubMed Abstract available

CALIP GS, Kidd J, Bernhisel R, Cox HC, et al
Family history of breast cancer in men with non-BRCA male breast cancer: implications for cancer risk counseling.
Breast Cancer Res Treat. 2020 Sep 11. pii: 10.1007/s10549-020-05922.
PubMed Abstract available

HISOSHIMA M, Urano M, Ohashi K, Ogawa M, et al
Utility of 70-kV single-energy CT in depicting the extent of breast cancer for preoperative planning.
Breast Cancer Res Treat. 2020 Sep 10. pii: 10.1007/s10549-020-05909.
PubMed Abstract available

XING CY, Doose M, Qin B, Lin Y, et al
Pre-diagnostic allostatic load and health-related quality of life in a cohort of Black breast cancer survivors.
Breast Cancer Res Treat. 2020 Sep 10. pii: 10.1007/s10549-020-05901.
PubMed Abstract available

YANG Y, Zhao J, Mao Y, Lin G, et al
UBR5 over-expression contributes to poor prognosis and tamoxifen resistance of ERa+ breast cancer by stabilizing beta-catenin.
Breast Cancer Res Treat. 2020 Sep 10. pii: 10.1007/s10549-020-05899.
PubMed Abstract available

SOLLENA P, Nikolaou V, Soupos N, Kotteas E, et al
Vitiligo-like lesions in patients with advanced breast cancer treated with cycline-dependent kinases 4 and 6 inhibitors.
Breast Cancer Res Treat. 2020 Sep 10. pii: 10.1007/s10549-020-05914.
PubMed Abstract available

LEE KT, Jacobs L, Walsh EM, Stearns V, et al
Effect of delays in initiation of adjuvant endocrine therapy on survival among women with breast cancer.
Breast Cancer Res Treat. 2020 Sep 10. pii: 10.1007/s10549-020-05910.
PubMed Abstract available

DE REZENDE LF, Francisco VE, Franco RL
Telerehabilitation for patients with breast cancer through the COVID-19 pandemic.
Breast Cancer Res Treat. 2020 Sep 10. pii: 10.1007/s10549-020-05926.
PubMed

CHA C, Lee J, Kim D, Park S, et al
Comparison of resection margin status after single or double radiopaque marker insertion for tumor localization in breast cancer patients receiving neoadjuvant chemotherapy.
Breast Cancer Res Treat. 2020 Sep 9. pii: 10.1007/s10549-020-05907.
PubMed Abstract available

SUN Y, Li Y, Wu J, Tian H, et al
Nomograms for prediction of overall and cancer-specific survival in young breast cancer.
Breast Cancer Res Treat. 2020 Sep 4. pii: 10.1007/s10549-020-05870.
PubMed Abstract available

CHEN R, Ma G, Xia T
Letter to the editor with regard to the manuscript titled "Circulating tumour cell enumeration does not correlate with Miller-Payne grade in a cohort of breast cancer patients undergoing neoadjuvant chemotherapy".
Breast Cancer Res Treat. 2020 Sep 4. pii: 10.1007/s10549-020-05886.
PubMed

KO NY, Qureshi MM, Oladeru OT, Cassidy MR, et al
Racial differences in genomic testing and receipt of endocrine therapy in early-stage breast cancer.
Breast Cancer Res Treat. 2020 Sep 4. pii: 10.1007/s10549-020-05888.
PubMed Abstract available

ZHANG Y, Liu J, Raj-Kumar PK, Sturtz LA, et al
Development and validation of prognostic gene signature for basal-like breast cancer and high-grade serous ovarian cancer.
Breast Cancer Res Treat. 2020 Sep 2. pii: 10.1007/s10549-020-05884.
PubMed Abstract available

GONZALEZ-SANTIAGO S, Saura C, Ciruelos E, Alonso JL, et al
Real-world effectiveness of dual HER2 blockade with pertuzumab and trastuzumab for neoadjuvant treatment of HER2-positive early breast cancer (The NEOPETRA Study).
Breast Cancer Res Treat. 2020 Sep 2. pii: 10.1007/s10549-020-05866.
PubMed Abstract available

SCHAIRER C, Hablas A, Eldein IAS, Gaafar R, et al
Risk factors for inflammatory and non-inflammatory breast cancer in North Africa.
Breast Cancer Res Treat. 2020 Sep 2. pii: 10.1007/s10549-020-05864.
PubMed Abstract available

NIETZ S, O'Neil DS, Ayeni O, Chen WC, et al
A comparison of complete pathologic response rates following neoadjuvant chemotherapy among South African breast cancer patients with and without concurrent HIV infection.
Breast Cancer Res Treat. 2020 Sep 1. pii: 10.1007/s10549-020-05889.
PubMed Abstract available

GUVAKOVA MA, Prabakaran I, Wu Z, Hoffman DI, et al
CDH2/N-cadherin and early diagnosis of invasion in patients with ductal carcinoma in situ.
Breast Cancer Res Treat. 2020;183:333-346.
PubMed Abstract available

BROWNE JL, Korsun N, Casas L, Rodriguez I, et al
"Are changes in breast density during the menstrual cycle relevant? To what?"
Breast Cancer Res Treat. 2020;183:451-458.
PubMed Abstract available

KAIDAR-PERSON O, Poortmans P, Offersen BV, Siesling S, et al
Spatial location of local recurrences after mastectomy: a systematic review.
Breast Cancer Res Treat. 2020;183:263-273.
PubMed Abstract available

WONG EC, Kaplan CP, Barulich M, Melisko M, et al
Assessing preferences for receiving supportive care resources among patients seen at a Breast Care Center.
Breast Cancer Res Treat. 2020;183:381-389.
PubMed Abstract available

JUNG JJ, Kang E, Kim EK, Kim SM, et al
External validation and modification of nomogram for predicting positive resection margins before breast conserving surgery.
Breast Cancer Res Treat. 2020;183:373-380.
PubMed Abstract available

LI K, Liao N, Chen B, Zhang G, et al
Genetic mutation profile of Chinese HER2-positive breast cancers and genetic predictors of responses to Neoadjuvant anti-HER2 therapy.
Breast Cancer Res Treat. 2020;183:321-332.
PubMed Abstract available

HENDRIKS MP, Verbeek XAAM, van Manen JG, van der Heijden SE, et al
Clinical decision trees support systematic evaluation of multidisciplinary team recommendations.
Breast Cancer Res Treat. 2020;183:355-363.
PubMed Abstract available

GOEL AK, Zamre V, Hari S
Variation in pathological complete response in HER2-positive breast cancers with intrinsic subtypes assessed by PAM50 testing: secondary analysis from NSABP B-41 trial.
Breast Cancer Res Treat. 2020;183:489-490.
PubMed

August 2020

LYNGE E, Beau AB, von Euler-Chelpin M, Napolitano G, et al
Breast cancer mortality and overdiagnosis after implementation of population-based screening in Denmark.
Breast Cancer Res Treat. 2020 Aug 30. pii: 10.1007/s10549-020-05896.
PubMed Abstract available

HOWELL SJ, Coe F, Wang X, Horsley L, et al
Carboplatin dose capping affects pCR rate in HER2-positive breast cancer patients treated with neoadjuvant Docetaxel, Carboplatin, Trastuzumab, Pertuzumab (TCHP).
Breast Cancer Res Treat. 2020 Aug 29. pii: 10.1007/s10549-020-05868.
PubMed Abstract available

KIM JY, Park K, Im SA, Jung KH, et al
Clinical implications of HER2 mRNA expression and intrinsic subtype in refractory HER2-positive metastatic breast cancer treated with pan-HER inhibitor, poziotinib.
Breast Cancer Res Treat. 2020 Aug 28. pii: 10.1007/s10549-020-05891.
PubMed Abstract available

ERBER R, Rubner M, Davenport S, Hauke S, et al
Impact of fibroblast growth factor receptor 1 (FGFR1) amplification on the prognosis of breast cancer patients.
Breast Cancer Res Treat. 2020 Aug 27. pii: 10.1007/s10549-020-05865.
PubMed Abstract available

PIZZATO M, Carioli G, Rosso S, Zanetti R, et al
The impact of selected risk factors among breast cancer molecular subtypes: a case-only study.
Breast Cancer Res Treat. 2020 Aug 26. pii: 10.1007/s10549-020-05820.
PubMed Abstract available

HERMANN N, Klil-Drori A, Angarita FA, Westergard S, et al
Screening women at high risk for breast cancer: one program fits all? : Subgroup analysis of a large population high risk breast screening program.
Breast Cancer Res Treat. 2020 Aug 26. pii: 10.1007/s10549-020-05895.
PubMed Abstract available

SUNDBOLL J, Farkas DK, Adelborg K, Schapira L, et al
Risk of primary urological and genital cancers following incident breast cancer: a Danish population-based cohort study.
Breast Cancer Res Treat. 2020 Aug 26. pii: 10.1007/s10549-020-05879.
PubMed Abstract available

TRANT AA, Walz L, Allen W, DeJesus J, et al
Increasing accrual of minority patients in breast cancer clinical trials.
Breast Cancer Res Treat. 2020 Aug 25. pii: 10.1007/s10549-020-05873.
PubMed Abstract available

OGIYA R, Niikura N, Kumamaru H, Takeuchi Y, et al
Breast cancer survival among Japanese individuals and US residents of Japanese and other origins: a comparative registry-based study.
Breast Cancer Res Treat. 2020 Aug 20. pii: 10.1007/s10549-020-05869.
PubMed Abstract available

RIEDEL F, Heil J, Feisst M, Moderow M, et al
Analyzing non-sentinel axillary metastases in patients with T3-T4 cN0 early breast cancer and tumor-involved sentinel lymph nodes undergoing breast-conserving therapy or mastectomy.
Breast Cancer Res Treat. 2020 Aug 20. pii: 10.1007/s10549-020-05876.
PubMed Abstract available

DE BOER AZ, van de Water W, Bastiaannet E, de Glas NA, et al
Early stage breast cancer treatment and outcome of older patients treated in an oncogeriatric care and a standard care setting: an international comparison.
Breast Cancer Res Treat. 2020 Aug 19. pii: 10.1007/s10549-020-05860.
PubMed Abstract available

KIM JY, Jung HH, Sohn I, Woo SY, et al
Prognostication of a 13-immune-related-gene signature in patients with early triple-negative breast cancer.
Breast Cancer Res Treat. 2020 Aug 18. pii: 10.1007/s10549-020-05874.
PubMed Abstract available

KILBREATH SL, Ward LC, Davis GM, Degnim AC, et al
Reduction of breast lymphoedema secondary to breast cancer: a randomised controlled exercise trial.
Breast Cancer Res Treat. 2020 Aug 18. pii: 10.1007/s10549-020-05863.
PubMed Abstract available

DIXON JM, Grewar J, Twelves D, Graham A, et al
Factors affecting the number of sentinel lymph nodes removed in patients having surgery for breast cancer.
Breast Cancer Res Treat. 2020 Aug 18. pii: 10.1007/s10549-020-05843.
PubMed Abstract available

BAGHERZADEH M, Szymiczek A, Donenberg T, Butler R, et al
Association of RAD51C germline mutations with breast cancer among Bahamians.
Breast Cancer Res Treat. 2020 Aug 18. pii: 10.1007/s10549-020-05872.
PubMed Abstract available

KAZMI S, Chatterjee D, Raju D, Hauser R, et al
Overall survival analysis in patients with metastatic breast cancer and liver or lung metastases treated with eribulin, gemcitabine, or capecitabine.
Breast Cancer Res Treat. 2020 Aug 17. pii: 10.1007/s10549-020-05867.
PubMed Abstract available

TEODOZIO CGC, Marchito LO, Fabro EAN, Macedo FO, et al
Shoulder amplitude movement does not influence postoperative wound complications after breast cancer surgery: a randomized clinical trial.
Breast Cancer Res Treat. 2020 Aug 17. pii: 10.1007/s10549-020-05826.
PubMed Abstract available

CAVALCANTE FP, Novita GG, Millen EC, Zerwes FP, et al
Management of early breast cancer during the COVID-19 pandemic in Brazil.
Breast Cancer Res Treat. 2020 Aug 16. pii: 10.1007/s10549-020-05877.
PubMed Abstract available

BRAAL CL, Hussaarts KGAM, Seuren L, Oomen-de Hoop E, et al
Influence of green tea consumption on endoxifen steady-state concentration in breast cancer patients treated with tamoxifen.
Breast Cancer Res Treat. 2020 Aug 16. pii: 10.1007/s10549-020-05829.
PubMed Abstract available

GEORGE MA, Lustberg MB, Orchard TS
Psychoneurological symptom cluster in breast cancer: the role of inflammation and diet.
Breast Cancer Res Treat. 2020 Aug 15. pii: 10.1007/s10549-020-05808.
PubMed Abstract available

LIANG R
Letter to the editor Re: Pan et al. "LLY17, a novel small molecule STAT3 inhibitor induces apoptosis and suppresses cell migration and tumor growth in triple-negative breast cancer".
Breast Cancer Res Treat. 2020 Aug 14. pii: 10.1007/s10549-020-05853.
PubMed

DIAMOND JR, Becerra C, Richards D, Mita A, et al
Phase Ib clinical trial of the anti-frizzled antibody vantictumab (OMP-18R5) plus paclitaxel in patients with locally advanced or metastatic HER2-negative breast cancer.
Breast Cancer Res Treat. 2020 Aug 14. pii: 10.1007/s10549-020-05817.
PubMed Abstract available

BARTLETT DB, Broadwater G, White HK, Shelby R, et al
Factors associated with falls in older women with breast cancer: the use of a brief geriatric screening tool in clinic.
Breast Cancer Res Treat. 2020 Aug 13. pii: 10.1007/s10549-020-05862.
PubMed Abstract available

D'HONDT C, Vanhoeij M, Van Moer E, Segers I, et al
Fertility preservation does not delay the initiation of chemotherapy in breast cancer patients treated with adjuvant or neo-adjuvant chemotherapy.
Breast Cancer Res Treat. 2020 Aug 13. pii: 10.1007/s10549-020-05858.
PubMed Abstract available

RUGO HS, Dieras V, Cortes J, Patt D, et al
Real-world survival outcomes of heavily pretreated patients with refractory HR+, HER2-metastatic breast cancer receiving single-agent chemotherapy-a comparison with MONARCH 1.
Breast Cancer Res Treat. 2020 Aug 12. pii: 10.1007/s10549-020-05838.
PubMed Abstract available

KANJANAPAN Y, Lok SW, Gibbs P, De Boer R, et al
Impact of prior (neo)adjuvant trastuzumab (NAT) exposure on the efficacy of HER2-targeted therapy for metastatic breast cancer.
Breast Cancer Res Treat. 2020 Aug 10. pii: 10.1007/s10549-020-05825.
PubMed Abstract available

CADY B, Fulton JP
57% decline in Rhode Island invasive breast cancer mortality between 1987 and 2017: mammography predominates in preventing mortality.
Breast Cancer Res Treat. 2020 Aug 10. pii: 10.1007/s10549-020-05834.
PubMed Abstract available

ZHANG Y, Dian L, Wei X, Huang J, et al
Physicians' attitudes towards reproduction in young patients with early breast cancer in China.
Breast Cancer Res Treat. 2020 Aug 10. pii: 10.1007/s10549-020-05854.
PubMed Abstract available

BI Z, Chen P, Liu YB, Zhao T, et al
Efficacy and safety analysis of paclitaxel, docetaxel and liposomal paclitaxel after neoadjuvant therapy in breast cancer.
Breast Cancer Res Treat. 2020 Aug 10. pii: 10.1007/s10549-020-05851.
PubMed Abstract available

SOKOLENKO AP, Sokolova TN, Ni VI, Preobrazhenskaya EV, et al
Frequency and spectrum of founder and non-founder BRCA1 and BRCA2 mutations in a large series of Russian breast cancer and ovarian cancer patients.
Breast Cancer Res Treat. 2020 Aug 9. pii: 10.1007/s10549-020-05827.
PubMed Abstract available

CRYSTAL JS, Rand J, Johnson J, Kim S, et al
Adjuvant endocrine therapy is associated with improved overall survival in elderly hormone receptor-positive breast cancer patients.
Breast Cancer Res Treat. 2020 Aug 9. pii: 10.1007/s10549-020-05823.
PubMed Abstract available

PAPAUTSKY EL, Hamlish T
Patient-reported treatment delays in breast cancer care during the COVID-19 pandemic.
Breast Cancer Res Treat. 2020 Aug 9. pii: 10.1007/s10549-020-05828.
PubMed Abstract available

TREVINO KM, Iyengar N, Li Q, Mao JJ, et al
Receipt of psychological counseling and integrative medicine services among breast cancer survivors with anxiety.
Breast Cancer Res Treat. 2020 Aug 9. pii: 10.1007/s10549-020-05859.
PubMed Abstract available

CHEN J, Lai YH, Ooi S, Song Y, et al
BTB domain-containing 7 predicts low recurrence and suppresses tumor progression by deactivating Notch1 signaling in breast cancer.
Breast Cancer Res Treat. 2020 Aug 8. pii: 10.1007/s10549-020-05857.
PubMed Abstract available

SCHETTINI F, Sobhani N, Ianza A, Triulzi T, et al
Immune system and angiogenesis-related potential surrogate biomarkers of response to everolimus-based treatment in hormone receptor-positive breast cancer: an exploratory study.
Breast Cancer Res Treat. 2020 Aug 7. pii: 10.1007/s10549-020-05856.
PubMed Abstract available

WILLIAMS CB, Nebhan CA, Yang J, Starnes LS, et al
Correlative studies investigating effects of PI3K inhibition on peripheral leukocytes in metastatic breast cancer: potential implications for immunotherapy.
Breast Cancer Res Treat. 2020 Aug 7. pii: 10.1007/s10549-020-05846.
PubMed Abstract available

SALTBAEK L, Horsboel TA, Offersen BV, Andersson M, et al
Patterns in detection of recurrence among patients treated for breast cancer.
Breast Cancer Res Treat. 2020 Aug 6. pii: 10.1007/s10549-020-05847.
PubMed Abstract available

PATEL MA, Shah JL, Abrahamse PH, Jagsi R, et al
A population-based study of invitation to and participation in clinical trials among women with early-stage breast cancer.
Breast Cancer Res Treat. 2020 Aug 5. pii: 10.1007/s10549-020-05844.
PubMed Abstract available

ZHOU YT, Zheng LY, Wang YJ, Yang L, et al
Effect of functional variant rs11466313 on breast cancer susceptibility and TGFB1 promoter activity.
Breast Cancer Res Treat. 2020 Aug 5. pii: 10.1007/s10549-020-05841.
PubMed Abstract available

SKRIVER SK, Jensen MB, Eriksen JO, Ahlborn LB, et al
Induction of PIK3CA alterations during neoadjuvant letrozole may improve outcome in postmenopausal breast cancer patients.
Breast Cancer Res Treat. 2020 Aug 3. pii: 10.1007/s10549-020-05833.
PubMed Abstract available

SPECHT M, Sobti N, Rosado N, Tomczyk E, et al
High-Efficiency Same-Day Approach to Breast Reconstruction During the COVID-19 Crisis.
Breast Cancer Res Treat. 2020;182:679-688.
PubMed Abstract available

GAO W, Zeng Y, Fei X, Chen X, et al
Axillary lymph node and non-sentinel lymph node metastasis among the ACOSOG Z0011 eligible breast cancer patients with invasive ductal, invasive lobular, or other histological special types: a multi-institutional retrospective analysis.
Breast Cancer Res Treat. 2020 Aug 1. pii: 10.1007/s10549-020-05842.
PubMed Abstract available

ZEIDMAN M, Alberty-Oller JJ, Ru M, Pisapati KV, et al
Use of neoadjuvant versus adjuvant chemotherapy for hormone receptor-positive breast cancer: a National Cancer Database (NCDB) study.
Breast Cancer Res Treat. 2020 Aug 1. pii: 10.1007/s10549-020-05809.
PubMed Abstract available

AOYAGI K, Higuchi Y, Matsunaga S, Serizawa T, et al
Impact of breast cancer subtype on clinical outcomes after Gamma Knife radiosurgery for brain metastases from breast cancer: a multi-institutional retrospective study (JLGK1702).
Breast Cancer Res Treat. 2020 Aug 1. pii: 10.1007/s10549-020-05835.
PubMed Abstract available

JOONA TB, Digkas E, Wennstig AK, Nystrom K, et al
Influenza vaccination in breast cancer patients during subcutaneous trastuzumab in adjuvant setting.
Breast Cancer Res Treat. 2020 Aug 1. pii: 10.1007/s10549-020-05815.
PubMed Abstract available

SANDERINK WBG, Strobbe LJA, Bult P, Schlooz-Vries MS, et al
Minimally invasive breast cancer excision using the breast lesion excision system under ultrasound guidance.
Breast Cancer Res Treat. 2020 Aug 1. pii: 10.1007/s10549-020-05814.
PubMed Abstract available

KOPPARTHY P, Daily K
A case for Tamoxifen with ovarian function suppression.
Breast Cancer Res Treat. 2020;183:241-242.
PubMed

AZAM S, Jacobsen KK, Aro AR, Lynge E, et al
Hormone replacement therapy and mammographic density: a systematic literature review.
Breast Cancer Res Treat. 2020;182:555-579.
PubMed Abstract available

ABBATE O, Rosado N, Sobti N, Vieira BL, et al
Meta-analysis of prepectoral implant-based breast reconstruction: guide to patient selection and current outcomes.
Breast Cancer Res Treat. 2020;182:543-554.
PubMed Abstract available

LEEVAN E, Ho BT, Seto S, Shen J, et al
Use of MarginProbe as an adjunct to standard operating procedure does not significantly reduce re-excision rates in breast conserving surgery.
Breast Cancer Res Treat. 2020;183:145-151.
PubMed Abstract available

NAOUM GE, Oladeru OT, Niemierko A, Salama L, et al
Optimal breast reconstruction type for patients treated with neoadjuvant chemotherapy, mastectomy followed by radiation therapy.
Breast Cancer Res Treat. 2020;183:127-136.
PubMed Abstract available

LIU D
Identification of a prognostic LncRNA signature for ER-positive, ER-negative and triple-negative breast cancers.
Breast Cancer Res Treat. 2020;183:95-105.
PubMed Abstract available

July 2020

HULL O, Niranjan SJ, Wallace AS, Williams BR, et al
Should we be talking about guidelines with patients? A qualitative analysis in metastatic breast cancer.
Breast Cancer Res Treat. 2020 Jul 31. pii: 10.1007/s10549-020-05832.
PubMed Abstract available

HOTTON J, Salleron J, Henrot P, Buhler J, et al
Pre-operative axillary ultrasound with fine-needle aspiration cytology performance and predictive factors of false negatives in axillary lymph node involvement in early breast cancer.
Breast Cancer Res Treat. 2020 Jul 31. pii: 10.1007/s10549-020-05830.
PubMed Abstract available

AL AMRI WS, Baxter DE, Hanby AM, Stead LF, et al
Identification of candidate mediators of chemoresponse in breast cancer through therapy-driven selection of somatic variants.
Breast Cancer Res Treat. 2020 Jul 30. pii: 10.1007/s10549-020-05836.
PubMed Abstract available

AKS R, Peleg Hasson S, Sivan A, Kohen T, et al
Diagnostic workup of early-stage breast cancer: can we choose more wisely?
Breast Cancer Res Treat. 2020 Jul 29. pii: 10.1007/s10549-020-05813.
PubMed Abstract available

ROSA DD, Bines J, Werutsky G, Barrios CH, et al
The impact of sociodemographic factors and health insurance coverage in the diagnosis and clinicopathological characteristics of breast cancer in Brazil: AMAZONA III study (GBECAM 0115).
Breast Cancer Res Treat. 2020 Jul 29. pii: 10.1007/s10549-020-05831.
PubMed Abstract available

CHAINITIKUN S, Long JP, Rodriguez-Bautista R, Iwase T, et al
The efficacy of first-line chemotherapy in endocrine-resistant hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer.
Breast Cancer Res Treat. 2020 Jul 27. pii: 10.1007/s10549-020-05837.
PubMed Abstract available

HARDER H, Shilling VM, May SF, Cella D, et al
The development and initial evaluation of the Diarrhoea Management Diary (DMD) in patients with metastatic breast cancer.
Breast Cancer Res Treat. 2020 Jul 27. pii: 10.1007/s10549-020-05798.
PubMed Abstract available

WANG L, He Y, Li J, Wang T, et al
Comparisons of breast conserving therapy versus mastectomy in young and old women with early-stage breast cancer: long-term results using propensity score adjustment method.
Breast Cancer Res Treat. 2020 Jul 26. pii: 10.1007/s10549-020-05821.
PubMed Abstract available

ZHAO J, Meisel J, Guo Y, Nahta R, et al
Evaluation of PD-L1, tumor-infiltrating lymphocytes, and CD8+ and FOXP3+ immune cells in HER2-positive breast cancer treated with neoadjuvant therapies.
Breast Cancer Res Treat. 2020 Jul 26. pii: 10.1007/s10549-020-05819.
PubMed Abstract available

KIM SH, Ahn S, Suh KJ, Kim YJ, et al
Identifying germline APOBEC3B deletion and immune phenotype in Korean patients with operable breast cancer.
Breast Cancer Res Treat. 2020 Jul 26. pii: 10.1007/s10549-020-05811.
PubMed Abstract available

SMITH BL, Nguyen A, Korotkin JE, Kelly BN, et al
A system for risk stratification and prioritization of breast cancer surgeries delayed by the COVID-19 pandemic: preparing for re-entry.
Breast Cancer Res Treat. 2020 Jul 25. pii: 10.1007/s10549-020-05792.
PubMed Abstract available

TAHIRI A, Tekpli X, Satheesh SV, DeWijn R, et al
Loss of progesterone receptor is associated with distinct tyrosine kinase profiles in breast cancer.
Breast Cancer Res Treat. 2020 Jul 24. pii: 10.1007/s10549-020-05763.
PubMed Abstract available

DUDEK AZ, Liu LC, Fischer JH, Wiley EL, et al
Phase 1 study of TTC-352 in patients with metastatic breast cancer progressing on endocrine and CDK4/6 inhibitor therapy.
Breast Cancer Res Treat. 2020 Jul 22. pii: 10.1007/s10549-020-05787.
PubMed Abstract available

KARLSSON F, Granath F, Smedby KE, Zedenius J, et al
Sarcoma of the breast: breast cancer history as etiologic and prognostic factor-A population-based case-control study.
Breast Cancer Res Treat. 2020 Jul 21. pii: 10.1007/s10549-020-05802.
PubMed Abstract available

CHEPIKOVA OE, Malin D, Strekalova E, Lukasheva EV, et al
Lysine oxidase exposes a dependency on the thioredoxin antioxidant pathway in triple-negative breast cancer cells.
Breast Cancer Res Treat. 2020 Jul 21. pii: 10.1007/s10549-020-05801.
PubMed Abstract available

YAP NY, Tan NYT, Tan CJ, Loh KW, et al
Associations of plasma brain-derived neurotrophic factor (BDNF) and Val66Met polymorphism (rs6265) with long-term cancer-related cognitive impairment in survivors of breast cancer.
Breast Cancer Res Treat. 2020 Jul 21. pii: 10.1007/s10549-020-05807.
PubMed Abstract available

FASANO J, Shao T, Huang HH, Kessler AJ, et al
Optimism and coping: do they influence health outcomes in women with breast cancer? A systemic review and meta-analysis.
Breast Cancer Res Treat. 2020 Jul 21. pii: 10.1007/s10549-020-05800.
PubMed Abstract available

MINAMI CA, King TA, Mittendorf EA
Patient preferences for locoregional therapy in early-stage breast cancer.
Breast Cancer Res Treat. 2020 Jul 20. pii: 10.1007/s10549-020-05737.
PubMed Abstract available

SCHAIRER C, Laurent CA, Moy LM, Gierach GL, et al
Obesity and related conditions and risk of inflammatory breast cancer: a nested case-control study.
Breast Cancer Res Treat. 2020 Jul 20. pii: 10.1007/s10549-020-05785.
PubMed Abstract available

BORTNIK S, Tessier-Cloutier B, Leung S, Xu J, et al
Differential expression and prognostic relevance of autophagy-related markers ATG4B, GABARAP, and LC3B in breast cancer.
Breast Cancer Res Treat. 2020 Jul 20. pii: 10.1007/s10549-020-05795.
PubMed Abstract available

FINN RS, Boer K, Bondarenko I, Patel R, et al
Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2- advanced breast cancer (PALOMA-1, TRIO-18).
Breast Cancer Res Treat. 2020 Jul 18. pii: 10.1007/s10549-020-05755.
PubMed Abstract available

ARABANDI P, Slade AN, Sutton AL, McGuire KP, et al
Racial differences in the relationship between surgical choice and subsequent patient-reported satisfaction outcomes among women with early-stage hormone-positive breast cancer.
Breast Cancer Res Treat. 2020 Jul 16. pii: 10.1007/s10549-020-05784.
PubMed Abstract available

MOFTAKHAR B, Lekkala M, Strawderman M, Smith TC, et al
Impact of early dose intensity reduction of Palbociclib on clinical outcomes in patients with hormone-receptor-positive metastatic breast cancer.
Breast Cancer Res Treat. 2020 Jul 15. pii: 10.1007/s10549-020-05793.
PubMed Abstract available

REN H, Mi X, Zhao P, Zhao X, et al
TRAF4, a new substrate of SIAH1, participates in chemotherapy resistance of breast cancer cell by counteracting SIAH1-mediated downregulation of beta-catenin.
Breast Cancer Res Treat. 2020 Jul 15. pii: 10.1007/s10549-020-05789.
PubMed Abstract available

HAM A, Kim MH, Kim GM, Kim JH, et al
Correction to: Palbociclib use with grade 3 neutropenia in hormone receptor-positive metastatic breast cancer.
Breast Cancer Res Treat. 2020 Jul 14. pii: 10.1007/s10549-020-05796.
PubMed Abstract available

BYRD BK, Krishnaswamy V, Gui J, Rooney T, et al
The shape of breast cancer.
Breast Cancer Res Treat. 2020 Jul 12. pii: 10.1007/s10549-020-05780.
PubMed Abstract available

MCEVOY AM, Poplack S, Nickel K, Olsen MA, et al
Cost-effectiveness analyses demonstrate that observation is superior to sentinel lymph node biopsy for postmenopausal women with HR + breast cancer and negative axillary ultrasound.
Breast Cancer Res Treat. 2020 Jul 10. pii: 10.1007/s10549-020-05768.
PubMed Abstract available

MISRA S, Lee G, Korzets Y, Wang L, et al
Patient-reported acute fatigue in elderly breast cancer patients treated with and without regional nodal radiation.
Breast Cancer Res Treat. 2020 Jul 10. pii: 10.1007/s10549-020-05781.
PubMed Abstract available

SANT M, Meneghini E, Bastos J, Rossi PG, et al
Endocrine treatment and incidence of relapse in women with oestrogen receptor-positive breast cancer in Europe: a population-based study.
Breast Cancer Res Treat. 2020 Jul 10. pii: 10.1007/s10549-020-05761.
PubMed Abstract available

DU ZL, Wang Y, Wang DY, Zhang L, et al
Evaluation of a beneficial effect of adjuvant chemotherapy in patients with stage I triple-negative breast cancer: a population-based study using the SEER 18 database.
Breast Cancer Res Treat. 2020 Jul 9. pii: 10.1007/s10549-020-05776.
PubMed Abstract available

THEIN KZ, Htut TW, Ball S, Swarup S, et al
Venous thromboembolism risk in patients with hormone receptor-positive HER2-negative metastatic breast cancer treated with combined CDK 4/6 inhibitors plus endocrine therapy versus endocrine therapy alone: a systematic review and meta-analysis of rand
Breast Cancer Res Treat. 2020 Jul 9. pii: 10.1007/s10549-020-05783.
PubMed Abstract available

ALTER BP, Best AF
Correction to: Frequency of heterozygous germline pathogenic variants in genes for Fanconi anemia in patients with non-BRCA1/BRCA2 breast cancer: a meta-analysis.
Breast Cancer Res Treat. 2020 Jul 8. pii: 10.1007/s10549-020-05775.
PubMed Abstract available

STOCKER A, Trojan A, Elfgen C, Hilbers ML, et al
Differential prognostic value of positive HER2 status determined by immunohistochemistry or fluorescence in situ hybridization in breast cancer.
Breast Cancer Res Treat. 2020 Jul 7. pii: 10.1007/s10549-020-05772.
PubMed Abstract available

BORRIE AE, Rose FA, Choi YH, Perera FE, et al
Genetic and clinical predictors of arthralgia during letrozole or anastrozole therapy in breast cancer patients.
Breast Cancer Res Treat. 2020 Jul 6. pii: 10.1007/s10549-020-05777.
PubMed Abstract available

WHITAKER KD, Sheth D, Olopade OI
Dynamic contrast-enhanced magnetic resonance imaging for risk-stratified screening in women with BRCA mutations or high familial risk for breast cancer: are we there yet?
Breast Cancer Res Treat. 2020 Jul 3. pii: 10.1007/s10549-020-05759.
PubMed Abstract available

CRISCITIELLO C, Vingiani A, Maisonneuve P, Viale G, et al
Tumor-infiltrating lymphocytes (TILs) in ER+/HER2- breast cancer.
Breast Cancer Res Treat. 2020 Jul 3. pii: 10.1007/s10549-020-05771.
PubMed Abstract available

WALTER V, Fischer C, Deutsch TM, Ersing C, et al
Estrogen, progesterone, and human epidermal growth factor receptor 2 discordance between primary and metastatic breast cancer.
Breast Cancer Res Treat. 2020 Jul 1. pii: 10.1007/s10549-020-05746.
PubMed Abstract available

VAN STEENHOVEN JEC, den Dekker BM, Kuijer A, van Diest PJ, et al
Patients' perceptions of 70-gene signature testing: commonly changing the initial inclination to undergo or forego chemotherapy and reducing decisional conflict.
Breast Cancer Res Treat. 2020;182:107-115.
PubMed Abstract available

RAMZI S, Najeeb E, Coulthard J, Jenkins S, et al
Does sentinel lymph node biopsy for screening high-grade ductal carcinoma in situ of the breast cause more harm than good?
Breast Cancer Res Treat. 2020;182:47-54.
PubMed Abstract available

DOFARA SG, Chang SL, Diorio C
Association between the polymorphisms in MMP-2 and MMP-9 with adiposity and mammographic features.
Breast Cancer Res Treat. 2020;182:169-179.
PubMed Abstract available

PASZAT L, Sutradhar R, Rakovitch E
The impact of ductal carcinoma in situ on health services utilization.
Breast Cancer Res Treat. 2020;182:159-168.
PubMed Abstract available

WATANABE T, Honda T, Totsuka H, Yoshida M, et al
Simple prediction model for homologous recombination deficiency in breast cancers in adolescents and young adults.
Breast Cancer Res Treat. 2020;182:491-502.
PubMed Abstract available

MISRA S, Lee G, Maganti M, Koch CA, et al
Utilization patterns and temporal trends of internal mammary nodal irradiation at a tertiary cancer center.
Breast Cancer Res Treat. 2020;182:367-379.
PubMed Abstract available

PALVE JS, Luukkaala TH, Kaariainen MT
Predictive risk factors of complications in different breast reconstruction methods.
Breast Cancer Res Treat. 2020;182:345-354.
PubMed Abstract available

IWAMOTO T, Hara F, Uemura Y, Mukai H, et al
NSAS-BC02 substudy of chemotherapy-induced amenorrhea (CIA) in premenopausal patients who received either taxane alone or doxorubicin(A) cyclophosphamide(C) followed by taxane as postoperative chemotherapy.
Breast Cancer Res Treat. 2020;182:325-332.
PubMed Abstract available

HASSAN Z, Boulos F, Abbas J, El Charif MH, et al
Intracystic papillary carcinoma: clinical presentation, patterns of practice, and oncological outcomes.
Breast Cancer Res Treat. 2020;182:317-323.
PubMed Abstract available

LEE MK, Sanaiha Y, Kusske AM, Thompson CK, et al
A comparison of two non-radioactive alternatives to wire for the localization of non-palpable breast cancers.
Breast Cancer Res Treat. 2020;182:299-303.
PubMed Abstract available

ANGARITA FA, Acuna SA, Cordeiro E, McCready DR, et al
Does oncoplastic surgery increase immediate (30-day) postoperative complications? An analysis of the American College of Surgeons National Surgical Quality Improvement Program (ACS NSQIP) database.
Breast Cancer Res Treat. 2020;182:429-438.
PubMed Abstract available

CRAGUN D, Weidner A, Tezak A, Clouse K, et al
Cancer risk management among female BRCA1/2, PALB2, CHEK2, and ATM carriers.
Breast Cancer Res Treat. 2020;182:421-428.
PubMed Abstract available

June 2020

GUO D, Hendryx M, Liang X, Manson JE, et al
Association between selenium intake and breast cancer risk: results from the Women's Health Initiative.
Breast Cancer Res Treat. 2020 Jun 30. pii: 10.1007/s10549-020-05764.
PubMed Abstract available

WANG DG, Barrios DM, Blinder VS, Bromberg JF, et al
Dermatologic adverse events related to the PI3Kalpha inhibitor alpelisib (BYL719) in patients with breast cancer.
Breast Cancer Res Treat. 2020 Jun 29. pii: 10.1007/s10549-020-05726.
PubMed Abstract available

KHALEFA HG, Shawki MA, Aboelhassan R, El Wakeel LM, et al
Evaluation of the effect of N-acetylcysteine on the prevention and amelioration of paclitaxel-induced peripheral neuropathy in breast cancer patients: a randomized controlled study.
Breast Cancer Res Treat. 2020 Jun 29. pii: 10.1007/s10549-020-05762.
PubMed Abstract available

YANG X, Zhao L, Pei J, Wang Z, et al
CELF6 modulates triple-negative breast cancer progression by regulating the stability of FBP1 mRNA.
Breast Cancer Res Treat. 2020 Jun 29. pii: 10.1007/s10549-020-05753.
PubMed Abstract available

CHEN FM, Huang LJ, Ou-Yang F, Kan JY, et al
Activation of mitochondrial unfolded protein response is associated with Her2-overexpression breast cancer.
Breast Cancer Res Treat. 2020 Jun 29. pii: 10.1007/s10549-020-05729.
PubMed Abstract available

DONAHUE PMC, Crescenzi R, Lee C, Garza M, et al
Magnetic resonance imaging and bioimpedance evaluation of lymphatic abnormalities in patients with breast cancer treatment-related lymphedema.
Breast Cancer Res Treat. 2020 Jun 29. pii: 10.1007/s10549-020-05765.
PubMed Abstract available

PERACHINO M, Poggio F, Lambertini M
Call for assessing treatment-induced gonadotoxicity of platinum-based chemotherapy in early breast cancer.
Breast Cancer Res Treat. 2020 Jun 28. pii: 10.1007/s10549-020-05767.
PubMed

YAO J, Liu Y, Cheng J
Standardize the management procedures for breast cancer patients during the outbreak of COVID-19 in Wuhan, China.
Breast Cancer Res Treat. 2020 Jun 27. pii: 10.1007/s10549-020-05743.
PubMed Abstract available

ACCORDINO MK, Wright JD, Buono D, Lin A, et al
Incidence and Predictors of Diabetes Mellitus after a Diagnosis of Early-Stage Breast Cancer in the Elderly Using Real-World Data.
Breast Cancer Res Treat. 2020 Jun 26. pii: 10.1007/s10549-020-05756.
PubMed Abstract available

HACKSHAW MD, Danysh HE, Singh J, Ritchey ME, et al
Incidence of pneumonitis/interstitial lung disease induced by HER2-targeting therapy for HER2-positive metastatic breast cancer.
Breast Cancer Res Treat. 2020 Jun 26. pii: 10.1007/s10549-020-05754.
PubMed Abstract available

CAVAZZA M, Banks H, Ercolanoni M, Cukaj G, et al
Factors influencing adherence to adjuvant endocrine therapy in breast cancer-treated women: using real-world data to inform a switch from acute to chronic disease management.
Breast Cancer Res Treat. 2020 Jun 26. pii: 10.1007/s10549-020-05748.
PubMed Abstract available

STASZEWSKY L, Robusto F, Lepore V, Bisceglia L, et al
Cardiovascular mortality and morbidity burden in successive and age pre-stratified case-control cohorts of breast cancer women. A population-based study.
Breast Cancer Res Treat. 2020 Jun 25. pii: 10.1007/s10549-020-05758.
PubMed Abstract available

HAM A, Kim MH, Kim GM, Kim JH, et al
Palbociclib use with grade 3 neutropenia in hormone receptor-positive metastatic breast cancer.
Breast Cancer Res Treat. 2020 Jun 23. pii: 10.1007/s10549-020-05750.
PubMed Abstract available

STARKINGS R, Shilling V, Jenkins V, Fallowfield L, et al
A systematic review of communication interventions to help healthcare professionals discuss genetic testing for breast cancer.
Breast Cancer Res Treat. 2020 Jun 23. pii: 10.1007/s10549-020-05741.
PubMed Abstract available

VERMA R, Hanby AM, Horgan K, Verghese ET, et al
Levels of different subtypes of tumour-infiltrating lymphocytes correlate with each other, with matched circulating lymphocytes, and with survival in breast cancer.
Breast Cancer Res Treat. 2020 Jun 23. pii: 10.1007/s10549-020-05757.
PubMed Abstract available

WEI Y, Wang X, Zhang Z, Zhao C, et al
Impact of NR5A2 and RYR2 3'UTR polymorphisms on the risk of breast cancer in a Chinese Han population.
Breast Cancer Res Treat. 2020 Jun 23. pii: 10.1007/s10549-020-05736.
PubMed Abstract available

ROBERTSON S, Acs B, Lippert M, Hartman J, et al
Prognostic potential of automated Ki67 evaluation in breast cancer: different hot spot definitions versus true global score.
Breast Cancer Res Treat. 2020 Jun 22. pii: 10.1007/s10549-020-05752.
PubMed Abstract available

HARBORG S, Heide-Jorgensen U, Ahern TP, Ewertz M, et al
Statin use and breast cancer recurrence in postmenopausal women treated with adjuvant aromatase inhibitors: a Danish population-based cohort study.
Breast Cancer Res Treat. 2020 Jun 22. pii: 10.1007/s10549-020-05749.
PubMed Abstract available

HORIMOTO Y, Sasahara N, Sasaki R, Hlaing MT, et al
High FOXA1 protein expression might predict late recurrence in patients with estrogen-positive and HER2-negative breast cancer.
Breast Cancer Res Treat. 2020 Jun 22. pii: 10.1007/s10549-020-05751.
PubMed Abstract available

XU B, Li W, Zhang Q, Shao Z, et al
Pertuzumab, trastuzumab, and docetaxel for Chinese patients with previously untreated HER2-positive locally recurrent or metastatic breast cancer (PUFFIN): a phase III, randomized, double-blind, placebo-controlled study.
Breast Cancer Res Treat. 2020 Jun 20. pii: 10.1007/s10549-020-05728.
PubMed Abstract available

CHENG AS, Leung SCY, Gao D, Burugu S, et al
Correction to: Mismatch repair protein loss in breast cancer: clinicopathological associations in a large British Columbia cohort.
Breast Cancer Res Treat. 2020 Jun 20. pii: 10.1007/s10549-020-05745.
PubMed Abstract available

CHAMBERLIN MD, Wells JD, Shee K, Bean JR, et al
Plasma DNA as a "liquid biopsy" incompletely complements tumor biopsy for identification of mutations in a case series of four patients with oligometastatic breast cancer.
Breast Cancer Res Treat. 2020 Jun 19. pii: 10.1007/s10549-020-05714.
PubMed Abstract available

HOWLADER NR, Rahman MM, Hossain MA, Sultana R, et al
Genetic polymorphisms in DNA repair genes XRCC1 and 3 are associated with increased risk of breast cancer in Bangladeshi population.
Breast Cancer Res Treat. 2020 Jun 19. pii: 10.1007/s10549-020-05738.
PubMed Abstract available

KAR A, Koto K, Walker D, Trudeau T, et al
ETS transcription factor ESE-1/Elf3 is an independent prognostic factor of survival in HR(+)HER2(+) breast cancer patients.
Breast Cancer Res Treat. 2020 Jun 19. pii: 10.1007/s10549-020-05734.
PubMed Abstract available

BESIC N, Smrekar J, Strazisar B
Chronic adverse effects after an axillary lymphadenectomy in breast cancer patients after administering weaker and stronger postoperative analgesia: results of a prospective double-blind randomized study.
Breast Cancer Res Treat. 2020 Jun 18. pii: 10.1007/s10549-020-05713.
PubMed Abstract available

OBENG-GYASI S, Oppong B, Paskett ED, Lustberg M, et al
Purposeful surgical delay and the coronavirus pandemic: how will black breast cancer patients fare?
Breast Cancer Res Treat. 2020 Jun 16. pii: 10.1007/s10549-020-05740.
PubMed Abstract available

AHMED M
The bottom line for lesion localization in breast cancer.
Breast Cancer Res Treat. 2020 Jun 13. pii: 10.1007/s10549-020-05735.
PubMed Abstract available

TOLLOSA DN, Holliday E, Hure A, Tavener M, et al
A 15-year follow-up study on long-term adherence to health behaviour recommendations in women diagnosed with breast cancer.
Breast Cancer Res Treat. 2020 Jun 13. pii: 10.1007/s10549-020-05704.
PubMed Abstract available

HOLMES DR
Breast cancer care during a pandemic: an opportune time for cryoablation?
Breast Cancer Res Treat. 2020 Jun 11. pii: 10.1007/s10549-020-05724.
PubMed Abstract available

RO EJ, Ryu SH, Park EY, Ryu JW, et al
PIBF1 suppresses the ATR/CHK1 signaling pathway and promotes proliferation and motility of triple-negative breast cancer cells.
Breast Cancer Res Treat. 2020 Jun 11. pii: 10.1007/s10549-020-05732.
PubMed Abstract available

O'KEEFE TJ, Wallace AM
Surveillance, Epidemiology, and End Results program underestimates breast cancer-specific mortality after ductal carcinoma in situ diagnosis.
Breast Cancer Res Treat. 2020 Jun 11. pii: 10.1007/s10549-020-05733.
PubMed

ZHANG J, Lin M, Jin Y, Gu L, et al
Cisplatin given at three divided doses for three consecutive days in metastatic breast cancer: an alternative schedule for one full dose with comparable efficacy but less CINV and hypomagnesaemia.
Breast Cancer Res Treat. 2020 Jun 10. pii: 10.1007/s10549-020-05730.
PubMed Abstract available

HEEG E, Jensen MB, Mureau MAM, Ejlertsen B, et al
Breast-contour preserving procedures for early-stage breast cancer: a population-based study of the trends, variation in practice and predictive characteristics in Denmark and the Netherlands.
Breast Cancer Res Treat. 2020 Jun 10. pii: 10.1007/s10549-020-05725.
PubMed Abstract available

ALTHOBITI M, Muftah AA, Aleskandarany MA, Joseph C, et al
The prognostic significance of BMI1 expression in invasive breast cancer is dependent on its molecular subtypes.
Breast Cancer Res Treat. 2020 Jun 10. pii: 10.1007/s10549-020-05719.
PubMed Abstract available

TZIKAS AK, Nemes S, Linderholm BK
A comparison between young and old patients with triple-negative breast cancer: biology, survival and metastatic patterns.
Breast Cancer Res Treat. 2020 Jun 10. pii: 10.1007/s10549-020-05727.
PubMed Abstract available

ALEIXO GFP, Shachar SS, Deal AM, Nyrop KA, et al
The association of body composition parameters and adverse events in women receiving chemotherapy for early breast cancer.
Breast Cancer Res Treat. 2020 Jun 9. pii: 10.1007/s10549-020-05731.
PubMed Abstract available

AKHTAR Z, Stearns V, Cartwright P, Blackford AL, et al
The effect of 1-day multidisciplinary clinic on breast cancer treatment.
Breast Cancer Res Treat. 2020 Jun 8. pii: 10.1007/s10549-020-05721.
PubMed Abstract available

VIDT ME, Potochny J, Dodge D, Green M, et al
The influence of mastectomy and reconstruction on residual upper limb function in breast cancer survivors.
Breast Cancer Res Treat. 2020 Jun 6. pii: 10.1007/s10549-020-05717.
PubMed Abstract available

PLYM A, Johansson ALV, Bower H, Wennstig AK, et al
Impact of chemotherapy, radiotherapy, and endocrine therapy on sick leave in women with early-stage breast cancer during a 5-year period: a population-based cohort study.
Breast Cancer Res Treat. 2020 Jun 6. pii: 10.1007/s10549-020-05720.
PubMed Abstract available

RAMIREZ-EXPOSITO MJ, Martinez-Martos JM, Duenas-Rodriguez B, Navarro-Cecilia J, et al
Neoadjuvant chemotherapy modifies serum pyrrolidone carboxypeptidase specific activity in women with breast cancer and influences circulating levels of GnRH and gonadotropins.
Breast Cancer Res Treat. 2020 Jun 6. pii: 10.1007/s10549-020-05723.
PubMed Abstract available

LEON-FERRE RA, Perez EA, Hillman DW, Bueno C, et al
N083E (Alliance): long-term outcomes of patients treated in a pilot phase II study of docetaxel, carboplatin, trastuzumab, and lapatinib as adjuvant therapy for early-stage HER2-positive breast cancer.
Breast Cancer Res Treat. 2020 Jun 5. pii: 10.1007/s10549-020-05709.
PubMed Abstract available

BUONO G, Crispo A, Giuliano M, De Angelis C, et al
Metabolic syndrome and early stage breast cancer outcome: results from a prospective observational study.
Breast Cancer Res Treat. 2020 Jun 4. pii: 10.1007/s10549-020-05701.
PubMed Abstract available

KRAJNAK S, Schnatz C, Almstedt K, Brenner W, et al
Low-dose metronomic chemotherapy as an efficient treatment option in metastatic breast cancer-results of an exploratory case-control study.
Breast Cancer Res Treat. 2020 Jun 3. pii: 10.1007/s10549-020-05711.
PubMed Abstract available

TREWIN CB, Johansson ALV, Hjerkind KV, Strand BH, et al
Stage-specific survival has improved for young breast cancer patients since 2000: but not equally.
Breast Cancer Res Treat. 2020 Jun 3. pii: 10.1007/s10549-020-05698.
PubMed Abstract available

ALTER BP, Best AF
Frequency of heterozygous germline pathogenic variants in genes for Fanconi anemia in patients with non-BRCA1/BRCA2 breast cancer: a meta-analysis.
Breast Cancer Res Treat. 2020 Jun 2. pii: 10.1007/s10549-020-05710.
PubMed Abstract available

REINHORN D, Yerushalmi R, Moore A, Desnoyers A, et al
Evolution in the risk of adverse events of adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer.
Breast Cancer Res Treat. 2020 Jun 1. pii: 10.1007/s10549-020-05715.
PubMed Abstract available

BERNSTEIN-MOLHO R, Friedman E, Kedar I, Laitman Y, et al
Diagnostic yield of multigene panel testing in an Israeli cohort: enrichment of low-penetrance variants.
Breast Cancer Res Treat. 2020;181:445-453.
PubMed Abstract available

NOORDMAN PCW, Klioueva NM, Weimann MN, Borgstein PJ, et al
Phyllodes tumors of the breast: a retrospective analysis of 57 cases.
Breast Cancer Res Treat. 2020;181:361-367.
PubMed Abstract available

DOLEN U, Thornton M, Tenenbaum MM, Aripoli A, et al
A prospective cohort study to analyze the interaction of tumor-to-breast volume in breast conservation therapy versus mastectomy with reconstruction.
Breast Cancer Res Treat. 2020;181:611-621.
PubMed Abstract available

BIJKERK E, van Kuijk SMJ, Lataster A, van der Hulst RRWJ, et al
Breast sensibility in bilateral autologous breast reconstruction with unilateral sensory nerve coaptation.
Breast Cancer Res Treat. 2020;181:599-610.
PubMed Abstract available

JIA M, Lin X, Zhou X, Yan H, et al
Diagnostic performance of automated breast ultrasound and handheld ultrasound in women with dense breasts.
Breast Cancer Res Treat. 2020;181:589-597.
PubMed Abstract available

SHEN T, Nitta H, Wei L, Parwani AV, et al
HER2 intratumoral heterogeneity is independently associated with distal metastasis and overall survival in HER2-positive breast carcinomas.
Breast Cancer Res Treat. 2020;181:519-527.
PubMed Abstract available

OBDEIJN IM, Mann RM, Loo CCE, Lobbes M, et al
The supplemental value of mammographic screening over breast MRI alone in BRCA2 mutation carriers.
Breast Cancer Res Treat. 2020;181:581-588.
PubMed Abstract available

May 2020

MIYASHITA H, Cruz C, Malamud S
Risk factors for skeletal-related events in patients with bone metastasis from breast cancer undergoing treatment with zoledronate.
Breast Cancer Res Treat. 2020 May 30. pii: 10.1007/s10549-020-05712.
PubMed Abstract available

WU AH, Tseng C, Vigen C, Yu Y, et al
Gut microbiome associations with breast cancer risk factors and tumor characteristics: a pilot study.
Breast Cancer Res Treat. 2020 May 28. pii: 10.1007/s10549-020-05702.
PubMed Abstract available

WARD MC, Vicini F, Al-Hilli Z, Chadha M, et al
Cost-effectiveness analysis of endocrine therapy alone versus partial-breast irradiation alone versus combined treatment for low-risk hormone-positive early-stage breast cancer in women aged 70 years or older.
Breast Cancer Res Treat. 2020 May 28. pii: 10.1007/s10549-020-05706.
PubMed Abstract available

CHO H, Lee S, Sim SH, Park IH, et al
Cumulative incidence of chemotherapy-induced cardiotoxicity during a 2-year follow-up period in breast cancer patients.
Breast Cancer Res Treat. 2020 May 28. pii: 10.1007/s10549-020-05703.
PubMed Abstract available

ONG CT, Ren Y, Thomas SM, Stashko I, et al
Overall health at diagnosis predicts the risk of complications within the first year after breast cancer diagnosis.
Breast Cancer Res Treat. 2020 May 28. pii: 10.1007/s10549-020-05700.
PubMed Abstract available

MUSTONEN L, Vollert J, Rice ASC, Kalso E, et al
Sensory profiles in women with neuropathic pain after breast cancer surgery.
Breast Cancer Res Treat. 2020 May 27. pii: 10.1007/s10549-020-05681.
PubMed Abstract available

BEITSCH P, Whitworth P, Patel R
Response to the article by Dietz et al. entitled "Recommendations for prioritization, treatment, and triage of breast cancer patients during the COVID19 pandemic. The COVID19 pandemic breast cancer consortium".
Breast Cancer Res Treat. 2020 May 26. pii: 10.1007/s10549-020-05694.
PubMed

HA SM, Chang JM, Lee SH, Kim ES, et al
Diffusion-weighted MRI at 3.0 T for detection of occult disease in the contralateral breast in women with newly diagnosed breast cancer.
Breast Cancer Res Treat. 2020 May 23. pii: 10.1007/s10549-020-05697.
PubMed Abstract available

DELGADO-RAMOS GM, Nasir SS, Wang J, Schwartzberg LS, et al
Real-world evaluation of effectiveness and tolerance of chemotherapy for early-stage breast cancer in older women.
Breast Cancer Res Treat. 2020 May 23. pii: 10.1007/s10549-020-05684.
PubMed Abstract available

JOSEPH C, Alsaleem M, Orah N, Narasimha PL, et al
Elevated MMP9 expression in breast cancer is a predictor of shorter patient survival.
Breast Cancer Res Treat. 2020 May 22. pii: 10.1007/s10549-020-05670.
PubMed Abstract available

SCATENA C, Scarpitta R, Innocenti L, Miccoli M, et al
Androgen receptor expression inversely correlates with histological grade and N stage in ER(+)/PgR(low) male breast cancer.
Breast Cancer Res Treat. 2020 May 21. pii: 10.1007/s10549-020-05682.
PubMed Abstract available

MEJDAHL MK, Wohlfahrt J, Holm M, Knoop AS, et al
Synchronous bilateral breast cancer: a nationwide study on histopathology and etiology.
Breast Cancer Res Treat. 2020 May 21. pii: 10.1007/s10549-020-05689.
PubMed Abstract available

DAHN H, Wilke D, Walsh G, Pignol JP, et al
Radiation and/or endocrine therapy? Recurrence and survival outcomes in women over 70 with early breast cancer after breast-conserving surgery.
Breast Cancer Res Treat. 2020 May 21. pii: 10.1007/s10549-020-05691.
PubMed Abstract available

WATANABE J
Reply to letters to the editor: Discordance in estrogen receptor and change of Ki67 between primary site and metastatic site of recurrent breast cancer.
Breast Cancer Res Treat. 2020 May 21. pii: 10.1007/s10549-020-05695.
PubMed

OMILIAN AR, Wei L, Hong CC, Bandera EV, et al
Somatic mutations of triple-negative breast cancer: a comparison between Black and White women.
Breast Cancer Res Treat. 2020 May 21. pii: 10.1007/s10549-020-05693.
PubMed Abstract available

O'SHAUGHNESSY J
Treatment options for patients with HR+/HER2- advanced breast cancer during the COVID-19 pandemic: dose reduction of ribociclib does not diminish efficacy.
Breast Cancer Res Treat. 2020 May 20. pii: 10.1007/s10549-020-05674.
PubMed

LOFTEROD T, Frydenberg H, Flote V, Eggen AE, et al
Exploring the effects of lifestyle on breast cancer risk, age at diagnosis, and survival: the EBBA-Life study.
Breast Cancer Res Treat. 2020 May 20. pii: 10.1007/s10549-020-05679.
PubMed Abstract available

DEUTSCH TM, Riethdorf S, Fremd C, Feisst M, et al
HER2-targeted therapy influences CTC status in metastatic breast cancer.
Breast Cancer Res Treat. 2020 May 20. pii: 10.1007/s10549-020-05687.
PubMed Abstract available

ALMSTEDT K, Mendoza S, Otto M, Battista MJ, et al
EndoPredict((R)) in early hormone receptor-positive, HER2-negative breast cancer.
Breast Cancer Res Treat. 2020 May 20. pii: 10.1007/s10549-020-05688.
PubMed Abstract available

TOMAO F, Verrico M, Tomao S
Fertility and reproduction in breast cancer patients.
Breast Cancer Res Treat. 2020 May 20. pii: 10.1007/s10549-020-05676.
PubMed

ZHONG Y, Xu Y, Zhou Y, Mao F, et al
Breast-conserving surgery without axillary lymph node surgery or radiotherapy is safe for HER2-positive and triple negative breast cancer patients over 70 years of age.
Breast Cancer Res Treat. 2020 May 19. pii: 10.1007/s10549-020-05686.
PubMed Abstract available

LI Y, Qin J, Wu J, Dai X, et al
High expression of OSR1 as a predictive biomarker for poor prognosis and lymph node metastasis in breast cancer.
Breast Cancer Res Treat. 2020 May 18. pii: 10.1007/s10549-020-05671.
PubMed Abstract available

BACH L, Kostev K, Schiffmann L, Kalder M, et al
Association between thyroid gland diseases and breast cancer: a case-control study.
Breast Cancer Res Treat. 2020 May 18. pii: 10.1007/s10549-020-05675.
PubMed Abstract available

KOUMARIANOU A, Makrantonakis P, Zagouri F, Papadimitriou C, et al
ABREAST: a prospective, real-world study on the effect of nab-paclitaxel treatment on clinical outcomes and quality of life of patients with metastatic breast cancer.
Breast Cancer Res Treat. 2020 May 16. pii: 10.1007/s10549-020-05677.
PubMed Abstract available

LEE HB, Han W, Kim SY, Cho N, et al
Prediction of pathologic complete response using image-guided biopsy after neoadjuvant chemotherapy in breast cancer patients selected based on MRI findings: a prospective feasibility trial.
Breast Cancer Res Treat. 2020 May 16. pii: 10.1007/s10549-020-05678.
PubMed Abstract available

HAO Y, Xu B, Yan Q, Zhou M, et al
Long-term excess body fat in adulthood and the risk of pre- and postmenopausal breast cancer in Chinese women.
Breast Cancer Res Treat. 2020 May 15. pii: 10.1007/s10549-020-05685.
PubMed Abstract available

ZHANG LY, Zhang YQ, Zeng YZ, Zhu JL, et al
TRPC1 inhibits the proliferation and migration of estrogen receptor-positive Breast cancer and gives a better prognosis by inhibiting the PI3K/AKT pathway.
Breast Cancer Res Treat. 2020 May 15. pii: 10.1007/s10549-020-05673.
PubMed Abstract available

SILVA CL, Perestrelo R, Sousa-Ferreira I, Capelinha F, et al
Lipid biosignature of breast cancer tissues by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry.
Breast Cancer Res Treat. 2020 May 15. pii: 10.1007/s10549-020-05672.
PubMed Abstract available

KALINSKY K, Accordino MK, Hosi K, Hawley JE, et al
Characteristics and outcomes of patients with breast cancer diagnosed with SARS-Cov-2 infection at an academic center in New York City.
Breast Cancer Res Treat. 2020 May 14:1-4. doi: 10.1007/s10549-020-05667.
PubMed

ZHOU L, Chen B, Sheng L, Turner A, et al
The effect of vitamin D supplementation on the risk of breast cancer: a trial sequential meta-analysis.
Breast Cancer Res Treat. 2020 May 13. pii: 10.1007/s10549-020-05669.
PubMed Abstract available

ROJAS KE, Manasseh DM, Rojas M, Mattocks A, et al
The natural history of untreated estrogen receptor-positive, Her2-negative invasive breast cancer.
Breast Cancer Res Treat. 2020 May 12. pii: 10.1007/s10549-020-05666.
PubMed Abstract available

SAITO T, Ono R, Kono S, Asano M, et al
Physical activity among patients with breast cancer receiving aromatase inhibitors is associated with bone health: a cross-sectional observational study.
Breast Cancer Res Treat. 2020 May 12. pii: 10.1007/s10549-020-05668.
PubMed Abstract available

DU F, Wang W, Wang Y, Li M, et al
Carboplatin plus taxanes are non-inferior to epirubicin plus cyclophosphamide followed by taxanes as adjuvant chemotherapy for early triple-negative breast cancer.
Breast Cancer Res Treat. 2020 May 11. pii: 10.1007/s10549-020-05648.
PubMed Abstract available

EZRATTY C, Vang S, Brown J, Margolies LR, et al
Racial/ethnic differences in supplemental imaging for breast cancer screening in women with dense breasts.
Breast Cancer Res Treat. 2020 May 11. pii: 10.1007/s10549-020-05652.
PubMed Abstract available

UMAMAHESWARAN G, Kadambari D, Muthuvel SK, Kalaivani S, et al
Association of CYP19A1 gene variations with adjuvant letrozole-induced adverse events in South Indian postmenopausal breast cancer cohort expressing hormone-receptor positivity.
Breast Cancer Res Treat. 2020 May 8. pii: 10.1007/s10549-020-05656.
PubMed Abstract available

EDMAN KESSLER L, Sigfridsson J, Hatzidaki D, Bergh J, et al
Chemotherapy use near the end-of-life in patients with metastatic breast cancer.
Breast Cancer Res Treat. 2020 May 7. pii: 10.1007/s10549-020-05663.
PubMed Abstract available

HEYDON-WHITE A, Suami H, Boyages J, Koelmeyer L, et al
Assessing breast lymphoedema following breast cancer treatment using indocyanine green lymphography.
Breast Cancer Res Treat. 2020 May 6. pii: 10.1007/s10549-020-05661.
PubMed Abstract available

O'TOOLE SA, Spillane C, Huang Y, Fitzgerald MC, et al
Circulating tumour cell enumeration does not correlate with Miller-Payne grade in a cohort of breast cancer patients undergoing neoadjuvant chemotherapy.
Breast Cancer Res Treat. 2020 May 6. pii: 10.1007/s10549-020-05658.
PubMed Abstract available

NINO DE GUZMAN E, Song Y, Alonso-Coello P, Canelo-Aybar C, et al
Healthcare providers' adherence to breast cancer guidelines in Europe: a systematic literature review.
Breast Cancer Res Treat. 2020 May 6. pii: 10.1007/s10549-020-05657.
PubMed Abstract available

O'DONNELL PH, Trubetskoy V, Nurhussein-Patterson A, Hall JP, et al
Clinical evaluation of germline polymorphisms associated with capecitabine toxicity in breast cancer: TBCRC-015.
Breast Cancer Res Treat. 2020 May 6. pii: 10.1007/s10549-020-05603.
PubMed Abstract available

WANG C, Mu Z, Ye Z, Zhang Z, et al
Prognostic value of HER2 status on circulating tumor cells in advanced-stage breast cancer patients with HER2-negative tumors.
Breast Cancer Res Treat. 2020 May 4. pii: 10.1007/s10549-020-05662.
PubMed Abstract available

WANG RX, Ji P, Gong Y, Shao ZM, et al
Value of CXCL8-CXCR1/2 axis in neoadjuvant chemotherapy for triple-negative breast cancer patients: a retrospective pilot study.
Breast Cancer Res Treat. 2020 May 2. pii: 10.1007/s10549-020-05660.
PubMed Abstract available

STOVGAARD ES, Bokharaey M, List-Jensen K, Roslind A, et al
PD-L1 diagnostics in the neoadjuvant setting: implications of intratumoral heterogeneity of PD-L1 expression in triple negative breast cancer for assessment in small biopsies.
Breast Cancer Res Treat. 2020 May 2. pii: 10.1007/s10549-020-05655.
PubMed Abstract available

MUKHTAR RA, Krings G, Chen YY, Mamounas ME, et al
Mitotic score and pleomorphic histology in invasive lobular carcinoma of the breast: impact on disease-free survival.
Breast Cancer Res Treat. 2020;181:23-29.
PubMed Abstract available

DO WL, Conneely K, Gabram-Mendola S, Krishnamurti U, et al
Obesity-associated methylation in breast tumors: a possible link to disparate outcomes?
Breast Cancer Res Treat. 2020;181:135-144.
PubMed Abstract available

PURRINGTON KS, Gorski D, Simon MS, Hastert TA, et al
Racial differences in estrogen receptor staining levels and implications for treatment and survival among estrogen receptor positive, HER2-negative invasive breast cancers.
Breast Cancer Res Treat. 2020;181:145-154.
PubMed Abstract available

OLIVERI S, Ongaro G, Durosini I, Curigliano G, et al
Breast implant-associated anaplastic large cell lymphoma: emotional impact and guidelines for psychological support.
Breast Cancer Res Treat. 2020;181:221-224.
PubMed Abstract available

LIU W, Li W, Li Z, Shi L, et al
Ultrasound characteristics of sclerosing adenosis mimicking breast carcinoma.
Breast Cancer Res Treat. 2020;181:127-134.
PubMed Abstract available

FRASSON AL, Lichtenfels M, de Souza AAB, Vollbrecht B, et al
Risk-reducing mastectomy: a case series of 124 procedures in Brazilian patients.
Breast Cancer Res Treat. 2020;181:69-75.
PubMed Abstract available

April 2020

GOMEZ-ACEBO I, Dierssen-Sotos T, Palazuelos-Calderon C, Perez-Gomez B, et al
Tumour characteristics and survivorship in a cohort of breast cancer: the MCC-Spain study.
Breast Cancer Res Treat. 2020 Apr 30. pii: 10.1007/s10549-020-05600.
PubMed Abstract available

SOARES LR, Rosa VDL, Freitas-Junior R
Anti-HER2 therapy for metastatic breast cancer in low- and middle-income countries: bridging the gap between clinical trials and real life.
Breast Cancer Res Treat. 2020 Apr 29. pii: 10.1007/s10549-020-05659.
PubMed

ALJOHANI AI, Joseph C, Kurozumi S, Mohammed OJ, et al
Myxovirus resistance 1 (MX1) is an independent predictor of poor outcome in invasive breast cancer.
Breast Cancer Res Treat. 2020 Apr 29. pii: 10.1007/s10549-020-05646.
PubMed Abstract available

TROGDON JG, Baggett CD, Gogate A, Reeder-Hayes KE, et al
Medical costs associated with metastatic breast cancer in younger, midlife, and older women.
Breast Cancer Res Treat. 2020 Apr 28. pii: 10.1007/s10549-020-05654.
PubMed Abstract available

HUNT BG, Wicker CA, Bourn JR, Lower EE, et al
MST1R (RON) expression is a novel prognostic biomarker for metastatic progression in breast cancer patients.
Breast Cancer Res Treat. 2020 Apr 27. pii: 10.1007/s10549-020-05653.
PubMed Abstract available

ALTUNDAG K
Is there any association between absolute lymphocyte count and increased tumor-infiltrating lymphocytes in metastatic sites in advanced breast cancer patients who get benefit from eribulin treatment?
Breast Cancer Res Treat. 2020 Apr 27. pii: 10.1007/s10549-020-05649.
PubMed

DIETZ JR, Moran MS, Isakoff SJ, Kurtzman SH, et al
Recommendations for prioritization, treatment, and triage of breast cancer patients during the COVID-19 pandemic. the COVID-19 pandemic breast cancer consortium.
Breast Cancer Res Treat. 2020 Apr 24. pii: 10.1007/s10549-020-05644.
PubMed Abstract available

YOO TK, Kang BJ, Kim SH, Song BJ, et al
Axillary lymph node dissection is not obligatory in breast cancer patients with biopsy-proven axillary lymph node metastasis.
Breast Cancer Res Treat. 2020 Apr 23. pii: 10.1007/s10549-020-05636.
PubMed Abstract available

GOTTSCHAU M, Kjaer SK, Settnes A, Aalborg GL, et al
Ovarian removal at or after benign hysterectomy and breast cancer: a nationwide cohort study.
Breast Cancer Res Treat. 2020 Apr 23. pii: 10.1007/s10549-020-05628.
PubMed Abstract available

BROWN TA 2ND, Mittendorf EA, Hale DF, Myers JW 3rd, et al
Prospective, randomized, single-blinded, multi-center phase II trial of two HER2 peptide vaccines, GP2 and AE37, in breast cancer patients to prevent recurrence.
Breast Cancer Res Treat. 2020 Apr 22. pii: 10.1007/s10549-020-05638.
PubMed Abstract available

JACENE HA, DiPiro PJ, Bellon J, Hu J, et al
Discrepancy between FDG-PET/CT and contrast-enhanced CT in the staging of patients with inflammatory breast cancer: implications for treatment planning.
Breast Cancer Res Treat. 2020 Apr 21. pii: 10.1007/s10549-020-05631.
PubMed Abstract available

MIYASHITA H, Satoi S, Kuno T, Cruz C, et al
Bone modifying agents for bone loss in patients with aromatase inhibitor as adjuvant treatment for breast cancer; insights from a network meta-analysis.
Breast Cancer Res Treat. 2020 Apr 21. pii: 10.1007/s10549-020-05640.
PubMed Abstract available

ZENG C, Guo X, Wen W, Shi J, et al
Evaluation of pathogenetic mutations in breast cancer predisposition genes in population-based studies conducted among Chinese women.
Breast Cancer Res Treat. 2020 Apr 21. pii: 10.1007/s10549-020-05643.
PubMed Abstract available

MALOUFF TD, Mahajan A, Mutter RW, Krishnan S, et al
Carbon ion radiation therapy in breast cancer: a new frontier.
Breast Cancer Res Treat. 2020 Apr 21. pii: 10.1007/s10549-020-05641.
PubMed Abstract available

KAWACHI A, Yamashita S, Okochi-Takada E, Hirakawa A, et al
BRCA1 promoter methylation in breast cancer patients is associated with response to olaparib/eribulin combination therapy.
Breast Cancer Res Treat. 2020 Apr 20. pii: 10.1007/s10549-020-05647.
PubMed Abstract available

KWAK A, Jacobs J, Haggett D, Jimenez R, et al
Evaluation and management of insomnia in women with breast cancer.
Breast Cancer Res Treat. 2020 Apr 20. pii: 10.1007/s10549-020-05635.
PubMed Abstract available

JING J, Feng R, Zhang X, Li M, et al
Financial toxicity and its associated patient and cancer factors among women with breast cancer: a single-center analysis of low-middle income region in China.
Breast Cancer Res Treat. 2020 Apr 18. pii: 10.1007/s10549-020-05632.
PubMed Abstract available

HERSHMAN DL, Till C, Wright JD, Accordino M, et al
Healthcare utilization and cost of care in elderly breast cancer patients enrolled in SWOG clinical trials.
Breast Cancer Res Treat. 2020 Apr 18. pii: 10.1007/s10549-020-05634.
PubMed Abstract available

HAAS CB, Nekhlyudov L, Lee JM, Javid SH, et al
Surveillance for second breast cancer events in women with a personal history of breast cancer using breast MRI: a systematic review and meta-analysis.
Breast Cancer Res Treat. 2020 Apr 17. pii: 10.1007/s10549-020-05637.
PubMed Abstract available

JORGENSEN CLT, Forsare C, Bendahl PO, Falck AK, et al
Expression of epithelial-mesenchymal transition-related markers and phenotypes during breast cancer progression.
Breast Cancer Res Treat. 2020 Apr 16. pii: 10.1007/s10549-020-05627.
PubMed Abstract available

ASAOKA M, Patnaik SK, Zhang F, Ishikawa T, et al
Lymphovascular invasion in breast cancer is associated with gene expression signatures of cell proliferation but not lymphangiogenesis or immune response.
Breast Cancer Res Treat. 2020 Apr 13. pii: 10.1007/s10549-020-05630.
PubMed Abstract available

GIARDIELLO D, Hauptmann M, Steyerberg EW, Adank MA, et al
Prediction of contralateral breast cancer: external validation of risk calculators in 20 international cohorts.
Breast Cancer Res Treat. 2020 Apr 11. pii: 10.1007/s10549-020-05611.
PubMed Abstract available

LAWS MJ, Ziegler Y, Shahoei SH, Dey P, et al
Suppression of breast cancer metastasis and extension of survival by a new antiestrogen in a preclinical model driven by mutant estrogen receptors.
Breast Cancer Res Treat. 2020 Apr 10. pii: 10.1007/s10549-020-05629.
PubMed Abstract available

GREENWELL K, Hussain L, Lee D, Bramlage M, et al
Complete pathologic response rate to neoadjuvant chemotherapy increases with increasing HER2/CEP17 ratio in HER2 overexpressing breast cancer: analysis of the National Cancer Database (NCDB).
Breast Cancer Res Treat. 2020 Apr 10. pii: 10.1007/s10549-020-05599.
PubMed Abstract available

DRULLINSKY PR, Hurvitz SA
Mechanistic basis for PI3K inhibitor antitumor activity and adverse reactions in advanced breast cancer.
Breast Cancer Res Treat. 2020 Apr 9. pii: 10.1007/s10549-020-05618.
PubMed Abstract available

RIBI K, Luo W, Walley BA, Burstein HJ, et al
Treatment-induced symptoms, depression and age as predictors of sexual problems in premenopausal women with early breast cancer receiving adjuvant endocrine therapy.
Breast Cancer Res Treat. 2020 Apr 9. pii: 10.1007/s10549-020-05622.
PubMed Abstract available

HIRAKATA T, Fujii T, Kurozumi S, Katayama A, et al
FDG uptake reflects breast cancer immunological features: the PD-L1 expression and degree of TILs in primary breast cancer.
Breast Cancer Res Treat. 2020 Apr 6. pii: 10.1007/s10549-020-05619.
PubMed Abstract available

PINERO-MADRONA A, Ripoll-Orts F, Sanchez-Mendez JI, Chaves-Benito A, et al
External validation of a prognostic model based on total tumor load of sentinel lymph node for early breast cancer patients.
Breast Cancer Res Treat. 2020 Apr 6. pii: 10.1007/s10549-020-05623.
PubMed Abstract available

ALEIXO GFP, Deal AM, Nyrop KA, Muss HB, et al
Association of body composition with function in women with early breast cancer.
Breast Cancer Res Treat. 2020 Apr 6. pii: 10.1007/s10549-020-05624.
PubMed Abstract available

WATANABE J, Saito M, Horimoto Y, Nakamoto S, et al
A maintained absolute lymphocyte count predicts the overall survival benefit from eribulin therapy, including eribulin re-administration, in HER2-negative advanced breast cancer patients: a single-institutional experience.
Breast Cancer Res Treat. 2020 Apr 5. pii: 10.1007/s10549-020-05626.
PubMed Abstract available

HIRAI T, Nemoto A, Ito Y, Matsuura M, et al
Meta-analyses on progression-free survival as a surrogate endpoint for overall survival in triple-negative breast cancer.
Breast Cancer Res Treat. 2020 Apr 3. pii: 10.1007/s10549-020-05615.
PubMed Abstract available

LE AN, Harton J, Desai H, Powers J, et al
Frequency of radiation-induced malignancies post-adjuvant radiotherapy for breast cancer in patients with Li-Fraumeni syndrome.
Breast Cancer Res Treat. 2020 Apr 3. pii: 10.1007/s10549-020-05612.
PubMed Abstract available

FRANZOI MA, Vandeputte C, Eiger D, Caparica R, et al
Computed tomography-based analyses of baseline body composition parameters and changes in breast cancer patients under treatment with CDK 4/6 inhibitors.
Breast Cancer Res Treat. 2020 Apr 3. pii: 10.1007/s10549-020-05617.
PubMed Abstract available

PAN L, Chen X, Fu S, Yu W, et al
LLY17, a novel small molecule STAT3 inhibitor induces apoptosis and suppresses cell migration and tumor growth in triple-negative breast cancer.
Breast Cancer Res Treat. 2020 Apr 2. pii: 10.1007/s10549-020-05613.
PubMed Abstract available

SUNDELIN EIO, Al-Suliman N, Vahl P, Vendelbo M, et al
Metformin is distributed to tumor tissue in breast cancer patients in vivo: A (11)C-metformin PET/CT study.
Breast Cancer Res Treat. 2020 Apr 2. pii: 10.1007/s10549-020-05621.
PubMed Abstract available

DENYS H, Martinez-Mena CL, Martens MT, D'Hondt RG, et al
Safety and tolerability of subcutaneous trastuzumab at home administration, results of the phase IIIb open-label BELIS study in HER2-positive early breast cancer.
Breast Cancer Res Treat. 2020 Apr 2. pii: 10.1007/s10549-020-05604.
PubMed Abstract available

LEI YY, Ho SC, Cheng A, Kwok C, et al
The association between soy isoflavone intake and menopausal symptoms after breast cancer diagnosis: a prospective longitudinal cohort study on Chinese breast cancer patients.
Breast Cancer Res Treat. 2020 Apr 1. pii: 10.1007/s10549-020-05616.
PubMed Abstract available

NEVEN P, Froyman W, Timmerman S, Timmerman D, et al
Uterine ultrasound and endometrial biopsy in tamoxifen users.
Breast Cancer Res Treat. 2020;180:833-834.
PubMed

ALTUNDAG K
HER2-positivity in mucinous cancer might be related to accompanying infiltrating ductal carcinoma histology.
Breast Cancer Res Treat. 2020;180:829.
PubMed

SUNAGUCHI N, Shimao D, Yuasa T, Ichihara S, et al
Three-dimensional microanatomy of human nipple visualized by X-ray dark-field computed tomography.
Breast Cancer Res Treat. 2020;180:397-405.
PubMed Abstract available

KATZ MS, McCall L, Ballman K, Jagsi R, et al
Nomogram-based estimate of axillary nodal involvement in ACOSOG Z0011 (Alliance): validation and association with radiation protocol variations.
Breast Cancer Res Treat. 2020;180:429-436.
PubMed Abstract available

SEOW DYB, Yeong JPS, Lim JX, Chia N, et al
Tertiary lymphoid structures and associated plasma cells play an important role in the biology of triple-negative breast cancers.
Breast Cancer Res Treat. 2020;180:369-377.
PubMed Abstract available

STUMPF CC, Zucatto AE, Cavalheiro JAC, de Melo MP, et al
Oncologic safety of immediate autologous fat grafting for reconstruction in breast-conserving surgery.
Breast Cancer Res Treat. 2020;180:301-309.
PubMed Abstract available

LI AC, Zhao J, Zhao C, Ma Z, et al
Quantitative digital imaging analysis of HER2 immunohistochemistry predicts the response to anti-HER2 neoadjuvant chemotherapy in HER2-positive breast carcinoma.
Breast Cancer Res Treat. 2020;180:321-329.
PubMed Abstract available

JENNARO TS, Fang F, Kidwell KM, Smith EML, et al
Vitamin D deficiency increases severity of paclitaxel-induced peripheral neuropathy.
Breast Cancer Res Treat. 2020;180:707-714.
PubMed Abstract available

YARDLEY DA, Peacock N, Daniel B, Anz B, et al
Phase II trial of eribulin in patients who do not achieve pathologic complete response (pCR) following neoadjuvant chemotherapy.
Breast Cancer Res Treat. 2020;180:647-655.
PubMed Abstract available

March 2020

GONG IY, Yan AT, Earle CC, Trudeau ME, et al
Comparison of outcomes in a population-based cohort of metastatic breast cancer patients receiving anti-HER2 therapy with clinical trial outcomes.
Breast Cancer Res Treat. 2020 Mar 31. pii: 10.1007/s10549-020-05614.
PubMed Abstract available

VRIENS IJH, Ter Welle-Butalid EM, de Boer M, de Die-Smulders CEM, et al
Preserving fertility in young women undergoing chemotherapy for early breast cancer; the Maastricht experience.
Breast Cancer Res Treat. 2020 Mar 31. pii: 10.1007/s10549-020-05598.
PubMed Abstract available

BHATTACHARJEE A, Rajendra J, Dikshit R, Dutt S, et al
HER2 borderline is a negative prognostic factor for primary malignant breast cancer.
Breast Cancer Res Treat. 2020 Mar 31. pii: 10.1007/s10549-020-05608.
PubMed Abstract available

BRANDBERG Y, Johansson H, Hellstrom M, Gnant M, et al
Long-term (up to 16 months) health-related quality of life after adjuvant tailored dose-dense chemotherapy vs. standard three-weekly chemotherapy in women with high-risk early breast cancer.
Breast Cancer Res Treat. 2020 Mar 31. pii: 10.1007/s10549-020-05602.
PubMed Abstract available

JOBSEN JJ, Struikmans H, van der Palen J, Siemerink E, et al
The Mitotic Activity Index in combination with Her2neu: a strong prognosticator in breast cancer.
Breast Cancer Res Treat. 2020 Mar 30. pii: 10.1007/s10549-020-05610.
PubMed Abstract available

EL ANSARI R, Alfarsi L, Craze ML, Masisi BK, et al
The solute carrier SLC7A8 is a marker of favourable prognosis in ER-positive low proliferative invasive breast cancer.
Breast Cancer Res Treat. 2020 Mar 21. pii: 10.1007/s10549-020-05586.
PubMed Abstract available

GENNARI A, Foca F, Zamarchi R, Rocca A, et al
Insulin-like growth factor-1 receptor (IGF-1R) expression on circulating tumor cells (CTCs) and metastatic breast cancer outcome: results from the TransMYME trial.
Breast Cancer Res Treat. 2020 Mar 21. pii: 10.1007/s10549-020-05596.
PubMed Abstract available

VAN MECHELEN M, Van Herck A, Punie K, Nevelsteen I, et al
Behavior of metastatic breast cancer according to subtype.
Breast Cancer Res Treat. 2020 Mar 19. pii: 10.1007/s10549-020-05597.
PubMed Abstract available

PANZIRONI G, Moffa G, Galati F, Marzocca F, et al
Peritumoral edema as a biomarker of the aggressiveness of breast cancer: results of a retrospective study on a 3 T scanner.
Breast Cancer Res Treat. 2020 Mar 17. pii: 10.1007/s10549-020-05592.
PubMed Abstract available

HASSETT MJ, Li H, Burstein HJ, Punglia RS, et al
Neoadjuvant treatment strategies for HER2-positive breast cancer: cost-effectiveness and quality of life outcomes.
Breast Cancer Res Treat. 2020 Mar 17. pii: 10.1007/s10549-020-05587.
PubMed Abstract available

SIMONS JM, Koppert LB, Luiten EJT, van der Pol CC, et al
De-escalation of axillary surgery in breast cancer patients treated in the neoadjuvant setting: a Dutch population-based study.
Breast Cancer Res Treat. 2020 Mar 16. pii: 10.1007/s10549-020-05589.
PubMed Abstract available

GONZALEZ TL, Hancock M, Sun S, Gersch CL, et al
Correction to: Targeted degradation of activating estrogen receptor alpha ligand-binding domain mutations in human breast cancer.
Breast Cancer Res Treat. 2020 Mar 16. pii: 10.1007/s10549-020-05594.
PubMed Abstract available

MA G, Zhang B, Xu J
Clinical significance of gene mutation in ctDNA analysis for hormone receptor-positive metastatic breast cancer.
Breast Cancer Res Treat. 2020 Mar 14. pii: 10.1007/s10549-020-05593.
PubMed

YUAN C, Xie Z, Bian J, Huo J, et al
Outcomes of primary endocrine therapy in elderly women with stage I-III breast cancer: a SEER database analysis.
Breast Cancer Res Treat. 2020 Mar 14. pii: 10.1007/s10549-020-05591.
PubMed Abstract available

CROLLEY VE, Marashi H, Rawther S, Sirohi B, et al
The impact of Oncotype DX breast cancer assay results on clinical practice: a UK experience.
Breast Cancer Res Treat. 2020 Mar 13. pii: 10.1007/s10549-020-05578.
PubMed Abstract available

ISHIGURO H, Masuda N, Sato N, Higaki K, et al
A randomized study comparing docetaxel/cyclophosphamide (TC), 5-fluorouracil/epirubicin/cyclophosphamide (FEC) followed by TC, and TC followed by FEC for patients with hormone receptor-positive HER2-negative primary breast cancer.
Breast Cancer Res Treat. 2020 Mar 13. pii: 10.1007/s10549-020-05590.
PubMed Abstract available

O'SULLIVAN CC, Irshad S, Wang Z, Tang Z, et al
Clinico-pathologic features, treatment and outcomes of breast cancer during pregnancy or the post-partum period.
Breast Cancer Res Treat. 2020 Mar 11. pii: 10.1007/s10549-020-05585.
PubMed Abstract available

IWASE M, Ando M, Aogi K, Aruga T, et al
Long-term survival analysis of addition of carboplatin to neoadjuvant chemotherapy in HER2-negative breast cancer.
Breast Cancer Res Treat. 2020 Mar 5. pii: 10.1007/s10549-020-05580.
PubMed Abstract available

ANDREANO KJ, Wardell SE, Baker JG, Desautels TK, et al
G1T48, an oral selective estrogen receptor degrader, and the CDK4/6 inhibitor lerociclib inhibit tumor growth in animal models of endocrine-resistant breast cancer.
Breast Cancer Res Treat. 2020 Mar 4. pii: 10.1007/s10549-020-05575.
PubMed Abstract available

TAYLOR LJ, Steiman JS, Anderson B, Schumacher JR, et al
Does persistent use of radiation in women > 70 years of age with early-stage breast cancer reflect tailored patient-centered care?
Breast Cancer Res Treat. 2020 Mar 3. pii: 10.1007/s10549-020-05579.
PubMed Abstract available

VAN HELLEMOND IEG, Smorenburg CH, Peer PGM, Swinkels ACP, et al
Breast cancer outcome in relation to bone mineral density and bisphosphonate use: a sub-study of the DATA trial.
Breast Cancer Res Treat. 2020 Mar 2. pii: 10.1007/s10549-020-05567.
PubMed Abstract available

MASUDA T, Fujimoto H, Teranaka R, Kuroda M, et al
Anti-HER2 antibody therapy using gene-transduced adipocytes for HER2-positive breast cancer.
Breast Cancer Res Treat. 2020 Mar 2. pii: 10.1007/s10549-020-05581.
PubMed Abstract available

February 2020

JEON YW, Bang HW, Suh YJ, Kim G, et al
The long-term effect of age on cardiovascular disease in patients with breast cancer who received chemotherapy.
Breast Cancer Res Treat. 2020 Feb 25. pii: 10.1007/s10549-020-05568.
PubMed Abstract available

PARACHA N, Reyes A, Dieras V, Krop I, et al
Evaluating the clinical effectiveness and safety of various HER2-targeted regimens after prior taxane/trastuzumab in patients with previously treated, unresectable, or metastatic HER2-positive breast cancer: a systematic review and network meta-analys
Breast Cancer Res Treat. 2020 Feb 25. pii: 10.1007/s10549-020-05577.
PubMed Abstract available

ROJAS-LIMA E, Gamboa-Loira B, Cebrian ME, Rothenberg SJ, et al
A cumulative index of exposure to endogenous estrogens and breast cancer by molecular subtypes in northern Mexican women.
Breast Cancer Res Treat. 2020 Feb 22. pii: 10.1007/s10549-020-05562.
PubMed Abstract available

LAMBERT-COTE L, Bouhnik AD, Bendiane MK, Berenger C, et al
Adherence trajectories of adjuvant endocrine therapy in the five years after its initiation among women with non-metastatic breast cancer: a cohort study using administrative databases.
Breast Cancer Res Treat. 2020 Feb 21. pii: 10.1007/s10549-020-05549.
PubMed Abstract available

PAN K, Ray RM, Cauley JA, Shadyab AH, et al
Trajectory of recurrent falls in post-menopausal breast cancer survivors and in matched cancer-free controls.
Breast Cancer Res Treat. 2020 Feb 19. pii: 10.1007/s10549-020-05576.
PubMed Abstract available

KIM M, Kim H, Ahn SH, Tabatabaie V, et al
Changes in bone mineral density during 5 years of adjuvant treatment in premenopausal breast cancer patients.
Breast Cancer Res Treat. 2020 Feb 19. pii: 10.1007/s10549-020-05566.
PubMed Abstract available

CHEN L, Fu F, Huang M, Lv J, et al
The spectrum of BRCA1 and BRCA2 mutations and clinicopathological characteristics in Chinese women with early-onset breast cancer.
Breast Cancer Res Treat. 2020 Feb 18. pii: 10.1007/s10549-020-05573.
PubMed Abstract available

GONZALEZ TL, Hancock M, Sun S, Gersch CL, et al
Targeted degradation of activating estrogen receptor alpha ligand-binding domain mutations in human breast cancer.
Breast Cancer Res Treat. 2020 Feb 17. pii: 10.1007/s10549-020-05564.
PubMed Abstract available

YUNG R, Ray RM, Roth J, Johnson L, et al
The association of delay in curative intent treatment with survival among breast cancer patients: findings from the Women's Health Initiative.
Breast Cancer Res Treat. 2020 Feb 15. pii: 10.1007/s10549-020-05572.
PubMed Abstract available

CORONA SP, Bortul M, Scomersi S, Bigal C, et al
Management of the axilla in breast cancer: outcome analysis in a series of ductal versus lobular invasive cancers.
Breast Cancer Res Treat. 2020 Feb 14. pii: 10.1007/s10549-020-05565.
PubMed Abstract available

ZHANG L, Hsieh MC, Petkov V, Yu Q, et al
Trend and survival benefit of Oncotype DX use among female hormone receptor-positive breast cancer patients in 17 SEER registries, 2004-2015.
Breast Cancer Res Treat. 2020 Feb 14. pii: 10.1007/s10549-020-05557.
PubMed Abstract available

CHEN Z, Xu L, Shi W, Zeng F, et al
Trends of female and male breast cancer incidence at the global, regional, and national levels, 1990-2017.
Breast Cancer Res Treat. 2020 Feb 13. pii: 10.1007/s10549-020-05561.
PubMed Abstract available

RYPENS C, Marsan M, Van Berckelaer C, Billiet C, et al
Inflammatory breast cancer cells are characterized by abrogated TGFbeta1-dependent cell motility and SMAD3 activity.
Breast Cancer Res Treat. 2020 Feb 10. pii: 10.1007/s10549-020-05571.
PubMed Abstract available

RACHNER TD, Gobel A, Hoffmann O, Erdmann K, et al
High serum levels of periostin are associated with a poor survival in breast cancer.
Breast Cancer Res Treat. 2020 Feb 10. pii: 10.1007/s10549-020-05570.
PubMed Abstract available

SARMIENTO S, McColl M, Musavi L, Gani F, et al
Male breast cancer: a closer look at patient and tumor characteristics and factors that affect survival using the National Cancer Database.
Breast Cancer Res Treat. 2020 Feb 10. pii: 10.1007/s10549-020-05556.
PubMed Abstract available

SORSCHER S, Ansley K, Delaney SD, Ramkissoon S, et al
The implications of BRCA loss of heterozygosity (LOH) and deficient mismatch repair gene (dMMR) expression in the breast cancer of a patient with both inherited breast and ovarian cancer syndrome (BRCA2) and Lynch syndrome (MLH1).
Breast Cancer Res Treat. 2020 Feb 10. pii: 10.1007/s10549-020-05569.
PubMed Abstract available

SUN X, Wang XE, Zhang ZP, Shi ZQ, et al
Neoadjuvant therapy and sentinel lymph node biopsy in HER2-positive breast cancer patients: results from the PEONY trial.
Breast Cancer Res Treat. 2020 Feb 7. pii: 10.1007/s10549-020-05559.
PubMed Abstract available

YU M, Chen Y, Wang Z, Ding X, et al
pHLIP(Var7)-P1AP suppresses tumor cell proliferation in MDA-MB-231 triple-negative breast cancer by targeting protease activated receptor 1.
Breast Cancer Res Treat. 2020 Feb 7. pii: 10.1007/s10549-020-05560.
PubMed Abstract available

MILLS MN, Figura NB, Arrington JA, Yu HM, et al
Management of brain metastases in breast cancer: a review of current practices and emerging treatments.
Breast Cancer Res Treat. 2020 Feb 6. pii: 10.1007/s10549-020-05552.
PubMed Abstract available

GUO S, Zhang C, Mottamal M, Hossain A, et al
GLL398, an oral selective estrogen receptor degrader (SERD), blocks tumor growth in xenograft breast cancer models.
Breast Cancer Res Treat. 2020 Feb 6. pii: 10.1007/s10549-020-05558.
PubMed Abstract available

JOOB B, Wiwanitkit V
CYP24A1 polymorphisms and breast cancer risk.
Breast Cancer Res Treat. 2020 Feb 6. pii: 10.1007/s10549-020-05553.
PubMed

UK Interdisciplinary Breast Cancer Symposium 2020.
Breast Cancer Res Treat. 2020 Feb 6. pii: 10.1007/s10549-019-05514.
PubMed

PAREKH VS, Jacobs MA
Multiparametric radiomics methods for breast cancer tissue characterization using radiological imaging.
Breast Cancer Res Treat. 2020 Feb 4. pii: 10.1007/s10549-020-05533.
PubMed Abstract available

KIM HS, Yoo TK, Park WC, Chae BJ, et al
The prognostic value of HER2 status and efficacy of anti-HER2 therapy in patients with HR-positive mucinous breast cancer: a nationwide study from the Korean Breast Cancer Society.
Breast Cancer Res Treat. 2020 Feb 4. pii: 10.1007/s10549-020-05550.
PubMed Abstract available

ZHU J, Wang F, Shi L, Cai H, et al
Accelerated aging in breast cancer survivors and its association with mortality and cancer recurrence.
Breast Cancer Res Treat. 2020 Feb 4. pii: 10.1007/s10549-020-05541.
PubMed Abstract available

SHIBAYAMA T, Low SK, Ono M, Kobayashi T, et al
Clinical significance of gene mutation in ctDNA analysis for hormone receptor-positive metastatic breast cancer.
Breast Cancer Res Treat. 2020 Feb 4. pii: 10.1007/s10549-019-05512.
PubMed Abstract available

DICORPO D, Tiwari A, Tang R, Griffin M, et al
The role of Micro-CT in imaging breast cancer specimens.
Breast Cancer Res Treat. 2020 Feb 4. pii: 10.1007/s10549-020-05547.
PubMed Abstract available

LI M, Xiong Y, Liao C, He Y, et al
Anastrozole plus fulvestrant vs. anastrozole alone for hormone receptor-positive advanced breast cancer: a meta-analysis of randomized controlled trials.
Breast Cancer Res Treat. 2020 Feb 1. pii: 10.1007/s10549-020-05551.
PubMed Abstract available

ZDRAVKOVIC D, Granic M, Crnokrak B
Proper treatment of breast angiosarcoma-mastectomy or breast conserving surgery?
Breast Cancer Res Treat. 2020;179:765.
PubMed

ALTUNDAG K
Do multifocal or multicentric pT1a node-negative HER2+ breast cancers get benefit from systemic treatment?
Breast Cancer Res Treat. 2020;179:763.
PubMed

TRACEY N, Creedon H, Kemp AJ, Culley J, et al
HO-1 drives autophagy as a mechanism of resistance against HER2-targeted therapies.
Breast Cancer Res Treat. 2020;179:543-555.
PubMed Abstract available

MEIER DR, Girtman MA, Lofgren KA, Kenny PA, et al
Amphiregulin deletion strongly attenuates the development of estrogen receptor-positive tumors in p53 mutant mice.
Breast Cancer Res Treat. 2020;179:653-660.
PubMed Abstract available

KYKER-SNOWMAN K, Hughes RM, Yankaskas CL, Cravero K, et al
TrkA overexpression in non-tumorigenic human breast cell lines confers oncogenic and metastatic properties.
Breast Cancer Res Treat. 2020;179:631-642.
PubMed Abstract available

BROWNE JL, Casas L, Santandreu G, Rodriguez I, et al
Breast density measured volumetrically in a clinical environment: cross-sectional study with photon counting technology.
Breast Cancer Res Treat. 2020;179:755-762.
PubMed Abstract available

LOOK HONG N, Wright FC, Semple M, Nicolae AM, et al
Results of a phase I, non-randomized study evaluating a Magnetic Occult Lesion Localization Instrument (MOLLI) for excision of non-palpable breast lesions.
Breast Cancer Res Treat. 2020;179:671-676.
PubMed Abstract available

PIROT F, Chaltiel D, Ben Lakhdar A, Mathieu MC, et al
Squamous cell carcinoma of the breast, are there two entities with distinct prognosis? A series of 39 patients.
Breast Cancer Res Treat. 2020;180:87-95.
PubMed Abstract available

ADHIKARY S, Hoskin TL, Stallings-Mann ML, Arshad M, et al
Cytotoxic T cell depletion with increasing epithelial abnormality in women with benign breast disease.
Breast Cancer Res Treat. 2020;180:55-61.
PubMed Abstract available

January 2020

LINNENBRINGER E, Geronimus AT, Davis KL, Bound J, et al
Associations between breast cancer subtype and neighborhood socioeconomic and racial composition among Black and White women.
Breast Cancer Res Treat. 2020 Jan 30. pii: 10.1007/s10549-020-05545.
PubMed Abstract available

QIAN XL, Xu P, Zhang YQ, Song YM, et al
Increased number of intratumoral IL-17+ cells, a harbinger of the adverse prognosis of triple-negative breast cancer.
Breast Cancer Res Treat. 2020 Jan 29. pii: 10.1007/s10549-020-05540.
PubMed Abstract available

RAINVILLE I, Hatcher S, Rosenthal E, Larson K, et al
High risk of breast cancer in women with biallelic pathogenic variants in CHEK2.
Breast Cancer Res Treat. 2020 Jan 28. pii: 10.1007/s10549-020-05543.
PubMed Abstract available

ROSE M, Svensson H, Handler J, Hoyer U, et al
Patient-reported outcome after oncoplastic breast surgery compared with conventional breast-conserving surgery in breast cancer.
Breast Cancer Res Treat. 2020 Jan 27. pii: 10.1007/s10549-020-05544.
PubMed Abstract available

DE BONIFACE J, Ahlgren J, Andersson Y, Bergkvist L, et al
The generalisability of randomised clinical trials: an interim external validity analysis of the ongoing SENOMAC trial in sentinel lymph node-positive breast cancer.
Breast Cancer Res Treat. 2020 Jan 27. pii: 10.1007/s10549-020-05537.
PubMed Abstract available

KANAI A, McNamara KM, Iwabuchi E, Miki Y, et al
Significance of glucocorticoid signaling in triple-negative breast cancer patients: a newly revealed interaction with androgen signaling.
Breast Cancer Res Treat. 2020 Jan 27. pii: 10.1007/s10549-020-05523.
PubMed Abstract available

MOUSLIM MC, Johnson RM, Dean LT
Healthcare system distrust and the breast cancer continuum of care.
Breast Cancer Res Treat. 2020 Jan 25. pii: 10.1007/s10549-020-05538.
PubMed Abstract available

ZENG F, Heng J, Guo X, Wang Y, et al
The novel TP53 3'-end methylation pattern associated with its expression would be a potential biomarker for breast cancer detection.
Breast Cancer Res Treat. 2020 Jan 25. pii: 10.1007/s10549-020-05536.
PubMed Abstract available

PLICHTA JK, Thomas SM, Vernon R, Fayanju OM, et al
Breast cancer tumor histopathology, stage at presentation, and treatment in the extremes of age.
Breast Cancer Res Treat. 2020 Jan 24. pii: 10.1007/s10549-020-05542.
PubMed Abstract available

FERRARIS C, Ballestra B, Listorti C, Cappelletti V, et al
Red clover and lifestyle changes to contrast menopausal symptoms in premenopausal patients with hormone-sensitive breast cancer receiving tamoxifen.
Breast Cancer Res Treat. 2020 Jan 24. pii: 10.1007/s10549-020-05534.
PubMed Abstract available

LEE C, Check DK, Manace Brenman L, Kushi LH, et al
Adjuvant endocrine therapy for breast cancer patients: impact of a health system outreach program to improve adherence.
Breast Cancer Res Treat. 2020 Jan 23. pii: 10.1007/s10549-020-05539.
PubMed Abstract available

LI J, Fu F, Yu L, Huang M, et al
Cyclin-dependent kinase 4 and 6 inhibitors in hormone receptor-positive, human epidermal growth factor receptor-2 negative advanced breast cancer: a meta-analysis of randomized clinical trials.
Breast Cancer Res Treat. 2020 Jan 22. pii: 10.1007/s10549-020-05528.
PubMed Abstract available

BANSOD S, Desai R
Nationwide prevalence and trends of acute cardiovascular and cerebrovascular events among adult breast cancer survivors with a history of radiation therapy.
Breast Cancer Res Treat. 2020 Jan 22. pii: 10.1007/s10549-020-05535.
PubMed

FAYANJU OM, Ren Y, Greenup RA, Plichta JK, et al
Extent of axillary surgery in inflammatory breast cancer: a survival analysis of 3500 patients.
Breast Cancer Res Treat. 2020 Jan 20. pii: 10.1007/s10549-020-05529.
PubMed Abstract available

HULSBERGEN AFC, Cho LD, Mammi M, Lamba N, et al
Systemic therapy following craniotomy in patients with a solitary breast cancer brain metastasis.
Breast Cancer Res Treat. 2020 Jan 17. pii: 10.1007/s10549-020-05531.
PubMed Abstract available

MASUDA N, Ohtani S, Takano T, Inoue K, et al
A randomized, 3-arm, neoadjuvant, phase 2 study comparing docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP), TCbHP followed by trastuzumab emtansine and pertuzumab (T-DM1+P), and T-DM1+P in HER2-positive primary breast cancer.
Breast Cancer Res Treat. 2020 Jan 17. pii: 10.1007/s10549-020-05524.
PubMed Abstract available

KLAESTAD E, Opdahl S, Engstrom MJ, Ytterhus B, et al
MRPS23 amplification and gene expression in breast cancer; association with proliferation and the non-basal subtypes.
Breast Cancer Res Treat. 2020 Jan 16. pii: 10.1007/s10549-020-05532.
PubMed Abstract available

YE ZJ, Zhang Z, Zhang XY, Tang Y, et al
Effectiveness of adjuvant supportive-expressive group therapy for breast cancer.
Breast Cancer Res Treat. 2020 Jan 16. pii: 10.1007/s10549-020-05526.
PubMed Abstract available

GARCIA X, Elia A, Galizzi L, May M, et al
Increased androgen receptor expression in estrogen receptor-positive/progesterone receptor-negative breast cancer.
Breast Cancer Res Treat. 2020 Jan 16. pii: 10.1007/s10549-020-05527.
PubMed Abstract available

LOPEZ G, Fusco N
RE: Mismatch repair protein loss in breast cancer: clinicopathological associations in a large British Columbia cohort.
Breast Cancer Res Treat. 2020 Jan 16. pii: 10.1007/s10549-020-05530.
PubMed

ROTILI A, Trimboli RM, Penco S, Pesapane F, et al
Double reading of diffusion-weighted magnetic resonance imaging for breast cancer detection.
Breast Cancer Res Treat. 2020 Jan 14. pii: 10.1007/s10549-019-05519.
PubMed Abstract available

BJERKESET E, Rohrl K, Schou-Bredal I
Symptom cluster of pain, fatigue, and psychological distress in breast cancer survivors: prevalence and characteristics.
Breast Cancer Res Treat. 2020 Jan 14. pii: 10.1007/s10549-020-05522.
PubMed Abstract available

TADROS AB, Moo TA, Stempel M, Zabor EC, et al
Axillary management for young women with breast cancer varies between patients electing breast-conservation therapy or mastectomy.
Breast Cancer Res Treat. 2020 Jan 14. pii: 10.1007/s10549-019-05520.
PubMed Abstract available

YAO S, Laurent CA, Roh JM, Lo J, et al
Serum bone markers and risk of osteoporosis and fragility fractures in women who received endocrine therapy for breast cancer: a prospective study.
Breast Cancer Res Treat. 2020 Jan 7. pii: 10.1007/s10549-019-05518.
PubMed Abstract available

WIJAYABAHU AT, Egan KM, Yaghjyan L
Uterine cancer in breast cancer survivors: a systematic review.
Breast Cancer Res Treat. 2020 Jan 2. pii: 10.1007/s10549-019-05516.
PubMed Abstract available

KIM SS, Lee MH, Lee MO
Histone methyltransferases regulate the transcriptional expression of ERalpha and the proliferation of tamoxifen-resistant breast cancer cells.
Breast Cancer Res Treat. 2020 Jan 2. pii: 10.1007/s10549-019-05517.
PubMed Abstract available

TYNAN M, Peshkin BN, Isaacs C, Willey S, et al
Predictors of contralateral prophylactic mastectomy in genetically high risk newly diagnosed breast cancer patients.
Breast Cancer Res Treat. 2020 Jan 1. pii: 10.1007/s10549-019-05515.
PubMed Abstract available

VITIELLO GAF, Amarante MK, Banin-Hirata BK, Campos CZ, et al
Authors' reply to the comment "Transforming growth factor beta receptor II (TGFBR2) promoter region polymorphism".
Breast Cancer Res Treat. 2020;179:519-520.
PubMed

GRADISHAR B
Editorial.
Breast Cancer Res Treat. 2020;179:1.
PubMed

DE AZAMBUJA E, Ponde N, Procter M, Rastogi P, et al
A pooled analysis of the cardiac events in the trastuzumab adjuvant trials.
Breast Cancer Res Treat. 2020;179:161-171.
PubMed Abstract available

HAWSE JR, Carter JM, Aspros KGM, Bruinsma ES, et al
Optimized immunohistochemical detection of estrogen receptor beta using two validated monoclonal antibodies confirms its expression in normal and malignant breast tissues.
Breast Cancer Res Treat. 2020;179:241-249.
PubMed Abstract available

MITRA D, Bhattacharyya S, Alam N, Sen S, et al
Phosphorylation of EphA2 receptor and vasculogenic mimicry is an indicator of poor prognosis in invasive carcinoma of the breast.
Breast Cancer Res Treat. 2020;179:359-370.
PubMed Abstract available

MERRILL NM, Lachacz EJ, Vandecan NM, Ulintz PJ, et al
Molecular determinants of drug response in TNBC cell lines.
Breast Cancer Res Treat. 2020;179:337-347.
PubMed Abstract available

FUNK A, Heil J, Harcos A, Gomez C, et al
Efficacy of intraoperative specimen radiography as margin assessment tool in breast conserving surgery.
Breast Cancer Res Treat. 2020;179:425-433.
PubMed Abstract available

MULLOOLY M, Withrow DR, Curtis RE, Fan S, et al
Association of lifestyle and clinical characteristics with receipt of radiotherapy treatment among women diagnosed with DCIS in the NIH-AARP Diet and Health Study.
Breast Cancer Res Treat. 2020;179:445-457.
PubMed Abstract available

BERRY DL, Blonquist TM, Halpenny B, Hong F, et al
The Jacki Jacket after mastectomy with reconstruction: a randomized pilot study.
Breast Cancer Res Treat. 2020;179:377-385.
PubMed Abstract available

NEALON KP, Sobti N, Gadd M, Specht M, et al
Assessing the additional surgical risk of contralateral prophylactic mastectomy and immediate breast implant reconstruction.
Breast Cancer Res Treat. 2020;179:255-265.
PubMed Abstract available

December 2019

LI Y, Zhou Y, Mao F, Lin Y, et al
Adjuvant addition of capecitabine to early-stage triple-negative breast cancer patients receiving standard chemotherapy: a meta-analysis.
Breast Cancer Res Treat. 2019 Dec 21. pii: 10.1007/s10549-019-05513.
PubMed Abstract available

CHEN HL, Du L, Li XM
Re: Association of depression and anxiety disorder with the risk of mortality in breast cancer.
Breast Cancer Res Treat. 2019 Dec 19. pii: 10.1007/s10549-019-05510.
PubMed

HEUBLEIN S, Egger M, Zhu J, Berger L, et al
Evaluation of the anti-Thomsen-Friedenreich antibodies Nemod-TF1 and Nemod-TF2 as prognostic markers in breast cancer.
Breast Cancer Res Treat. 2019 Dec 11. pii: 10.1007/s10549-019-05503.
PubMed Abstract available

KIM MH, Kim GM, Kim JH, Kim JY, et al
Intermediate HER2 expression is associated with poor prognosis in estrogen receptor-positive breast cancer patients aged 55 years and older.
Breast Cancer Res Treat. 2019 Dec 6. pii: 10.1007/s10549-019-05505.
PubMed Abstract available

YASRI S, Wiwanitkit V
Transforming growth factor beta receptor II (TGFBR2) promoter region polymorphism.
Breast Cancer Res Treat. 2019;178:713.
PubMed

November 2019

HII LW, Chung FF, Soo JS, Tan BS, et al
Histone deacetylase (HDAC) inhibitors and doxorubicin combinations target both breast cancer stem cells and non-stem breast cancer cells simultaneously.
Breast Cancer Res Treat. 2019 Nov 29. pii: 10.1007/s10549-019-05504.
PubMed Abstract available

CLAESSENS AKM, Timman R, Busschbach JJ, Bouma JM, et al
The influence on quality of life of intermittent scheduling in first- and second-line chemotherapy of patients with HER2-negative advanced breast cancer.
Breast Cancer Res Treat. 2019 Nov 28. pii: 10.1007/s10549-019-05495.
PubMed Abstract available

ANDERSEN JLM, Hansen L, Thomsen BLR, Christiansen LR, et al
Pre- and post-diagnostic intake of whole grain and dairy products and breast cancer prognosis: the Danish Diet, Cancer and Health cohort.
Breast Cancer Res Treat. 2019 Nov 26. pii: 10.1007/s10549-019-05497.
PubMed Abstract available

WU Y, Ouyang T, Li J, Wang T, et al
Spectrum and clinical relevance of PALB2 germline mutations in 7657 Chinese BRCA1/2-negative breast cancer patients.
Breast Cancer Res Treat. 2019 Nov 25. pii: 10.1007/s10549-019-05483.
PubMed Abstract available

KULIGINA ES, Sokolenko AP, Bizin IV, Romanko AA, et al
Exome sequencing study of Russian breast cancer patients suggests a predisposing role for USP39.
Breast Cancer Res Treat. 2019 Nov 21. pii: 10.1007/s10549-019-05492.
PubMed Abstract available

ALMEIDA M, Soares M, Ramalhinho AC, Moutinho JF, et al
The prognostic value of NRF2 in breast cancer patients: a systematic review with meta-analysis.
Breast Cancer Res Treat. 2019 Nov 19. pii: 10.1007/s10549-019-05494.
PubMed Abstract available

FERNANDEZ AI, Geng X, Chaldekas K, Harris B, et al
The orphan nuclear receptor estrogen-related receptor beta (ERRbeta) in triple-negative breast cancer.
Breast Cancer Res Treat. 2019 Nov 19. pii: 10.1007/s10549-019-05485.
PubMed Abstract available

ROSENBERGER LH, Ren Y, Thomas SM, Greenup RA, et al
Axillary lymph node dissection in node-positive breast cancer: are ten nodes adequate and when is enough, enough?
Breast Cancer Res Treat. 2019 Nov 18. pii: 10.1007/s10549-019-05500.
PubMed Abstract available

FRISELL A, Lagergren J, Halle M, de Boniface J, et al
Socioeconomic status differs between breast cancer patients treated with mastectomy and breast conservation, and affects patient-reported preoperative information.
Breast Cancer Res Treat. 2019 Nov 18. pii: 10.1007/s10549-019-05496.
PubMed Abstract available

NYROP KA, Deal AM, Shachar SS, Park J, et al
Weight trajectories in women receiving systemic adjuvant therapy for breast cancer.
Breast Cancer Res Treat. 2019 Nov 16. pii: 10.1007/s10549-019-05501.
PubMed Abstract available

WARDELL SE, Yllanes AP, Chao CA, Bae Y, et al
Correction to: Pharmacokinetic and pharmacodynamic analysis of fulvestrant in preclinical models of breast cancer to assess the importance of its estrogen receptor-alpha degrader activity in antitumor efficacy.
Breast Cancer Res Treat. 2019 Nov 16. pii: 10.1007/s10549-019-05498.
PubMed Abstract available

DREWS-ELGER K, Sandoval-Leon AC, Ergonul AB, Jegg AM, et al
Paget's disease of the nipple in a Her2-positive breast cancer xenograft model.
Breast Cancer Res Treat. 2019 Nov 13. pii: 10.1007/s10549-019-05490.
PubMed Abstract available

TIAINEN S, Masarwah A, Oikari S, Rilla K, et al
Tumor microenvironment and breast cancer survival: combined effects of breast fat, M2 macrophages and hyaluronan create a dismal prognosis.
Breast Cancer Res Treat. 2019 Nov 12. pii: 10.1007/s10549-019-05491.
PubMed Abstract available

KANSTRUP C, Teilum D, Rejnmark L, Bigaard JV, et al
25-Hydroxyvitamin D at time of breast cancer diagnosis and breast cancer survival.
Breast Cancer Res Treat. 2019 Nov 9. pii: 10.1007/s10549-019-05486.
PubMed Abstract available

KUROZUMI S, Alsaeed S, Orah N, Miligy IM, et al
Clinicopathological significance of lipocalin 2 nuclear expression in invasive breast cancer.
Breast Cancer Res Treat. 2019 Nov 9. pii: 10.1007/s10549-019-05488.
PubMed Abstract available

CAO S, Wei F, Zhou J, Zhu Z, et al
The synergistic effect between adult weight changes and CYP24A1 polymorphisms is associated with pre- and postmenopausal breast cancer risk.
Breast Cancer Res Treat. 2019 Nov 6. pii: 10.1007/s10549-019-05484.
PubMed Abstract available

KARIRI YA, Joseph C, Kurozumi S, Toss MS, et al
Prognostic significance of KN motif and ankyrin repeat domains 1 (KANK1) in invasive breast cancer.
Breast Cancer Res Treat. 2019 Nov 2. pii: 10.1007/s10549-019-05466.
PubMed Abstract available

STRIZOVA Z, Vachtenheim J Jr, Bartunkova J
The potential role of neutrophil trogocytosis and G-CSF in the loss of HER2 expression.
Breast Cancer Res Treat. 2019;178:247-248.
PubMed

TRIMBOLI RM, Schiaffino S, Sardanelli F
In BRCA mutation carriers breast conserving surgery may not be the best choice.
Breast Cancer Res Treat. 2019;178:245-246.
PubMed

October 2019

SHIM EJ, Lee JW, Cho J, Jung HK, et al
Association of depression and anxiety disorder with the risk of mortality in breast cancer: A National Health Insurance Service study in Korea.
Breast Cancer Res Treat. 2019 Oct 31. pii: 10.1007/s10549-019-05479.
PubMed Abstract available

SRIDHAR S, Rajesh C, Jishnu PV, Jayaram P, et al
Increased expression of P-cadherin is an indicator of poor prognosis in breast cancer: a systematic review and meta-analysis.
Breast Cancer Res Treat. 2019 Oct 29. pii: 10.1007/s10549-019-05477.
PubMed Abstract available

ZHENG L, Li X, Gu Y, Lv X, et al
Correction to: The 3'UTR of the pseudogene CYP4Z2P promotes tumor angiogenesis in breast cancer by acting as a ceRNA for CYP4Z1.
Breast Cancer Res Treat. 2019 Oct 26. pii: 10.1007/s10549-019-05478.
PubMed Abstract available

BATENBURG MCT, Gregorowitsch ML, Maarse W, Witkamp A, et al
Patient-reported cosmetic satisfaction and the long-term association with quality of life in irradiated breast cancer patients.
Breast Cancer Res Treat. 2019 Oct 24. pii: 10.1007/s10549-019-05470.
PubMed Abstract available

CHOI Y, Smith KC, Shukla A, Blackford AL, et al
Breast cancer survivorship care plans: what are they covering and how well do they align with national guidelines?
Breast Cancer Res Treat. 2019 Oct 24. pii: 10.1007/s10549-019-05480.
PubMed Abstract available

BEDNAREK R, Selmi A, Wojkowska D, Karolczak K, et al
Functional inhibition of F11 receptor (F11R/junctional adhesion molecule-A/JAM-A) activity by a F11R-derived peptide in breast cancer and its microenvironment.
Breast Cancer Res Treat. 2019 Oct 24. pii: 10.1007/s10549-019-05471.
PubMed Abstract available

BANYS-PALUCHOWSKI M, Milde-Langosch K, Fehm T, Witzel I, et al
Clinical relevance of H-RAS, K-RAS, and N-RAS mRNA expression in primary breast cancer patients.
Breast Cancer Res Treat. 2019 Oct 23. pii: 10.1007/s10549-019-05474.
PubMed Abstract available

KOMOROWSKI AS, Pezo RC
Untapped "-omics": the microbial metagenome, estrobolome, and their influence on the development of breast cancer and response to treatment.
Breast Cancer Res Treat. 2019 Oct 23. pii: 10.1007/s10549-019-05472.
PubMed Abstract available

LEE YJ, Park H, Kang CM, Gwark SC, et al
Risk stratification system for groups with a low, intermediate, and high risk of subsequent distant metastasis and death following isolated locoregional recurrence of breast cancer.
Breast Cancer Res Treat. 2019 Oct 23. pii: 10.1007/s10549-019-05469.
PubMed Abstract available

NAIK H, Leung B, Laskin J, McDonald M, et al
Emotional distress and psychosocial needs in patients with breast cancer in British Columbia: younger versus older adults.
Breast Cancer Res Treat. 2019 Oct 19. pii: 10.1007/s10549-019-05468.
PubMed Abstract available

JEONG SH, An Y, Ahn C, Park B, et al
Body mass index and risk of breast cancer molecular subtypes in Korean women: a case-control study.
Breast Cancer Res Treat. 2019 Oct 18. pii: 10.1007/s10549-019-05451.
PubMed Abstract available

IWASE T, Sangai T, Fujimoto H, Sawabe Y, et al
Quality and quantity of visceral fat tissue are associated with insulin resistance and survival outcomes after chemotherapy in patients with breast cancer.
Breast Cancer Res Treat. 2019 Oct 16. pii: 10.1007/s10549-019-05467.
PubMed Abstract available

CARENE D, Tran-Dien A, Lemonnier J, Dalenc F, et al
Association between FGFR1 copy numbers, MAP3K1 mutations, and survival in axillary node-positive, hormone receptor-positive, and HER2-negative early breast cancer in the PACS04 and METABRIC studies.
Breast Cancer Res Treat. 2019 Oct 16. pii: 10.1007/s10549-019-05462.
PubMed Abstract available

HERRSCHER H, Velten M, Leblanc J, Kalish-Weindling M, et al
Fulvestrant and palbociclib combination in heavily pretreated hormone receptor-positive, HER2-negative metastatic breast cancer patients.
Breast Cancer Res Treat. 2019 Oct 14. pii: 10.1007/s10549-019-05439.
PubMed Abstract available

RODRIGUES-FERREIRA S, Molina A, Nahmias C
Microtubule-associated tumor suppressors as prognostic biomarkers in breast cancer.
Breast Cancer Res Treat. 2019 Oct 12. pii: 10.1007/s10549-019-05463.
PubMed Abstract available

QIAN X, Li Z, Ruan G, Tu C, et al
Efficacy and toxicity of extended aromatase inhibitors after adjuvant aromatase inhibitors-containing therapy for hormone-receptor-positive breast cancer: a literature-based meta-analysis of randomized trials.
Breast Cancer Res Treat. 2019 Oct 12. pii: 10.1007/s10549-019-05464.
PubMed Abstract available

AMMITZBOLL G, Andersen KG, Bidstrup PE, Johansen C, et al
Effect of progressive resistance training on persistent pain after axillary dissection in breast cancer: a randomized controlled trial.
Breast Cancer Res Treat. 2019 Oct 11. pii: 10.1007/s10549-019-05461.
PubMed Abstract available

SHI Z, Rundle A, Genkinger JM, Cheung YK, et al
Distinct trajectories of fruits and vegetables, dietary fat, and alcohol intake following a breast cancer diagnosis: the Pathways Study.
Breast Cancer Res Treat. 2019 Oct 10. pii: 10.1007/s10549-019-05457.
PubMed Abstract available

ALJOHANI AI, Toss MS, Kurozumi S, Joseph C, et al
The prognostic significance of wild-type isocitrate dehydrogenase 2 (IDH2) in breast cancer.
Breast Cancer Res Treat. 2019 Oct 10. pii: 10.1007/s10549-019-05459.
PubMed Abstract available

GONZALEZ-RODRIGUEZ E, Aubry-Rozier B, Stoll D, Zaman K, et al
Sixty spontaneous vertebral fractures after denosumab discontinuation in 15 women with early-stage breast cancer under aromatase inhibitors.
Breast Cancer Res Treat. 2019 Oct 9. pii: 10.1007/s10549-019-05458.
PubMed Abstract available

HWANG KT, Kim J, Jung J, Kim BH, et al
Long-term prognostic effect of hormone receptor subtype on breast cancer.
Breast Cancer Res Treat. 2019 Oct 8. pii: 10.1007/s10549-019-05456.
PubMed Abstract available

BLANCHETTE PS, Lam M, Richard L, Allen B, et al
Factors associated with endocrine therapy adherence among post-menopausal women treated for early-stage breast cancer in Ontario, Canada.
Breast Cancer Res Treat. 2019 Oct 1. pii: 10.1007/s10549-019-05430.
PubMed Abstract available

September 2019

WARDELL SE, Yllanes AP, Chao CA, Bae Y, et al
Pharmacokinetic and pharmacodynamic analysis of fulvestrant in preclinical models of breast cancer to assess the importance of its estrogen receptor-alpha degrader activity in antitumor efficacy.
Breast Cancer Res Treat. 2019 Sep 27. pii: 10.1007/s10549-019-05454.
PubMed Abstract available

SAMUEL CA, Spencer JC, Rosenstein DL, Reeder-Hayes KE, et al
Racial differences in employment and cost-management behaviors in patients with metastatic breast cancer.
Breast Cancer Res Treat. 2019 Sep 25. pii: 10.1007/s10549-019-05449.
PubMed Abstract available

PU M, Messer K, Davies SR, Vickery TL, et al
Research-based PAM50 signature and long-term breast cancer survival.
Breast Cancer Res Treat. 2019 Sep 21. pii: 10.1007/s10549-019-05446.
PubMed Abstract available

YEN TWF, Laud PW, McGinley EL, Pezzin LE, et al
Prevalence and scope of advanced practice provider oncology care among Medicare beneficiaries with breast cancer.
Breast Cancer Res Treat. 2019 Sep 21. pii: 10.1007/s10549-019-05447.
PubMed Abstract available

WOLFS JAGN, de Joode LGEH, van der Hulst RRWJ, Qiu SS, et al
Correlation between patency and clinical improvement after lymphaticovenous anastomosis (LVA) in breast cancer-related lymphedema: 12-month follow-up.
Breast Cancer Res Treat. 2019 Sep 21. pii: 10.1007/s10549-019-05450.
PubMed Abstract available

JEON J, Kim SE, Lee DY, Choi D, et al
Factors associated with endometrial pathology during tamoxifen therapy in women with breast cancer: a retrospective analysis of 821 biopsies.
Breast Cancer Res Treat. 2019 Sep 20. pii: 10.1007/s10549-019-05448.
PubMed Abstract available

LEONE JP, Duda DG, Hu J, Barry WT, et al
A phase II study of cabozantinib alone or in combination with trastuzumab in breast cancer patients with brain metastases.
Breast Cancer Res Treat. 2019 Sep 20. pii: 10.1007/s10549-019-05445.
PubMed Abstract available

SYNNOTT NC, O'Connell D, Crown J, Duffy MJ, et al
COTI-2 reactivates mutant p53 and inhibits growth of triple-negative breast cancer cells.
Breast Cancer Res Treat. 2019 Sep 19. pii: 10.1007/s10549-019-05435.
PubMed Abstract available

TERADA M, Yoshimura A, Sawaki M, Hattori M, et al
Patient-reported outcomes and objective assessments with arm measurement and bioimpedance analysis for lymphedema among breast cancer survivors.
Breast Cancer Res Treat. 2019 Sep 18. pii: 10.1007/s10549-019-05443.
PubMed Abstract available

ALLOTT EH, Shan Y, Chen M, Sun X, et al
Bimodal age distribution at diagnosis in breast cancer persists across molecular and genomic classifications.
Breast Cancer Res Treat. 2019 Sep 18. pii: 10.1007/s10549-019-05442.
PubMed Abstract available

VANGANGELT KMH, Kramer CJH, Bastiaannet E, Putter H, et al
The intra-tumoural stroma in patients with breast cancer increases with age.
Breast Cancer Res Treat. 2019 Sep 18. pii: 10.1007/s10549-019-05422.
PubMed Abstract available

BATTISTI NML, True V, Chaabouni N, Chopra N, et al
Pathological complete response to neoadjuvant systemic therapy in 789 early and locally advanced breast cancer patients: The Royal Marsden experience.
Breast Cancer Res Treat. 2019 Sep 18. pii: 10.1007/s10549-019-05444.
PubMed Abstract available

GORBOUNOV M, Carleton NM, Asch-Kendrick RJ, Xian L, et al
High mobility group A1 (HMGA1) protein and gene expression correlate with ER-negativity and poor outcomes in breast cancer.
Breast Cancer Res Treat. 2019 Sep 17. pii: 10.1007/s10549-019-05419.
PubMed Abstract available

PINARD C, Debled M, Ben Rejeb H, Velasco V, et al
Residual cancer burden index and tumor-infiltrating lymphocyte subtypes in triple-negative breast cancer after neoadjuvant chemotherapy.
Breast Cancer Res Treat. 2019 Sep 16. pii: 10.1007/s10549-019-05437.
PubMed Abstract available

CHENG AS, Leung SCY, Gao D, Burugu S, et al
Mismatch repair protein loss in breast cancer: clinicopathological associations in a large British Columbia cohort.
Breast Cancer Res Treat. 2019 Sep 14. pii: 10.1007/s10549-019-05438.
PubMed Abstract available

BRINKHAUS B, Kirschbaum B, Stockigt B, Binting S, et al
Prophylactic acupuncture treatment during chemotherapy with breast cancer: a randomized pragmatic trial with a retrospective nested qualitative study.
Breast Cancer Res Treat. 2019 Sep 13. pii: 10.1007/s10549-019-05431.
PubMed Abstract available

DU T, Liu B, Wang Z, Wan X, et al
CpG methylation signature predicts prognosis in breast cancer.
Breast Cancer Res Treat. 2019 Sep 13. pii: 10.1007/s10549-019-05417.
PubMed Abstract available

DE LIGT KM, Heins M, Verloop J, Ezendam NPM, et al
The impact of health symptoms on health-related quality of life in early-stage breast cancer survivors.
Breast Cancer Res Treat. 2019 Sep 11. pii: 10.1007/s10549-019-05433.
PubMed Abstract available

SCARPITTA R, Zanna I, Aretini P, Gambino G, et al
Germline investigation in male breast cancer of DNA repair genes by next-generation sequencing.
Breast Cancer Res Treat. 2019 Sep 11. pii: 10.1007/s10549-019-05429.
PubMed Abstract available

COUGHLIN SS, Caplan LS, Williams V
Home-based physical activity interventions for breast cancer patients receiving primary therapy: a systematic review.
Breast Cancer Res Treat. 2019 Sep 6. pii: 10.1007/s10549-019-05424.
PubMed Abstract available

STEENBRUGGEN TG, Bouwer NI, Smorenburg CH, Rier HN, et al
Radiological complete remission in HER2-positive metastatic breast cancer patients: what to do with trastuzumab?
Breast Cancer Res Treat. 2019 Sep 6. pii: 10.1007/s10549-019-05427.
PubMed Abstract available

JEON YW, You SH, Lee JE, Youn HJ, et al
Optimal treatment of breast cancer in women older than 75 years: a Korea Breast Cancer Registry analysis.
Breast Cancer Res Treat. 2019 Sep 6. pii: 10.1007/s10549-019-05426.
PubMed Abstract available

KACZMAREK E, Saint-Martin C, Pierga JY, Brain E, et al
Long-term survival in HER2-positive metastatic breast cancer treated with first-line trastuzumab: results from the french real-life curie database.
Breast Cancer Res Treat. 2019 Sep 5. pii: 10.1007/s10549-019-05423.
PubMed Abstract available

LAGACE F, Ghazawi FM, Le M, Rahme E, et al
Analysis of incidence, mortality trends, and geographic distribution of breast cancer patients in Canada.
Breast Cancer Res Treat. 2019 Sep 4. pii: 10.1007/s10549-019-05418.
PubMed Abstract available

RIEDEL F, Heil J, Feisst M, Rezai M, et al
Non-sentinel axillary tumor burden applying the ACOSOG Z0011 eligibility criteria to a large routine cohort.
Breast Cancer Res Treat. 2019;177:457-467.
PubMed Abstract available

NIRAVATH P, Hilsenbeck SG, Wang T, Jiralerspong S, et al
Randomized controlled trial of high-dose versus standard-dose vitamin D3 for prevention of aromatase inhibitor-induced arthralgia.
Breast Cancer Res Treat. 2019;177:427-435.
PubMed Abstract available

BLACKWOOD J, Wright FC, Hong NJL, Gagliardi AR, et al
Quality of DCIS information on the internet: a content analysis.
Breast Cancer Res Treat. 2019;177:295-305.
PubMed Abstract available

YU Q, Huang K, Zhu Y, Chen X, et al
Preliminary results of computer-aided diagnosis for magnetic resonance imaging of solid breast lesions.
Breast Cancer Res Treat. 2019;177:419-426.
PubMed Abstract available

YANG Y, Li S, Liu G, Shao Z, et al
Is core needle biopsy effective at diagnosing male breast lesions?
Breast Cancer Res Treat. 2019;177:507-511.
PubMed Abstract available

August 2019

LI C, Fan H, Xiang Q, Xu L, et al
Prognostic value of receptor status conversion following neoadjuvant chemotherapy in breast cancer patients: a systematic review and meta-analysis.
Breast Cancer Res Treat. 2019 Aug 30. pii: 10.1007/s10549-019-05421.
PubMed Abstract available

HOVELING LA, van Maaren MC, Hueting T, Strobbe LJA, et al
Validation of the online prediction model CancerMath in the Dutch breast cancer population.
Breast Cancer Res Treat. 2019 Aug 30. pii: 10.1007/s10549-019-05399.
PubMed Abstract available

ALFARSI LH, Ansari RE, Craze ML, Toss MS, et al
CDC20 expression in oestrogen receptor positive breast cancer predicts poor prognosis and lack of response to endocrine therapy.
Breast Cancer Res Treat. 2019 Aug 30. pii: 10.1007/s10549-019-05420.
PubMed Abstract available

KLUZNIAK W, Wokolorczyk D, Rusak B, Huzarski T, et al
Inherited variants in XRCC2 and the risk of breast cancer.
Breast Cancer Res Treat. 2019 Aug 28. pii: 10.1007/s10549-019-05415.
PubMed Abstract available

ZHI WI, Chen P, Kwon A, Chen C, et al
Chemotherapy-induced peripheral neuropathy (CIPN) in breast cancer survivors: a comparison of patient-reported outcomes and quantitative sensory testing.
Breast Cancer Res Treat. 2019 Aug 27. pii: 10.1007/s10549-019-05416.
PubMed Abstract available

CHEN J, Douglass J, Prasath V, Neace M, et al
The microbiome and breast cancer: a review.
Breast Cancer Res Treat. 2019 Aug 27. pii: 10.1007/s10549-019-05407.
PubMed Abstract available

KUBO M, Kawai M, Kumamaru H, Miyata H, et al
A population-based recurrence risk management study of patients with pT1 node-negative HER2+ breast cancer: a National Clinical Database study.
Breast Cancer Res Treat. 2019 Aug 26. pii: 10.1007/s10549-019-05413.
PubMed Abstract available

VERBEEK JGE, Atema V, Mewes JC, van Leeuwen M, et al
Cost-utility, cost-effectiveness, and budget impact of Internet-based cognitive behavioral therapy for breast cancer survivors with treatment-induced menopausal symptoms.
Breast Cancer Res Treat. 2019 Aug 26. pii: 10.1007/s10549-019-05410.
PubMed Abstract available

DE BOER AZ, Bastiaannet E, de Glas NA, Marang-van de Mheen PJ, et al
Effectiveness of radiotherapy after breast-conserving surgery in older patients with T1-2N0 breast cancer.
Breast Cancer Res Treat. 2019 Aug 26. pii: 10.1007/s10549-019-05412.
PubMed Abstract available

D'AMBROSIO V, Vena F, Di Mascio D, Faralli I, et al
Obstetrical outcomes in women with history of breast cancer: a systematic review and meta-analysis.
Breast Cancer Res Treat. 2019 Aug 26. pii: 10.1007/s10549-019-05408.
PubMed Abstract available

CERRETINI R, Mercado G, Morganstein J, Schiaffi J, et al
Germline pathogenic variants in BRCA1, BRCA2, PALB2 and RAD51C in breast cancer women from Argentina.
Breast Cancer Res Treat. 2019 Aug 24. pii: 10.1007/s10549-019-05411.
PubMed Abstract available

LUNDGREN C, Bendahl PO, Borg A, Ehinger A, et al
Agreement between molecular subtyping and surrogate subtype classification: a contemporary population-based study of ER-positive/HER2-negative primary breast cancer.
Breast Cancer Res Treat. 2019 Aug 20. pii: 10.1007/s10549-019-05378.
PubMed Abstract available

SIDDAPPA CM, Pillai SG, Snider J, Alldredge P, et al
Gene expression analysis to detect disseminated tumor cells in the bone marrow of triple-negative breast cancer patients predicts metastatic relapse.
Breast Cancer Res Treat. 2019 Aug 20. pii: 10.1007/s10549-019-05405.
PubMed Abstract available

BATTISTI NML, Tong D, Ring A, Smith I, et al
Long-term outcome with targeted therapy in advanced/metastatic HER2-positive breast cancer: The Royal Marsden experience.
Breast Cancer Res Treat. 2019 Aug 20. pii: 10.1007/s10549-019-05406.
PubMed Abstract available

WANG X, Kong X, Fang Y, Wang J, et al
Letter regarding Sopik V et al. entitled "Impact of microinvasion on breast cancer mortality in women with ductal carcinoma in situ".
Breast Cancer Res Treat. 2019 Aug 20. pii: 10.1007/s10549-019-05389.
PubMed

ROCCA A, Melegari E, Palleschi M
Precision medicine: PI3K targeting in advanced breast cancer.
Breast Cancer Res Treat. 2019 Aug 19. pii: 10.1007/s10549-019-05409.
PubMed

VIALE G, Hanlon Newell AE, Walker E, Harlow G, et al
Ki-67 (30-9) scoring and differentiation of Luminal A- and Luminal B-like breast cancer subtypes.
Breast Cancer Res Treat. 2019 Aug 17. pii: 10.1007/s10549-019-05402.
PubMed Abstract available

EAGLEHOUSE YL, Georg MW, Shriver CD, Zhu K, et al
Time-to-surgery and overall survival after breast cancer diagnosis in a universal health system.
Breast Cancer Res Treat. 2019 Aug 14. pii: 10.1007/s10549-019-05404.
PubMed Abstract available

BARRETO-COELHO P, Cerbon D, Schlumbrecht M, Parra CM, et al
Differences in breast cancer outcomes amongst Black US-born and Caribbean-born immigrants.
Breast Cancer Res Treat. 2019 Aug 14. pii: 10.1007/s10549-019-05403.
PubMed Abstract available

LIU YL, Wang DW, Yang ZC, Ma R, et al
Marital status is an independent prognostic factor in inflammatory breast cancer patients: an analysis of the surveillance, epidemiology, and end results database.
Breast Cancer Res Treat. 2019 Aug 14. pii: 10.1007/s10549-019-05385.
PubMed Abstract available

LAI CPT, Yeong JPS, Tan AS, Ong CHC, et al
Evaluation of phospho-histone H3 in Asian triple-negative breast cancer using multiplex immunofluorescence.
Breast Cancer Res Treat. 2019 Aug 13. pii: 10.1007/s10549-019-05396.
PubMed Abstract available

RUSAK B, Kluzniak W, Wokolorczyk D, Stempa K, et al
Allelic modification of breast cancer risk in women with an NBN mutation.
Breast Cancer Res Treat. 2019 Aug 13. pii: 10.1007/s10549-019-05391.
PubMed Abstract available

KIM JY, Lee E, Park K, Im SA, et al
Exploratory biomarker analysis from a phase II clinical trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine for HER2-negative metastatic breast cancer patients (KCSG BR13-11).
Breast Cancer Res Treat. 2019 Aug 12. pii: 10.1007/s10549-019-05400.
PubMed Abstract available

HIDA AI, Watanabe T, Sagara Y, Kashiwaba M, et al
Diffuse distribution of tumor-infiltrating lymphocytes is a marker for better prognosis and chemotherapeutic effect in triple-negative breast cancer.
Breast Cancer Res Treat. 2019 Aug 12. pii: 10.1007/s10549-019-05390.
PubMed Abstract available

TANG E, Rowland A, McKinnon RA, Sorich MJ, et al
Effect of early adverse events resulting in ado-trastuzumab emtansine dose adjustments on survival outcomes of HER2+ advanced breast cancer patients.
Breast Cancer Res Treat. 2019 Aug 9. pii: 10.1007/s10549-019-05393.
PubMed Abstract available

ARNAOUT A, Robertson S, Pond GR, Vieth R, et al
Randomized window of opportunity trial evaluating high-dose vitamin D in breast cancer patients.
Breast Cancer Res Treat. 2019 Aug 9. pii: 10.1007/s10549-019-05392.
PubMed Abstract available

ROBINSON A, Stober C, Fergusson D, Kehoe A, et al
A multicentre, randomized pilot trial comparing vascular access strategies for early stage breast cancer patients receiving non-trastuzumab containing chemotherapy.
Breast Cancer Res Treat. 2019 Aug 7. pii: 10.1007/s10549-019-05388.
PubMed Abstract available

ARNAOUT A, Robertson SJ, Pond GR, Lee H, et al
A randomized, double-blind, window of opportunity trial evaluating the effects of chloroquine in breast cancer patients.
Breast Cancer Res Treat. 2019 Aug 7. pii: 10.1007/s10549-019-05381.
PubMed Abstract available

LIU ZB, Ezzedine NE, Eterovic AK, Ensor JE, et al
Detection of breast cancer stem cell gene mutations in circulating free DNA during the evolution of metastases.
Breast Cancer Res Treat. 2019 Aug 6. pii: 10.1007/s10549-019-05374.
PubMed Abstract available

HE J, McLaughlin RP, van der Noord V, Foekens JA, et al
Multi-targeted kinase inhibition alleviates mTOR inhibitor resistance in triple-negative breast cancer.
Breast Cancer Res Treat. 2019 Aug 6. pii: 10.1007/s10549-019-05380.
PubMed Abstract available

LIU Y, Wu S, Shi X, Luo Y, et al
HER2 double-equivocal breast cancer in Chinese patients: a high concordance of HER2 status between different blocks from the same tumor.
Breast Cancer Res Treat. 2019 Aug 6. pii: 10.1007/s10549-019-05387.
PubMed Abstract available

PEARSON A, Booker A, Tio M, Marx G, et al
Vaginal CO2 laser for the treatment of vulvovaginal atrophy in women with breast cancer: LAAVA pilot study.
Breast Cancer Res Treat. 2019 Aug 3. pii: 10.1007/s10549-019-05384.
PubMed Abstract available

ALTUNDAG K
HER2+ and triple-negative phenotypes in invasive lobular carcinoma might have different specific biological features.
Breast Cancer Res Treat. 2019;176:719.
PubMed

ZDRAVKOVIC D, Ivanovic N, Crnokrak B
Microinvasion: could it be sufficient diagnostic criteria for the optimal treatment decision?
Breast Cancer Res Treat. 2019;176:717.
PubMed

ZHANG L, Bailleul J, Yazal T, Dong K, et al
PK-M2-mediated metabolic changes in breast cancer cells induced by ionizing radiation.
Breast Cancer Res Treat. 2019 Aug 1. pii: 10.1007/s10549-019-05376.
PubMed Abstract available

ANGARITA FA, Dossa F, Zuckerman J, McCready DR, et al
Is immediate breast reconstruction safe in women over 70? An analysis of the National Surgical Quality Improvement Program (NSQIP) database.
Breast Cancer Res Treat. 2019;177:215-224.
PubMed Abstract available

HELLAND T, Hagen KB, Haugstoyl ME, Kvaloy JT, et al
Drug monitoring of tamoxifen metabolites predicts vaginal dryness and verifies a low discontinuation rate from the Norwegian Prescription Database.
Breast Cancer Res Treat. 2019;177:185-195.
PubMed Abstract available

MARMOR S, Altman AM, Mayleben WT, Hui JYC, et al
The use of contralateral prophylactic mastectomy among elderly patients in the United States.
Breast Cancer Res Treat. 2019;177:175-183.
PubMed Abstract available

CHEN XY, Yeong J, Thike AA, Bay BH, et al
Prognostic role of immune infiltrates in breast ductal carcinoma in situ.
Breast Cancer Res Treat. 2019;177:17-27.
PubMed Abstract available

ALTUNDAG K
ER(+)/HER2(+) and ER-/HER2(+) breast cancers might have different intracranial recurrence patterns after brain-directed radiation for brain metastases.
Breast Cancer Res Treat. 2019;177:233.
PubMed

MALTONI R, Bravaccini S
What is the best clinical pathological score to identify high-risk patients with lobular carcinoma of the breast who are likely to benefit from adjuvant chemotherapy?
Breast Cancer Res Treat. 2019;177:231-232.
PubMed

July 2019

ABRAMSON VG, Oliveira M, Cervantes A, Wildiers H, et al
A phase Ib, open-label, dose-escalation study of the safety and pharmacology of taselisib (GDC-0032) in combination with either docetaxel or paclitaxel in patients with HER2-negative, locally advanced, or metastatic breast cancer.
Breast Cancer Res Treat. 2019 Jul 31. pii: 10.1007/s10549-019-05360.
PubMed Abstract available

VITIELLO GAF, Amarante MK, Banin-Hirata BK, Campos CZ, et al
Transforming growth factor beta receptor II (TGFBR2) promoter region polymorphism in Brazilian breast cancer patients: association with susceptibility, clinicopathological features, and interaction with TGFB1 haplotypes.
Breast Cancer Res Treat. 2019 Jul 30. pii: 10.1007/s10549-019-05370.
PubMed Abstract available

ZHOU H, Wang XJ, Jiang X, Qian Z, et al
Plasma cell-free DNA chromosomal instability analysis by low-pass whole-genome sequencing to monitor breast cancer relapse.
Breast Cancer Res Treat. 2019 Jul 30. pii: 10.1007/s10549-019-05375.
PubMed Abstract available

GOTTSCHAU M, Jensen A, Reinholdt K, Guleria S, et al
Risk of breast cancer among women with benign ovarian tumors: a Danish nationwide cohort study.
Breast Cancer Res Treat. 2019 Jul 30. pii: 10.1007/s10549-019-05369.
PubMed Abstract available

HUANG W, Ran R, Shao B, Li H, et al
Prognostic and clinicopathological value of PD-L1 expression in primary breast cancer: a meta-analysis.
Breast Cancer Res Treat. 2019 Jul 29. pii: 10.1007/s10549-019-05371.
PubMed Abstract available

DEL RE M, Bertolini I, Crucitta S, Fontanelli L, et al
Overexpression of TK1 and CDK9 in plasma-derived exosomes is associated with clinical resistance to CDK4/6 inhibitors in metastatic breast cancer patients.
Breast Cancer Res Treat. 2019 Jul 26. pii: 10.1007/s10549-019-05365.
PubMed Abstract available

KIM EK, Park AK, Ko E, Park WY, et al
Risk stratification of triple-negative breast cancer with core gene signatures associated with chemoresponse and prognosis.
Breast Cancer Res Treat. 2019 Jul 24. pii: 10.1007/s10549-019-05366.
PubMed Abstract available

VROMANS R, Tenfelde K, Pauws S, van Eenbergen M, et al
Assessing the quality and communicative aspects of patient decision aids for early-stage breast cancer treatment: a systematic review.
Breast Cancer Res Treat. 2019 Jul 24. pii: 10.1007/s10549-019-05351.
PubMed Abstract available

ZHOU K, Li J, Li X
Effects of cyclic adjustment training delivered via a mobile device on psychological resilience, depression, and anxiety in Chinese post-surgical breast cancer patients.
Breast Cancer Res Treat. 2019 Jul 24. pii: 10.1007/s10549-019-05368.
PubMed Abstract available

SAYYAD MR, Puchalapalli M, Vergara NG, Wangensteen SM, et al
Syndecan-1 facilitates breast cancer metastasis to the brain.
Breast Cancer Res Treat. 2019 Jul 20. pii: 10.1007/s10549-019-05347.
PubMed Abstract available

DE GLAS N, Bastiaannet E, de Boer A, Siesling S, et al
Improved survival of older patients with advanced breast cancer due to an increase in systemic treatments: a population-based study.
Breast Cancer Res Treat. 2019 Jul 19. pii: 10.1007/s10549-019-05356.
PubMed Abstract available

ADEMUYIWA FO, Salyer P, Ma Y, Fisher S, et al
Assessing the effectiveness of the National Comprehensive Cancer Network genetic testing guidelines in identifying African American breast cancer patients with deleterious genetic mutations.
Breast Cancer Res Treat. 2019 Jul 19. pii: 10.1007/s10549-019-05359.
PubMed Abstract available

SAKAI T, Ozkurt E, DeSantis S, Wong SM, et al
National trends of synchronous bilateral breast cancer incidence in the United States.
Breast Cancer Res Treat. 2019 Jul 19. pii: 10.1007/s10549-019-05363.
PubMed Abstract available

HUERTA JM, Molina AJ, Chirlaque MD, Yepes P, et al
Domain-specific patterns of physical activity and risk of breast cancer sub-types in the MCC-Spain study.
Breast Cancer Res Treat. 2019 Jul 17. pii: 10.1007/s10549-019-05358.
PubMed Abstract available

NAM SE, Lim W, Jeong J, Lee S, et al
The prognostic significance of preoperative tumor marker (CEA, CA15-3) elevation in breast cancer patients: data from the Korean Breast Cancer Society Registry.
Breast Cancer Res Treat. 2019 Jul 16. pii: 10.1007/s10549-019-05357.
PubMed Abstract available

ISNALDI E, Ferraioli D, Ferrando L, Brohee S, et al
Correction to: Schlafen-11 expression is associated with immune signatures and basal-like phenotype in breast cancer.
Breast Cancer Res Treat. 2019 Jul 12. pii: 10.1007/s10549-019-05348.
PubMed Abstract available

JOHNSON HM, Irish W, Muzaffar M, Vohra NA, et al
Quantifying the relationship between age at diagnosis and breast cancer-specific mortality.
Breast Cancer Res Treat. 2019 Jul 11. pii: 10.1007/s10549-019-05353.
PubMed Abstract available

JACOT W, Dalenc F, Lopez-Crapez E, Chaltiel L, et al
PIK3CA mutations early persistence in cell-free tumor DNA as a negative prognostic factor in metastatic breast cancer patients treated with hormonal therapy.
Breast Cancer Res Treat. 2019 Jul 11. pii: 10.1007/s10549-019-05349.
PubMed Abstract available

ALEIXO GFP, Williams GR, Nyrop KA, Muss HB, et al
Muscle composition and outcomes in patients with breast cancer: meta-analysis and systematic review.
Breast Cancer Res Treat. 2019 Jul 11. pii: 10.1007/s10549-019-05352.
PubMed Abstract available

KUROZUMI S, Kaira K, Matsumoto H, Hirakata T, et al
beta2-Adrenergic receptor expression is associated with biomarkers of tumor immunity and predicts poor prognosis in estrogen receptor-negative breast cancer.
Breast Cancer Res Treat. 2019 Jul 9. pii: 10.1007/s10549-019-05341.
PubMed Abstract available

MURATA T, Yanagisawa T, Kurihara T, Kaneko M, et al
Salivary metabolomics with alternative decision tree-based machine learning methods for breast cancer discrimination.
Breast Cancer Res Treat. 2019 Jul 8. pii: 10.1007/s10549-019-05330.
PubMed Abstract available

MARINO MA, Gucalp A, Leithner D, Keating D, et al
Mammographic screening in male patients at high risk for breast cancer: is it worth it?
Breast Cancer Res Treat. 2019 Jul 6. pii: 10.1007/s10549-019-05338.
PubMed Abstract available

YEO W, Ueno T, Lin CH, Liu Q, et al
Treating HR+/HER2- breast cancer in premenopausal Asian women: Asian Breast Cancer Cooperative Group 2019 Consensus and position on ovarian suppression.
Breast Cancer Res Treat. 2019 Jul 4. pii: 10.1007/s10549-019-05318.
PubMed Abstract available

HARBORG S, Cronin-Fenton DP, Borgquist S
RE.: Impact of long-term lipid-lowering therapy on clinical outcomes in breast cancer.
Breast Cancer Res Treat. 2019 Jul 4. pii: 10.1007/s10549-019-05337.
PubMed

COUGHLIN SS
Social determinants of breast cancer risk, stage, and survival.
Breast Cancer Res Treat. 2019 Jul 3. pii: 10.1007/s10549-019-05340.
PubMed Abstract available

ZEINDLER J, Angehrn F, Droeser R, Daster S, et al
Infiltration by myeloperoxidase-positive neutrophils is an independent prognostic factor in breast cancer.
Breast Cancer Res Treat. 2019 Jul 2. pii: 10.1007/s10549-019-05336.
PubMed Abstract available

SASADA S, Shiroma N, Goda N, Kajitani K, et al
The relationship between ring-type dedicated breast PET and immune microenvironment in early breast cancer.
Breast Cancer Res Treat. 2019 Jul 2. pii: 10.1007/s10549-019-05339.
PubMed Abstract available

BAS O, Dizdar O
Classifying sarcopenia: using median value or cut-off values?
Breast Cancer Res Treat. 2019;176:479.
PubMed

GIANNAKEAS V, Narod SA
A generalizable relationship between mortality and time-to-death among breast cancer patients can be explained by tumour dormancy.
Breast Cancer Res Treat. 2019 Jul 1. pii: 10.1007/s10549-019-05334.
PubMed Abstract available

PUVANESARAJAH S, Gapstur SM, Patel AV, Sherman ME, et al
Mode of detection and breast cancer mortality by follow-up time and tumor characteristics among screened women in Cancer Prevention Study-II.
Breast Cancer Res Treat. 2019 Jul 1. pii: 10.1007/s10549-019-05322.
PubMed Abstract available

BEUGELS J, Meijvogel JLW, Tuinder SMH, Tjan-Heijnen VCG, et al
The influence of neoadjuvant chemotherapy on complications of immediate DIEP flap breast reconstructions.
Breast Cancer Res Treat. 2019;176:367-375.
PubMed Abstract available

WEISS A, Lin H, Babiera GV, Bedrosian I, et al
Evolution in practice patterns of axillary management following mastectomy in patients with 1-2 positive sentinel nodes.
Breast Cancer Res Treat. 2019;176:435-444.
PubMed Abstract available

DUAZO-CASSIN L, Le Guellec S, Lusque A, Chantalat E, et al
Breast desmoid tumor management in France: toward a new strategy.
Breast Cancer Res Treat. 2019;176:329-335.
PubMed Abstract available

BOUNDOUKI G, Wong Sik Hee JR, Croghan N, Stocking K, et al
Comparing long-term local recurrence rates of surgical and non-surgical management of close anterior margins in breast conserving surgery.
Breast Cancer Res Treat. 2019;176:311-319.
PubMed Abstract available

RODRIGUES-DUARTE H, van Nijnatten TJA, Khoury T, Cody H, et al
Does every woman presenting with malignant calcifications require a post lumpectomy mammogram?
Breast Cancer Res Treat. 2019;176:401-406.
PubMed Abstract available

SPERANSKY S, Serafini P, Caroli J, Bicciato S, et al
A novel RNA aptamer identifies plasma membrane ATP synthase beta subunit as an early marker and therapeutic target in aggressive cancer.
Breast Cancer Res Treat. 2019;176:271-289.
PubMed Abstract available

MENG P, Vaapil M, Tagmount A, Loguinov A, et al
Propagation of functional estrogen receptor positive normal human breast cells in 3D cultures.
Breast Cancer Res Treat. 2019;176:131-140.
PubMed Abstract available

LEE J, Kim HE, Song YS, Cho EY, et al
miR-106b-5p and miR-17-5p could predict recurrence and progression in breast ductal carcinoma in situ based on the transforming growth factor-beta pathway.
Breast Cancer Res Treat. 2019;176:119-130.
PubMed Abstract available

BAEZ-VALLECILLO L, Raghavendra AS, Hess KR, Barcenas CH, et al
Lapatinib activity in metastatic human epidermal growth factor receptor 2-positive breast cancers that received prior therapy with trastuzumab, pertuzumab, and/or ado-trastuzumab emtansine (T-DM1).
Breast Cancer Res Treat. 2019;176:227-234.
PubMed Abstract available

NEALON K, Rebello M, Sobti N, Sherburne A, et al
Improving surgical efficiency of immediate implant-based breast reconstruction following mastectomy.
Breast Cancer Res Treat. 2019;176:159-164.
PubMed Abstract available

MONTAGNE L, Gal J, Chand ME, Schiappa R, et al
GEC-ESTRO APBI classification as a decision-making tool for the management of 2nd ipsilateral breast tumor event.
Breast Cancer Res Treat. 2019;176:149-157.
PubMed Abstract available

June 2019

LI E, Guida JL, Tian Y, Sung H, et al
Associations between mammographic density and tumor characteristics in Chinese women with breast cancer.
Breast Cancer Res Treat. 2019 Jun 28. pii: 10.1007/s10549-019-05325.
PubMed Abstract available

KOROBEYNIKOV V, Borakove M, Feng Y, Wuest WM, et al
Combined inhibition of Aurora A and p21-activated kinase 1 as a new treatment strategy in breast cancer.
Breast Cancer Res Treat. 2019 Jun 28. pii: 10.1007/s10549-019-05329.
PubMed Abstract available

MICHEL LL, Sommer L, Gonzalez Silos R, Lorenzo Bermejo J, et al
Locoregional risk assessment after neoadjuvant chemotherapy in patients with primary breast cancer: clinical utility of the CPS + EG score.
Breast Cancer Res Treat. 2019 Jun 24. pii: 10.1007/s10549-019-05314.
PubMed Abstract available

NEWELL M, Goruk S, Mazurak V, Postovit L, et al
Role of docosahexaenoic acid in enhancement of docetaxel action in patient-derived breast cancer xenografts.
Breast Cancer Res Treat. 2019 Jun 24. pii: 10.1007/s10549-019-05331.
PubMed Abstract available

ANDERSSON Y, Bergkvist L, Frisell J, de Boniface J, et al
Do clinical trials truly mirror their target population? An external validity analysis of national register versus trial data from the Swedish prospective SENOMIC trial on sentinel node micrometastases in breast cancer.
Breast Cancer Res Treat. 2019 Jun 24. pii: 10.1007/s10549-019-05328.
PubMed Abstract available

LEE K, Kang I, Mack WJ, Mortimer J, et al
Effects of high-intensity interval training on vascular endothelial function and vascular wall thickness in breast cancer patients receiving anthracycline-based chemotherapy: a randomized pilot study.
Breast Cancer Res Treat. 2019 Jun 24. pii: 10.1007/s10549-019-05332.
PubMed Abstract available

FORNVIK D, Aaltonen KE, Chen Y, George AM, et al
Detection of circulating tumor cells and circulating tumor DNA before and after mammographic breast compression in a cohort of breast cancer patients scheduled for neoadjuvant treatment.
Breast Cancer Res Treat. 2019 Jun 24. pii: 10.1007/s10549-019-05326.
PubMed Abstract available

GRANT CV, Carver CM, Hastings SD, Ramachandran K, et al
Triple-negative breast cancer cell line sensitivity to englerin A identifies a new, targetable subtype.
Breast Cancer Res Treat. 2019 Jun 22. pii: 10.1007/s10549-019-05324.
PubMed Abstract available

ISNALDI E, Ferraioli D, Ferrando L, Brohee S, et al
Schlafen-11 expression is associated with immune signatures and basal-like phenotype in breast cancer.
Breast Cancer Res Treat. 2019 Jun 20. pii: 10.1007/s10549-019-05313.
PubMed Abstract available

TURTURRO SB, Najor MS, Yung T, Portt L, et al
Somatic loss of PIK3R1 may sensitize breast cancer to inhibitors of the MAPK pathway.
Breast Cancer Res Treat. 2019 Jun 17. pii: 10.1007/s10549-019-05320.
PubMed Abstract available

SHAWKY MS, Huo CW, Henderson MA, Redfern A, et al
A review of the influence of mammographic density on breast cancer clinical and pathological phenotype.
Breast Cancer Res Treat. 2019 Jun 8. pii: 10.1007/s10549-019-05300.
PubMed Abstract available

OLIAI C, Douek ML, Rhoane C, Bhutada A, et al
Clinical features of pseudocirrhosis in metastatic breast cancer.
Breast Cancer Res Treat. 2019 Jun 7. pii: 10.1007/s10549-019-05311.
PubMed Abstract available

NAYAK D, Katoch A, Sharma D, Faheem MM, et al
Indolylkojyl methane analogue IKM5 potentially inhibits invasion of breast cancer cells via attenuation of GRP78.
Breast Cancer Res Treat. 2019 Jun 7. pii: 10.1007/s10549-019-05301.
PubMed Abstract available

DIERAS V, Bonnefoi H, Alba E, Awada A, et al
Iniparib administered weekly or twice-weekly in combination with gemcitabine/carboplatin in patients with metastatic triple-negative breast cancer: a phase II randomized open-label study with pharmacokinetics.
Breast Cancer Res Treat. 2019 Jun 6. pii: 10.1007/s10549-019-05305.
PubMed Abstract available

BHANDARI S, Ngo P, Kute B, Mandadi M, et al
Adherence to anti-estrogen therapy in women with hormone receptor-positive breast cancer utilizing bubble packaging: a pilot study.
Breast Cancer Res Treat. 2019 Jun 6. pii: 10.1007/s10549-019-05308.
PubMed Abstract available

MELISKO ME, Assefa M, Hwang J, DeLuca A, et al
Phase II study of irinotecan and temozolomide in breast cancer patients with progressing central nervous system disease.
Breast Cancer Res Treat. 2019 Jun 6. pii: 10.1007/s10549-019-05309.
PubMed Abstract available

LAO C, Lawrenson R, Edwards M, Campbell I, et al
Treatment and survival of Asian women diagnosed with breast cancer in New Zealand.
Breast Cancer Res Treat. 2019 Jun 5. pii: 10.1007/s10549-019-05310.
PubMed Abstract available

JERUSALEM G, Lancellotti P, Kim SB
HER2+ breast cancer treatment and cardiotoxicity: monitoring and management.
Breast Cancer Res Treat. 2019 Jun 5. pii: 10.1007/s10549-019-05303.
PubMed Abstract available

TEYSIR J, Gegechkori N, Wisnivesky JP, Lin JJ, et al
Correction to: Racial disparities in surveillance mammography among older breast cancer survivors.
Breast Cancer Res Treat. 2019 Jun 5. pii: 10.1007/s10549-019-05291.
PubMed Abstract available

MURPHY JD, Sandler D, White AJ, O'Brien KM, et al
Severe acne and risk of breast cancer.
Breast Cancer Res Treat. 2019 Jun 5. pii: 10.1007/s10549-019-05302.
PubMed Abstract available

WOLFF JL, Aufill J, Echavarria D, Heughan JA, et al
Sharing in care: engaging care partners in the care and communication of breast cancer patients.
Breast Cancer Res Treat. 2019 Jun 4. pii: 10.1007/s10549-019-05306.
PubMed Abstract available

PLASTERER C, Tsaih SW, Peck AR, Chervoneva I, et al
Neuronatin is a modifier of estrogen receptor-positive breast cancer incidence and outcome.
Breast Cancer Res Treat. 2019 Jun 4. pii: 10.1007/s10549-019-05307.
PubMed Abstract available

MCCLELLAND S 3RD, Rhome RM, Zellars RC
Radiation oncology crossword: breast cancer.
Breast Cancer Res Treat. 2019 Jun 1. pii: 10.1007/s10549-019-05304.
PubMed

ZHAO H, Shen J, Moore SC, Ye Y, et al
Correction to: Breast cancer risk in relation to plasma metabolites among Hispanic and African American women.
Breast Cancer Res Treat. 2019 Jun 1. pii: 10.1007/s10549-019-05292.
PubMed Abstract available

ELFGEN C, Varga Z, Reeve K, Moskovszky L, et al
The impact of distinct triple-negative breast cancer subtypes on misdiagnosis and diagnostic delay.
Breast Cancer Res Treat. 2019 Jun 1. pii: 10.1007/s10549-019-05298.
PubMed Abstract available

POODT IGM, Schipper RJ, de Greef BTA, Vugts G, et al
Screening for distant metastases in patients with ipsilateral breast tumor recurrence: the impact of different imaging modalities on distant recurrence-free interval.
Breast Cancer Res Treat. 2019;175:419-428.
PubMed Abstract available

SHECKTER CC, Matros E, Lee GK, Selber JC, et al
Applying a value-based care framework to post-mastectomy reconstruction.
Breast Cancer Res Treat. 2019;175:547-551.
PubMed Abstract available

WILLOUGHBY LI, D'Abbondanza JA, Baltzer HL, Mahoney JL, et al
Body mass index impacts infection rates in immediate autogenous breast reconstruction.
Breast Cancer Res Treat. 2019;175:765-773.
PubMed Abstract available

BOLAM KA, Mijwel S, Rundqvist H, Wengstrom Y, et al
Two-year follow-up of the OptiTrain randomised controlled exercise trial.
Breast Cancer Res Treat. 2019;175:637-648.
PubMed Abstract available

FONT R, Espinas JA, Barnadas A, Izquierdo A, et al
Influence of adherence to adjuvant endocrine therapy on disease-free and overall survival: a population-based study in Catalonia, Spain.
Breast Cancer Res Treat. 2019;175:733-740.
PubMed Abstract available

FIGURA NB, Rizk VT, Mohammadi H, Evernden B, et al
Clinical outcomes of breast leptomeningeal disease treated with intrathecal trastuzumab, intrathecal chemotherapy, or whole brain radiation therapy.
Breast Cancer Res Treat. 2019;175:781-788.
PubMed Abstract available

CLIFTON K, Min Y, Kimmel J, Litton J, et al
Progression-free survival (PFS) and toxicities of palbociclib in a geriatric population.
Breast Cancer Res Treat. 2019;175:667-674.
PubMed Abstract available

DEKLERCK E, Denys H, Kreps EO
Corneal features in trastuzumab emtansine treatment: not a rare occurrence.
Breast Cancer Res Treat. 2019;175:525-530.
PubMed Abstract available

MCCLELLAND S 3RD, Hatfield J, Degnin C, Chen Y, et al
Extent of resection and role of adjuvant treatment in resected localized breast angiosarcoma.
Breast Cancer Res Treat. 2019;175:409-418.
PubMed Abstract available

IGNATOV T, Gorbunow F, Eggemann H, Ortmann O, et al
Loss of HER2 after HER2-targeted treatment.
Breast Cancer Res Treat. 2019;175:401-408.
PubMed Abstract available

May 2019

RUIZ-BORREGO M, Guerrero-Zotano A, Bermejo B, Ramos M, et al
Phase III evaluating the addition of fulvestrant (F) to anastrozole (A) as adjuvant therapy in postmenopausal women with hormone receptor-positive HER2-negative (HR+/HER2-) early breast cancer (EBC): results from the GEICAM/2006-10 study.
Breast Cancer Res Treat. 2019 May 31. pii: 10.1007/s10549-019-05296.
PubMed Abstract available

JOZSA F, Ahmed M, Baker R, Douek M, et al
Is sentinel node biopsy necessary in the radiologically negative axilla in breast cancer?
Breast Cancer Res Treat. 2019 May 31. pii: 10.1007/s10549-019-05299.
PubMed Abstract available

SAW S, Lim J, Lim SH, Wong M, et al
Patterns of relapse after neoadjuvant chemotherapy in breast cancer: implications for surveillance in clinical practice.
Breast Cancer Res Treat. 2019 May 30. pii: 10.1007/s10549-019-05290.
PubMed Abstract available

ROSENBERG SM, Vaz-Luis I, Gong J, Rajagopal PS, et al
Employment trends in young women following a breast cancer diagnosis.
Breast Cancer Res Treat. 2019 May 30. pii: 10.1007/s10549-019-05293.
PubMed Abstract available

KRYSTEL-WHITTEMORE M, Xu J, Brogi E, Ventura K, et al
Pathologic complete response rate according to HER2 detection methods in HER2-positive breast cancer treated with neoadjuvant systemic therapy.
Breast Cancer Res Treat. 2019 May 29. pii: 10.1007/s10549-019-05295.
PubMed Abstract available

LAMBERTINI M, Campbell C, Gelber RD, Viale G, et al
Dissecting the effect of hormone receptor status in patients with HER2-positive early breast cancer: exploratory analysis from the ALTTO (BIG 2-06) randomized clinical trial.
Breast Cancer Res Treat. 2019 May 27. pii: 10.1007/s10549-019-05284.
PubMed Abstract available

ENGMANN NJ, Scott CG, Jensen MR, Winham S, et al
Combined effect of volumetric breast density and body mass index on breast cancer risk.
Breast Cancer Res Treat. 2019 May 25. pii: 10.1007/s10549-019-05283.
PubMed Abstract available

JOHNSON HM, Irish W, Vohra NA, Wong JH, et al
The effect of local therapy on breast cancer-specific mortality of women with occult breast cancer and advanced nodal disease (N2/N3): a population analysis.
Breast Cancer Res Treat. 2019 May 24. pii: 10.1007/s10549-019-05285.
PubMed Abstract available

BASULAIMAN B, Awan AA, Fergusson D, Vandermeer L, et al
Creating a pragmatic trials program for breast cancer patients: Rethinking Clinical Trials (REaCT).
Breast Cancer Res Treat. 2019 May 24. pii: 10.1007/s10549-019-05274.
PubMed Abstract available

PINEDA-MONCUSI M, Servitja S, Tusquets I, Diez-Perez A, et al
Assessment of early therapy discontinuation and health-related quality of life in breast cancer patients treated with aromatase inhibitors: B-ABLE cohort study.
Breast Cancer Res Treat. 2019 May 24. pii: 10.1007/s10549-019-05289.
PubMed Abstract available

DONG B, Xie C, Jing X, Lin L, et al
Yoga has a solid effect on cancer-related fatigue in patients with breast cancer: a meta-analysis.
Breast Cancer Res Treat. 2019 May 24. pii: 10.1007/s10549-019-05278.
PubMed Abstract available

PRAWIRA A, Munusamy P, Yuan J, Chan CHT, et al
Assessment of PARP4 as a candidate breast cancer susceptibility gene.
Breast Cancer Res Treat. 2019 May 22. pii: 10.1007/s10549-019-05286.
PubMed Abstract available

AL-HILLI Z, Choong G, Keeney MG, Visscher DW, et al
Metaplastic breast cancer has a poor response to neoadjuvant systemic therapy.
Breast Cancer Res Treat. 2019 May 22. pii: 10.1007/s10549-019-05264.
PubMed Abstract available

HEDRICK E, Li X, Cheng Y, Lacey A, et al
Potent inhibition of breast cancer by bis-indole-derived nuclear receptor 4A1 (NR4A1) antagonists.
Breast Cancer Res Treat. 2019 May 22. pii: 10.1007/s10549-019-05279.
PubMed Abstract available

TURKKI R, Byckhov D, Lundin M, Isola J, et al
Breast cancer outcome prediction with tumour tissue images and machine learning.
Breast Cancer Res Treat. 2019 May 22. pii: 10.1007/s10549-019-05281.
PubMed Abstract available

POMPONIO MK, Keele LJ, Fox KR, Clark AS, et al
Does time to adjuvant chemotherapy (TTC) affect outcomes in patients with triple-negative breast cancer?
Breast Cancer Res Treat. 2019 May 22. pii: 10.1007/s10549-019-05282.
PubMed Abstract available

DECKER T, Marschner N, Muendlein A, Welt A, et al
VicTORia: a randomised phase II study to compare vinorelbine in combination with the mTOR inhibitor everolimus versus vinorelbine monotherapy for second-line chemotherapy in advanced HER2-negative breast cancer.
Breast Cancer Res Treat. 2019 May 21. pii: 10.1007/s10549-019-05280.
PubMed Abstract available

JONGEN L, Floris G, Wildiers H, Claessens F, et al
Tumor characteristics and outcome by androgen receptor expression in triple-negative breast cancer patients treated with neo-adjuvant chemotherapy.
Breast Cancer Res Treat. 2019 May 20. pii: 10.1007/s10549-019-05252.
PubMed Abstract available

ZHANG JY, Liao YH, Lin Y, Liu Q, et al
Effects of tea consumption and the interactions with lipids on breast cancer survival.
Breast Cancer Res Treat. 2019 May 16. pii: 10.1007/s10549-019-05253.
PubMed Abstract available

SILBERHOLZ J, Bertsimas D, Vahdat L
Clinical benefit, toxicity and cost of metastatic breast cancer therapies: systematic review and meta-analysis.
Breast Cancer Res Treat. 2019 May 14. pii: 10.1007/s10549-019-05208.
PubMed Abstract available

PILEVARZADEH M, Amirshahi M, Afsargharehbagh R, Rafiemanesh H, et al
Global prevalence of depression among breast cancer patients: a systematic review and meta-analysis.
Breast Cancer Res Treat. 2019 May 13. pii: 10.1007/s10549-019-05271.
PubMed Abstract available

LI YR, Ro V, Steel L, Carrigan E, et al
Impact of long-term lipid-lowering therapy on clinical outcomes in breast cancer.
Breast Cancer Res Treat. 2019 May 13. pii: 10.1007/s10549-019-05267.
PubMed Abstract available

AWAN AA, Hutton B, Hilton J, Mazzarello S, et al
De-escalation of bone-modifying agents in patients with bone metastases from breast cancer: a systematic review and meta-analysis.
Breast Cancer Res Treat. 2019 May 11. pii: 10.1007/s10549-019-05265.
PubMed Abstract available

SHENG JY, Blackford AL, Bardia A, Venkat R, et al
Prospective evaluation of finger two-point discrimination and carpal tunnel syndrome among women with breast cancer receiving adjuvant aromatase inhibitor therapy.
Breast Cancer Res Treat. 2019 May 11. pii: 10.1007/s10549-019-05270.
PubMed Abstract available

GOLDBERG M, Sutradhar R, Paszat L, Whelan TJ, et al
Patterns of adjuvant care and outcomes of elderly women with stage I breast cancer after breast-conserving surgery: a population-based analysis.
Breast Cancer Res Treat. 2019 May 10. pii: 10.1007/s10549-019-05266.
PubMed Abstract available

AZRAD M, Blair CK, Rock CL, Sedjo RL, et al
Adult weight gain accelerates the onset of breast cancer.
Breast Cancer Res Treat. 2019 May 9. pii: 10.1007/s10549-019-05268.
PubMed Abstract available

MORI H, Kubo M, Kai M, Yamada M, et al
T-bet(+) lymphocytes infiltration as an independent better prognostic indicator for triple-negative breast cancer.
Breast Cancer Res Treat. 2019 May 8. pii: 10.1007/s10549-019-05256.
PubMed Abstract available

FONTAINE C, Renard V, Van den Bulk H, Vuylsteke P, et al
Weekly carboplatin plus neoadjuvant anthracycline-taxane-based regimen in early triple-negative breast cancer: a prospective phase II trial by the Breast Cancer Task Force of the Belgian Society of Medical Oncology (BSMO).
Breast Cancer Res Treat. 2019 May 8. pii: 10.1007/s10549-019-05259.
PubMed Abstract available

LUX MP, Bohme S, Hucherig S, Jeratsch U, et al
Surrogate threshold effect based on a meta-analysis for the predictive value of progression-free survival for overall survival in hormone receptor-positive, HER2-negative metastatic breast cancer.
Breast Cancer Res Treat. 2019 May 7. pii: 10.1007/s10549-019-05262.
PubMed Abstract available

CAZZANIGA ME, Danesi R, Girmenia C, Invernizzi P, et al
Management of toxicities associated with targeted therapies for HR-positive metastatic breast cancer: a multidisciplinary approach is the key to success.
Breast Cancer Res Treat. 2019 May 7. pii: 10.1007/s10549-019-05261.
PubMed Abstract available

AARTS BM, Klompenhouwer EG, Dresen RC, Laenen A, et al
Intra-arterial Mitomycin C infusion in a large cohort of advanced liver metastatic breast cancer patients: safety, efficacy and factors influencing survival.
Breast Cancer Res Treat. 2019 May 7. pii: 10.1007/s10549-019-05254.
PubMed Abstract available

COHEN EN, Fouad TM, Lee BN, Arun BK, et al
Elevated serum levels of sialyl Lewis X (sLe(X)) and inflammatory mediators in patients with breast cancer.
Breast Cancer Res Treat. 2019 May 3. pii: 10.1007/s10549-019-05258.
PubMed Abstract available

IRENE SU H, Stark S, Kwan B, Boles S, et al
Efficacy of a web-based women's health survivorship care plan for young breast cancer survivors: a randomized controlled trial.
Breast Cancer Res Treat. 2019 May 3. pii: 10.1007/s10549-019-05260.
PubMed Abstract available

ELFGEN C, Montagna G, Schmid SM, Bierbauer W, et al
Noncompliance with palliative systemic therapy in patients with distant metastatic breast cancer: a blind spot for oncologists?
Breast Cancer Res Treat. 2019 May 2. pii: 10.1007/s10549-019-05255.
PubMed Abstract available

SAVVA C, De Souza K, Ali R, Rakha EA, et al
Clinicopathological significance of ataxia telangiectasia-mutated (ATM) kinase and ataxia telangiectasia-mutated and Rad3-related (ATR) kinase in MYC overexpressed breast cancers.
Breast Cancer Res Treat. 2019;175:105-115.
PubMed Abstract available

JUNG J, Han W, Lee ES, Jung SY, et al
Retrospectively validating the results of the ACOSOG Z0011 trial in a large Asian Z0011-eligible cohort.
Breast Cancer Res Treat. 2019;175:203-215.
PubMed Abstract available

April 2019

BAKER HA, Fabian CJ, Hastings RC, Dixon DA, et al
Circulating adipose stromal cells as a response biomarker in phase II energy balance trials of obese breast cancer survivors and high-risk women.
Breast Cancer Res Treat. 2019 Apr 30. pii: 10.1007/s10549-019-05251.
PubMed Abstract available

WAGONER CW, Choi SK, Deal AM, Lee JT, et al
Establishing physical activity in breast cancer: self-report versus activity tracker.
Breast Cancer Res Treat. 2019 Apr 30. pii: 10.1007/s10549-019-05263.
PubMed Abstract available

SESTAK I, Martin M, Dubsky P, Kronenwett R, et al
Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone.
Breast Cancer Res Treat. 2019 Apr 30. pii: 10.1007/s10549-019-05226.
PubMed Abstract available

ACKLAND SP, Gebski V, Zdenkowski N, Wilson A, et al
Dose intensity in anthracycline-based chemotherapy for metastatic breast cancer: mature results of the randomised clinical trial ANZ 9311.
Breast Cancer Res Treat. 2019 Apr 26. pii: 10.1007/s10549-019-05187.
PubMed Abstract available

TEYSIR J, Gegechkori N, Wisnivesky JP, Lin JJ, et al
Racial disparities in surveillance mammography among older breast cancer survivors.
Breast Cancer Res Treat. 2019 Apr 26. pii: 10.1007/s10549-019-05250.
PubMed Abstract available

KIM JY, Lee DW, Lee KH, Min A, et al
Prognostic role of body mass index is different according to menopausal status and tumor subtype in breast cancer patients.
Breast Cancer Res Treat. 2019 Apr 26. pii: 10.1007/s10549-019-05249.
PubMed Abstract available

ROTTER J, Wilson L, Greiner MA, Pollack CE, et al
Shared-patient physician networks and their impact on the uptake of genomic testing in breast cancer.
Breast Cancer Res Treat. 2019 Apr 26. pii: 10.1007/s10549-019-05248.
PubMed Abstract available

ABU-KHALAF MM, Safonov A, Stratton J, Wang S, et al
Examining the cost-effectiveness of baseline left ventricular function assessment among breast cancer patients undergoing anthracycline-based therapy.
Breast Cancer Res Treat. 2019 Apr 24. pii: 10.1007/s10549-019-05178.
PubMed Abstract available

LEE HM, Kim BW, Park S, Park S, et al
Childbirth in young Korean women with previously treated breast cancer: The SMARTSHIP study.
Breast Cancer Res Treat. 2019 Apr 24. pii: 10.1007/s10549-019-05244.
PubMed Abstract available

WANG M, Chen H, Wu K, Ding A, et al
Post-mastectomy immediate breast reconstruction is oncologically safe in well-selected T4 locally advanced breast cancer: a large population-based study and matched case-control analysis.
Breast Cancer Res Treat. 2019 Apr 24. pii: 10.1007/s10549-019-05240.
PubMed Abstract available

SAMBADE MJ, Prince G, Deal AM, Trembath D, et al
Examination and prognostic implications of the unique microenvironment of breast cancer brain metastases.
Breast Cancer Res Treat. 2019 Apr 23. pii: 10.1007/s10549-019-05211.
PubMed Abstract available

ALTUNDAG K
Oral or intravenous vinorelbine plus capecitabine in heavily pretreated HER2 negative metastatic breast cancer; similar effect or quality of life?
Breast Cancer Res Treat. 2019 Apr 23. pii: 10.1007/s10549-019-05220.
PubMed

SCHAIRER C, Hablas A, Eldein IAS, Gaafar R, et al
Clinico-pathologic and mammographic characteristics of inflammatory and non-inflammatory breast cancer at six centers in North Africa.
Breast Cancer Res Treat. 2019 Apr 22. pii: 10.1007/s10549-019-05237.
PubMed Abstract available

GAO C, Yuan X, Jiang Z, Gan D, et al
Regulation of AKT phosphorylation by GSK3beta and PTEN to control chemoresistance in breast cancer.
Breast Cancer Res Treat. 2019 Apr 20. pii: 10.1007/s10549-019-05239.
PubMed Abstract available

BELLON JR, Guo H, Barry WT, Dang CT, et al
Local-regional recurrence in women with small node-negative, HER2-positive breast cancer: results from a prospective multi-institutional study (the APT trial).
Breast Cancer Res Treat. 2019 Apr 19. pii: 10.1007/s10549-019-05238.
PubMed Abstract available

BAHRI N, Fathi Najafi T, Homaei Shandiz F, Tohidinik HR, et al
The relation between stressful life events and breast cancer: a systematic review and meta-analysis of cohort studies.
Breast Cancer Res Treat. 2019 Apr 19. pii: 10.1007/s10549-019-05231.
PubMed Abstract available

NOORDHOEK I, de Groot AF, Cohen D, Liefers GJ, et al
Higher ER load is not associated with better outcome in stage 1-3 breast cancer: a descriptive overview of quantitative HR analysis in operable breast cancer.
Breast Cancer Res Treat. 2019 Apr 17. pii: 10.1007/s10549-019-05233.
PubMed Abstract available

KHAN KA, Mazuquin B, Canaway A, Petrou S, et al
Systematic review of economic evaluations of exercise and physiotherapy for patients treated for breast cancer.
Breast Cancer Res Treat. 2019 Apr 17. pii: 10.1007/s10549-019-05235.
PubMed Abstract available

FLORES-DIAZ D, Arce C, Flores-Luna L, Reynoso-Noveron N, et al
Impact of invasive lobular carcinoma on long-term outcomes in Mexican breast cancer patients.
Breast Cancer Res Treat. 2019 Apr 17. pii: 10.1007/s10549-019-05234.
PubMed Abstract available

MA X, Dang C, Min W, Diao Y, et al
Downregulation of APE1 potentiates breast cancer cells to olaparib by inhibiting PARP-1 expression.
Breast Cancer Res Treat. 2019 Apr 15. pii: 10.1007/s10549-019-05189.
PubMed Abstract available

LEE J, Lim B, Pearson T, Choi K, et al
Correction to: Anti-tumor and anti-metastasis efficacy of E6201, a MEK1 inhibitor, in preclinical models of triple-negative breast cancer.
Breast Cancer Res Treat. 2019 Apr 15. pii: 10.1007/s10549-019-05218.
PubMed Abstract available

CHEN BT, Jin T, Patel SK, Ye N, et al
Intrinsic brain activity changes associated with adjuvant chemotherapy in older women with breast cancer: a pilot longitudinal study.
Breast Cancer Res Treat. 2019 Apr 13. pii: 10.1007/s10549-019-05230.
PubMed Abstract available

CAGNEY DN, Lamba N, Montoya S, Li P, et al
Breast cancer subtype and intracranial recurrence patterns after brain-directed radiation for brain metastases.
Breast Cancer Res Treat. 2019 Apr 13. pii: 10.1007/s10549-019-05236.
PubMed Abstract available

DARCEY E, Lloyd R, Cadby G, Pilkington L, et al
The association between mammographic density and breast cancer risk in Western Australian Aboriginal women.
Breast Cancer Res Treat. 2019 Apr 12. pii: 10.1007/s10549-019-05225.
PubMed Abstract available

BERNSTEIN-MOLHO R, Singer A, Laitman Y, Netzer I, et al
Multigene panel testing in unselected Israeli breast cancer cases: mutational spectrum and use of BRCA1/2 mutation prediction algorithms.
Breast Cancer Res Treat. 2019 Apr 12. pii: 10.1007/s10549-019-05228.
PubMed Abstract available

MUTONGA M, Speedy S, Rademaker A, Liu D, et al
Relationship of pathological features and a 21 gene expression assay in younger versus older women with node-negative endocrine receptor-positive breast cancer.
Breast Cancer Res Treat. 2019 Apr 11. pii: 10.1007/s10549-018-05088.
PubMed Abstract available

VAN UDEN DJP, van Maaren MC, Bult P, Strobbe LJA, et al
Pathologic complete response and overall survival in breast cancer subtypes in stage III inflammatory breast cancer.
Breast Cancer Res Treat. 2019 Apr 10. pii: 10.1007/s10549-019-05219.
PubMed Abstract available

NEUNER JM, Nattinger AB, Yen T, McGinley E, et al
Temporal trends and regional variation in the utilization of low-value breast cancer care: has the Choosing Wisely campaign made a difference?
Breast Cancer Res Treat. 2019 Apr 10. pii: 10.1007/s10549-019-05213.
PubMed Abstract available

KREUTZ C, Schmidt ME, Steindorf K
Effects of physical and mind-body exercise on sleep problems during and after breast cancer treatment: a systematic review and meta-analysis.
Breast Cancer Res Treat. 2019 Apr 6. pii: 10.1007/s10549-019-05217.
PubMed Abstract available

HOUGHTON SC, Eliassen AH, Zhang SM, Selhub J, et al
Plasma B-vitamins and one-carbon metabolites and the risk of breast cancer in younger women.
Breast Cancer Res Treat. 2019 Apr 6. pii: 10.1007/s10549-019-05223.
PubMed Abstract available

LU Y, Li J, Zhao X, Li J, et al
Breast cancer research and treatment reconstruction of unilateral breast structure using three-dimensional ultrasound imaging to assess breast neoplasm.
Breast Cancer Res Treat. 2019 Apr 5. pii: 10.1007/s10549-019-05202.
PubMed Abstract available

KUSAMA H, Shimoda M, Miyake T, Tanei T, et al
Prognostic value of tumor cell DNA content determined by flow cytometry using formalin-fixed paraffin-embedded breast cancer tissues.
Breast Cancer Res Treat. 2019 Apr 4. pii: 10.1007/s10549-019-05222.
PubMed Abstract available

EVANS DGR, Harkness EF, Brentnall AR, van Veen EM, et al
Breast cancer pathology and stage are better predicted by risk stratification models that include mammographic density and common genetic variants.
Breast Cancer Res Treat. 2019 Apr 2. pii: 10.1007/s10549-019-05210.
PubMed Abstract available

KUROZUMI S, Joseph C, Raafat S, Sonbul S, et al
Utility of ankyrin 3 as a prognostic marker in androgen-receptor-positive breast cancer.
Breast Cancer Res Treat. 2019 Apr 2. pii: 10.1007/s10549-019-05216.
PubMed Abstract available

WANG G, Qin S, Zayas J, Ingle JN, et al
4-Hydroxytamoxifen enhances sensitivity of estrogen receptor alpha-positive breast cancer to docetaxel in an estrogen and ZNF423 SNP-dependent fashion.
Breast Cancer Res Treat. 2019 Apr 1. pii: 10.1007/s10549-019-05194.
PubMed Abstract available

LIN Y, Wang C, Huang X, Zhou X, et al
Efficacy and safety of taxane plus anthracycline with or without cyclophosphamide in Chinese node-positive breast cancer patients: an open-label, randomized controlled trial.
Breast Cancer Res Treat. 2019 Apr 1. pii: 10.1007/s10549-019-05207.
PubMed Abstract available

March 2019

KORZETS Y, Fyles A, Shepshelovich D, Amir E, et al
Toxicity and clinical outcomes of partial breast irradiation compared to whole breast irradiation for early-stage breast cancer: a systematic review and meta-analysis.
Breast Cancer Res Treat. 2019 Mar 30. pii: 10.1007/s10549-019-05209.
PubMed Abstract available

DANIELL KM, Bardia A, Sun F, Roberts SA, et al
Incidence of peripheral edema in patients receiving PI3K/mTOR/CDK4/6 inhibitors for metastatic breast cancer.
Breast Cancer Res Treat. 2019 Mar 27. pii: 10.1007/s10549-019-05206.
PubMed Abstract available

AURIT SJ, Devesa SS, Soliman AS, Schairer C, et al
Inflammatory and other breast cancer incidence rate trends by estrogen receptor status in the Surveillance, Epidemiology, and End Results database (2001-2015).
Breast Cancer Res Treat. 2019 Mar 26. pii: 10.1007/s10549-019-05193.
PubMed Abstract available

TORRES A, Ramdial JL, Aguirre LE, Mahtani R, et al
Vinorelbine plus Capecitabine (Vinocap): a retrospective analysis in heavily pretreated HER2 negative metastatic breast cancer patients.
Breast Cancer Res Treat. 2019 Mar 21. pii: 10.1007/s10549-019-05203.
PubMed Abstract available

CAMARA RJA, Schwentner L, Friedl TWP, Deniz M, et al
Quality of life during and after adjuvant anthracycline-taxane-based chemotherapy with or without Gemcitabine in high-risk early breast cancer: results of the SUCCESS A trial.
Breast Cancer Res Treat. 2019 Mar 21. pii: 10.1007/s10549-019-05171.
PubMed Abstract available

CAO W, Xie Y, He Y, Li J, et al
Risk of ipsilateral breast tumor recurrence in primary invasive breast cancer following breast-conserving surgery with BRCA1 and BRCA2 mutation in China.
Breast Cancer Res Treat. 2019 Mar 20. pii: 10.1007/s10549-019-05199.
PubMed Abstract available

VARELLA L, Eziokwu AS, Jia X, Kruse M, et al
Real-world clinical outcomes and toxicity in metastatic breast cancer patients treated with palbociclib and endocrine therapy.
Breast Cancer Res Treat. 2019 Mar 20. pii: 10.1007/s10549-019-05176.
PubMed Abstract available

HOSIO M, Urpilainen E, Marttila M, Hautakoski A, et al
Association of antidiabetic medication and statins with breast cancer incidence in women with type 2 diabetes.
Breast Cancer Res Treat. 2019 Mar 20. pii: 10.1007/s10549-019-05185.
PubMed Abstract available

DAVIS LE, Fulton C, Bubis LD, Sussman J, et al
Patient-reported symptoms following mastectomy alone or lumpectomy plus radiation for early stage breast cancer: a cohort study.
Breast Cancer Res Treat. 2019 Mar 16. pii: 10.1007/s10549-019-05196.
PubMed Abstract available

HOLM-RASMUSSEN EV, Jensen MB, Balslev E, Kroman N, et al
Sentinel and non-sentinel lymph node metastases in patients with microinvasive breast cancer: a nationwide study.
Breast Cancer Res Treat. 2019 Mar 14. pii: 10.1007/s10549-019-05200.
PubMed Abstract available

YU C, Qin N, Pu Z, Song C, et al
Integrating of genomic and transcriptomic profiles for the prognostic assessment of breast cancer.
Breast Cancer Res Treat. 2019 Mar 13. pii: 10.1007/s10549-019-05177.
PubMed Abstract available

MARSCHNER N, Trarbach T, Rauh J, Meyer D, et al
Quality of life in pre- and postmenopausal patients with early breast cancer: a comprehensive analysis from the prospective MaLife project.
Breast Cancer Res Treat. 2019 Mar 13. pii: 10.1007/s10549-019-05197.
PubMed Abstract available

DE GROOT AF, Blok EJ, Charehbili A, Engels CC, et al
Strong CD8+ lymphocyte infiltration in combination with expression of HLA class I is associated with better tumor control in breast cancer patients treated with neoadjuvant chemotherapy.
Breast Cancer Res Treat. 2019 Mar 13. pii: 10.1007/s10549-019-05195.
PubMed Abstract available

FASCHING PA, Gass P, Haberle L, Volz B, et al
Prognostic effect of Ki-67 in common clinical subgroups of patients with HER2-negative, hormone receptor-positive early breast cancer.
Breast Cancer Res Treat. 2019 Mar 13. pii: 10.1007/s10549-019-05198.
PubMed Abstract available

TIAN J, Chen X, Fu S, Zhang R, et al
Bazedoxifene is a novel IL-6/GP130 inhibitor for treating triple-negative breast cancer.
Breast Cancer Res Treat. 2019 Mar 9. pii: 10.1007/s10549-019-05183.
PubMed Abstract available

LYNCE F, Barac A, Geng X, Dang C, et al
Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: the SAFE-HEaRt study.
Breast Cancer Res Treat. 2019 Mar 9. pii: 10.1007/s10549-019-05191.
PubMed Abstract available

CHRISCHILLES EA, Riley D, Letuchy E, Koehler L, et al
Upper extremity disability and quality of life after breast cancer treatment in the Greater Plains Collaborative clinical research network.
Breast Cancer Res Treat. 2019 Mar 9. pii: 10.1007/s10549-019-05184.
PubMed Abstract available

ZHANG B, Long EF
Cost-effectiveness analysis of palbociclib or ribociclib in the treatment of advanced hormone receptor-positive, HER2-negative breast cancer.
Breast Cancer Res Treat. 2019 Mar 7. pii: 10.1007/s10549-019-05190.
PubMed Abstract available

PLAVC G, Ratosa I, Zagar T, Zadnik V, et al
Explaining variation in quality of breast cancer care and its impact: a nationwide population-based study from Slovenia.
Breast Cancer Res Treat. 2019 Mar 7. pii: 10.1007/s10549-019-05186.
PubMed Abstract available

KAISER K, Cameron KA, Beaumont J, Garcia SF, et al
What does risk of future cancer mean to breast cancer patients?
Breast Cancer Res Treat. 2019 Mar 6. pii: 10.1007/s10549-019-05182.
PubMed Abstract available

WANG Z, Katsaros D, Biglia N, Shen Y, et al
ERalpha upregulates the expression of long non-coding RNA LINC00472 which suppresses the phosphorylation of NF-kappaB in breast cancer.
Breast Cancer Res Treat. 2019 Mar 4. pii: 10.1007/s10549-018-05108.
PubMed Abstract available

DOEGE D, Thong MS, Koch-Gallenkamp L, Bertram H, et al
Health-related quality of life in long-term disease-free breast cancer survivors versus female population controls in Germany.
Breast Cancer Res Treat. 2019 Mar 2. pii: 10.1007/s10549-019-05188.
PubMed Abstract available

LEE J, Lim B, Pearson T, Choi K, et al
Anti-tumor and anti-metastasis efficacy of E6201, a MEK1 inhibitor, in preclinical models of triple-negative breast cancer.
Breast Cancer Res Treat. 2019 Mar 2. pii: 10.1007/s10549-019-05166.
PubMed Abstract available

VAN DOOIJEWEERT C, Deckers IAG, Baas IO, van der Wall E, et al
Hormone- and HER2-receptor assessment in 33,046 breast cancer patients: a nationwide comparison of positivity rates between pathology laboratories in the Netherlands.
Breast Cancer Res Treat. 2019 Mar 1. pii: 10.1007/s10549-019-05180.
PubMed Abstract available

February 2019

AFZALI F, Akbari P, Naderi-Manesh H, Gardaneh M, et al
The next generation personalized models to screen hidden layers of breast cancer tumorigenicity.
Breast Cancer Res Treat. 2019 Feb 27. pii: 10.1007/s10549-019-05159.
PubMed Abstract available

MARKS DH, Okhovat JP, Hagigeorges D, Manatis-Lornell AJ, et al
The effect of scalp cooling on CIA-related quality of life in breast cancer patients: a systematic review.
Breast Cancer Res Treat. 2019 Feb 26. pii: 10.1007/s10549-019-05169.
PubMed Abstract available

SAGAWA N, Ohno S, Hiratsuka T, Kondo N, et al
The utility of DHL-HisZnNa, a novel antioxidant, against anticancer agent-induced alopecia in breast cancer patients: a multicenter phase II clinical trial.
Breast Cancer Res Treat. 2019 Feb 26. pii: 10.1007/s10549-019-05164.
PubMed Abstract available

RICE SR, Feigenberg SJ, Hamza M, Molitoris JK, et al
Trends in utilization of hypofractionated whole breast irradiation (HF-WBI) in triple negative breast cancer (TNBC): a national cancer database (NCDB) analysis.
Breast Cancer Res Treat. 2019 Feb 22. pii: 10.1007/s10549-019-05150.
PubMed Abstract available

ACETO GM, Awadelkarim KD, Di Nicola M, Moscatello C, et al
Germline TP53 mutation spectrum in Sudanese premenopausal breast cancer patients: correlations with reproductive factors.
Breast Cancer Res Treat. 2019 Feb 22. pii: 10.1007/s10549-019-05168.
PubMed Abstract available

TICE JA, Bissell MCS, Miglioretti DL, Gard CC, et al
Validation of the breast cancer surveillance consortium model of breast cancer risk.
Breast Cancer Res Treat. 2019 Feb 22. pii: 10.1007/s10549-019-05167.
PubMed Abstract available

WUERSTLEIN R, Kates R, Gluz O, Grischke EM, et al
Strong impact of MammaPrint and BluePrint on treatment decisions in luminal early breast cancer: results of the WSG-PRIMe study.
Breast Cancer Res Treat. 2019 Feb 22. pii: 10.1007/s10549-018-05075.
PubMed Abstract available

GUO L, Chen G, Zhang W, Zhou L, et al
A high-risk luminal A dominant breast cancer subtype with increased mobility.
Breast Cancer Res Treat. 2019 Feb 19. pii: 10.1007/s10549-019-05135.
PubMed Abstract available

ZHAO H, Shen J, Moore SC, Ye Y, et al
Breast cancer risk in relation to plasma metabolites among Hispanic and African American women.
Breast Cancer Res Treat. 2019 Feb 15. pii: 10.1007/s10549-019-05165.
PubMed Abstract available

KOTSOPOULOS J, Lubinski J, Lynch HT, Tung N, et al
Oophorectomy and risk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriers.
Breast Cancer Res Treat. 2019 Feb 12. pii: 10.1007/s10549-019-05162.
PubMed Abstract available

STAVRAKA C, Pouptsis A, Okonta L, DeSouza K, et al
Clinical implementation of pre-treatment DPYD genotyping in capecitabine-treated metastatic breast cancer patients.
Breast Cancer Res Treat. 2019 Feb 12. pii: 10.1007/s10549-019-05144.
PubMed Abstract available

GREGOROWITSCH ML, Ghedri A, Young-Afat DA, Bijlsma R, et al
The effect of chemotherapy on subjective cognitive function in younger early-stage breast cancer survivors treated with chemotherapy compared to older patients.
Breast Cancer Res Treat. 2019 Feb 12. pii: 10.1007/s10549-019-05149.
PubMed Abstract available

YANG SX, Polley EC
Systemic treatment and radiotherapy, breast cancer subtypes, and survival after long-term clinical follow-up.
Breast Cancer Res Treat. 2019 Feb 12. pii: 10.1007/s10549-019-05142.
PubMed Abstract available

LAN Y, Zhao E, Luo S, Xiao Y, et al
Revealing clonality and subclonality of driver genes for clinical survival benefits in breast cancer.
Breast Cancer Res Treat. 2019 Feb 9. pii: 10.1007/s10549-019-05153.
PubMed Abstract available

O'MEARA T, Safonov A, Casadevall D, Qing T, et al
Immune microenvironment of triple-negative breast cancer in African-American and Caucasian women.
Breast Cancer Res Treat. 2019 Feb 6. pii: 10.1007/s10549-019-05156.
PubMed Abstract available

BICK U, Engel C, Krug B, Heindel W, et al
High-risk breast cancer surveillance with MRI: 10-year experience from the German consortium for hereditary breast and ovarian cancer.
Breast Cancer Res Treat. 2019 Feb 6. pii: 10.1007/s10549-019-05152.
PubMed Abstract available

LIU Y, Pandey PR, Sharma S, Xing F, et al
ID2 and GJB2 promote early-stage breast cancer progression by regulating cancer stemness.
Breast Cancer Res Treat. 2019 Feb 6. pii: 10.1007/s10549-018-05126.
PubMed Abstract available

HUSSAIN Y, Drill E, Dang CT, Liu JE, et al
Cardiac outcomes of trastuzumab therapy in patients with HER2-positive breast cancer and reduced left ventricular ejection fraction.
Breast Cancer Res Treat. 2019 Feb 5. pii: 10.1007/s10549-019-05139.
PubMed Abstract available

DICKINSON SL, Golzarri-Arroyo L, Brown AW, McComb B, et al
Change in study randomization allocation needs to be included in statistical analysis: comment on 'Randomized controlled trial of weight loss versus usual care on telomere length in women with breast cancer: the lifestyle, exercise, and nutrition (LEA
Breast Cancer Res Treat. 2019 Feb 5. pii: 10.1007/s10549-019-05155.
PubMed

SUN M, Wu D, Zhou K, Li H, et al
An eight-lncRNA signature predicts survival of breast cancer patients: a comprehensive study based on weighted gene co-expression network analysis and competing endogenous RNA network.
Breast Cancer Res Treat. 2019 Feb 4. pii: 10.1007/s10549-019-05147.
PubMed Abstract available

LIGABUE MB, Campanini I, Veroni P, Cepelli A, et al
Efficacy of self-administered complex decongestive therapy on breast cancer-related lymphedema: a single-blind randomized controlled trial.
Breast Cancer Res Treat. 2019 Feb 2. pii: 10.1007/s10549-019-05136.
PubMed Abstract available

LIU ZH, Wang K, Lin DY, Xu J, et al
Impact of the updated 2018 ASCO/CAP guidelines on HER2 FISH testing in invasive breast cancer: a retrospective study of HER2 fish results of 2233 cases.
Breast Cancer Res Treat. 2019 Feb 2. pii: 10.1007/s10549-019-05148.
PubMed Abstract available

ALTUNDAG K
HER2 positive breast cancer patients having HER2 loss after neoadjuvant chemotherapy should still be treated with adjuvant anti-HER2 treatment.
Breast Cancer Res Treat. 2019 Feb 1. pii: 10.1007/s10549-019-05151.
PubMed

ESEN E, Aslan M, Sonbahar BC, Kerimoglu RS, et al
YouTube English videos as a source of information on breast self-examination.
Breast Cancer Res Treat. 2019;173:629-635.
PubMed Abstract available

SILVER MI, Klein W, Samimi G, Minasian L, et al
Concordance with BRCA1/2 testing guidelines among women in The Health of Women (HOW) Study((R)).
Breast Cancer Res Treat. 2019;173:719-726.
PubMed Abstract available

HEINEY SP, Parker PD, Felder TM, Adams SA, et al
A systematic review of interventions to improve adherence to endocrine therapy.
Breast Cancer Res Treat. 2019;173:499-510.
PubMed Abstract available

January 2019

FATEHI S, Maasoumi R, Atashsokhan G, Hamidzadeh A, et al
The effects of psychosexual counseling on sexual quality of life and function in Iranian breast cancer survivors: a randomized controlled trial.
Breast Cancer Res Treat. 2019 Jan 30. pii: 10.1007/s10549-019-05140.
PubMed Abstract available

SZIJGYARTO Z, Flach KD, Opdam M, Palmieri C, et al
Dissecting the predictive value of MAPK/AKT/estrogen-receptor phosphorylation axis in primary breast cancer to treatment response for tamoxifen over exemestane: a Translational Report of the Intergroup Exemestane Study (IES)-PathIES.
Breast Cancer Res Treat. 2019 Jan 24. pii: 10.1007/s10549-018-05110.
PubMed Abstract available

CAMP NJ, Madsen MJ, Herranz J, Rodriguez-Lescure A, et al
Re-interpretation of PAM50 gene expression as quantitative tumor dimensions shows utility for clinical trials: application to prognosis and response to paclitaxel in breast cancer.
Breast Cancer Res Treat. 2019 Jan 23. pii: 10.1007/s10549-018-05097.
PubMed Abstract available

SUH KJ, Ryu HS, Lee KH, Kim H, et al
Prognostic effects of abnormal DNA damage response protein expression in breast cancer.
Breast Cancer Res Treat. 2019 Jan 22. pii: 10.1007/s10549-019-05128.
PubMed Abstract available

EL-ANSARI R, Craze ML, Alfarsi L, Soria D, et al
The combined expression of solute carriers is associated with a poor prognosis in highly proliferative ER+ breast cancer.
Breast Cancer Res Treat. 2019 Jan 22. pii: 10.1007/s10549-018-05111.
PubMed Abstract available

WEISS A, Grossmith S, Cutts D, Mikami SA, et al
Customized breast cancer risk assessment in an ambulatory clinic: a portal for identifying women at risk.
Breast Cancer Res Treat. 2019 Jan 21. pii: 10.1007/s10549-018-05116.
PubMed Abstract available

COOPEY SB, Kartal K, Li C, Yala A, et al
Atypical ductal hyperplasia in men with gynecomastia: what is their breast cancer risk?
Breast Cancer Res Treat. 2019 Jan 21. pii: 10.1007/s10549-018-05117.
PubMed Abstract available

ROBERTSON S, Ronnlund C, de Boniface J, Hartman J, et al
Re-testing of predictive biomarkers on surgical breast cancer specimens is clinically relevant.
Breast Cancer Res Treat. 2019 Jan 18. pii: 10.1007/s10549-018-05119.
PubMed Abstract available

PETRELLI F, Ghidini A, Pedersini R, Cabiddu M, et al
Comparative efficacy of palbociclib, ribociclib and abemaciclib for ER+ metastatic breast cancer: an adjusted indirect analysis of randomized controlled trials.
Breast Cancer Res Treat. 2019 Jan 18. pii: 10.1007/s10549-019-05133.
PubMed Abstract available

XU X, Chlebowski RT, Shi J, Barac A, et al
Aromatase inhibitor and tamoxifen use and the risk of venous thromboembolism in breast cancer survivors.
Breast Cancer Res Treat. 2019 Jan 18. pii: 10.1007/s10549-018-05086.
PubMed Abstract available

BATTISTI NML, Kingston B, King J, Denton A, et al
Palbociclib and endocrine therapy in heavily pretreated hormone receptor-positive HER2-negative advanced breast cancer: the UK Compassionate Access Programme experience.
Breast Cancer Res Treat. 2019 Jan 17. pii: 10.1007/s10549-019-05134.
PubMed Abstract available

FRIEDLAENDER A, Vuilleumier A, Viassolo V, Ayme A, et al
BRCA1/BRCA2 germline mutations and chemotherapy-related hematological toxicity in breast cancer patients.
Breast Cancer Res Treat. 2019 Jan 11. pii: 10.1007/s10549-018-05127.
PubMed Abstract available

RUGO HS, Finn RS, Dieras V, Ettl J, et al
Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up.
Breast Cancer Res Treat. 2019 Jan 10. pii: 10.1007/s10549-018-05125.
PubMed Abstract available

HASHEMI SM, Balouchi A, Al-Mawali A, Rafiemanesh H, et al
Health-related quality of life of breast cancer patients in the Eastern Mediterranean region: a systematic review and meta-analysis.
Breast Cancer Res Treat. 2019 Jan 10. pii: 10.1007/s10549-019-05131.
PubMed Abstract available

GADALLA R, Hassan H, Ibrahim SA, Abdullah MS, et al
Tumor microenvironmental plasmacytoid dendritic cells contribute to breast cancer lymph node metastasis via CXCR4/SDF-1 axis.
Breast Cancer Res Treat. 2019 Jan 10. pii: 10.1007/s10549-019-05129.
PubMed Abstract available

NITZ U, Gluz O, Christgen M, Kates RE, et al
Correction to: Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial.
Breast Cancer Res Treat. 2019 Jan 10. pii: 10.1007/s10549-018-05105.
PubMed Abstract available

STOVGAARD ES, Dyhl-Polk A, Roslind A, Balslev E, et al
PD-L1 expression in breast cancer: expression in subtypes and prognostic significance: a systematic review.
Breast Cancer Res Treat. 2019 Jan 10. pii: 10.1007/s10549-019-05130.
PubMed Abstract available

LUBINSKI J, Huzarski T, Gronwald J, Cybulski C, et al
Age-specific risks of incident, contralateral and ipsilateral breast cancer among 1776 Polish BRCA1 mutation carriers.
Breast Cancer Res Treat. 2019 Jan 5. pii: 10.1007/s10549-018-05076.
PubMed Abstract available

ALHUDIRI IM, Nolan CC, Ellis IO, Elzagheid A, et al
Expression of Lamin A/C in early-stage breast cancer and its prognostic value.
Breast Cancer Res Treat. 2019 Jan 4. pii: 10.1007/s10549-018-05092.
PubMed Abstract available

VANE MLG, Willemsen MA, van Roozendaal LM, van Kuijk SMJ, et al
Extracapsular extension in the positive sentinel lymph node: a marker of poor prognosis in cT1-2N0 breast cancer patients?
Breast Cancer Res Treat. 2019 Jan 4. pii: 10.1007/s10549-018-05074.
PubMed Abstract available

BOWDEN AR, Tischkowitz M
Clinical implications of germline mutations in breast cancer genes: RECQL.
Breast Cancer Res Treat. 2019 Jan 4. pii: 10.1007/s10549-018-05096.
PubMed Abstract available

CHENG ES, Yu XQ
Re: The relationship between patient and tumor characteristics, patterns of breast cancer care, and 5-year survival among elderly women with incident breast cancer. Breast Cancer Res Treat. Sep 2018;171(2):477-488.
Breast Cancer Res Treat. 2019 Jan 4. pii: 10.1007/s10549-018-05101.
PubMed

AUSTIN AM, Kapadia NS, Brooks GA, Onega TL, et al
Comparison of treatment of early-stage breast cancer among Nurses' Health Study participants and other Medicare beneficiaries.
Breast Cancer Res Treat. 2019 Jan 3. pii: 10.1007/s10549-018-05098.
PubMed Abstract available

YAMAMOTO T, Kanaya N, Somlo G, Chen S, et al
Synergistic anti-cancer activity of CDK4/6 inhibitor palbociclib and dual mTOR kinase inhibitor MLN0128 in pRb-expressing ER-negative breast cancer.
Breast Cancer Res Treat. 2019 Jan 3. pii: 10.1007/s10549-018-05104.
PubMed Abstract available

YANG Z, Ouyang T, Li J, Wang T, et al
Prevalence and characterization of ATM germline mutations in Chinese BRCA1/2-negative breast cancer patients.
Breast Cancer Res Treat. 2019 Jan 3. pii: 10.1007/s10549-018-05124.
PubMed Abstract available

LUSTIG DB, Warburton R, Dingee CK, Kuusk U, et al
Is microductectomy still necessary to diagnose breast cancer: a 10-year study on the effectiveness of duct excision and galactography.
Breast Cancer Res Treat. 2019 Jan 3. pii: 10.1007/s10549-018-05109.
PubMed Abstract available

OCANA A, Gil-Martin M, Antolin S, Atienza M, et al
Efficacy and safety of dasatinib with trastuzumab and paclitaxel in first line HER2-positive metastatic breast cancer: results from the phase II GEICAM/2010-04 study.
Breast Cancer Res Treat. 2019 Jan 3. pii: 10.1007/s10549-018-05100.
PubMed Abstract available

KENSLER KH, Eliassen AH, Rosner BA, Hankinson SE, et al
Pre-diagnostic sex hormone levels and survival among breast cancer patients.
Breast Cancer Res Treat. 2019 Jan 2. pii: 10.1007/s10549-018-05121.
PubMed Abstract available

PATEL DA, Xi J, Luo J, Hassan B, et al
Neutrophil-to-lymphocyte ratio as a predictor of survival in patients with triple-negative breast cancer.
Breast Cancer Res Treat. 2019 Jan 2. pii: 10.1007/s10549-018-05106.
PubMed Abstract available

O'BRIEN P, Matheson K, Jeyakumar A, Anderson K, et al
The clinical utility of baseline cardiac assessments prior to adjuvant anthracycline chemotherapy in breast cancer: a systematic review and meta-analysis.
Breast Cancer Res Treat. 2019 Jan 2. pii: 10.1007/s10549-018-05114.
PubMed Abstract available

KIM SJ, Zhang CXW, Demsky R, Armel S, et al
Folic acid supplement use and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a case-control study.
Breast Cancer Res Treat. 2019 Jan 2. pii: 10.1007/s10549-018-05118.
PubMed Abstract available

CARUANA E, Foucher Y, Tessier P, Frenel JS, et al
Patient-centered simulations to assess the usefulness of the 70-gene signature for adjuvant chemotherapy administration in early-stage breast cancer.
Breast Cancer Res Treat. 2019 Jan 2. pii: 10.1007/s10549-018-05107.
PubMed Abstract available

WUNDERLE M, Pretscher J, Brucker SY, Volz B, et al
Association between breast cancer risk factors and molecular type in postmenopausal patients with hormone receptor-positive early breast cancer.
Breast Cancer Res Treat. 2019 Jan 2. pii: 10.1007/s10549-018-05115.
PubMed Abstract available

GOGATE A, Rotter JS, Trogdon JG, Meng K, et al
An updated systematic review of the cost-effectiveness of therapies for metastatic breast cancer.
Breast Cancer Res Treat. 2019 Jan 2. pii: 10.1007/s10549-018-05099.
PubMed Abstract available

HU J, Wang X, Guo S, Chen F, et al
Peer support interventions for breast cancer patients: a systematic review.
Breast Cancer Res Treat. 2019 Jan 2. pii: 10.1007/s10549-018-5033.
PubMed Abstract available

December 2018

LYES MA, Payne S, Ferrell P, Pizzo SV, et al
Adipose stem cell crosstalk with chemo-residual breast cancer cells: implications for tumor recurrence.
Breast Cancer Res Treat. 2018 Dec 29. pii: 10.1007/s10549-018-05103.
PubMed Abstract available

THEBERGE I, Vandal N, Guertin MH, Perron L, et al
The mammography screening detection of ductal carcinoma in situ and invasive breast cancer according to women's characteristics: is it the same?
Breast Cancer Res Treat. 2018 Dec 18. pii: 10.1007/s10549-018-05095.
PubMed Abstract available

MALMGREN J, Hurlbert M, Atwood M, Kaplan HG, et al
Examination of a paradox: recurrent metastatic breast cancer incidence decline without improved distant disease survival: 1990-2011.
Breast Cancer Res Treat. 2018 Dec 17. pii: 10.1007/s10549-018-05090.
PubMed Abstract available

BUTTON B, Croessmann S, Chu D, Rosen DM, et al
The estrogen receptor-alpha S118P variant does not affect breast cancer incidence or response to endocrine therapies.
Breast Cancer Res Treat. 2018 Dec 17. pii: 10.1007/s10549-018-05087.
PubMed Abstract available

KIM JH, Yoon KH, Hur H, Park S, et al
Prevalence of breast cancer-related risk factors in underweight premenopausal women: the Korea National Health and Nutrition Examination Survey IV-VI.
Breast Cancer Res Treat. 2018 Dec 17. pii: 10.1007/s10549-018-05091.
PubMed Abstract available

JOSEPH C, Arshad M, Kurozomi S, Althobiti M, et al
Overexpression of the cancer stem cell marker CD133 confers a poor prognosis in invasive breast cancer.
Breast Cancer Res Treat. 2018 Dec 15. pii: 10.1007/s10549-018-05085.
PubMed Abstract available

JOHANSSON ALV, Weibull CE, Fredriksson I, Lambe M, et al
Diagnostic pathways and management in women with pregnancy-associated breast cancer (PABC): no evidence of treatment delays following a first healthcare contact.
Breast Cancer Res Treat. 2018 Dec 14. pii: 10.1007/s10549-018-05083.
PubMed Abstract available

DURAN-LOZANO L, Montalban G, Bonache S, Moles-Fernandez A, et al
Alternative transcript imbalance underlying breast cancer susceptibility in a family carrying PALB2 c.3201+5G>T.
Breast Cancer Res Treat. 2018 Dec 14. pii: 10.1007/s10549-018-05094.
PubMed Abstract available

RAGHAVENDRA A, Wecsler J, Ji L, Sheth P, et al
Clinical findings and outcomes of MRI staging of breast cancer in a diverse population.
Breast Cancer Res Treat. 2018 Dec 12. pii: 10.1007/s10549-018-05084.
PubMed Abstract available

WANG XM, Zhang Z, Pan LH, Cao XC, et al
KRT19 and CEACAM5 mRNA-marked circulated tumor cells indicate unfavorable prognosis of breast cancer patients.
Breast Cancer Res Treat. 2018 Dec 8. pii: 10.1007/s10549-018-05069.
PubMed Abstract available

NANNI O, Amadori D, De Censi A, Rocca A, et al
Metformin plus chemotherapy versus chemotherapy alone in the first-line treatment of HER2-negative metastatic breast cancer. The MYME randomized, phase 2 clinical trial.
Breast Cancer Res Treat. 2018 Dec 7. pii: 10.1007/s10549-018-05070.
PubMed Abstract available

PARANJPE R, John G, Trivedi M, Abughosh S, et al
Identifying adherence barriers to oral endocrine therapy among breast cancer survivors.
Breast Cancer Res Treat. 2018 Dec 6. pii: 10.1007/s10549-018-05073.
PubMed Abstract available

DONENBERG T, George S, Ali J, Bravo G, et al
A clinically structured and partnered approach to genetic testing in Trinidadian women with breast cancer and their families.
Breast Cancer Res Treat. 2018 Dec 4. pii: 10.1007/s10549-018-5045.
PubMed Abstract available

COUGHLIN SS, Paxton RJ, Moore N, Stewart JL, et al
Survivorship issues in older breast cancer survivors.
Breast Cancer Res Treat. 2018 Dec 1. pii: 10.1007/s10549-018-05078.
PubMed Abstract available

MCCLATCHY DM 3RD, Zuurbier RA, Wells WA, Paulsen KD, et al
Micro-computed tomography enables rapid surgical margin assessment during breast conserving surgery (BCS): correlation of whole BCS micro-CT readings to final histopathology.
Breast Cancer Res Treat. 2018;172:587-595.
PubMed Abstract available

MCMULLEN ER, Gonzalez ME, Skala SL, Tran M, et al
CCN6 regulates IGF2BP2 and HMGA2 signaling in metaplastic carcinomas of the breast.
Breast Cancer Res Treat. 2018;172:577-586.
PubMed Abstract available

November 2018

LIDBRINK E, Chmielowska E, Otremba B, Bouhlel A, et al
A real-world study of cardiac events in > 3700 patients with HER2-positive early breast cancer treated with trastuzumab: final analysis of the OHERA study.
Breast Cancer Res Treat. 2018 Nov 30. pii: 10.1007/s10549-018-5058.
PubMed Abstract available

WALSH EM, Shalaby A, O'Loughlin M, Keane N, et al
Outcome for triple negative breast cancer in a retrospective cohort with an emphasis on response to platinum-based neoadjuvant therapy.
Breast Cancer Res Treat. 2018 Nov 28. pii: 10.1007/s10549-018-5066.
PubMed Abstract available

HOLLERN DP, Contreras CM, Dance-Barnes S, Silva GO, et al
A mouse model featuring tissue-specific deletion of p53 and Brca1 gives rise to mammary tumors with genomic and transcriptomic similarities to human basal-like breast cancer.
Breast Cancer Res Treat. 2018 Nov 27. pii: 10.1007/s10549-018-5061.
PubMed Abstract available

SHTAM T, Naryzhny S, Samsonov R, Karasik D, et al
Plasma exosomes stimulate breast cancer metastasis through surface interactions and activation of FAK signaling.
Breast Cancer Res Treat. 2018 Nov 27. pii: 10.1007/s10549-018-5043.
PubMed Abstract available

ABOUEGYLAH M, Braunstein LZ, Alm El-Din MA, Niemierko A, et al
Evaluation of radiation-induced cardiac toxicity in breast cancer patients treated with Trastuzumab-based chemotherapy.
Breast Cancer Res Treat. 2018 Nov 26. pii: 10.1007/s10549-018-5053.
PubMed Abstract available

GIBBS LD, Chaudhary P, Mansheim K, Hare RJ, et al
ANXA2 expression in African American triple-negative breast cancer patients.
Breast Cancer Res Treat. 2018 Nov 26. pii: 10.1007/s10549-018-5030.
PubMed Abstract available

IGNATOV T, Claus M, Nass N, Haybaeck J, et al
G-protein-coupled estrogen receptor GPER-1 expression in hormone receptor-positive breast cancer is associated with poor benefit of tamoxifen.
Breast Cancer Res Treat. 2018 Nov 26. pii: 10.1007/s10549-018-5064.
PubMed Abstract available

CHASAMPALIOTI M, Green AR, Ellis IO, Rakha EA, et al
Connexin 43 is an independent predictor of patient outcome in breast cancer patients.
Breast Cancer Res Treat. 2018 Nov 24. pii: 10.1007/s10549-018-5063.
PubMed Abstract available

HENRY DA, Lee MC, Almanza D, Ahmed KA, et al
Trends in use of bilateral prophylactic mastectomy vs high-risk surveillance in unaffected carriers of inherited breast cancer syndromes in the Inherited Cancer Registry (ICARE).
Breast Cancer Res Treat. 2018 Nov 24. pii: 10.1007/s10549-018-5057.
PubMed Abstract available

CRAZE ML, El-Ansari R, Aleskandarany MA, Cheng KW, et al
Glutamate dehydrogenase (GLUD1) expression in breast cancer.
Breast Cancer Res Treat. 2018 Nov 23. pii: 10.1007/s10549-018-5060.
PubMed Abstract available

LOO LWM, Gao C, Shvetsov YB, Okoro DR, et al
MDM2, MDM2-C, and mutant p53 expression influence breast cancer survival in a multiethnic population.
Breast Cancer Res Treat. 2018 Nov 23. pii: 10.1007/s10549-018-5065.
PubMed Abstract available

WANG J, Xu B, Wang W, Zhai X, et al
Correction to: Efficacy and safety of fulvestrant in postmenopausal patients with hormone receptor-positive advanced breast cancer: a systematic literature review and meta-analysis.
Breast Cancer Res Treat. 2018 Nov 23. pii: 10.1007/s10549-018-5047.
PubMed Abstract available

ROZNER RN, Freites-Martinez A, Shapiro J, Geer EB, et al
Safety of 5alpha-reductase inhibitors and spironolactone in breast cancer patients receiving endocrine therapies.
Breast Cancer Res Treat. 2018 Nov 22. pii: 10.1007/s10549-018-4996.
PubMed Abstract available

DIBABA DT, Ogunsina K, Braithwaite D, Akinyemiju T, et al
Metabolic syndrome and risk of breast cancer mortality by menopause, obesity, and subtype.
Breast Cancer Res Treat. 2018 Nov 21. pii: 10.1007/s10549-018-5056.
PubMed Abstract available

HASKINS CB, McDowell BD, Carnahan RM, Fiedorowicz JG, et al
Impact of preexisting mental illness on breast cancer endocrine therapy adherence.
Breast Cancer Res Treat. 2018 Nov 21. pii: 10.1007/s10549-018-5050.
PubMed Abstract available

CAPARICA R, Bruzzone M, Poggio F, Ceppi M, et al
Anthracycline and taxane-based chemotherapy versus docetaxel and cyclophosphamide in the adjuvant treatment of HER2-negative breast cancer patients: a systematic review and meta-analysis of randomized controlled trials.
Breast Cancer Res Treat. 2018 Nov 21. pii: 10.1007/s10549-018-5055.
PubMed Abstract available

ZOOROB RJ, Salemi JL, Mejia de Grubb MC, Modak S, et al
A nationwide study of breast cancer, depression, and multimorbidity among hospitalized women and men in the United States.
Breast Cancer Res Treat. 2018 Nov 21. pii: 10.1007/s10549-018-5059.
PubMed Abstract available

LEE KWC, Lord S, Finn RS, Lim E, et al
The impact of ethnicity on efficacy and toxicity of cyclin D kinase 4/6 inhibitors in advanced breast cancer: a meta-analysis.
Breast Cancer Res Treat. 2018 Nov 21. pii: 10.1007/s10549-018-5054.
PubMed Abstract available

CAO J, Eshak ES, Liu K, Muraki I, et al
Sleep duration and risk of breast cancer: The JACC Study.
Breast Cancer Res Treat. 2018 Nov 20. pii: 10.1007/s10549-018-4995.
PubMed Abstract available

JONGEN L, Floris G, Boeckx B, Smeets D, et al
Identification, clinical-pathological characteristics and treatment outcomes of patients with metastatic breast cancer and somatic human epidermal growth factor receptor 2 (ERBB2) mutations.
Breast Cancer Res Treat. 2018 Nov 19. pii: 10.1007/s10549-018-5049.
PubMed Abstract available

LIU J, Liu L, Yague E, Yang Q, et al
GGNBP2 suppresses triple-negative breast cancer aggressiveness through inhibition of IL-6/STAT3 signaling activation.
Breast Cancer Res Treat. 2018 Nov 19. pii: 10.1007/s10549-018-5052.
PubMed Abstract available

CORSO G, Pravettoni G, Galimberti V, Veronesi P, et al
Clinical implication of E-cadherin deficiency in lobular breast cancer.
Breast Cancer Res Treat. 2018 Nov 17. pii: 10.1007/s10549-018-5051.
PubMed

XU R, Tang P, Li C
Association between pre-operative magnetic resonance imaging (MRI) and surgical outcomes in breast cancer: not yet determined.
Breast Cancer Res Treat. 2018 Nov 16. pii: 10.1007/s10549-018-5010.
PubMed

BLEICHER RJ, Chang C, Wang CE, Goldstein LJ, et al
Treatment delays from transfers of care and their impact on breast cancer quality measures.
Breast Cancer Res Treat. 2018 Nov 15. pii: 10.1007/s10549-018-5046.
PubMed Abstract available

MORTEN BC, Chiu S, Oldmeadow C, Lubinski J, et al
The intron 3 16 bp duplication polymorphism of p53 (rs17878362) is not associated with increased risk of developing triple-negative breast cancer.
Breast Cancer Res Treat. 2018 Nov 14. pii: 10.1007/s10549-018-5039.
PubMed Abstract available

DESANTIS CE, Ma J, Jemal A
Trends in stage at diagnosis for young breast cancer patients in the United States.
Breast Cancer Res Treat. 2018 Nov 13. pii: 10.1007/s10549-018-5042.
PubMed Abstract available

KIM YH, Hwang JH, Bae JH, Choi JY, et al
Predictive value of lymphoscintigraphy in patients with breast cancer-related lymphedema undergoing complex decongestive therapy.
Breast Cancer Res Treat. 2018 Nov 12. pii: 10.1007/s10549-018-5041.
PubMed Abstract available

DROGEMOLLER BI, Wright GEB, Shih J, Monzon JG, et al
CYP2D6 as a treatment decision aid for ER-positive non-metastatic breast cancer patients: a systematic review with accompanying clinical practice guidelines.
Breast Cancer Res Treat. 2018 Nov 8. pii: 10.1007/s10549-018-5027.
PubMed Abstract available

BUSCARIOLLO DL, Cronin AM, Borstelmann NA, Punglia RS, et al
Impact of pre-diagnosis depressive symptoms and health-related quality of life on treatment choice for ductal carcinoma in situ and stage I breast cancer in older women.
Breast Cancer Res Treat. 2018 Nov 8. pii: 10.1007/s10549-018-5006.
PubMed Abstract available

GUDINA AT, Copeland G, Soliman AS, Hirko KA, et al
Racial/ethnic disparities in inflammatory breast cancer survival in the Michigan Cancer Surveillance Program.
Breast Cancer Res Treat. 2018 Nov 7. pii: 10.1007/s10549-018-5037.
PubMed Abstract available

SKULI SJ, Sheng JY, Bantug ET, Zafman N, et al
Survivorship care visits in a high-risk population of breast cancer survivors.
Breast Cancer Res Treat. 2018 Nov 7. pii: 10.1007/s10549-018-5028.
PubMed Abstract available

XUE C, Wei W, Sun P, Zheng W, et al
Pretreatment anti-Mullerian hormone-based nomogram predicts menstruation status after chemotherapy for premenopausal women with hormone receptor-positive early breast cancer.
Breast Cancer Res Treat. 2018 Nov 3. pii: 10.1007/s10549-018-4997.
PubMed Abstract available

HOPPE EJ, Hussain LR, Grannan KJ, Dunki-Jacobs EM, et al
Racial disparities in breast cancer persist despite early detection: analysis of treatment of stage 1 breast cancer and effect of insurance status on disparities.
Breast Cancer Res Treat. 2018 Nov 3. pii: 10.1007/s10549-018-5036.
PubMed Abstract available

LI T, Yang J, Lv Y, Yin F, et al
Quantitative comparison of drug efficacy in treating hot flashes in patients with breast cancer.
Breast Cancer Res Treat. 2018 Nov 2. pii: 10.1007/s10549-018-5029.
PubMed Abstract available

PARK S, Moon BI, Oh SJ, Lee HB, et al
Clinical subtypes and prognosis in breast cancer according to parity: a nationwide study in Korean Breast Cancer Society.
Breast Cancer Res Treat. 2018 Nov 2. pii: 10.1007/s10549-018-5032.
PubMed Abstract available

HENG YJ, Wang J, Ahearn TU, Brown SB, et al
Molecular mechanisms linking high body mass index to breast cancer etiology in post-menopausal breast tumor and tumor-adjacent tissues.
Breast Cancer Res Treat. 2018 Nov 1. pii: 10.1007/s10549-018-5034.
PubMed Abstract available

SZOSTAKOWSKA M, Trebinska-Stryjewska A, Grzybowska EA, Fabisiewicz A, et al
Resistance to endocrine therapy in breast cancer: molecular mechanisms and future goals.
Breast Cancer Res Treat. 2018 Nov 1. pii: 10.1007/s10549-018-5023.
PubMed Abstract available

SUNG JS, Corben AD, Brooks JD, Edelweiss M, et al
Histopathologic characteristics of background parenchymal enhancement (BPE) on breast MRI.
Breast Cancer Res Treat. 2018;172:487-496.
PubMed Abstract available

NARAYAN AK, Elkin EB, Lehman CD, Morris EA, et al
Quantifying performance thresholds for recommending screening mammography: a revealed preference analysis of USPSTF guidelines.
Breast Cancer Res Treat. 2018;172:463-468.
PubMed Abstract available

SANCHEZ-SPITMAN AB, Dezentje VO, Swen JJ, Moes DJAR, et al
Genetic polymorphisms of 3'-untranslated region of SULT1A1 and their impact on tamoxifen metabolism and efficacy.
Breast Cancer Res Treat. 2018;172:401-411.
PubMed Abstract available

WU NC, Wong W, Ho KE, Chu VC, et al
Comparison of central laboratory assessments of ER, PR, HER2, and Ki67 by IHC/FISH and the corresponding mRNAs (ESR1, PGR, ERBB2, and MKi67) by RT-qPCR on an automated, broadly deployed diagnostic platform.
Breast Cancer Res Treat. 2018;172:327-338.
PubMed Abstract available

REGMI S, Fung TS, Lim S, Luo KQ, et al
Fluidic shear stress increases the anti-cancer effects of ROS-generating drugs in circulating tumor cells.
Breast Cancer Res Treat. 2018;172:297-312.
PubMed Abstract available

TUDINI E, Moghadasi S, Parsons MT, van der Kolk L, et al
Substantial evidence for the clinical significance of missense variant BRCA1 c.5309G>T p.(Gly1770Val).
Breast Cancer Res Treat. 2018;172:497-503.
PubMed Abstract available

YEAP PM, Evans A, Purdie CA, Jordan LB, et al
A comparison of the imaging features of pleomorphic and classical invasive lobular carcinoma.
Breast Cancer Res Treat. 2018;172:381-389.
PubMed Abstract available

PAREKH A, Fu W, Hu C, Shen CJ, et al
Impact of race, ethnicity, and socioeconomic factors on receipt of radiation after breast conservation surgery: analysis of the national cancer database.
Breast Cancer Res Treat. 2018;172:201-208.
PubMed Abstract available

ALSHAKER H, Srivats S, Monteil D, Wang Q, et al
Field template-based design and biological evaluation of new sphingosine kinase 1 inhibitors.
Breast Cancer Res Treat. 2018;172:33-43.
PubMed Abstract available

BARNES-KEDAR I, Bernstein-Molho R, Ginzach N, Hartmajer S, et al
The yield of full BRCA1/2 genotyping in Israeli high-risk breast/ovarian cancer patients who do not carry the predominant mutations.
Breast Cancer Res Treat. 2018;172:151-157.
PubMed Abstract available

October 2018

YOON TI, Kwak BS, Yi OV, Kim S, et al
Age-related risk factors associated with primary contralateral breast cancer among younger women versus older women.
Breast Cancer Res Treat. 2018 Oct 30. pii: 10.1007/s10549-018-5031.
PubMed Abstract available

VALLET S, Fan F, Malvestiti S, Pecherstorfer M, et al
Rationally derived drug combinations with the novel Mcl-1 inhibitor EU-5346 in breast cancer.
Breast Cancer Res Treat. 2018 Oct 29. pii: 10.1007/s10549-018-5022.
PubMed Abstract available

RODRIGUES-FERREIRA S, Nehlig A, Monchecourt C, Nasr S, et al
Combinatorial expression of microtubule-associated EB1 and ATIP3 biomarkers improves breast cancer prognosis.
Breast Cancer Res Treat. 2018 Oct 27. pii: 10.1007/s10549-018-5026.
PubMed Abstract available

CAO S, Zhou J, Zhu Z, Wei F, et al
Adult weight change and the risk of pre- and postmenopausal breast cancer in the Chinese Wuxi Exposure and Breast Cancer Study.
Breast Cancer Res Treat. 2018 Oct 27. pii: 10.1007/s10549-018-5016.
PubMed Abstract available

WALTER KR, Ford ME, Gregoski MJ, Kramer RM, et al
Advanced glycation end products are elevated in estrogen receptor-positive breast cancer patients, alter response to therapy, and can be targeted by lifestyle intervention.
Breast Cancer Res Treat. 2018 Oct 27. pii: 10.1007/s10549-018-4992.
PubMed Abstract available

MASKARINEC G, Shvetsov YB, Conroy SM, Haiman CA, et al
Type 2 diabetes as a predictor of survival among breast cancer patients: the multiethnic cohort.
Breast Cancer Res Treat. 2018 Oct 26. pii: 10.1007/s10549-018-5025.
PubMed Abstract available

LIU GY, Li JW, Zuo WJ, Ivanova D, et al
Metronomic capecitabine combined with aromatase inhibitors for new chemoendocrine treatment of advanced breast cancer: a phase II clinical trial.
Breast Cancer Res Treat. 2018 Oct 25. pii: 10.1007/s10549-018-5024.
PubMed Abstract available

OHARA AM, Naoi Y, Shimazu K, Kagara N, et al
PAM50 for prediction of response to neoadjuvant chemotherapy for ER-positive breast cancer.
Breast Cancer Res Treat. 2018 Oct 25. pii: 10.1007/s10549-018-5020.
PubMed Abstract available

JONCZYK MM, Jean J, Graham R, Chatterjee A, et al
Surgical trends in breast cancer: a rise in novel operative treatment options over a 12 year analysis.
Breast Cancer Res Treat. 2018 Oct 25. pii: 10.1007/s10549-018-5018.
PubMed Abstract available

CABEL L, Carton M, Cheaib B, Pierga JY, et al
Oral etoposide in heavily pre-treated metastatic breast cancer: results from the ESME cohort and comparison with other chemotherapy regimens.
Breast Cancer Res Treat. 2018 Oct 24. pii: 10.1007/s10549-018-5017.
PubMed Abstract available

VAN DEN BERG MMGA, Kok DE, Posthuma L, Kamps L, et al
Body composition is associated with risk of toxicity-induced modifications of treatment in women with stage I-IIIB breast cancer receiving chemotherapy.
Breast Cancer Res Treat. 2018 Oct 23. pii: 10.1007/s10549-018-5014.
PubMed Abstract available

JEREVALL PL, Brock J, Palazzo J, Wieczorek T, et al
Discrepancy in risk assessment of hormone receptor positive early-stage breast cancer patients using breast cancer index and recurrence score.
Breast Cancer Res Treat. 2018 Oct 22. pii: 10.1007/s10549-018-5013.
PubMed Abstract available

RYU JM, Choi HJ, Kim I, Nam SJ, et al
Prevalence and oncologic outcomes of BRCA 1/2 mutations in unselected triple-negative breast cancer patients in Korea.
Breast Cancer Res Treat. 2018 Oct 22. pii: 10.1007/s10549-018-5015.
PubMed Abstract available

BLANCO C, Markowitz JC, Hellerstein DJ, Nezu AM, et al
A randomized trial of interpersonal psychotherapy, problem solving therapy, and supportive therapy for major depressive disorder in women with breast cancer.
Breast Cancer Res Treat. 2018 Oct 20. pii: 10.1007/s10549-018-4994.
PubMed Abstract available

WU T, Sultan LR, Tian J, Cary TW, et al
Machine learning for diagnostic ultrasound of triple-negative breast cancer.
Breast Cancer Res Treat. 2018 Oct 20. pii: 10.1007/s10549-018-4984.
PubMed Abstract available

ALTUNDAG K
Extranodular extension in sentinel lymph node-positive breast cancer might predict further initiation of completion axillary lymph node dissection.
Breast Cancer Res Treat. 2018 Oct 20. pii: 10.1007/s10549-018-5019.
PubMed

HE X, Ji J, Dong R, Liu H, et al
Prognosis in different subtypes of metaplastic breast cancer: a population-based analysis.
Breast Cancer Res Treat. 2018 Oct 19. pii: 10.1007/s10549-018-5005.
PubMed Abstract available

SOPIK V, Sun P, Narod SA
Predictors of time to death after distant recurrence in breast cancer patients.
Breast Cancer Res Treat. 2018 Oct 16. pii: 10.1007/s10549-018-5002.
PubMed Abstract available

LEONARDIS JM, Diefenbach BJ, Lyons DA, Olinger TA, et al
The influence of reconstruction choice and inclusion of radiation therapy on functional shoulder biomechanics in women undergoing mastectomy for breast cancer.
Breast Cancer Res Treat. 2018 Oct 16. pii: 10.1007/s10549-018-5003.
PubMed Abstract available

CAIN EH, Saha A, Harowicz MR, Marks JR, et al
Multivariate machine learning models for prediction of pathologic response to neoadjuvant therapy in breast cancer using MRI features: a study using an independent validation set.
Breast Cancer Res Treat. 2018 Oct 16. pii: 10.1007/s10549-018-4990.
PubMed Abstract available

FASCHING PA, Hartkopf AD, Gass P, Haberle L, et al
Efficacy of neoadjuvant pertuzumab in addition to chemotherapy and trastuzumab in routine clinical treatment of patients with primary breast cancer: a multicentric analysis.
Breast Cancer Res Treat. 2018 Oct 15. pii: 10.1007/s10549-018-5008.
PubMed Abstract available

ALTUNDAG K
Better pathological tumor characteristics might occur in recurrent metastatic breast cancer patients after 10-year metastatic free interval.
Breast Cancer Res Treat. 2018 Oct 15. pii: 10.1007/s10549-018-5011.
PubMed

HWANG HW, Jung H, Hyeon J, Park YH, et al
A nomogram to predict pathologic complete response (pCR) and the value of tumor-infiltrating lymphocytes (TILs) for prediction of response to neoadjuvant chemotherapy (NAC) in breast cancer patients.
Breast Cancer Res Treat. 2018 Oct 15. pii: 10.1007/s10549-018-4981.
PubMed Abstract available

TERADA M
Challenge for identifying the origin of occult breast cancer for optimizing local therapy.
Breast Cancer Res Treat. 2018 Oct 15. pii: 10.1007/s10549-018-4931.
PubMed

INNO A, Barni S, Ghidini A, Zaniboni A, et al
One year versus a shorter duration of adjuvant trastuzumab for HER2-positive early breast cancer: a systematic review and meta-analysis.
Breast Cancer Res Treat. 2018 Oct 13. pii: 10.1007/s10549-018-5001.
PubMed Abstract available

ASTASHCHANKA A, Shroka TM, Jacobsen BM
Mucin 2 (MUC2) modulates the aggressiveness of breast cancer.
Breast Cancer Res Treat. 2018 Oct 13. pii: 10.1007/s10549-018-4989.
PubMed Abstract available

HENNIGS A, Kopke M, Feisst M, Riedel F, et al
Which patients with sentinel node-positive breast cancer after breast conservation still receive completion axillary lymph node dissection in routine clinical practice?
Breast Cancer Res Treat. 2018 Oct 12. pii: 10.1007/s10549-018-5009.
PubMed Abstract available

NYROP KA, Deal AM, Choi SK, Wagoner CW, et al
Correction to: Measuring and understanding adherence in a home-based exercise intervention during chemotherapy for early breast cancer.
Breast Cancer Res Treat. 2018 Oct 11. pii: 10.1007/s10549-018-4975.
PubMed Abstract available

GUESTINI F, Ono K, Miyashita M, Ishida T, et al
Impact of Topoisomerase IIalpha, PTEN, ABCC1/MRP1, and KI67 on triple-negative breast cancer patients treated with neoadjuvant chemotherapy.
Breast Cancer Res Treat. 2018 Oct 10. pii: 10.1007/s10549-018-4985.
PubMed Abstract available

ALFARSI LH, Elansari R, Toss MS, Diez-Rodriguez M, et al
Kinesin family member-18A (KIF18A) is a predictive biomarker of poor benefit from endocrine therapy in early ER+ breast cancer.
Breast Cancer Res Treat. 2018 Oct 10. pii: 10.1007/s10549-018-4978.
PubMed Abstract available

KUSSAIBI H, Alkharsah KR, Altamimi D, Alsayyah A, et al
Alternative splicing is an important mechanism behind KAI1 loss of function in breast cancer patients from Saudi Arabia.
Breast Cancer Res Treat. 2018 Oct 10. pii: 10.1007/s10549-018-4999.
PubMed Abstract available

KRAMER CJH, Vangangelt KMH, van Pelt GW, Dekker TJA, et al
The prognostic value of tumour-stroma ratio in primary breast cancer with special attention to triple-negative tumours: a review.
Breast Cancer Res Treat. 2018 Oct 9. pii: 10.1007/s10549-018-4987.
PubMed Abstract available

REN JX, Gong Y, Ling H, Hu X, et al
Racial/ethnic differences in the outcomes of patients with metastatic breast cancer: contributions of demographic, socioeconomic, tumor and metastatic characteristics.
Breast Cancer Res Treat. 2018 Oct 6. pii: 10.1007/s10549-018-4956.
PubMed Abstract available

JAUCH SF, Riethdorf S, Sprick MR, Schutz F, et al
Sustained prognostic impact of circulating tumor cell status and kinetics upon further progression of metastatic breast cancer.
Breast Cancer Res Treat. 2018 Oct 1. pii: 10.1007/s10549-018-4972.
PubMed Abstract available

JANSEN LE, Teft WA, Rose RV, Lizotte DJ, et al
CYP2D6 genotype and endoxifen plasma concentration do not predict hot flash severity during tamoxifen therapy.
Breast Cancer Res Treat. 2018;171:701-708.
PubMed Abstract available

LURASCHI R, Lazzari R, Galimberti V, Rondi E, et al
Dosimetric study to assess the feasibility of intraoperative radiotherapy with electrons (ELIOT) as partial breast irradiation for patients with cardiac implantable electronic device (CIED).
Breast Cancer Res Treat. 2018;171:693-699.
PubMed Abstract available

COELHO BA, Paiva SPC, da Silva Filho AL
Extremely brief mindfulness interventions for women undergoing breast biopsies: a randomized controlled trial.
Breast Cancer Res Treat. 2018;171:685-692.
PubMed Abstract available

EULER-CHELPIN MV, Lillholm M, Napolitano G, Vejborg I, et al
Screening mammography: benefit of double reading by breast density.
Breast Cancer Res Treat. 2018;171:767-776.
PubMed Abstract available

September 2018

GUCALP A, Traina TA, Eisner JR, Parker JS, et al
Male breast cancer: a disease distinct from female breast cancer.
Breast Cancer Res Treat. 2018 Sep 28. pii: 10.1007/s10549-018-4921.
PubMed Abstract available

SIMONE BA, Ko K, Simone NL
Re: Elevated BMI might more significantly affect the outcome negatively in luminal type breast cancer patients with brain metastases.
Breast Cancer Res Treat. 2018 Sep 27. pii: 10.1007/s10549-018-4940.
PubMed

ZUNIGA KE, Parma DL, Munoz E, Spaniol M, et al
Dietary intervention among breast cancer survivors increased adherence to a Mediterranean-style, anti-inflammatory dietary pattern: the Rx for Better Breast Health Randomized Controlled Trial.
Breast Cancer Res Treat. 2018 Sep 26. pii: 10.1007/s10549-018-4982.
PubMed Abstract available

RESNICOW K, Patel MR, Mcleod MC, Katz SJ, et al
Physician attitudes about cost consciousness for breast cancer treatment: differences by cancer sub-specialty.
Breast Cancer Res Treat. 2018 Sep 26. pii: 10.1007/s10549-018-4976.
PubMed Abstract available

SMETANAY K, Junio P, Feisst M, Seitz J, et al
COOLHAIR: a prospective randomized trial to investigate the efficacy and tolerability of scalp cooling in patients undergoing (neo)adjuvant chemotherapy for early breast cancer.
Breast Cancer Res Treat. 2018 Sep 25. pii: 10.1007/s10549-018-4983.
PubMed Abstract available

XU R, Zhu J
Association between red and processed meat with breast cancer: Comment on "Red and processed meat intake and risk of breast cancer: a meta-analysis of prospective studies" by Guo et al.
Breast Cancer Res Treat. 2018 Sep 24. pii: 10.1007/s10549-018-4977.
PubMed

BHARGAVA A, Saha S
T-Type voltage gated calcium channels: a target in breast cancer?
Breast Cancer Res Treat. 2018 Sep 21. pii: 10.1007/s10549-018-4970.
PubMed Abstract available

SHEN Y, Fujii T, Ueno NT, Tripathy D, et al
Comparative efficacy of adjuvant trastuzumab-containing chemotherapies for patients with early HER2-positive primary breast cancer: a network meta-analysis.
Breast Cancer Res Treat. 2018 Sep 21. pii: 10.1007/s10549-018-4969.
PubMed Abstract available

IWATA H, Masuda N, Yamamoto Y, Fujisawa T, et al
Validation of the 21-gene test as a predictor of clinical response to neoadjuvant hormonal therapy for ER+, HER2-negative breast cancer: the TransNEOS study.
Breast Cancer Res Treat. 2018 Sep 21. pii: 10.1007/s10549-018-4964.
PubMed Abstract available

CHANG E, Mougalian SS, Adelson KB, Young MR, et al
Association between prolonged metastatic free interval and recurrent metastatic breast cancer survival: findings from the SEER database.
Breast Cancer Res Treat. 2018 Sep 21. pii: 10.1007/s10549-018-4968.
PubMed Abstract available

ACEVEDO F, Armengol VD, Deng Z, Tang R, et al
Pathologic findings in reduction mammoplasty specimens: a surrogate for the population prevalence of breast cancer and high-risk lesions.
Breast Cancer Res Treat. 2018 Sep 20. pii: 10.1007/s10549-018-4962.
PubMed Abstract available

LEE SK, Kim SW, Yu JH, Lee JE, et al
Is the high proportion of young age at breast cancer onset a unique feature of Asian breast cancer?
Breast Cancer Res Treat. 2018 Sep 20. pii: 10.1007/s10549-018-4947.
PubMed Abstract available

HOUVENAEGHEL G, de Nonneville A, Cohen M, Classe JM, et al
Isolated ipsilateral local recurrence of breast cancer: predictive factors and prognostic impact.
Breast Cancer Res Treat. 2018 Sep 20. pii: 10.1007/s10549-018-4944.
PubMed Abstract available

NIRAULA S, Gyawali B
Optimal duration of adjuvant trastuzumab in treatment of early breast cancer: a meta-analysis of randomized controlled trials.
Breast Cancer Res Treat. 2018 Sep 20. pii: 10.1007/s10549-018-4967.
PubMed Abstract available

TONG WL, Callahan BM, Tu YN, Zaman S, et al
Immune receptor recombinations from breast cancer exome files, independently and in combination with specific HLA alleles, correlate with better survival rates.
Breast Cancer Res Treat. 2018 Sep 18. pii: 10.1007/s10549-018-4961.
PubMed Abstract available

FALATO C, Taylor SK, Szulkin R, Nordblom A, et al
Prognosis in patients diagnosed with loco-regional failure of breast cancer: 34 years longitudinal data from the Stockholm-Gotland cancer registry.
Breast Cancer Res Treat. 2018 Sep 17. pii: 10.1007/s10549-018-4936.
PubMed Abstract available

LIU Z, Sahli Z, Wang Y, Wolff AC, et al
Young age at diagnosis is associated with worse prognosis in the Luminal A breast cancer subtype: a retrospective institutional cohort study.
Breast Cancer Res Treat. 2018 Sep 17. pii: 10.1007/s10549-018-4950.
PubMed Abstract available

SPRING L, Niemierko A, Haddad S, Yuen M, et al
Effectiveness and tolerability of neoadjuvant pertuzumab-containing regimens for HER2-positive localized breast cancer.
Breast Cancer Res Treat. 2018 Sep 15. pii: 10.1007/s10549-018-4959.
PubMed Abstract available

RYU JM, Choi HJ, Kim I, Lee SK, et al
Only estrogen receptor "positive" is not enough to predict the prognosis of breast cancer.
Breast Cancer Res Treat. 2018 Sep 14. pii: 10.1007/s10549-018-4948.
PubMed Abstract available

KHALED H, Gamal H, Lotayef M, Knauer M, et al
The St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017: Egyptian view.
Breast Cancer Res Treat. 2018 Sep 14. pii: 10.1007/s10549-018-4945.
PubMed Abstract available

OLIVA-MORENO J, Pena-Longobardo LM
Labour productivity loss caused by premature deaths associated with breast cancer: results from Spain over a 10-year period.
Breast Cancer Res Treat. 2018 Sep 12. pii: 10.1007/s10549-018-4963.
PubMed Abstract available

JEON SH, Shin KH, Kim JH, Kim K, et al
Effects of trastuzumab on locoregional recurrence in human epidermal growth factor receptor 2-overexpressing breast cancer patients treated with chemotherapy and radiotherapy.
Breast Cancer Res Treat. 2018 Sep 12. pii: 10.1007/s10549-018-4966.
PubMed Abstract available

PEREZ-PENA J, Gyorffy B, Amir E, Pandiella A, et al
Epigenetic modulation of FOXM1-gene interacting network by BET inhibitors in breast cancer.
Breast Cancer Res Treat. 2018 Sep 11. pii: 10.1007/s10549-018-4965.
PubMed Abstract available

TAKADA M, Sugimoto M, Masuda N, Iwata H, et al
Prediction of postoperative disease-free survival and brain metastasis for HER2-positive breast cancer patients treated with neoadjuvant chemotherapy plus trastuzumab using a machine learning algorithm.
Breast Cancer Res Treat. 2018 Sep 7. pii: 10.1007/s10549-018-4958.
PubMed Abstract available

FENTIMAN IS
Surgical options for male breast cancer.
Breast Cancer Res Treat. 2018 Sep 5. pii: 10.1007/s10549-018-4952.
PubMed Abstract available

ALTUNDAG K
Regular exercise might be associated with higher skeletal muscle volume, favorable prognostic factor in breast cancer patients.
Breast Cancer Res Treat. 2018 Sep 3. pii: 10.1007/s10549-018-4949.
PubMed

OZAWA PMM, Alkhilaiwi F, Cavalli IJ, Malheiros D, et al
Extracellular vesicles from triple-negative breast cancer cells promote proliferation and drug resistance in non-tumorigenic breast cells.
Breast Cancer Res Treat. 2018 Sep 1. pii: 10.1007/s10549-018-4925.
PubMed Abstract available

August 2018

NAROD SA, Giannakeas V, Sopik V
Time to death in breast cancer patients as an indicator of treatment response.
Breast Cancer Res Treat. 2018 Aug 30. pii: 10.1007/s10549-018-4935.
PubMed Abstract available

SHEN S, Unger JM, Crew KD, Till C, et al
Omega-3 fatty acid use for obese breast cancer patients with aromatase inhibitor-related arthralgia (SWOG S0927).
Breast Cancer Res Treat. 2018 Aug 29. pii: 10.1007/s10549-018-4946.
PubMed Abstract available

MOORE AH, Trentham-Dietz A, Burns M, Gangnon RE, et al
Obesity and mortality after locoregional breast cancer diagnosis.
Breast Cancer Res Treat. 2018 Aug 29. pii: 10.1007/s10549-018-4932.
PubMed Abstract available

ZHANG Z, Li C, Fan H, Xiang Q, et al
Prognostic value of baseline serum HER2 extracellular domain level with a cut-off value of 15 ng/mL in patients with breast cancer: a systematic review and meta-analysis.
Breast Cancer Res Treat. 2018 Aug 29. pii: 10.1007/s10549-018-4942.
PubMed Abstract available

DE SOUZA TIMOTEO AR, Goncalves AEMM, Sales LAP, Albuquerque BM, et al
A portrait of germline mutation in Brazilian at-risk for hereditary breast cancer.
Breast Cancer Res Treat. 2018 Aug 29. pii: 10.1007/s10549-018-4938.
PubMed Abstract available

THOMAS R, Rowell R, Crichton S, Cain H, et al
Patients electing to have PET rather than surgery for operable breast cancer are a high risk of treatment failure.
Breast Cancer Res Treat. 2018 Aug 29. pii: 10.1007/s10549-018-4943.
PubMed Abstract available

FRONTERA ED, Khansa RM, Schalk DL, Leakan LE, et al
IgA Fc-folate conjugate activates and recruits neutrophils to directly target triple-negative breast cancer cells.
Breast Cancer Res Treat. 2018 Aug 28. pii: 10.1007/s10549-018-4941.
PubMed Abstract available

GOTO-YAMAGUCHI L, Yamamoto-Ibusuki M, Yamamoto Y, Fujiki Y, et al
Therapeutic predictors of neoadjuvant endocrine therapy response in estrogen receptor-positive breast cancer with reference to optimal gene expression profiling.
Breast Cancer Res Treat. 2018 Aug 27. pii: 10.1007/s10549-018-4933.
PubMed Abstract available

YANG J, Lv Q
Theoretical possibility of primary breast cancer originates from ectopic breast tissue in axillary lymph nodes.
Breast Cancer Res Treat. 2018 Aug 27. pii: 10.1007/s10549-018-4926.
PubMed

ALTUNDAG K
Elevated BMI might more significantly affect the outcome negatively in luminal type breast cancer patients with brain metastases.
Breast Cancer Res Treat. 2018 Aug 24. pii: 10.1007/s10549-018-4934.
PubMed

BALLINGER TJ, Reddy A, Althouse SK, Nelson EM, et al
Impact of primary breast cancer therapy on energetic capacity and body composition.
Breast Cancer Res Treat. 2018 Aug 22. pii: 10.1007/s10549-018-4924.
PubMed Abstract available

WANG B, Yuan F
The association between estrogen receptor alpha gene rs746432 polymorphism and the risk of breast cancer.
Breast Cancer Res Treat. 2018 Aug 21. pii: 10.1007/s10549-018-4929.
PubMed

BAE SY, Nam SJ, Jung Y, Lee SB, et al
Differences in prognosis and efficacy of chemotherapy by p53 expression in triple-negative breast cancer.
Breast Cancer Res Treat. 2018 Aug 21. pii: 10.1007/s10549-018-4928.
PubMed Abstract available

BEMANIAN V, Noone JC, Sauer T, Touma J, et al
Somatic EP300-G211S mutations are associated with overall somatic mutational patterns and breast cancer specific survival in triple-negative breast cancer.
Breast Cancer Res Treat. 2018 Aug 21. pii: 10.1007/s10549-018-4927.
PubMed Abstract available

SONG EJ, Lee CW, Jung SY, Kim BN, et al
Prognostic impact of skeletal muscle volume derived from cross-sectional computed tomography images in breast cancer.
Breast Cancer Res Treat. 2018 Aug 21. pii: 10.1007/s10549-018-4915.
PubMed Abstract available

RAMOS J, Das J, Felty Q, Yoo C, et al
NRF1 motif sequence-enriched genes involved in ER/PR -ve HER2 +ve breast cancer signaling pathways.
Breast Cancer Res Treat. 2018 Aug 20. pii: 10.1007/s10549-018-4905.
PubMed Abstract available

CLAESSENS AKM, Bos MEMM, Lopez-Yurda M, Bouma JM, et al
Intermittent versus continuous first-line treatment for HER2-negative metastatic breast cancer: the Stop & Go study of the Dutch Breast Cancer Research Group (BOOG).
Breast Cancer Res Treat. 2018 Aug 18. pii: 10.1007/s10549-018-4906.
PubMed Abstract available

KENN M, Cacsire Castillo-Tong D, Singer CF, Cibena M, et al
Co-expressed genes enhance precision of receptor status identification in breast cancer patients.
Breast Cancer Res Treat. 2018 Aug 16. pii: 10.1007/s10549-018-4920.
PubMed Abstract available

KRABY MR, Valla M, Opdahl S, Haugen OA, et al
The prognostic value of androgen receptors in breast cancer subtypes.
Breast Cancer Res Treat. 2018 Aug 14. pii: 10.1007/s10549-018-4904.
PubMed Abstract available

BUHL ASK, Christensen TD, Christensen IJ, Nelausen KM, et al
Predicting efficacy of epirubicin by a multigene assay in advanced breast cancer within a Danish Breast Cancer Cooperative Group (DBCG) cohort: a retrospective-prospective blinded study.
Breast Cancer Res Treat. 2018 Aug 11. pii: 10.1007/s10549-018-4918.
PubMed Abstract available

WANG SY, Long JB, Killelea BK, Evans SB, et al
Associations of preoperative breast magnetic resonance imaging with subsequent mastectomy and breast cancer mortality.
Breast Cancer Res Treat. 2018 Aug 11. pii: 10.1007/s10549-018-4919.
PubMed Abstract available

BARBOSA C ROCHA F, Falcone AB, Buzaid AC, Pimenta JM, et al
Neoadjuvant therapy for breast cancer treatment: an expert panel recommendation from the Brazilian Society of Breast Surgeons 2018.
Breast Cancer Res Treat. 2018 Aug 11. pii: 10.1007/s10549-018-4912.
PubMed Abstract available

GREEN AK, Aviki EM, Matsoukas K, Patil S, et al
Racial disparities in chemotherapy administration for early-stage breast cancer: a systematic review and meta-analysis.
Breast Cancer Res Treat. 2018 Aug 9. pii: 10.1007/s10549-018-4909.
PubMed Abstract available

BORRIE AE, Rose RV, Choi YH, Perera FE, et al
Letrozole concentration is associated with CYP2A6 variation but not with arthralgia in patients with breast cancer.
Breast Cancer Res Treat. 2018 Aug 9. pii: 10.1007/s10549-018-4910.
PubMed Abstract available

LEE SB, Ko SS, Park CH, Nam SJ, et al
Chronologically changing patterns in the survival of korean patients with breast cancer and related clinical factors: a nationwide registry-based study.
Breast Cancer Res Treat. 2018 Aug 7. pii: 10.1007/s10549-018-4892.
PubMed Abstract available

CHEN BT, Jin T, Patel SK, Ye N, et al
Gray matter density reduction associated with adjuvant chemotherapy in older women with breast cancer.
Breast Cancer Res Treat. 2018 Aug 7. pii: 10.1007/s10549-018-4911.
PubMed Abstract available

BAE SY, Kim SJ, Lee J, Lee ES, et al
Clinical subtypes and prognosis of pregnancy-associated breast cancer: results from the Korean Breast Cancer Society Registry database.
Breast Cancer Res Treat. 2018 Aug 7. pii: 10.1007/s10549-018-4908.
PubMed Abstract available

MURPHY J, Pfeiffer RM, Lynn BCD, Caballero AI, et al
Pro-inflammatory cytokines and growth factors in human milk: an exploratory analysis of racial differences to inform breast cancer etiology.
Breast Cancer Res Treat. 2018 Aug 6. pii: 10.1007/s10549-018-4907.
PubMed Abstract available

ZDRAVKOVIC D, Nikolic D, Zdravkovic M
Heterogeneity of tumor cells and metastases in breast cancer patients: cause or consequence?
Breast Cancer Res Treat. 2018 Aug 4. pii: 10.1007/s10549-018-4913.
PubMed

LIN CH, Tang CH
Rebuttal comments on "Glucocorticoids in breast cancer treatment: Real benefit or selection bias?"
Breast Cancer Res Treat. 2018 Aug 2. pii: 10.1007/s10549-018-4872.
PubMed

July 2018

SANFT T, Usiskin I, Harrigan M, Cartmel B, et al
Randomized controlled trial of weight loss versus usual care on telomere length in women with breast cancer: the lifestyle, exercise, and nutrition (LEAN) study.
Breast Cancer Res Treat. 2018 Jul 30. pii: 10.1007/s10549-018-4895.
PubMed Abstract available

SUN F, Hall A, Tighe MP, Brunelle CL, et al
Perometry versus simulated circumferential tape measurement for the detection of breast cancer-related lymphedema.
Breast Cancer Res Treat. 2018 Jul 30. pii: 10.1007/s10549-018-4902.
PubMed Abstract available

FELIZ-MOSQUEA YR, Christensen AA, Wilson AS, Westwood B, et al
Combination of anthracyclines and anti-CD47 therapy inhibit invasive breast cancer growth while preventing cardiac toxicity by regulation of autophagy.
Breast Cancer Res Treat. 2018 Jul 28. pii: 10.1007/s10549-018-4884.
PubMed Abstract available

KUROZUMI S, Joseph C, Sonbul S, Aleskandarany MA, et al
Clinicopathological and prognostic significance of Ras association and pleckstrin homology domains 1 (RAPH1) in breast cancer.
Breast Cancer Res Treat. 2018 Jul 28. pii: 10.1007/s10549-018-4891.
PubMed Abstract available

MESSINA C, Cattrini C, Buzzatti G, Cerbone L, et al
CDK4/6 inhibitors in advanced hormone receptor-positive/HER2-negative breast cancer: a systematic review and meta-analysis of randomized trials.
Breast Cancer Res Treat. 2018 Jul 27. pii: 10.1007/s10549-018-4901.
PubMed Abstract available

LIN JH, Tu SH, Chen LC, Huang CC, et al
Oestrogen receptor-regulated glutathione S-transferase mu 3 expression attenuates hydrogen peroxide-induced cytotoxicity, which confers tamoxifen resistance on breast cancer cells.
Breast Cancer Res Treat. 2018 Jul 27. pii: 10.1007/s10549-018-4897.
PubMed Abstract available

GUNER G, Dizdar O
Glucocorticoids in breast cancer treatment: real benefit or selection bias?
Breast Cancer Res Treat. 2018 Jul 26. pii: 10.1007/s10549-018-4871.
PubMed

FARSHID G, Walters D
Molecular subtypes of screen-detected breast cancer.
Breast Cancer Res Treat. 2018 Jul 25. pii: 10.1007/s10549-018-4899.
PubMed Abstract available

MADDEN JM, Murphy L, Zgaga L, Bennett K, et al
De novo vitamin D supplement use post-diagnosis is associated with breast cancer survival.
Breast Cancer Res Treat. 2018 Jul 23. pii: 10.1007/s10549-018-4896.
PubMed Abstract available

SHARIF-ASKARI B, Amrein L, Aloyz R, Panasci L, et al
PARP3 inhibitors ME0328 and olaparib potentiate vinorelbine sensitization in breast cancer cell lines.
Breast Cancer Res Treat. 2018 Jul 23. pii: 10.1007/s10549-018-4888.
PubMed Abstract available

WULANINGSIH W, Garmo H, Ahlgren J, Holmberg L, et al
Determinants of non-adherence to adjuvant endocrine treatment in women with breast cancer: the role of comorbidity.
Breast Cancer Res Treat. 2018 Jul 21. pii: 10.1007/s10549-018-4890.
PubMed Abstract available

TERADA M, Adachi Y, Sawaki M, Hattori M, et al
Occult breast cancer may originate from ectopic breast tissue present in axillary lymph nodes.
Breast Cancer Res Treat. 2018 Jul 20. pii: 10.1007/s10549-018-4898.
PubMed Abstract available

SOLDERA SV, Ennis M, Lohmann AE, Goodwin PJ, et al
Sexual health in long-term breast cancer survivors.
Breast Cancer Res Treat. 2018 Jul 19. pii: 10.1007/s10549-018-4894.
PubMed Abstract available

ABDEL-RAHMAN O
Population-based validation of the National Cancer Comprehensive Network recommendations for breast cancer staging.
Breast Cancer Res Treat. 2018 Jul 18. pii: 10.1007/s10549-018-4893.
PubMed Abstract available

MCCALL NS, Simone BA, Mehta M, Zhan T, et al
Onco-metabolism: defining the prognostic significance of obesity and diabetes in women with brain metastases from breast cancer.
Breast Cancer Res Treat. 2018 Jul 18. pii: 10.1007/s10549-018-4880.
PubMed Abstract available

MARTIN M, de la Torre-Montero JC, Lopez-Tarruella S, Pinilla K, et al
Correction to: Persistent major alopecia following adjuvant docetaxel for breast cancer: incidence, characteristics, and prevention with scalp cooling.
Breast Cancer Res Treat. 2018 Jul 16. pii: 10.1007/s10549-018-4883.
PubMed Abstract available

VAN NULAND M, Vreman RA, Ten Ham RMT, de Vries Schultink AHM, et al
Cost-effectiveness of monitoring endoxifen levels in breast cancer patients adjuvantly treated with tamoxifen.
Breast Cancer Res Treat. 2018 Jul 13. pii: 10.1007/s10549-018-4886.
PubMed Abstract available

O'BRIEN KM, Mooney T, Fitzpatrick P, Sharp L, et al
Screening status, tumour subtype, and breast cancer survival: a national population-based analysis.
Breast Cancer Res Treat. 2018 Jul 13. pii: 10.1007/s10549-018-4877.
PubMed Abstract available

REDITI M, Messina C
Towards treatment personalisation in triple negative breast cancer: role of platinum-based neoadjuvant chemotherapy.
Breast Cancer Res Treat. 2018 Jul 12. pii: 10.1007/s10549-018-4885.
PubMed

BANYS-PALUCHOWSKI M, Witzel I, Riethdorf S, Pantel K, et al
The clinical relevance of serum vascular endothelial growth factor (VEGF) in correlation to circulating tumor cells and other serum biomarkers in patients with metastatic breast cancer.
Breast Cancer Res Treat. 2018 Jul 12. pii: 10.1007/s10549-018-4882.
PubMed Abstract available

SAHA A, Harowicz MR, Cain EH, Hall AH, et al
Intra-tumor molecular heterogeneity in breast cancer: definitions of measures and association with distant recurrence-free survival.
Breast Cancer Res Treat. 2018 Jul 10. pii: 10.1007/s10549-018-4879.
PubMed Abstract available

NIKOLIC D, Granic M, Ivanovic N, Zdravkovic D, et al
Breast cancer and its impact in male transsexuals.
Breast Cancer Res Treat. 2018 Jul 5. pii: 10.1007/s10549-018-4875.
PubMed Abstract available

ANGARITA FA, Elmi M, Zhang Y, Look Hong NJ, et al
Patient-reported factors influencing the treatment decision-making process of older women with non-metastatic breast cancer: a systematic review of qualitative evidence.
Breast Cancer Res Treat. 2018 Jul 4. pii: 10.1007/s10549-018-4865.
PubMed Abstract available

ROBINSON A, Souied O, Bota AB, Levasseur N, et al
Optimal vascular access strategies for patients receiving chemotherapy for early-stage breast cancer: a systematic review.
Breast Cancer Res Treat. 2018 Jul 4. pii: 10.1007/s10549-018-4868.
PubMed Abstract available

WANG J, Xu B, Wang W, Zhai X, et al
Efficacy and safety of fulvestrant in postmenopausal patients with hormone receptor-positive advanced breast cancer: a systematic literature review and meta-analysis.
Breast Cancer Res Treat. 2018 Jul 4. pii: 10.1007/s10549-018-4867.
PubMed Abstract available

KABIL N, Bayraktar R, Kahraman N, Mokhlis HA, et al
Thymoquinone inhibits cell proliferation, migration, and invasion by regulating the elongation factor 2 kinase (eEF-2K) signaling axis in triple-negative breast cancer.
Breast Cancer Res Treat. 2018 Jul 3. pii: 10.1007/s10549-018-4847.
PubMed Abstract available

BERTHE A, Zaffino M, Muller C, Foulquier F, et al
Protein N-glycosylation alteration and glycolysis inhibition both contribute to the antiproliferative action of 2-deoxyglucose in breast cancer cells.
Breast Cancer Res Treat. 2018 Jul 3. pii: 10.1007/s10549-018-4874.
PubMed Abstract available

SAGARA Y, Takada M, Ohi Y, Ohtani S, et al
Effectiveness of neo-adjuvant systemic therapy with trastuzumab for basal HER2 type breast cancer: results from retrospective cohort study of Japan Breast Cancer Research Group (JBCRG)-C03.
Breast Cancer Res Treat. 2018 Jul 3. pii: 10.1007/s10549-018-4873.
PubMed Abstract available

June 2018

BRENNAN M, Gass P, Haberle L, Wang D, et al
The effect of participation in neoadjuvant clinical trials on outcomes in patients with early breast cancer.
Breast Cancer Res Treat. 2018 Jun 27. pii: 10.1007/s10549-018-4829.
PubMed Abstract available

STOUT NK, Cronin AM, Uno H, Ozanne EM, et al
Estrogen-receptor status and risk of contralateral breast cancer following DCIS.
Breast Cancer Res Treat. 2018 Jun 26. pii: 10.1007/s10549-018-4860.
PubMed Abstract available

LEE DY, Park YH, Lee JE, Choi D, et al
Prediction of ovarian function recovery in young breast cancer patients after protection with gonadotropin-releasing hormone agonist during chemotherapy.
Breast Cancer Res Treat. 2018 Jun 25. pii: 10.1007/s10549-018-4863.
PubMed Abstract available

VAN SWEARINGEN AED, Siegel MB, Deal AM, Sambade MJ, et al
LCCC 1025: a phase II study of everolimus, trastuzumab, and vinorelbine to treat progressive HER2-positive breast cancer brain metastases.
Breast Cancer Res Treat. 2018 Jun 25. pii: 10.1007/s10549-018-4852.
PubMed Abstract available

YAP YS, Munusamy P, Lim C, Chan CHT, et al
Breast cancer in women with neurofibromatosis type 1 (NF1): a comprehensive case series with molecular insights into its aggressive phenotype.
Breast Cancer Res Treat. 2018 Jun 21. pii: 10.1007/s10549-018-4851.
PubMed Abstract available

KIM JY, Lim JE, Jung HH, Cho SY, et al
Validation of the new AJCC eighth edition of the TNM classification for breast cancer with a single-center breast cancer cohort.
Breast Cancer Res Treat. 2018 Jun 21. pii: 10.1007/s10549-018-4858.
PubMed Abstract available

BAUER ECA, Schochter F, Widschwendter P, DeGregorio A, et al
Prevalence of circulating tumor cells in early breast cancer patients 2 and 5 years after adjuvant treatment.
Breast Cancer Res Treat. 2018 Jun 21. pii: 10.1007/s10549-018-4856.
PubMed Abstract available

MARTIN M, de la Torre-Montero JC, Lopez-Tarruella S, Pinilla K, et al
Persistent major alopecia following adjuvant docetaxel for breast cancer: incidence, characteristics, and prevention with scalp cooling.
Breast Cancer Res Treat. 2018 Jun 19. pii: 10.1007/s10549-018-4855.
PubMed Abstract available

PEREIRA PTVT, Reis AD, Diniz RR, Lima FA, et al
Dietary supplements and fatigue in patients with breast cancer: a systematic review.
Breast Cancer Res Treat. 2018 Jun 18. pii: 10.1007/s10549-018-4857.
PubMed Abstract available

JERZAK KJ, Cockburn JG, Dhesy-Thind SK, Pond GR, et al
Thyroid hormone receptor beta-1 expression in early breast cancer: a validation study.
Breast Cancer Res Treat. 2018 Jun 18. pii: 10.1007/s10549-018-4844.
PubMed Abstract available

KOGAWA T, Fujii T, Fouad TM, Liu DD, et al
Impact of change in body mass index during neoadjuvant chemotherapy and survival among breast cancer subtypes.
Breast Cancer Res Treat. 2018 Jun 18. pii: 10.1007/s10549-018-4853.
PubMed Abstract available

LI X, Zhang Y, Meisel J, Jiang R, et al
Validation of the newly proposed American Joint Committee on Cancer (AJCC) breast cancer prognostic staging group and proposing a new staging system using the National Cancer Database.
Breast Cancer Res Treat. 2018 Jun 15. pii: 10.1007/s10549-018-4832.
PubMed Abstract available

LANGBALLE R, Frederiksen K, Jensen MB, Andersson M, et al
Mortality after contralateral breast cancer in Denmark.
Breast Cancer Res Treat. 2018 Jun 11. pii: 10.1007/s10549-018-4846.
PubMed Abstract available

MANDUJANO-TINOCO EA, Garcia-Venzor A, Melendez-Zajgla J, Maldonado V, et al
New emerging roles of microRNAs in breast cancer.
Breast Cancer Res Treat. 2018 Jun 9. pii: 10.1007/s10549-018-4850.
PubMed Abstract available

SMITH BL, Gadd MA, Lanahan CR, Rai U, et al
Real-time, intraoperative detection of residual breast cancer in lumpectomy cavity walls using a novel cathepsin-activated fluorescent imaging system.
Breast Cancer Res Treat. 2018 Jun 9. pii: 10.1007/s10549-018-4845.
PubMed Abstract available

LOTSCH J, Sipila R, Tasmuth T, Kringel D, et al
Machine-learning-derived classifier predicts absence of persistent pain after breast cancer surgery with high accuracy.
Breast Cancer Res Treat. 2018 Jun 6. pii: 10.1007/s10549-018-4841.
PubMed Abstract available

KONG AL, Nattinger AB, McGinley E, Pezzin LE, et al
The relationship between patient and tumor characteristics, patterns of breast cancer care, and 5-year survival among elderly women with incident breast cancer.
Breast Cancer Res Treat. 2018 Jun 5. pii: 10.1007/s10549-018-4837.
PubMed Abstract available

ROUMELIOTIS M, Long K, Phan T, Graham D, et al
Including internal mammary lymph nodes in radiation therapy for synchronous bilateral breast cancer: an international survey of treatment technique and clinical priorities.
Breast Cancer Res Treat. 2018 Jun 5. pii: 10.1007/s10549-018-4848.
PubMed Abstract available

CHA YJ, Ahn SG, Bae SJ, Yoon CI, et al
Comparison of tumor-infiltrating lymphocytes of breast cancer in core needle biopsies and resected specimens: a retrospective analysis.
Breast Cancer Res Treat. 2018 Jun 5. pii: 10.1007/s10549-018-4842.
PubMed Abstract available

PICADO O, Khazeni K, Allen C, Yakoub D, et al
Extent of regional lymph node surgery and impact on outcomes in patients with early-stage breast cancer and limited axillary disease undergoing mastectomy.
Breast Cancer Res Treat. 2018 Jun 5. pii: 10.1007/s10549-018-4840.
PubMed Abstract available

LEOPOLD C, Wagner AK, Zhang F, Lu CY, et al
Total and out-of-pocket expenditures among women with metastatic breast cancer in low-deductible versus high-deductible health plans.
Breast Cancer Res Treat. 2018 Jun 1. pii: 10.1007/s10549-018-4819.
PubMed Abstract available

REDDY JP, Atkinson RL, Larson R, Burks JK, et al
Mammary stem cell and macrophage markers are enriched in normal tissue adjacent to inflammatory breast cancer.
Breast Cancer Res Treat. 2018 Jun 1. pii: 10.1007/s10549-018-4835.
PubMed Abstract available

ARIAS-PULIDO H, Cimino-Mathews A, Chaher N, Qualls C, et al
The combined presence of CD20 + B cells and PD-L1 + tumor-infiltrating lymphocytes in inflammatory breast cancer is prognostic of improved patient outcome.
Breast Cancer Res Treat. 2018 Jun 1. pii: 10.1007/s10549-018-4834.
PubMed Abstract available

EVANS A, Sim YT, Pourreyron C, Thompson A, et al
Pre-operative stromal stiffness measured by shear wave elastography is independently associated with breast cancer-specific survival.
Breast Cancer Res Treat. 2018 Jun 1. pii: 10.1007/s10549-018-4836.
PubMed Abstract available

May 2018

JAIN S, Shah AN, Santa-Maria CA, Siziopikou K, et al
Phase I study of alpelisib (BYL-719) and trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer (MBC) after trastuzumab and taxane therapy.
Breast Cancer Res Treat. 2018 May 30. pii: 10.1007/s10549-018-4792.
PubMed Abstract available

ANDERSSON Y, Bergkvist L, Frisell J, de Boniface J, et al
Long-term breast cancer survival in relation to the metastatic tumor burden in axillary lymph nodes.
Breast Cancer Res Treat. 2018 May 30. pii: 10.1007/s10549-018-4820.
PubMed Abstract available

JACOB L, Scholten PC, Kostev K, Kalder M, et al
Association between sleep disorders and the presence of breast cancer metastases in gynecological practices in Germany: a case-control study of 11,412 women.
Breast Cancer Res Treat. 2018 May 29. pii: 10.1007/s10549-018-4831.
PubMed Abstract available

WANG Z, Katsaros D, Biglia N, Shen Y, et al
High expression of long non-coding RNA MALAT1 in breast cancer is associated with poor relapse-free survival.
Breast Cancer Res Treat. 2018 May 29. pii: 10.1007/s10549-018-4839.
PubMed Abstract available

LIU J, Yang Y, Wang H, Wang B, et al
Syntenin1/MDA-9 (SDCBP) induces immune evasion in triple-negative breast cancer by upregulating PD-L1.
Breast Cancer Res Treat. 2018 May 29. pii: 10.1007/s10549-018-4833.
PubMed Abstract available

ELMI M, Sequeira S, Azin A, Elnahas A, et al
Evolving surgical treatment decisions for male breast cancer: an analysis of the National Surgical Quality Improvement Program (NSQIP) database.
Breast Cancer Res Treat. 2018 May 28. pii: 10.1007/s10549-018-4830.
PubMed Abstract available

LI D, McCall LM, Hahn OM, Hudis CA, et al
Identification of risk factors for toxicity in patients with hormone receptor-positive advanced breast cancer treated with bevacizumab plus letrozole: a CALGB 40503 (alliance) correlative study.
Breast Cancer Res Treat. 2018 May 22. pii: 10.1007/s10549-018-4828.
PubMed Abstract available

MASUMOTO N, Kadoya T, Sasada S, Emi A, et al
Intratumoral heterogeneity on dedicated breast positron emission tomography predicts malignancy grade of breast cancer.
Breast Cancer Res Treat. 2018 May 19. pii: 10.1007/s10549-018-4791.
PubMed Abstract available

KOTSOPOULOS J, Gronwald J, Lynch HT, Eisen A, et al
Age at first full-term birth and breast cancer risk in BRCA1 and BRCA2 mutation carriers.
Breast Cancer Res Treat. 2018 May 17. pii: 10.1007/s10549-018-4822.
PubMed Abstract available

O'LOUGHLIN M, Andreu X, Bianchi S, Chemielik E, et al
Reproducibility and predictive value of scoring stromal tumour infiltrating lymphocytes in triple-negative breast cancer: a multi-institutional study.
Breast Cancer Res Treat. 2018 May 17. pii: 10.1007/s10549-018-4825.
PubMed Abstract available

WILLIAMSON TJ, Love SM, Clague DeHart JN, Jorge-Miller A, et al
Metastatic Breast Cancer Collateral Damage Project (MBCCD): Scale development and preliminary results of the Survey of Health, Impact, Needs, and Experiences (SHINE).
Breast Cancer Res Treat. 2018 May 16. pii: 10.1007/s10549-018-4823.
PubMed Abstract available

HOSTE G, Punie K, Wildiers H, Beuselinck B, et al
Palbociclib in highly pretreated metastatic ER-positive HER2-negative breast cancer.
Breast Cancer Res Treat. 2018 May 16. pii: 10.1007/s10549-018-4827.
PubMed Abstract available

BLOK EJ, Engels CC, Dekker-Ensink G, Meershoek-Klein Kranenbarg E, et al
Exploration of tumour-infiltrating lymphocytes as a predictive biomarker for adjuvant endocrine therapy in early breast cancer.
Breast Cancer Res Treat. 2018 May 15. pii: 10.1007/s10549-018-4785.
PubMed Abstract available

LIN CH, Chuang PY, You SL, Chiang CJ, et al
Effect of glucocorticoid use on survival in patients with stage I-III breast cancer.
Breast Cancer Res Treat. 2018 May 14. pii: 10.1007/s10549-018-4787.
PubMed Abstract available

LU CY, Zhang F, Wagner AK, Nekhlyudov L, et al
Impact of high-deductible insurance on adjuvant hormonal therapy use in breast cancer.
Breast Cancer Res Treat. 2018 May 12. pii: 10.1007/s10549-018-4821.
PubMed Abstract available

ONO H, Sowa Y, Horinaka M, Iizumi Y, et al
The histone deacetylase inhibitor OBP-801 and eribulin synergistically inhibit the growth of triple-negative breast cancer cells with the suppression of survivin, Bcl-xL, and the MAPK pathway.
Breast Cancer Res Treat. 2018 May 11. pii: 10.1007/s10549-018-4815.
PubMed Abstract available

LOWRY KP, Braunstein LZ, Economopoulos KP, Salama L, et al
Predictors of surveillance mammography outcomes in women with a personal history of breast cancer.
Breast Cancer Res Treat. 2018 May 10. pii: 10.1007/s10549-018-4808.
PubMed Abstract available

WANG S, Beeghly-Fadiel A, Cai Q, Cai H, et al
Gene expression in triple-negative breast cancer in relation to survival.
Breast Cancer Res Treat. 2018 May 10. pii: 10.1007/s10549-018-4816.
PubMed Abstract available

HUANG Z, Shi Y, Bao P, Cai H, et al
Associations of dietary intake and supplement use with post-therapy cognitive recovery in breast cancer survivors.
Breast Cancer Res Treat. 2018 May 9. pii: 10.1007/s10549-018-4805.
PubMed Abstract available

BARDIA A, Gucalp A, DaCosta N, Gabrail N, et al
Phase 1 study of seviteronel, a selective CYP17 lyase and androgen receptor inhibitor, in women with estrogen receptor-positive or triple-negative breast cancer.
Breast Cancer Res Treat. 2018 May 9. pii: 10.1007/s10549-018-4813.
PubMed Abstract available

CHOI JY, Cho EY, Choi YJ, Lee JH, et al
Incidence and risk factors for congestive heart failure in patients with early breast cancer who received anthracycline and/or trastuzumab: a big data analysis of the Korean Health Insurance Review and Assessment service database.
Breast Cancer Res Treat. 2018 May 8. pii: 10.1007/s10549-018-4809.
PubMed Abstract available

CUI P, Zhao Y, Chu X, He N, et al
SNP rs2071095 in LincRNA H19 is associated with breast cancer risk.
Breast Cancer Res Treat. 2018 May 8. pii: 10.1007/s10549-018-4814.
PubMed Abstract available

DANIELS B, Kiely BE, Lord SJ, Houssami N, et al
Long-term survival in trastuzumab-treated patients with HER2-positive metastatic breast cancer: real-world outcomes and treatment patterns in a whole-of-population Australian cohort (2001-2016).
Breast Cancer Res Treat. 2018 May 7. pii: 10.1007/s10549-018-4804.
PubMed Abstract available

TELLI ML, Stover DG, Loi S, Aparicio S, et al
Homologous recombination deficiency and host anti-tumor immunity in triple-negative breast cancer.
Breast Cancer Res Treat. 2018 May 7. pii: 10.1007/s10549-018-4807.
PubMed Abstract available

TSUNASHIMA R, Naoi Y, Shimazu K, Kagara N, et al
Construction of a novel multi-gene assay (42-gene classifier) for prediction of late recurrence in ER-positive breast cancer patients.
Breast Cancer Res Treat. 2018 May 4. pii: 10.1007/s10549-018-4812.
PubMed Abstract available

ABRAHAM J, Coleman R, Elias A, Holmes FA, et al
Use of cyclin-dependent kinase (CDK) 4/6 inhibitors for hormone receptor-positive, human epidermal growth factor receptor 2-negative, metastatic breast cancer: a roundtable discussion by The Breast Cancer Therapy Expert Group (BCTEG).
Breast Cancer Res Treat. 2018 May 4. pii: 10.1007/s10549-018-4783.
PubMed Abstract available

WUNDERLE M, Gass P, Haberle L, Flesch VM, et al
BRCA mutations and their influence on pathological complete response and prognosis in a clinical cohort of neoadjuvantly treated breast cancer patients.
Breast Cancer Res Treat. 2018 May 3. pii: 10.1007/s10549-018-4797.
PubMed Abstract available

KOMMALAPATI A, Tella SH, Goyal G, Ganti AK, et al
A prognostic scoring model for survival after locoregional therapy in de novo stage IV breast cancer.
Breast Cancer Res Treat. 2018 May 2. pii: 10.1007/s10549-018-4802.
PubMed Abstract available

ERIN N, Ogan N, Yerlikaya A
Correction to: Secretomes reveal several novel proteins as well as TGF-beta1 as the top upstream regulator of metastatic process in breast cancer.
Breast Cancer Res Treat. 2018 May 2. pii: 10.1007/s10549-018-4781.
PubMed Abstract available

April 2018

KIM S, Ko Y, Lee HJ, Lim JE, et al
Menopausal hormone therapy and the risk of breast cancer by histological type and race: a meta-analysis of randomized controlled trials and cohort studies.
Breast Cancer Res Treat. 2018 Apr 30. pii: 10.1007/s10549-018-4782.
PubMed Abstract available

SHIMA H, Kida K, Adachi S, Yamada A, et al
Lnc RNA H19 is associated with poor prognosis in breast cancer patients and promotes cancer stemness.
Breast Cancer Res Treat. 2018 Apr 24. pii: 10.1007/s10549-018-4793.
PubMed Abstract available

VOCI A, Lee D, Ho E, Crane-Okada R, et al
Impact of port site scar on perception of patients with breast cancer: patient-reported outcomes.
Breast Cancer Res Treat. 2018 Apr 24. pii: 10.1007/s10549-018-4790.
PubMed Abstract available

BACHAND J, Soulos PR, Herrin J, Pollack CE, et al
Physician peer group characteristics and timeliness of breast cancer surgery.
Breast Cancer Res Treat. 2018 Apr 24. pii: 10.1007/s10549-018-4789.
PubMed Abstract available

HAQUE W, Verma V, Hatch S, Suzanne Klimberg V, et al
Response rates and pathologic complete response by breast cancer molecular subtype following neoadjuvant chemotherapy.
Breast Cancer Res Treat. 2018 Apr 24. pii: 10.1007/s10549-018-4801.
PubMed Abstract available

SOPIK V, Narod SA
The relationship between tumour size, nodal status and distant metastases: on the origins of breast cancer.
Breast Cancer Res Treat. 2018 Apr 24. pii: 10.1007/s10549-018-4796.
PubMed Abstract available

HACKETT J, Thorneloe R, Side L, Wolf M, et al
Uptake of breast cancer preventive therapy in the UK: results from a multicentre prospective survey and qualitative interviews.
Breast Cancer Res Treat. 2018 Apr 24. pii: 10.1007/s10549-018-4775.
PubMed Abstract available

O'SHAUGHNESSY J, DeMichele A, Ma CX, Richards P, et al
A randomized, double-blind, phase 2 study of ruxolitinib or placebo in combination with capecitabine in patients with advanced HER2-negative breast cancer and elevated C-reactive protein, a marker of systemic inflammation.
Breast Cancer Res Treat. 2018 Apr 19. pii: 10.1007/s10549-018-4770.
PubMed Abstract available

KROENKE CH, Hershman DL, Gomez SL, Adams SR, et al
Personal and clinical social support and adherence to adjuvant endocrine therapy among hormone receptor-positive breast cancer patients in an integrated health care system.
Breast Cancer Res Treat. 2018 Apr 18. pii: 10.1007/s10549-018-4774.
PubMed Abstract available

SOARES FALCETTA F, de Araujo Vianna Trasel H, de Almeida FK, Rangel Ribeiro Falcetta M, et al
Effects of physical exercise after treatment of early breast cancer: systematic review and meta-analysis.
Breast Cancer Res Treat. 2018 Apr 13. pii: 10.1007/s10549-018-4786.
PubMed Abstract available

VERMA S, O'Shaughnessy J, Burris HA, Campone M, et al
Health-related quality of life of postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treated with ribociclib + letrozole: results from MONALEESA-2.
Breast Cancer Res Treat. 2018 Apr 13. pii: 10.1007/s10549-018-4769.
PubMed Abstract available

GUINTER MA, McLain AC, Merchant AT, Sandler DP, et al
An estrogen-related lifestyle score is associated with risk of postmenopausal breast cancer in the PLCO cohort.
Breast Cancer Res Treat. 2018 Apr 12. pii: 10.1007/s10549-018-4784.
PubMed Abstract available

ARTHUR R, Wang Y, Ye K, Glass AG, et al
Correction to: Association between lifestyle, menstrual/reproductive history, and histological factors and risk of breast cancer in women biopsied for benign breast disease.
Breast Cancer Res Treat. 2018 Apr 11. pii: 10.1007/s10549-018-4780.
PubMed Abstract available

LARSEN SB, Torstensson M, Kenborg L, Christensen J, et al
Pre-diagnostic changes in body mass index and mortality among breast cancer patients.
Breast Cancer Res Treat. 2018 Apr 10. pii: 10.1007/s10549-018-4771.
PubMed Abstract available

KUROZUMI S, Joseph C, Sonbul S, Gorringe KL, et al
Clinical and biological roles of Kelch-like family member 7 in breast cancer: a marker of poor prognosis.
Breast Cancer Res Treat. 2018 Apr 9. pii: 10.1007/s10549-018-4777.
PubMed Abstract available

PETROSSIAN K, Nguyen D, Lo C, Kanaya N, et al
Use of dual mTOR inhibitor MLN0128 against everolimus-resistant breast cancer.
Breast Cancer Res Treat. 2018 Apr 5. pii: 10.1007/s10549-018-4779.
PubMed Abstract available

CHECK DK, Chawla N, Kwan ML, Pinheiro L, et al
Understanding racial/ethnic differences in breast cancer-related physical well-being: the role of patient-provider interactions.
Breast Cancer Res Treat. 2018 Apr 5. pii: 10.1007/s10549-018-4776.
PubMed Abstract available

RAU KM, Ou-Yang F, Chao TC, Kuo YL, et al
Effect of eribulin on patients with metastatic breast cancer: multicenter retrospective observational study in Taiwan.
Breast Cancer Res Treat. 2018 Apr 5. pii: 10.1007/s10549-018-4778.
PubMed Abstract available

GHILLI M, Mariniello MD, Scatena C, Dosa L, et al
Male secretory breast cancer: case in a 6-year-old boy with a peculiar gene duplication and review of the literature.
Breast Cancer Res Treat. 2018 Apr 3. pii: 10.1007/s10549-018-4772.
PubMed Abstract available

SCHWARTZ MD, Peshkin BN, Isaacs C, Willey S, et al
Randomized trial of proactive rapid genetic counseling versus usual care for newly diagnosed breast cancer patients.
Breast Cancer Res Treat. 2018 Apr 2. pii: 10.1007/s10549-018-4773.
PubMed Abstract available

March 2018

MUNZONE E, Gray KP, Fumagalli C, Guerini-Rocco E, et al
Mutational analysis of triple-negative breast cancers within the International Breast Cancer Study Group (IBCSG) Trial 22-00.
Breast Cancer Res Treat. 2018 Mar 27. pii: 10.1007/s10549-018-4767.
PubMed Abstract available

CHOWDHURY M, Euhus D, Arun B, Umbricht C, et al
Validation of a personalized risk prediction model for contralateral breast cancer.
Breast Cancer Res Treat. 2018 Mar 24. pii: 10.1007/s10549-018-4763.
PubMed Abstract available

BHAT RR, Yadav P, Sahay D, Bhargava DK, et al
GPCRs profiling and identification of GPR110 as a potential new target in HER2+ breast cancer.
Breast Cancer Res Treat. 2018 Mar 24. pii: 10.1007/s10549-018-4751.
PubMed Abstract available

CAI H, Guo W, Zhang S, Li N, et al
A qualitative transcriptional signature to reclassify estrogen receptor status of breast cancer patients.
Breast Cancer Res Treat. 2018 Mar 23. pii: 10.1007/s10549-018-4758.
PubMed Abstract available

PHILLIPS M, Cataneo RN, Cruz-Ramos JA, Huston J, et al
Prediction of breast cancer risk with volatile biomarkers in breath.
Breast Cancer Res Treat. 2018 Mar 23. pii: 10.1007/s10549-018-4764.
PubMed Abstract available

RISI E, Grilli A, Migliaccio I, Biagioni C, et al
A gene expression signature of Retinoblastoma loss-of-function predicts resistance to neoadjuvant chemotherapy in ER-positive/HER2-positive breast cancer patients.
Breast Cancer Res Treat. 2018 Mar 22. pii: 10.1007/s10549-018-4766.
PubMed Abstract available

AGERSBORG S, Mixon C, Nguyen T, Aithal S, et al
Immunohistochemistry and alternative FISH testing in breast cancer with HER2 equivocal amplification.
Breast Cancer Res Treat. 2018 Mar 22. pii: 10.1007/s10549-018-4755.
PubMed Abstract available

HILL DA, Friend S, Lomo L, Wiggins C, et al
Breast cancer survival, survival disparities, and guideline-based treatment.
Breast Cancer Res Treat. 2018 Mar 22. pii: 10.1007/s10549-018-4761.
PubMed Abstract available

DUFFY MJ, Synnott NC, Crown J
Mutant p53 in breast cancer: potential as a therapeutic target and biomarker.
Breast Cancer Res Treat. 2018 Mar 21. pii: 10.1007/s10549-018-4753.
PubMed Abstract available

CHATTERJEE S, Chaubal R, Maitra A, Gardi N, et al
Pre-operative progesterone benefits operable breast cancer patients by modulating surgical stress.
Breast Cancer Res Treat. 2018 Mar 21. pii: 10.1007/s10549-018-4749.
PubMed Abstract available

BOYD J
A parallel model for breast cancer metastasis.
Breast Cancer Res Treat. 2018 Mar 21. pii: 10.1007/s10549-018-4759.
PubMed

SCHAYEK H, Korach H, Laitman Y, Bernstein-Molho R, et al
Mutational analysis of candidate genes in Israeli male breast cancer cases.
Breast Cancer Res Treat. 2018 Mar 21. pii: 10.1007/s10549-018-4765.
PubMed Abstract available

LI M, Zhou Y, Xia T, Zhou X, et al
Circulating microRNAs from the miR-106a-363 cluster on chromosome X as novel diagnostic biomarkers for breast cancer.
Breast Cancer Res Treat. 2018 Mar 20. pii: 10.1007/s10549-018-4757.
PubMed Abstract available

ALTUNDAG K
Receptor conversion in breast cancer patients with liver metastases after hepatectomy might affect survival.
Breast Cancer Res Treat. 2018 Mar 20. pii: 10.1007/s10549-018-4762.
PubMed

ERIN N, Ogan N, Yerlikaya A
Secretomes reveal several novel proteins as well as TGF-beta1 as the top upstream regulator of metastatic process in breast cancer.
Breast Cancer Res Treat. 2018 Mar 20. pii: 10.1007/s10549-018-4752.
PubMed Abstract available

THONE K, Rudolph A, Obi N, Chang-Claude J, et al
Prognostic impact of surgery for early-stage invasive breast cancer on breast cancer-specific survival, overall survival, and recurrence risk: a population-based analysis.
Breast Cancer Res Treat. 2018 Mar 19. pii: 10.1007/s10549-018-4754.
PubMed Abstract available

KYKER-SNOWMAN K, Erlanger Avigdor B, Nasim M, Cimino-Mathews A, et al
A primary breast cancer with distinct foci of estrogen receptor-alpha positive and negative cells derived from the same clonal origin as revealed by whole exome sequencing.
Breast Cancer Res Treat. 2018 Mar 15. pii: 10.1007/s10549-018-4742.
PubMed Abstract available

ANGARITA FA, Acuna SA, Cordeiro E, Elnahas A, et al
Thirty-day postoperative morbidity and mortality in elderly women with breast cancer: an analysis of the NSQIP database.
Breast Cancer Res Treat. 2018 Mar 15. pii: 10.1007/s10549-018-4747.
PubMed Abstract available

BOUYA S, Koochakzai M, Rafiemanesh H, Balouchi A, et al
Health-related quality of life of Iranian breast cancer patients: a meta-analysis and systematic review.
Breast Cancer Res Treat. 2018 Mar 14. pii: 10.1007/s10549-018-4750.
PubMed Abstract available

NAROD SA
Reply to Hollingsworth: does breast cancer metastasize in the clinical window between the mammogram and the mass?
Breast Cancer Res Treat. 2018 Mar 14. pii: 10.1007/s10549-018-4739.
PubMed

WILSON LE, Pollack CE, Greiner MA, Dinan MA, et al
Association between physician characteristics and the use of 21-gene recurrence score genomic testing among Medicare beneficiaries with early-stage breast cancer, 2008-2011.
Breast Cancer Res Treat. 2018 Mar 13. pii: 10.1007/s10549-018-4746.
PubMed Abstract available

TURNER TH, Alzubi MA, Sohal SS, Olex AL, et al
Characterizing the efficacy of cancer therapeutics in patient-derived xenograft models of metastatic breast cancer.
Breast Cancer Res Treat. 2018 Mar 12. pii: 10.1007/s10549-018-4748.
PubMed Abstract available

ROY P, Leizorovicz A, Villet R, Mercier C, et al
Systematic versus sentinel-lymph-node-driven axillary-lymph-node dissection in clinically node-negative patients with operable breast cancer. Results of the GF-GS01 randomized trial.
Breast Cancer Res Treat. 2018 Mar 10. pii: 10.1007/s10549-018-4733.
PubMed Abstract available

LI Y, Opyrchal M, Yao S, Peng X, et al
The role of programmed death ligand-1 and tumor-infiltrating lymphocytes in breast cancer overexpressing HER2 gene.
Breast Cancer Res Treat. 2018 Mar 9. pii: 10.1007/s10549-018-4745.
PubMed Abstract available

BAO T, Iris Zhi W, Vertosick EA, Li QS, et al
Acupuncture for breast cancer-related lymphedema: a randomized controlled trial.
Breast Cancer Res Treat. 2018 Mar 8. pii: 10.1007/s10549-018-4743.
PubMed Abstract available

BLANCHETTE PS, Desautels DN, Pond GR, Bartlett JMS, et al
Factors influencing survival among patients with HER2-positive metastatic breast cancer treated with trastuzumab.
Breast Cancer Res Treat. 2018 Mar 8. pii: 10.1007/s10549-018-4734.
PubMed Abstract available

PARK SJ, Lee MH, Kong SY, Song MK, et al
Use of adjuvant chemotherapy in hormone receptor-positive breast cancer patients with or without the 21-gene expression assay.
Breast Cancer Res Treat. 2018 Mar 8. pii: 10.1007/s10549-018-4740.
PubMed Abstract available

VELASQUEZ GARCIA HA, Sobolev BG, Gotay CC, Wilson CM, et al
Mammographic non-dense area and breast cancer risk in postmenopausal women: a causal inference approach in a case-control study.
Breast Cancer Res Treat. 2018 Mar 7. pii: 10.1007/s10549-018-4737.
PubMed Abstract available

ONEGA T, Zhu W, Weiss JE, Goodrich M, et al
Preoperative breast MRI and mortality in older women with breast cancer.
Breast Cancer Res Treat. 2018 Mar 7. pii: 10.1007/s10549-018-4732.
PubMed Abstract available

ADAMS BD, Arem H, Hubal MJ, Cartmel B, et al
Exercise and weight loss interventions and miRNA expression in women with breast cancer.
Breast Cancer Res Treat. 2018 Mar 6. pii: 10.1007/s10549-018-4738.
PubMed Abstract available

CHOWDHURY M, Euhus D, O'Donnell M, Onega T, et al
Dose-dependent effect of mammographic breast density on the risk of contralateral breast cancer.
Breast Cancer Res Treat. 2018 Mar 6. pii: 10.1007/s10549-018-4736.
PubMed Abstract available

RICE MS, Tamimi RM, Bertrand KA, Scott CG, et al
Does mammographic density mediate risk factor associations with breast cancer? An analysis by tumor characteristics.
Breast Cancer Res Treat. 2018 Mar 3. pii: 10.1007/s10549-018-4735.
PubMed Abstract available

Febr